
<html lang="en"     class="pb-page"  data-request-id="6cbe7180-6095-49ce-9d53-af1c9c16b56b"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2014.57.issue-3;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm401073p;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARK5)" /></meta><meta name="dc.Creator" content="M. V. Ramana  Reddy" /></meta><meta name="dc.Creator" content="Balireddy  Akula" /></meta><meta name="dc.Creator" content="Stephen C.  Cosenza" /></meta><meta name="dc.Creator" content="Saikrishna  Athuluridivakar" /></meta><meta name="dc.Creator" content="Muralidhar R.  Mallireddigari" /></meta><meta name="dc.Creator" content="Venkat R.  Pallela" /></meta><meta name="dc.Creator" content="Vinay K.  Billa" /></meta><meta name="dc.Creator" content="D. R. C. Venkata  Subbaiah" /></meta><meta name="dc.Creator" content="E. Vijaya  Bharathi" /></meta><meta name="dc.Creator" content="Rodrigo  Vasquez-Del Carpio" /></meta><meta name="dc.Creator" content="Amol  Padgaonkar" /></meta><meta name="dc.Creator" content="Stacey J.  Baker" /></meta><meta name="dc.Creator" content="E. Premkumar  Reddy" /></meta><meta name="dc.Description" content="The success of imatinib, a BCR-ABL inhibitor for the treatment of chronic myelogenous leukemia, has created a great impetus for the development of additional kinase inhibitors as therapeutic agents..." /></meta><meta name="Description" content="The success of imatinib, a BCR-ABL inhibitor for the treatment of chronic myelogenous leukemia, has created a great impetus for the development of additional kinase inhibitors as therapeutic agents..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 24, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm401073p" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm401073p" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm401073p" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm401073p" /></link>
        
    
    

<title>Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARK5) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm401073p" /></meta><meta property="og:title" content="Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARK5)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0025.jpeg" /></meta><meta property="og:description" content="The success of imatinib, a BCR-ABL inhibitor for the treatment of chronic myelogenous leukemia, has created a great impetus for the development of additional kinase inhibitors as therapeutic agents. However, the complexity of cancer has led to recent interest in polypharmacological approaches for developing multikinase inhibitors with low toxicity profiles. With this goal in mind, we analyzed more than 150 novel cyano pyridopyrimidine compounds and identified structure–activity relationship trends that can be exploited in the design of potent kinase inhibitors. One compound, 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x), was found to be the most active, inducing apoptosis of tumor cells at a concentration of approximately 30–100 nM. In vitro kinase profiling revealed that 7x is a multikinase inhibitor with potent inhibitory activity against the CDK4/CYCLIN D1 and ARK5 kinases. Here, we report the synthesis, structure–activity relationship, kinase inhibitory profile, in vitro cytotoxicity, and in vivo tumor regression studies by this lead compound." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm401073p"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm401073p">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm401073p&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm401073p&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm401073p&amp;href=/doi/10.1021/jm401073p" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 3</span><span class="cit-fg-pageRange">, 578-599</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/3" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm401800k" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm401117t" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7x</b>) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARK5)</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=M.+V.+Ramana++Reddy">M. V. Ramana Reddy</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Balireddy++Akula">Balireddy Akula</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephen+C.++Cosenza">Stephen C. Cosenza</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Saikrishna++Athuluridivakar">Saikrishna Athuluridivakar</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Muralidhar+R.++Mallireddigari">Muralidhar R. Mallireddigari</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Venkat+R.++Pallela">Venkat R. Pallela</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vinay+K.++Billa">Vinay K. Billa</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=D.+R.+C.+Venkata++Subbaiah">D. R. C. Venkata Subbaiah</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=E.+Vijaya++Bharathi">E. Vijaya Bharathi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rodrigo++Vasquez-Del+Carpio">Rodrigo Vasquez-Del Carpio</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Amol++Padgaonkar">Amol Padgaonkar</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stacey+J.++Baker">Stacey J. Baker</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=E.+Premkumar++Reddy">E. Premkumar Reddy</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, New York 10029-6514, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Medicinal Chemistry, Onconova Therapeutics Inc., 375 Pheasant Run, Newtown, Pennsylvania 18940-3423, United States</span></div><div class="corresp-info"><strong>*</strong>For M.V.R.R.: phone, 212-659-6875; fax, 215-893-6989; e-mail, <a href="/cdn-cgi/l/email-protection#60124e1205040419200d13130d4e050415"><span class="__cf_email__" data-cfemail="e694c8948382829fa68b95958bc8838293">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For E.P.R.: phone, (212) 659-5571; e-mail, <a href="/cdn-cgi/l/email-protection#e18491cf9384858598a18c92928ccf848594"><span class="__cf_email__" data-cfemail="5237227c203736362b123f21213f7c373627">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm401073p&amp;href=/doi/10.1021%2Fjm401073p" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 3</span><span class="cit-pageRange">, 578–599</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 13, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>16 July 2013</li><li><span class="item_label"><b>Published</b> online</span>24 January 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 February 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm401073p" title="DOI URL">https://doi.org/10.1021/jm401073p</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm401073p"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5968</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">40</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm401073p" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARK5)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;M.&quot;,&quot;last_name&quot;:&quot;V. Ramana Reddy&quot;},{&quot;first_name&quot;:&quot;Balireddy&quot;,&quot;last_name&quot;:&quot;Akula&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;C. Cosenza&quot;},{&quot;first_name&quot;:&quot;Saikrishna&quot;,&quot;last_name&quot;:&quot;Athuluridivakar&quot;},{&quot;first_name&quot;:&quot;Muralidhar&quot;,&quot;last_name&quot;:&quot;R. Mallireddigari&quot;},{&quot;first_name&quot;:&quot;Venkat&quot;,&quot;last_name&quot;:&quot;R. Pallela&quot;},{&quot;first_name&quot;:&quot;Vinay&quot;,&quot;last_name&quot;:&quot;K. Billa&quot;},{&quot;first_name&quot;:&quot;D.&quot;,&quot;last_name&quot;:&quot;R. C. Venkata Subbaiah&quot;},{&quot;first_name&quot;:&quot;E.&quot;,&quot;last_name&quot;:&quot;Vijaya Bharathi&quot;},{&quot;first_name&quot;:&quot;Rodrigo&quot;,&quot;last_name&quot;:&quot;Vasquez-Del Carpio&quot;},{&quot;first_name&quot;:&quot;Amol&quot;,&quot;last_name&quot;:&quot;Padgaonkar&quot;},{&quot;first_name&quot;:&quot;Stacey&quot;,&quot;last_name&quot;:&quot;J. Baker&quot;},{&quot;first_name&quot;:&quot;E.&quot;,&quot;last_name&quot;:&quot;Premkumar Reddy&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;24&quot;,&quot;issue&quot;:&quot;3&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;578-599&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm401073p&quot;},&quot;abstract&quot;:&quot;The success of imatinib, a BCR-ABL inhibitor for the treatment of chronic myelogenous leukemia, has created a great impetus for the development of additional kinase inhibitors as therapeutic agents. However, the complexity of cancer has led to recent interest in polypharmacological approaches for developing multikinase inhibitors with low toxicity profiles. With this goal in mind, we analyzed more than 150 novel cyano pyridopyrimidine compounds and identified structure–activity relationship trends that can be exploited in the design of potent kinase inhibitors. One compound, 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x), was found to be the most active, inducing apoptosis of tumor cells at a concentration of approximately 30–100 nM. In vitro kinase profiling revealed that 7x is a multikinase inhibitor with potent inhibitory activity against the CDK4/CYCLIN D1 and ARK5 kinases. Here, we report the synthesis, structure–activity relationsh&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401073p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401073p" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401073p&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401073p" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401073p&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401073p" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm401073p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401073p&amp;href=/doi/10.1021/jm401073p" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm401073p" /></input><a href="/doi/pdf/10.1021/jm401073p" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm401073p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm401073p%26sid%3Dliteratum%253Aachs%26pmid%3D24417566%26genre%3Darticle%26aulast%3DReddy%26date%3D2014%26atitle%3DDiscovery%2Bof%2B8-Cyclopentyl-2-%255B4-%25284-methyl-piperazin-1-yl%2529-phenylamino%255D-7-oxo-7%252C8-dihydro-pyrido%255B2%252C3-d%255Dpyrimidine-6-carbonitrile%2B%25287x%2529%2Bas%2Ba%2BPotent%2BInhibitor%2Bof%2BCyclin-Dependent%2BKinase%2B4%2B%2528CDK4%2529%2Band%2BAMPK-Related%2BKinase%2B5%2B%2528ARK5%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D3%26spage%3D578%26epage%3D599%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292317" title="Ethyl groups">Ethyl groups</a>,</li><li><a href="/action/doSearch?ConceptID=290808" title="Toxicity">Toxicity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/3" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jmcmar.2014.57.issue-3/production/jmcmar.2014.57.issue-3.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0025.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The success of imatinib, a BCR-ABL inhibitor for the treatment of chronic myelogenous leukemia, has created a great impetus for the development of additional kinase inhibitors as therapeutic agents. However, the complexity of cancer has led to recent interest in polypharmacological approaches for developing multikinase inhibitors with low toxicity profiles. With this goal in mind, we analyzed more than 150 novel cyano pyridopyrimidine compounds and identified structure–activity relationship trends that can be exploited in the design of potent kinase inhibitors. One compound, 8<b>-</b>cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7x</b>), was found to be the most active, inducing apoptosis of tumor cells at a concentration of approximately 30–100 nM. In vitro kinase profiling revealed that <b>7x</b> is a multikinase inhibitor with potent inhibitory activity against the CDK4/CYCLIN D1 and ARK5 kinases. Here, we report the synthesis, structure–activity relationship, kinase inhibitory profile, in vitro cytotoxicity, and in vivo tumor regression studies by this lead compound.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64422" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64422" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cancer is now believed to result from perturbations in cell cycle that result in unlimited proliferation and an inability of a cell to undergo differentiation and/or apoptosis.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5">(1-5)</a> The cell cycle is typically divided into four phases, G<sub>1</sub>, S, G<sub>2</sub>, and M, and it is apparent that the order and timing of each phase is critical for accurate transmission of genetic information. Consequently, a number of biochemical pathways have evolved to ensure that initiation of a particular cell cycle event is dependent on the accurate completion of another. These biochemical pathways have been termed “checkpoints.”<a onclick="showRef(event, 'ref1 ref2 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref5">(1, 2, 5)</a></div><div class="NLM_p">When cells proliferate, mitogenic growth factors bind to their cognate receptors and initiate a cascade of events that culminate in the expression and assembly of different kinase holoenzymes that are composed of a regulatory subunit, called a cyclin, and a catalytic subunit, termed a cyclin-dependent kinase (CDK).<a onclick="showRef(event, 'ref1 ref2 ref3 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref5">(1-3, 5)</a> CDKs are serine/threonine kinases that are inactive when they are under-phosphorylated and monomeric.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The primary mechanism of CDK activation is association with its partner cyclin. In the mammalian cell cycle, CDK4/6 associate with D-type cyclins and control progression through the G<sub>1</sub> phase when the cell prepares to initiate DNA synthesis.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> Activation of CDK4/6/cyclin D complexes contribute to hyperphosphorylation of the retinoblastoma (RB) family of proteins, which results in the release of associated protein factors.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> One key RB-binding partner is the E2F-1 transcription factor, which appears to activate the transcription of genes whose products are required for S-phase progression. E2F-1 and other members of the E2F family are known to bind to pRB and heterodimerize with DP-1 and -2, an interaction that is required for the DNA-binding capacity of E2F family proteins.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5 ref6 ref7 ref8">(1-8)</a> Once the cell has made the G<sub>1</sub>/S transition, cyclin E/CDK2 phosphorylates the remaining residues on the RB family proteins that are critical for E2F activation. Activation of E2F-mediated transcription allows the cell to transit into S phase and to initiate DNA replication, which is controlled, in part, through cyclin A/CDK2. Cyclin A/CDK2 ultimately forces the cell through the G<sub>2</sub> phase prior to the assembly of the cyclin B/CDK1 complex and the initiation of mitosis.<a onclick="showRef(event, 'ref5 ref8'); return false;" href="javascript:void(0);" class="ref ref5 ref8">(5, 8)</a></div><div class="NLM_p">There is considerable evidence showing that a vast majority of human tumors exhibit deregulation of the CDK4/6-cyclin D-RB pathway.<a onclick="showRef(event, 'ref1 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref1 ref9 ref10">(1, 9, 10)</a> For example, CDK4/6 is hyperactivated in a number of human cancers as a result of overexpression of positive regulators such as cyclin D or deletion and/or epigenetic alterations of substrates such as RB.<a onclick="showRef(event, 'ref1 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref1 ref9 ref10">(1, 9, 10)</a> In addition, mutations and chromosomal translocations in the CDK4 locus have also been described. One prominent example is the CDK4<sup>R24C</sup> mutation that results in insensitivity of CDK4 to INK4 family inhibitors and was first described in patients with familial melanoma.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> Finally, CDK4/6 amplification or overexpression has been observed in a wide spectrum of tumors, including gliomas, sarcomas, lymphomas, melanomas, carcinomas of breast, squamous cell carcinomas, and leukemias.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">Because cyclin D, CDK4, and CDK6 activities are upregulated in a variety of tumor types, several groups have focused their efforts on the development of small molecule CDK4 inhibitors. Experimental evidence indicating that CDK4 is dispensable for development<a onclick="showRef(event, 'ref14 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17">(14-17)</a> suggests that inhibitors of this kinase might be both nontoxic and effective in the treatment of cancers that are dependent on CDK4 activity for proliferation. The first generation of CDK inhibitors, flavopiridol (<b>23</b>)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and roscovitine (CYC202) (<b>24</b>)<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> (see Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>), were potent CDK4 inhibitors but were nonselective and inhibited multiple kinases including CDK1 and CDK7 and caused severe toxic side effects in clinical trials.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20, 21)</a> Several other pan-CDK inhibitors have since entered clinical trials, but the therapeutic efficacy of these molecules has been modest due to dose-limiting toxicity and poor pharmacokinetics. Several early trials have since been discontinued.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a></div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. CDK Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In an attempt to overcome the toxicity profile of pan-CDK inhibitors, small molecules belonging to additional chemical classes such as oxindoles (<b>25</b>),<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> triaminopyrimidines (<b>26</b>),<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> diarylureas (<b>27</b>),<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> thioacridones (<b>28</b>),<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> aminothiazoles (<b>29</b>),<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> indolocarbazoles (<b>30</b>),<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and pyrido[2,3-<i>d</i>]pyrimidines (<b>31</b>)<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30-32)</a> (see Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>) have been developed that are specific for individual CDKs. Some of these compounds exhibited a high degree of selectivity toward CDK4/6 by targeting the ATP binding site of CDK4/6-cyclin D complexes. Of these, one CDK4/6 selective compound, PD-0332991, which is a pyrido[2,3-<i>d</i>]pyrimidine derivative, is highly specific for CDK4 and CDK6, inhibiting these two kinases with IC<sub>50</sub> values of 0.011 and 0.015 μM, respectively, with little or no inhibitory activity against a large panel of kinases including other CDKs and a wide variety of serine, threonine, and tyrosine kinases.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30, 31)</a> PD-0332991 has been extensively studied for its efficacy in tissue culture model systems as well as in mouse xenograft models of colorectal cancer, mantle cell lymphoma (MCL), and disseminated myeloma.<a onclick="showRef(event, 'ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38">(31-38)</a> PD-0332991 causes G<sub>1</sub> arrest in cultured tumor cell lines and inhibits tumor growth in xenograft models of RB-positive human tumor cell lines derived from breast, ovarian, lung, colon, prostate, brain, and blood such as multiple myeloma and mantle cell lymphoma.<a onclick="showRef(event, 'ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38">(31-38)</a> Therapeutic doses of PD-0332991 resulted in a reduction of both phosphorylated RB and the proliferative marker Ki-67 in the tumor tissue as well as downregulation of E2F-target genes.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37, 38)</a> On the basis of these promising results, this compound entered clinical trials in 2004 and results from phase I and phase II trials indicate that the side effects are tolerable.<a onclick="showRef(event, 'ref39 ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41 ref42">(39-42)</a> Phase I studies with palbociclib (PD-0332991) indicated that the clinical response was mostly cytostatic where disease stabilization was observed in a significant number of patients (<a href="http://clinicaltrials.gov" class="extLink">http://clinicaltrials.gov</a>). However, few partial or complete remissions were observed in phase I and II clinical trials where PD-0332991 was used as a single agent. However, combination studies have yielded more promising results.<a onclick="showRef(event, 'ref43 ref44 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref43 ref44 ref45 ref46">(43-46)</a> This drug is currently being evaluated in phase III trials in combination with letrozole for the treatment of ER+/HER2– advanced breast cancer.<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45, 46)</a> These studies suggest that reduction of tumor burden in patients whose tumors express high levels of cyclin D/CDK4 might require inhibition not only of CDK4 but of other aberrantly activated proteins. With this in mind, our goal was to identify potent inhibitors that possess sufficient cross-reactivity with a small number of kinases, such that the combined inhibition of these kinases will result in a more effective treatment of these tumors. Here, we describe the synthesis, structure–activity relationship (SAR), cytotoxic properties, kinase inhibition profile, and mechanism of action of <b>7x</b>. <b>7x</b>, which is a member of the pyridopyrimidine series of compounds, is a potent CDK4/6 inhibitor that exhibits cross-reactivity with a small number of kinases that play critical roles in mitogenic signaling. Mice treated with <b>7x</b> did not exhibit signs of toxicity and tumor formation in <b>7x</b>-treated xenograft nude mouse models was inhibited over an 18-day period. Together, these studies indicate that pyridopyrimidine compounds might represent a safe and effective chemotype to treat tumors whose cell cycle progression is altered as a result of CDK4/6-RB hyperactivity.</div></div><div id="sec1_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62037" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62037" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To generate an ATP-competitive kinase inhibitor library, we used pyrido[2,3-<i>d</i>]pyrimidines (<b>7</b>) as the backbone because this class of compounds have been shown to possess kinase inhibitory activity.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47, 48)</a> To facilitate the synthesis of a large number of compounds, we developed a unique and simple method which is summarized in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Pyrido[2,3-<i>d</i>]pyrimidines (<b>7</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions (i) X-NH<sub>2</sub>, Et<sub>3</sub>N, THF, rt, 1–3 h, 80–95%; (ii) LiAlH<sub>4</sub>, THF, −10 °C to rt, 1 h, 80–86%; (iii) MnO<sub>2</sub>, CHCl<sub>3</sub>, rt, 24 h, 70–90%; (iv) CNCH<sub>2</sub>CO<sub>2</sub>H or NO<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>Et or <b>10</b> or <b>13</b> or <b>16</b>, BnNH<sub>2</sub>, AcOH, 100 °C, 6 h, 62–73%; (v) <i>m</i>-CPBA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 3 h, 87–94%; (vi) Z-H, toluene, 100 °C, 3–8 h, 40–65%.</p></p></figure><div class="NLM_p">The commercially available compound 4-chloro-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester <b>1</b> was treated with acyclic and cyclic amines in the presence of triethylamine (Et<sub>3</sub>N) to yield <b>2a</b>–<b>2j</b>. The ester group in compounds <b>2a</b>–<b>2j</b> was then reduced with lithium aluminum hydride (LiAlH<sub>4</sub>) to obtain the corresponding alcohols <b>3a</b>–<b>3j</b>, which when further oxidized with manganese dioxide (MnO<sub>2</sub>), yielded the corresponding pyrimidine carbaldehyde <b>4a</b>–<b>4j</b>. The aldehyde <b>4a</b>–<b>4j</b> were converted to pyridopyrimidines <b>5a</b>–<b>5s</b> by Knoevenagel condensation, with each aldehyde treated with active methylene compounds (cyanoacetic acid or nitro-acetic acid ethyl ester or <b>10</b> or <b>13</b> or <b>16</b>) in the presence of benzylamine to generate their corresponding intermediates <b>5a</b>–<b>5s</b>. This approach permitted the introduction of cyano, nitro, sulfonyl, and carboxamide groups at the <i>C</i>-6 position of the pyrido[2,3-<i>d</i>]pyrimidines. To replace methylsulfide at the <i>C</i>-2 position with substituted aryl/heteroaryl amines, it was oxidized to methyl sulfoxides <b>6a</b>–<b>6s</b> using <i>m</i>-chloroperbenzoic acid (<i>m</i>-CPBA). The methyl sulfoxide was then substituted with different aryl/heteroaryl amines to achieve the desired pyridopyrimidine compounds <b>7a</b>–<b>7ap</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>).</div><div class="NLM_p">Alternatively, the compounds <b>5b</b>–<b>5j</b> were also prepared by alkylation of <b>5a</b> with different alkyl iodides in the presence of sodium hydride (NaH) in <i>N</i>,<i>N</i>-dimethylformamide (DMF) at 50 °C as shown in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 8-Alkyl/cycloalkyl-2-methylsulfanyl-7-oxo-7,8-dihydro[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>5b</b>–<b>5j</b>) from 2-Methylsulfanyl-7-oxo-7,8-dihydro[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>5a</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) X-I, NaH, DMF, 50 °C, 1 h, 64–75%.</p></p></figure><div class="NLM_p">Later, we evaluated the role of NH proton at the <i>C</i>-2 position of <b>7x</b> in cytotoxicity assays by acylating and benzoylating <b>7x</b> with acetic anhydride and 4-trifluoromethylbenzoyl chloride to obtain <b>7aq</b> and <b>7ar</b> respectively (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>).</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Acylation and Benzoylation of NH Group of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7- oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7x</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) AC<sub>2</sub>O, 120 °C, 3 h, 64%; (ii) 4-CF<sub>3</sub>PhCOCl, NaH, DMF, rt, 3 h, 62%.</p></p></figure><div class="NLM_p">The active methylene compounds, arylmethanesulfonylacetic acids (<b>10a</b>–<b>10c</b>), 4-chlorophenylsulfonylacetic acid (<b>13</b>), and <i>N</i>-arylmalonamic acids (<b>16a</b>–<b>16b</b>) were prepared as shown in Schemes <a class="ref internalNav" href="#sch4" aria-label="4">4</a>, <a class="ref internalNav" href="#sch5" aria-label="5">5</a>, and <a class="ref internalNav" href="#sch6" aria-label="6">6</a> as per the reported procedures.<a onclick="showRef(event, 'ref49 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51">(49-51)</a></div><div class="NLM_p">Arylmethyl bromides (<b>8a</b>–<b>8c</b>) were treated with thioglycolic acid in the presence of sodium hydroxide to produce corresponding arylmethylsulfanyl acetic acids (<b>9a</b>–<b>9c</b>). Deprotection of <i>tert</i>-butyldimethylsilyl ether (TBDMS) group in <b>9c</b> with tetrabutylammonium fluoride (TBAF) yielded <b>9d</b>.<a onclick="showRef(event, 'cit49a'); return false;" href="javascript:void(0);" class="ref cit49a">(49a)</a> The oxidation of <b>9a</b>–<b>9b</b> and <b>9d</b> with 30% H<sub>2</sub>O<sub>2</sub> in acetic acid yielded the corresponding arylmethylsulfonyl acetic acids (<b>10a</b>–<b>10c</b>) (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>).</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0013.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Arylmethanesulfonyl Acetic Acids<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) HSCH<sub>2</sub>CO<sub>2</sub>H, NaOH, MeOH, HCl, rt, 3 h, 90–95%; (ii) TBAF solution in THF, rt, 2 h, 50%; (iii) 30% H<sub>2</sub>O<sub>2</sub>, AcOH, rt, 24 h, 85–90%.</p></p></figure><div class="NLM_p">As shown in Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>, 4-chlorothiophenol (<b>11</b>) was treated with chloroacetic acid in the presence of NaOH and subsequent oxidation with 30% H<sub>2</sub>O<sub>2</sub> to produce 4-chlorophenylsulfanyl acetic acid (<b>12</b>) and 4-chlorophenylsulfonyl acetic acid (<b>13</b>), respectively.</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0014.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of 4-Chlorophenylsulfonyl Acetic Acids<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) ClCH<sub>2</sub>CO<sub>2</sub>H, NaOH, MeOH, HCl, rt, 3 h, 98%; (ii) 30% H<sub>2</sub>O<sub>2</sub>, AcOH, rt, 24 h, 80%.</p></p></figure><div class="NLM_p">The reaction of aromatic amines (<b>14a</b>–<b>14b</b>) with methyl-3-chloro-3-oxopropionate in the presence of triethylamine generated 3-anilino-3-oxopropionic acid methyl esters (<b>15a</b>–<b>15b</b>), which, when subjected to hydrolysis, resulted in the formation of 3-anilino-3-oxopropionic acids (<b>16a</b>–<b>16b</b>) (Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>).</div><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0015.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <i>N</i>-Arylmalonamic Acids<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) ClCOCH<sub>2</sub>CO<sub>2</sub>Me, Et<sub>3</sub>N, DCM, rt, 3 h, 90%; (ii) 10% NaOH, HCl, rt, 1 h, 78–80%.</p></p></figure><div class="NLM_p">Commercially unavailable bicyclic amines were prepared in two steps as shown in Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Aromatic nucleophilic substitution of halogen in 1-nitro-4-fluorobenzene (<b>17</b>) and 5-bromo-2-nitropyridine (<b>18</b>) by <i>N</i>-methylpiperazine was achieved under heating conditions. The resulting nitro compounds <b>19</b> and <b>20</b> were reduced to corresponding amines <b>21</b> and <b>22</b> with Pd/C in the presence of hydrazine hydrate in methanol.</div><figure id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0016.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of <i>N</i>-Methylpiperazine Arylamines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) <i>N</i>-methylpiperazine, acetonitrile, 100 °C, 5 h, 70%; (ii) <i>N</i>-methylpiperazine, tetra-<i>n</i>-butyl ammonium iodide, DMSO, 80 °C, overnight, 65%; (iii) 10% Pd/C, NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O, rt, 4 h, 75%.</p></p></figure></div><div id="sec1_2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Structure–Activity Relationships (SARs)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71018" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71018" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">It is evident from Table<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> that the nature of substituents X (<i>N</i>-8 position), Y (<i>C</i>-6 position), and Z (<i>C</i>-2 position) in the general structure (<b>7</b>) (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) specify the cytotoxicity activity of the molecules on the cancer cells. Hence, by varying X, Y, and Z using various combinations of atoms or groups, we were able to generate compounds with excellent cytotoxicity. We initially kept X and Y constant, where X = C<sub>5</sub>H<sub>9</sub> and Y = CN, and varied the substitutions at the Z position. In our initial attempts, we have included simple anilines at the Z position and placed C<sub>5</sub>H<sub>9</sub> and CN at the X and Y positions, respectively. The cytotoxicity data from Table<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> shows that 2-pyridine (<b>7m</b>) and 2-methoxy-6-quinoline (<b>7s</b>) at the Z-position showed better activity when compared to benzyl (<b>7a</b>), chlorophenyl (<b>7b</b>), cyanophenyl (<b>7c</b>), hydroxy phenyl (<b>7d</b>), methoxyphenyl (<b>7e</b>–<b>7l</b>), substituted pyridyl (<b>7n</b>), indolyl (<b>7o</b>, <b>7p</b>), and substituted quinolines (<b>7q</b>, <b>7r</b>). Encouraged by these results, we then attached bicyclic amines, such as substituted morpholino-aniline (<b>7t</b>), morpholino-pyridine (<b>7u</b>), piperazino-pyridine (<b>7v</b>), and pyridyl-piperazine (<b>7w</b>), which can bring both potency and water solubility to the molecule. These morpholino-anilines, morpholino-pyridines, and piperazino-pyridines easily form water-soluble salts of hydrochlorides, lactates, and citrates from hydrochloric acid, lactic acid, and citric acid. Although the salts of bicyclic amines (<b>7t</b>, <b>7u</b>, <b>7v</b>, and <b>7w</b>) showed enhanced water solubility when compared to the salts of monocyclic amines (<b>7m</b> and <b>7s</b>), the cytotoxicity properties of these compounds was decreased by several fold when compared to <b>7m</b> and <b>7s</b>. We further tested the effect of incorporating additional bicyclic amines at the Z position that might enhance the molecules’ cytotoxicity properties. Substituted piperazino-anilines could readily be placed at the Z position, and all of the compounds tested, <b>7x</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), <b>7aq</b>, and <b>7ar</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>), showed enhanced cytotoxic activity against these cancer cell lines. However, of these three compounds, <b>7x</b> showed superior cytotoxic activity against both leukemic (K562) and prostate (DU145) cancer cell lines when compared to any of the molecules listed in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Cytotoxicity of Pyrido[2,3-<i>d</i>]pyrimidines (<b>7a</b>–<b>7x</b>) with Variables at <i>C</i>-2 Position</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0017.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0018.gif" alt="" id="fx2" /></img><div></div></div><div class="NLM_p">Following optimization of the Z position with <i>N</i>-methylpiperazino-aniline, we then focused our efforts on varying the X position using different substituents. The Y and Z positions were kept constant using cyano and <i>N</i>-methyl-piperazino-aniline groups on the pyridopyrimidine ring. To understand the significance and role of the alkyl group at the X position of the ring with respect to the cytotoxic properties of the molecule, we replaced the <i>N</i>-cyclopentyl group of <b>7x</b> with hydrogen (<b>7y</b>), methyl (<b>7z</b>), ethyl (<b>7aa</b>), <i>n</i>-propyl (<b>7ab</b>), isopropyl (<b>7ac</b>), butyl (<b>7ad</b>), pentyl (<b>7ae</b>), cyclopropyl (<b>7af</b>), and cyclohexyl (<b>7ag</b>) moieties (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). The cytotoxic activities of the resulting molecules were then tested using our panel of cancer cell lines, and all were found to be substantially less active than the original compound (<b>7x</b>). These data clearly show that a cyclopentyl group at X position is the most optimal substituent, as compound <b>7x</b> showed the highest level of cytotoxicity when compared to other molecules (7<b>y</b>–<b>7ag</b>). Once we identified suitable substituents for the X and Z positions, we then focused our efforts on optimizing the Y position of the pyridopyrimidine ring. Because <b>7x</b>, with a cyano group at Y position, is an active compound, we further explored the possibility of enhancing the antiproliferative activity by replacing the cyano group with other chemical moieties. As the cyano group is an electron withdrawing group, we considered replacing it with nitro (<b>7ah</b>), sulfonyl (<b>7ai</b>–<b>7an</b>), and carboxamide (<b>7ao</b> and <b>7ap</b>) groups (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>), all of which are electron withdrawers and are therefore similar to the cyano group with respect to that property. All of the resulting compounds were then tested in cytotoxicity assays using K562 and DU145 cells. The results of these studies showed that all of the molecules were several-fold less active than <b>7x</b>, suggesting that the cyano group at the Y position of the pyridopyrimidinone ring is critical for its activity. Furthermore, the polarized nitrogen atom of the moiety might also be interacting with the key amino acids of the enzymatic pocket of the target kinase. Because SAR analysis clearly shows that <b>7x</b> is best in this class, we performed all subsequent in vitro and in vivo biological studies using this compound.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro Cytotoxicity of Pyrido[2,3-<i>d</i>]pyrimidines (<b>7y</b>–<b>7ag</b>) with Variables at <i>N</i>-8 Position</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0019.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0020.gif" alt="" id="fx4" /></img><div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Cytotoxicity of Pyrido[2,3-<i>d</i>]pyrimidines (<b>7ah</b>–<b>7ap</b>) with Variables at <i>C</i>-6 Position</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0021.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0022.gif" alt="" id="fx6" /></img><div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro Cytotoxicity of <b>7aq</b> and <b>7ar</b> Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0023.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0024.gif" alt="" id="fx8" /></img><div></div></div></div><div id="sec1_3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Biological Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77640" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77640" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> In Vitro Antitumor Activity of Compound <b>7x</b></h3><div class="NLM_p">We next tested the cyototoxic activity of the most active compound (<b>7x</b>) against a panel of human tumor cell lines. The results of this study, which are listed in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>, show that treatment with <b>7x</b> induces growth arrest of most tumor cell lines, with GI<sub>50</sub> values ranging from 0.025 to 2 μM (selected data is shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). The evidence of growth inhibition across multiple tumor cell types suggests that this compound inhibits cellular proliferation by blocking key signaling pathways that are required for growth. A comparison of growth inhibitory activities of <b>7x</b> and PD-0332991 for a panel of breast cancer cell lines is given in <a class="ref internalNav" href="#notes-3" aria-label="Supporting Information Table 1">Supporting Information Table 1</a>.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Evaluation of <b>7x</b> against a Panel of Human Tumor Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">tumor type</th><th class="colsep0 rowsep0" align="center" char=".">GI<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DU145</td><td class="colsep0 rowsep0" align="left">prostate (AR−)</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">K562</td><td class="colsep0 rowsep0" align="left">CML</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BT474</td><td class="colsep0 rowsep0" align="left">breast (ER+)</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SK-BR-3</td><td class="colsep0 rowsep0" align="left">breast (ER−)</td><td class="colsep0 rowsep0" align="char" char=".">0.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Granta-519</td><td class="colsep0 rowsep0" align="left">mantle cell lymphoma</td><td class="colsep0 rowsep0" align="char" char=".">0.025</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Z138C</td><td class="colsep0 rowsep0" align="left">mantle cell lymphoma</td><td class="colsep0 rowsep0" align="char" char=".">0.025</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">N87</td><td class="colsep0 rowsep0" align="left">gastric carcinoma</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SNU-5</td><td class="colsep0 rowsep0" align="left">gastric carcinoma</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MIA-Paca-2</td><td class="colsep0 rowsep0" align="left">pancreatic</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SK-OV3</td><td class="colsep0 rowsep0" align="left">ovarian</td><td class="colsep0 rowsep0" align="char" char=".">0.75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">U87</td><td class="colsep0 rowsep0" align="left">glioblastoma</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MCF-7</td><td class="colsep0 rowsep0" align="left">breast (ER+)</td><td class="colsep0 rowsep0" align="char" char=".">0.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Raji</td><td class="colsep0 rowsep0" align="left">Burkitt’s lymphoma (B-cell)</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Jurkat</td><td class="colsep0 rowsep0" align="left">acute T cell leukemia</td><td class="colsep0 rowsep0" align="char" char=".">0.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">U266</td><td class="colsep0 rowsep0" align="left">multiple myeloma</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">N417</td><td class="colsep0 rowsep0" align="left">SCLC</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Hela</td><td class="colsep0 rowsep0" align="left">cervical</td><td class="colsep0 rowsep0" align="char" char=".">0.75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A549</td><td class="colsep0 rowsep0" align="left">NSCLC</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BT-20</td><td class="colsep0 rowsep0" align="left">breast (ER−)</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SNU-398</td><td class="colsep0 rowsep0" align="left">hepatocellular carcinoma</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SNU-449</td><td class="colsep0 rowsep0" align="left">hepatocellular carcinoma</td><td class="colsep0 rowsep0" align="char" char=".">0.75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SNU-475</td><td class="colsep0 rowsep0" align="left">hepatocellular carcinoma</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A431</td><td class="colsep0 rowsep0" align="left">epidermoid</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DLD-1</td><td class="colsep0 rowsep0" align="left">colorectal</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SW-480</td><td class="colsep0 rowsep0" align="left">colorectal</td><td class="colsep0 rowsep0" align="char" char=".">0.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDA-MB-468</td><td class="colsep0 rowsep0" align="left">breast (triple negative)</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Colo-205</td><td class="colsep0 rowsep0" align="left">colorectal</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCC70</td><td class="colsep0 rowsep0" align="left">breast</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCC1428</td><td class="colsep0 rowsep0" align="left">breast</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDA-MB-231</td><td class="colsep0 rowsep0" align="left">breast (triple negative)</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDA-MB-157</td><td class="colsep0 rowsep0" align="left">breast (triple negative)</td><td class="colsep0 rowsep0" align="char" char=".">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2008</td><td class="colsep0 rowsep0" align="left">ovarian</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2008/1714</td><td class="colsep0 rowsep0" align="left">resistant ovarian</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MES-SA</td><td class="colsep0 rowsep0" align="left">sarcoma</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MES-SA/DX5</td><td class="colsep0 rowsep0" align="left">resistant sarcoma</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCT15</td><td class="colsep0 rowsep0" align="left">colorectal</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CAPAN-1</td><td class="colsep0 rowsep0" align="left">pancreatic</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HFL</td><td class="colsep0 rowsep0" align="left">normal fibroblast</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td></tr></tbody></table></div></div><div class="NLM_p">It is interesting to note that this compound exhibited highest growth inhibitory activity against two mantle cell lymphoma cell lines, both of which are known to exhibit a chromosomal translocation that results in the overexpression of cyclin D1 and an associated increase in CDK4 activity. Because of its excellent potency, the kinase inhibition profile of <b>7x</b> was subsequently tested against a series of 285 functional kinases (Reaction Biology Corp.), the results of which are provided in <a class="ref internalNav" href="#notes-3" aria-label="Supporting Information Table 2">Supporting Information Table 2</a>. Interestingly, this study revealed that <b>7x</b> is a multikinase inhibitor, with the highest inhibitory activity against CDK4, CDK6, ARK5, FGFR1, PDGFRβ, and PI3K-δ, all of which are intimately associated with the growth, survival, and metastasis in human tumor cells.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52, 53)</a> The kinome inhibition map of 365 kinases encoded by the human genome, as well as the IC<sub>50</sub> values for selected kinases (as compared to the CDK4/6 inhibitor PD-0332991), are shown in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>, respectively.</div><figure id="fig1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0003.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Kinome inhibition map of compound <b>7x</b>: The kinases targeted by <b>7x</b> are indicated. Red circles represent kinases targeted below 20 nM. Yellow, amber, green, and blue circles represent kinases inhibited between 20–50, 50–100, 100–150, and 150–250 nM, respectively. The human kinome map is adapted with permission from Reaction Biology Corp. (<a href="http://reactionbiology.com" class="extLink">http://reactionbiology.com</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Kinase Inhibition Profile of <b>7x</b> and PD-0332991</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char="."><b>7x</b> IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">PD-0332991 IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK4/cyclin D1</td><td class="colsep0 rowsep0" align="char" char=".">3.87</td><td class="colsep0 rowsep0" align="char" char=".">5.36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK6/cyclin D1</td><td class="colsep0 rowsep0" align="char" char=".">9.82</td><td class="colsep0 rowsep0" align="char" char=".">3.76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ARK5</td><td class="colsep0 rowsep0" align="char" char=".">4.95</td><td class="colsep0 rowsep0" align="char" char=".">>5000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FLT3</td><td class="colsep0 rowsep0" align="char" char=".">12.22</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FYN</td><td class="colsep0 rowsep0" align="char" char=".">11.09</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FMS</td><td class="colsep0 rowsep0" align="char" char=".">10.00</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFRβ</td><td class="colsep0 rowsep0" align="char" char=".">26.00</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR1</td><td class="colsep0 rowsep0" align="char" char=".">26.00</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ABL</td><td class="colsep0 rowsep0" align="char" char=".">53.32</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PI3K-δ</td><td class="colsep0 rowsep0" align="char" char=".">144</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr></tbody></table></div></div></div></div><div id="sec1_4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Molecular Modeling of <b>7x</b></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73462" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73462" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Docking Prediction of <b>7x</b> to CDK6 Suggest Different Binding than PD-0332991</h3><div class="NLM_p">To explain the difference in inhibitor potency between <b>7x</b> and PD-0332991, binding of <b>7x</b> to the kinase domain of CDK6 was predicted by molecular docking and energy minimization based upon the X-ray cocrystal structure of CDK6–Vcyclin–PD-0332991. CDK6 was used instead of CDK4 given the high amino acid similarity between these two CDKs and because CDK6 and not CDK4 has been crystallized in the presence of PD-0332991. In addition, a CDK4 small-molecule inhibitor X-ray cocrystal structure is not available to date. Prediction shows that <b>7x</b> may bind to the CDK6 active site in a different orientation than PD-0332991 (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A). This change in binding may be mainly achieved by new interactions formed by the cyano (CN) group of <b>7x</b>, which is substituted for an acetyl group (COCH<sub>3</sub>) in PD-0332991. The nitrogen of the cyano group is in close contact with several residues of CDK6, in particular at a hydrogen bonding distance with the side chain ε-amino group of Lys43 and main chain α-nitrogen of Ala23 (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B). Similar interactions in this binding mode might not be energetically favorable for PD-0332991 due to the perpendicular orientation seen in the cocrystal structure of the carbonyl group (CO) plus its lower hydrogen bond acceptor potential when compared with the cyano group in <b>7x</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>C). Moreover, the presence of the methyl group and the negative charges contributed by the side chain carbonyl groups of Glu61 and Asp163 might not favor the stabilization of the acetyl group in a position that is similar to the one predicted for the cyano group in <b>7x</b>. The presence of a rigid and more electron withdrawing cyano group instead of an acetyl group may be the main reason for the stabilization of the molecule in this new orientation and also may explain the higher potency observed for <b>7x</b> with another closely related member of the CDK family.</div><figure id="fig2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0004.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Model of <b>7x</b> binding to CDK6. Small molecule <b>7x</b> binding was predicted by docking and energy minimization using the X-ray crystal structure of CDK6–Vcyclin–PD-0332991 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2EUF">2EUF</a>) as a reference. Representations of the superimposition of X-ray crystal structure (CDK6/PD-0332991) and predicted lowest energy binding (CDK6/<b>7x</b>) were prepared using PyMOL. (A) Ribbon representation of CDK6 (green) bound to PD-0332991 (red) and <b>7x</b> (cyan). Small molecules are shown as sticks. (B,C) Close up view showing proximal residues of CDK6 to <b>7x</b> (blue) and PD-0332991 (pink), respectively. Hydrogen bonds are shown as a dotted back lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Positioning of PD-0332991 in the ATP binding pocket of CDK6 is mainly given by hydrogen bond interactions between N3 and N2–H to the backbone of Val101 and <i>C</i>6-acetyl group to the main chain amide of Asp163. Similar to what is observed in the X-ray structure of CDK6 and PD-0332991, <b>7x</b> docking prediction shows multiple residues with distances under 4.5 Å that may be involved in van der Waals interactions that aid in the stabilization of the small molecule. It is worth emphasizing that the difference in potency and mode of action in PD-0332991 and <b>7x</b> might be due to a change in binding orientation inside the ATP binding pocket of CDK6 and further explained by gain and loss of interactions. In this regard, <b>7x</b> does not present the same hydrogen bond interactions described above for PD-0332991 but, as predicted by the docking, present new ones implied by the presence of the cyano group in <b>7x</b> and residues Ala23 and Lys43 of CDK6. This slightly deeper binding of <b>7x</b> into the ATP binding site of CDK6 when compared with the binding of PD-0332991 may explain a difference in potency in the CDK family observed for the two compounds, where <b>7x</b> may interfere more efficiently with ATP binding and make it a better inhibitor of the CDK kinase activity.</div><div class="NLM_p last">Docking calculations of <b>7x</b> with ABL, FGFR, and FMS were performed to see the interactions of the cyano group with the amino acids in the ATP binding site of these kinases (given in <a class="ref internalNav" href="#notes-3" aria-label="Supporting Information">Supporting Information</a>). Results of these docking studies show a great variability of binding between kinases, and because crystal structures of these kinases in complex with compound with similar structure to <b>7x</b> are not available for reference and comparison, docking simulations become hypothetical.</div></div><div id="sec1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Inhibition of CDK4 Kinase Activity and RB by <b>7x</b></h3><div class="NLM_p">To further validate the results from RBC corporation (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) and molecular modeling studies, we independently tested the inhibitory activity of <b>7x</b> in an in vitro kinase assay using recombinant CDK4 (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A). Our results showed that <b>7x</b> is a potent inhibitor of CDK4 with an IC<sub>50</sub> of 3.87 nM, with little inhibitory activity against CDKs 1, 2, 5, 8, and 9 (data not shown). Flavopiridol, a pan-CDK inhibitor, and PD-0332991, a highly selective CDK4/6 inhibitor that is currently in clinical trials, were used as positive controls.<a onclick="showRef(event, 'ref40 ref54'); return false;" href="javascript:void(0);" class="ref ref40 ref54">(40, 54)</a> These assays showed that PD-0332991 showed a similar level of CDK4 inhibition, with an IC<sub>50</sub> of 5.36 nM. It is now well established that the retinoblastoma family of proteins (pRb, p107, and p130) are primary targets of CDK4. RB is hypophosphorylated in quiescent cells and becomes phosphorylated on Ser<sup>780</sup> and Ser<sup>795</sup> by CDK4/CDK6 during mid to late G<sub>1</sub>. The hypophosphorylated form of pRB associates with several cellular proteins and its phosphorylation results in the disassociation of RB from its binding partners.<a onclick="showRef(event, 'ref55 ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref55 ref56 ref57">(55-57)</a> To determine whether <b>7x</b> inhibits the activity of pRB in vivo, two human breast carcinoma cell lines, MCF-7 (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>B) and MDA-MB-231 (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>C), were incubated with increasing concentrations of <b>7x</b> for 24 h and the levels of phosphorylated RB (Ser<sup>780</sup>) determined by Western blot analysis. The results of this study (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>) show that <b>7x</b> inhibits RB phosphorylation at Ser<sup>780</sup> as well as PD-0332991, confirming that CDK4 and CDK6 are targets of this compound (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).</div><figure id="fig3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0005.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Inhibition of CDK4/cyclin D1 activity by <b>7x</b>: 10 ng of recombinant CDK4/cyclin D1 complex was incubated with the indicated concentrations of <b>7x</b>, flavopiridol (FP), or PD-0332991 for 30 min at room temperature. Kinase reactions were initiated by the addition of the substrate mixture (5 μM ATP, 10 μci γ<sup><sup>32</sup>P</sup>-ATP, 10 mM MgCl<sub>2</sub>, and 1 μg recombinant RB substrate) and incubated at 30 °C for 20 min. The reactions were terminated by the addition of 2× Laemmli sample buffer and heated at 95 °C for 3 min. Proteins were resolved by 12% SDS-PAGE and the resulting gel subjected to autoradiography. (B) <b>7x</b> inhibits RB phosphorylation at serine 780: An estrogen-dependent breast cancer cell line, MCF-7, and the triple negative (C) human breast carcinoma cell line, MDA-MB-231, were treated with increasing concentrations of <b>7x</b> or PD-0332991 (control) for 24 h. Western blot analysis was performed using antibodies directed against phosphorylated (Ser<sup>780</sup>) and nonphosphorylated forms of the retinoblastoma protein. Both <b>7x</b> and PD-0332991 inhibit RB phosphorylation at Ser<sup>780</sup>, a known substrate of CDK4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Effect of <b>7x</b> on Cell Cycle Progression of Human Tumor Cells</h3><div class="NLM_p">We next examined the effect of <b>7x</b> treatment on MCF-7 (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A) and MDA-MB-231 (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B) cell cycle kinetics. For these studies, cells were treated with <b>7x</b> or PD-0332991 for 24 h and subjected to flow cytometric analysis to determine the distribution of cells in various phases of the cell cycle. At time 0, the majority of cells were in the G<sub>1</sub> phase of the cell cycle, with smaller percentages of the population in the S and G<sub>2</sub> phases (data not shown). While there was no significant change in the profile of cells treated with DMSO throughout the course of the experiment, an accumulation in the G<sub>1</sub> phase was evident following treatment with <b>7x</b> and PD-0332991 (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Prolonged treatment of cells with <b>7x</b> (greater than 48 h) resulted in the appearance of a sub-G<sub>1</sub> population, which is indicative of cells undergoing apoptosis. This population was absent in PD-0332991 treated cells.</div><figure id="fig4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0006.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of <b>7x</b> on cell cycle progression: MCF-7 (A) and MDA-MB-231 (B) human breast carcinoma cell lines were treated with increasing concentrations of <b>7x</b> or PD-0332991 (control) for 24 h. The cells were then harvested, fixed, and stained with propidium iodide prior to flow cytometric analysis. The percentage of cells at each phase of the cell cycle was calculated and represented as % cells in each phase in the bar graph.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <b>7x</b> Activates Programmed Cell Death</h3><div class="NLM_p">Because flow cytometric analysis indicated that cells treated with <b>7x</b> for longer periods of time might be undergoing apoptosis, we next determined the levels of poly-ADP ribose polymerase (PARP) cleavage, which is a marker of apoptosis. These studies show a dose-dependent accumulation of the ∼89 kDa cleaved PARP polypeptide in cells treated with 1 μM <b>7x</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). PARP cleavage was not observed in cells treated with PD-0332991, suggesting that <b>7x</b> exhibits a strong pro-apoptotic activity that is not seen with PD-0332991.</div><figure id="fig5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0007.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <b>7x</b> treatment induces apoptosis of breast carcinoma cell lines: MCF-7 (A) and MDA-MB-231 (B) human breast carcinoma cell lines were treated with increasing concentrations of <b>7x</b> or PD-0332991 (control) for 24 h. Total cell lysates were subjected to Western blot analysis using a PARP-specific antibody. The cleaved protein, which is expressed in <b>7x</b> treated cells, is indicative of apoptosis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Inhibition of the PI3Kinase/AKT Pathway by <b>7x</b></h3><div class="NLM_p">Kinase inhibition assays performed with <b>7x</b> show inhibition of two important growth factor receptors, PDGFRβ and FGFR1, with an IC<sub>50</sub> of 26 nM (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). Because these kinases are involved in the activation of the PI3Kinase/AKT survival pathway, we next examined the ability of <b>7x</b> to inhibit PI3Kinase/AKT activity in cells treated with this compound. We accomplished this by examining the phosphorylation status of AKT (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>), PI3Ks (see <a class="ref internalNav" href="#notes-3" aria-label="Supporting Information Table 3">Supporting Information Table 3</a>), and mTOR (data not shown) proteins, which are well established modulators of cell survival. The results presented in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a> shows that <b>7x</b> (but not PD-0332991) inhibits the phosphorylation of AKT, which plays a critical role in the survival of tumor cells. This observation might explain the differential effects of <b>7x</b> and PD-0332991 on their ability to induce apoptotic death of breast tumor cells (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).</div><figure id="fig6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0008.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <b>7x</b> treatment inhibits AKT phosphorylation: MDA-MB-231 human breast carcinoma cells were treated with increasing concentrations of <b>7x</b> or PD-0332991 or LY294002 (2-morpholino-8-phenyl-4<i>H</i>-chromen-4-one) (PI3Kinase inhibitor) for 24 h. Total cell lysates were subjected to Western blot analysis using antibodies directed against phosphorylated (Ser<sup>473</sup>) and nonphosphorylated forms of AKT. GAPDH was used as a loading control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Pharmacological Safety and in Vivo Efficacy of <b>7x</b></h3><div class="NLM_p">We next carried out studies to determine the maximum tolerated dose of <b>7x</b> in mice. CD-1 female mice (<i>n</i> = 3) received single doses of <b>7x</b> 100 or 200 mg/kg intraperitoneally and were monitored over a 7 day period. We observed no signs of toxicity or weight loss, with a survival rate of 100%. We next injected mice with 200 mg/kg of <b>7x</b> (ip) for 5 consecutive days and again monitored them for signs of toxicity. One hundred percent of the mice survived for more than 10 days after injection (data not shown). To determine the efficacy of <b>7x</b> in vivo using tumor xenograft models, MDA-MB-231 cells were orthotopically implanted into the mammary fat pads of 6–8 week old female nude mice. Once the tumors reached an average volume of 100 mm<sup>3</sup>, either placebo or <b>7x</b> (50 mg/kg body weight) was administered on alternate days (Q2D) via IP injection. The results of this study (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>A) showed that <b>7x</b> administered on this schedule led to a dose-dependent inhibition of tumor growth over a 21 day period. A decrease in tumor weight was also observed at the end-point of the study (data not shown). No overt signs of toxicity were observed in the <b>7x</b> treated groups (body weights shown in Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>B), indicating that the compound is well-tolerated. In vivo pharmacokinetic studies with <b>7x</b> exhibited favorable cytotoxicity, brain penetration, and better half-life.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div><figure id="fig7" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0009.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo efficacy of <b>7x</b> against subcutaneous breast tumor xenografts: MDA-MB-231 cells were orthotopically implanted into the mammary fat pad of 6–8 week old female nude mice (<i>n</i> = 11 per group). Treatment was started when the average tumor volume reached 100 mm<sup>3</sup>. <b>7x</b> (lactate salt dissolved in PBS) or vehicle was administered intraperitoneally every other day (Q2D). Tumor volumes (A) and body weights (B) were recorded every 2 days. All values represent mean ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11575" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11575" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In this article, we describe the synthesis of pyrido[2,3-<i>d</i>]pyrimidine analogues that induce apoptotic death of a wide variety of human tumor cell lines at nanomolar concentrations while exhibiting little or no in vivo toxicity. Structure–function studies described here suggest that the cytotoxic activity of pyrido[2,3-<i>d</i>]pyrimidines is dependent on the nature and position of substituents at <i>C</i>-2, <i>C</i>-6, and <i>N</i>-8 positions. Compound <b>7x</b>, with a 4-(4-methyl-piperazin-1-yl) phenylamine group at <i>C</i>-2 position, cyano group at <i>C</i>-6 position, and cyclopentyl at <i>N</i>-8 position showed optimum biological activity. The biochemical and biological studies presented here show that this compound is a potent inhibitor of CDK4 and CDK6 kinases and in this aspect is comparable to PD-0332991, a dual CDK4/6 inhibitor that is currently in clinical trials. However, unlike PD-0332991, <b>7x</b> inhibits other kinases such as ARK5, FGFR, and PDGFRβ, which are known to play critical roles in proliferation and survival signaling in tumor cells. As has been stated in the <a class="ref internalNav" href="#sec1" aria-label="Introduction">Introduction</a>, considerable evidence implicates the deregulation of the CDK4/Rb pathway in tumor cell growth, and up-regulation of this pathway is observed in greater than 90% of all human tumors. However, clinical trials with PD-0332991 suggest that reduction of tumor burden in human tumors that have increased levels of cyclin D/CDK4 activity might require inhibition of not only CDK4 but also other signaling pathways.<a onclick="showRef(event, 'ref44 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref44 ref45 ref46">(44-46)</a> Because most kinase inhibitors are promiscuous in their target specificity and invariably bind to more than one kinase, we took advantage of this property to develop multitargeted kinase inhibitors that can inhibit multiple signaling pathways that activated in a given tumor type. Our approach to kinase inhibitor design, which incorporates tumor cell growth inhibition as an integral parameter, led to the development of <b>7x</b>. This compound inhibits other pathways that are deregulated in tumor cells, such as the ARK5 and PI3K/AKT pathways, in addition to inhibition of CDK4/RB. As a result, tumor cells treated with <b>7x</b> underwent apoptosis, an effect that is not seen in PD-0332991-treated cells. The low toxicity profile and the potent tumor inhibitory activity observed in nude mouse xenograft assays highlight the potential value of this compound as a safe and targeted therapy for human cancers that overexpress cyclin D/CDK4 complexes.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23415" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23415" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Chemistry: General Methods</h3><div class="NLM_p">All reagents and solvents were obtained from commercial suppliers and used without further purification unless otherwise stated. Solvents were dried using standard procedures, and reactions requiring anhydrous conditions were performed under N<sub>2</sub> atmosphere. Reactions were monitored by thin layer chromatography (TLC) on preloaded silica gel F254 plates (Sigma-Aldrich) with a UV indicator. Column chromatography was performed using Merck 70-230 mesh silica gel 60 Å. Yields were of purified product and were not optimized. Melting points were determined using an Electro-thermal Mel-Temp 3.0 micromelting point apparatus and are uncorrected. <sup>1</sup>H NMR spectra were obtained using a Bruker AVANCE 300 and 400 MHz spectrometer. Chemical shifts are reported in parts per million (δ) downfield using tetramethylsilane (SiMe<sub>4</sub>) as internal standard. Spin multiplicities are given as s (singlet), d (doublet), t (triplet), dd (double doublet) bs (broad singlet), m (multiplet), and q (quartet). All LC/MS data were gathered on an Agilent 1200 LC with Agilent 6410 triple quadrupole mass spectrometer detectors. The compound solution was infused into the electrospray ionization source operating positive and negative modes in methanol:water:TFA (50:50:0.1% v/v) at 0.4 mL/min. The sample cone (declustering) voltage was set at 100 V. The instrument was externally calibrated for the mass range <i>m</i>/<i>z</i> 100–1000. The purity of the final compounds was determined by HPLC and is 95% or higher unless specified otherwise. Zorbax Exlipse XDB C18 (150 mm × 4.6 mm, 5 μm particle size) using gradient elution of acetonitrile in water, 20–90%, for 25 min at a flow rate of 1 mL/min with detection at 235 nm wavelength. For all samples 0.00154% AcONH<sub>4</sub> was added to water. The active methylene compounds <b>10</b>,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a><b>13</b>,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> and <b>16</b><a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> and amino compounds (<b>21</b> and <b>22</b>)<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> were prepared as per the reported procedures.</div><div id="sec3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> General Procedure for the Synthesis of 4-Alkyl/cycloalkylamino-2-methylsulfanyl-pyrimidine-5-carboxylic Acid Ethyl Ester (<b>2</b>)</h4><div class="NLM_p last">4-Chloro-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester <b>1</b> (107 mmol) was dissolved in THF to which triethylamine (322 mmol) and alkylamine (117 mmol) was added and stirred for overnight at room temperature. The precipitated salts were filtered and the solvent evaporated in vacuo. The resultant oil was dissolved in ethyl acetate and washed with sodium bicarbonate then dried over Na<sub>2</sub>SO<sub>4</sub>. The salts were filtered, and the solvent was evaporated in vacuum to obtain the product.</div></div><div id="sec3_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 4-Amino-2-methylsulfanyl-pyrimidine-5-carboxylic Acid Ethyl Ester (<b>2a</b>)</h4><div class="NLM_p last">Starting from 4-chloro-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester <b>1</b> and ammonium hydroxide, 90% of <b>2a</b> was obtained as solid according to the method described for the synthesis of <b>2</b>; mp 130–131 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.58 (s, 1H), 8.10 (bs, 2H), 4.30 (q, 2H), 2.45 (s, 3H), 1.25 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 214.10; calcd for C<sub>8</sub>H<sub>11</sub>N<sub>3</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 213.06.</div></div><div id="sec3_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 4-Methylamino-2-methylsulfanyl-pyrimidine-5-carboxylic Acid Ethyl Ester (<b>2b</b>)</h4><div class="NLM_p last">Starting from 4-chloro-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester <b>1</b> and methylamine (40 wt % solution in water), 80% of <b>2b</b> was obtained as solid according to the method described for the synthesis of <b>2</b>; mp 82–83 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.61 (s, 1H), 8.18 (bs, 1H), 4.33 (q, 2H), 3.09 (d, 3H), 2.55 (s, 3H), 1.37 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 228.10; calcd for C<sub>9</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 227.07.</div></div><div id="sec3_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 4-Ethylamino-2-methylsulfanyl-pyrimidine-5-carboxylic Acid Ethyl Ester (<b>2c</b>)</h4><div class="NLM_p last">Starting from 4-chloro-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester <b>1</b> and ethylamine (70 wt % solution in water), 92% of <b>2c</b> was obtained as liquid according to the method described for the synthesis of <b>2</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.59 (s, 1H), 8.18 (bs, 1H), 4.26 (q, 2H), 3.50 (q, 2H), 2.51 (s, 3H), 1.35 (t, 3H), 1.25 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 242.10; calcd for C<sub>10</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 241.09.</div></div><div id="sec3_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 2-Methylsulfanyl-4-propylmino-pyrimidine-5-carboxylic Acid Ethyl Ester (<b>2d</b>)</h4><div class="NLM_p last">Starting from 4-chloro-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester <b>1</b> and propylamine, 89% of <b>2d</b> was obtained as liquid according to the method described for the synthesis of <b>2</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.60 (s, 1H), 8.26 (bs, 1H), 4.25 (q, 2H), 3.47–3.54 (m, 2H), 2.52 (s, 3H), 1.65–1.61 (m, 2H), 1.35 (t, 3H), 1.00 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 256.10; calcd for C<sub>11</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 255.10.</div></div><div id="sec3_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 4-Isopropylamino-2-methylsulfanyl-pyrimidine-5-carboxylic Acid Ethyl Ester (<b>2e</b>)</h4><div class="NLM_p last">Starting from 4-chloro-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester <b>1</b> and isopropylamine, 95% of <b>2e</b> was obtained as liquid according to the method described for the synthesis of <b>2</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.58 (s, 1H), 8.15 (bs, 1H), 5.70–5.67 (m, 1H), 4.24 (q, 2H), 2.49 (s, 3H), 1.26 (t, 3H), 1.21 (d, 6H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 256.10; calcd for C<sub>11</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 255.10.</div></div><div id="sec3_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 4-Butylamino-2-methylsulfanyl-pyrimidine-5-carboxylic Acid Ethyl Ester (<b>2f</b>)</h4><div class="NLM_p last">Starting from 4-chloro-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester <b>1</b> and butylamine, 95% of <b>2f</b> was obtained as liquid according to the method described for the synthesis of <b>2</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.61 (s, 1H), 8.25 (bs, 1H), 4.43 (q, 2H), 3.59–3.52 (m, 2H), 2.53 (s, 3H), 1.65–1.60 (m, 2H), 1.46–1.35 (m, 5H), 0.96 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 270.20; calcd for C<sub>12</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 269.12.</div></div><div id="sec3_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 2-Methylsulfanyl-4-pentylamino-pyrimidine-5-carboxylic Acid Ethyl Ester (<b>2g</b>)</h4><div class="NLM_p last">Starting from 4-chloro-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester <b>1</b> and amylamine, 95% of <b>2g</b> was obtained as liquid according to the method described for the synthesis of <b>2</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.62 (s, 1H), 8.25 (bs, 1H), 4.35 (q, 2H), 3.58–3.51 (m, 2H), 2.53 (s, 3H), 1.67–1.62 (m, 2H), 1.40–1.34 (m, 7H), 0.93 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 284.20; calcd for C<sub>13</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 283.14.</div></div><div id="sec3_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 4-Cyclopropylamino-2-methylsulfanyl-pyrimidine-5-carboxylic Acid Ethyl Ester (<b>2h</b>)</h4><div class="NLM_p last">Starting from 4-chloro-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester <b>1</b> and cylcopropylamine, 95% of <b>2h</b> was obtained as liquid according to the method described for the synthesis of <b>2</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.59 (s, 1H), 8.48 (bs, 1H), 4.27 (q, 2H), 2.95–2.89 (m, 1H), 2.51 (s, 3H), 1.34 (t, 3H), 0.84–0.79 (m, 2H), 0.61–0.58 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 254.10; calcd for C<sub>11</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 253.09.</div></div><div id="sec3_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 4-Cyclopentylamino-2-methylsulfanyl-pyrimidine-5-carboxylic Acid Ethyl Ester (<b>2i</b>)</h4><div class="NLM_p last">Starting from 4-chloro-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester <b>1</b> and cyclopentyl amine, 90% of <b>2i</b> was obtained as liquid according to the method described for the synthesis of <b>2</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.60 (s, 1H), 8.25 (bs, 1H), 4.49–4.54 (m, 1H), 4.30 (q, 2H), 2.52 (s, 3H), 2.00–2.10 (m, 2H), 1.50–1.79 (m, 6H). 1.35 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 282.20; calcd for C<sub>13</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 281.12.</div></div><div id="sec3_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 4-Cyclohexylamino-2-methylsulfanyl-pyrimidine-5-carboxylic Acid Ethyl Ester (<b>2j</b>)</h4><div class="NLM_p last">Starting from 4-chloro-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester <b>1</b> and cyclohexyl amine, 85% of <b>2j</b> was obtained as liquid according to the method described for the synthesis of <b>2</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.60 (s, 1H), 8.22 (bs, 1H), 4.30 (q, 2H), 4.09–4.14 (m, 1H), 2.51 (s, 3H), 1.94–2.27 (m, 2H), 1.73–1.81 (m, 2H), 1.59–1.64 (m, 2H), 1.30–1.41 (m, 4H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 296.10; calcd for C<sub>14</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 295.14.</div></div><div id="sec3_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> General Procedure for the Synthesis of (4-Alkyl/cycloalkylamino-2-methylsulfanyl-pyridine-5-yl)-methanol (<b>3</b>)</h4><div class="NLM_p last">Lithium aluminum hydride (53.3 mmol) was suspended in THF under nitrogen atmosphere and cooled with dry ice. The compound <b>2</b> (35.5 mmol) was dissolved in THF and added dropwise to the cooled LiAlH<sub>4</sub> solution while keeping the reaction temperature bellow −10 °C. The reaction was brought to room temperature and stirred for 1 h. The reaction was quenched by the addition of water (5 mL), 15% NaOH (10 mL), and then water (15 mL) again. The white solid that precipitated was filtered and the filtrate evaporated in vacuo to afford the product.</div></div><div id="sec3_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (4-Amino-2-methylsulfanyl-pyridine-5-yl)-methanol (<b>3a</b>)</h4><div class="NLM_p last">Starting from <b>2a</b>, 85% of <b>3a</b> was obtained according to method described for the synthesis of <b>3</b>; mp 157–159 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.85 (s, 1H), 6.70 (bs, 2H), 5.30 (bs, 1H), 4.25 (s, 2H), 2.56 (s, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 172.00; calcd for C<sub>6</sub>H<sub>9</sub>N<sub>3</sub>OS <i>m</i>/<i>z</i>, 171.05.</div></div><div id="sec3_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (4-Methylamino-2-methylsulfanyl-pyridine-5-yl)-methanol (<b>3b</b>)</h4><div class="NLM_p last">Starting from <b>2b</b>, 80% of <b>3b</b> was obtained according to method described for the synthesis of <b>3</b>; mp 145–146 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.64 (s, 1H), 5.93 (bs, 1H), 4.50 (s, 2H), 3.05 (d, 3H), 2.53 (s, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 186.00; calcd for C<sub>7</sub>H<sub>11</sub>N<sub>3</sub>OS <i>m</i>/<i>z</i>, 185.06.</div></div><div id="sec3_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (4-Ethylamino-2-methylsulfanyl-pyridine-5-yl)-methanol (<b>3c</b>)</h4><div class="NLM_p last">Starting from <b>2c</b>, 84% of <b>3c</b> was obtained according to method described for the synthesis of <b>3</b>; mp 155–157 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.63 (s, 1H), 6. 55 (bs, 1H), 4.10 (s, 2H), 3.33 (q, 2H), 2.52 (s, 3H), 1.17 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 200.10; calcd for C<sub>8</sub>H<sub>13</sub>N<sub>3</sub>OS <i>m</i>/<i>z</i>, 199.08.</div></div><div id="sec3_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (2-Methylsulfanyl-4-propylamino-pyridine-5-yl)-methanol (<b>3d</b>)</h4><div class="NLM_p last">Starting from <b>2d</b>, 83% of <b>3d</b> was obtained according to method described for the synthesis of <b>3</b>; mp 120–121 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.58 (s, 1H), 6.00 (bs, 1H), 4.48 (s, 2H), 3.42–3.37 (m, 2H), 2.49 (s, 3H), 1.55–1.68 (m, 2H), 0.97 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 214.10; calcd for C<sub>9</sub>H<sub>15</sub>N<sub>3</sub>OS <i>m</i>/<i>z</i>, 213.09.</div></div><div id="sec3_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (4-Isopropylamino-2-methylsulfanyl-pyridine-5-yl)-methanol (<b>3e</b>)</h4><div class="NLM_p last">Starting from <b>2e</b>, 85% of <b>3e</b> was obtained according to method described for the synthesis of <b>3</b>; mp 127–129 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.60 (s, 1H), 5.58 (bs, 1H), 4.52–4.41 (m, 3H), 2.53 (s, 3H). 1.31 (d, 6H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 214.10; calcd for C<sub>9</sub>H<sub>15</sub>N<sub>3</sub>OS <i>m</i>/<i>z</i>, 213.09.</div></div><div id="sec3_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (4-Butylamino-2-methylsulfanyl-pyridine-5-yl)-methanol (<b>3f</b>)</h4><div class="NLM_p last">Starting from <b>2f</b>, 83% of <b>3f</b> was obtained according to method described for the synthesis of <b>3</b>; mp 105–107 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.65 (s, 1H), 5.92 (bs, 1H), 4.50 (s, 2H), 3.54–3.48 (m, 2H), 2.52 (s, 3H), 1.64–1.57 (m, 2H), 1.45–1.37 (m, 2H), 0.96 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 228.20; calcd for C<sub>10</sub>H<sub>17</sub>N<sub>3</sub>OS <i>m</i>/<i>z</i>, 227.11.</div></div><div id="sec3_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (2-Methylsulfanyl-4-pentylamino-pyridine-5-yl)-methanol (<b>3g</b>)</h4><div class="NLM_p last">Starting from <b>2g</b>, 86% of <b>3g</b> was obtained according to method described for the synthesis of <b>3</b>; mp 110–112 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.64 (s, 1H), 5.93 (bs, 1H), 4.50 (s, 2H), 3.53–3.46 (m, 2H), 2.51 (s, 3H), 1.66–1.59 (m, 2H), 1.40–1.33 (m, 4H), 0.95–0.92 (m, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 242.20; calcd for C<sub>11</sub>H<sub>19</sub>N<sub>3</sub>OS <i>m</i>/<i>z</i>, 241.12.</div></div><div id="sec3_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (4-Cyclopropylmino-2-methylsulfanyl-pyridine-5-yl)-methanol (<b>3h</b>)</h4><div class="NLM_p last">Starting from <b>2h</b>, 82% of <b>3h</b> was obtained according to method described for the synthesis of <b>3</b>; mp 135–137 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.69 (s, 1H), 6.08 (bs, 1H), 4.48 (s, 2H), 2.92–2.86 (m, 1H), 2.54 (s, 3H), 0.87–0.80 (m, 2H), 0.59–0.56 (m, 2H), MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 212.10; calcd for C<sub>9</sub>H<sub>13</sub>N<sub>3</sub>OS <i>m</i>/<i>z</i>, 211.08.</div></div><div id="sec3_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (4-Cyclopentylamino-2-methylsulfanyl-pyridine-5-yl)-methanol (<b>3i</b>)</h4><div class="NLM_p last">Starting from <b>2i</b>, 84% of <b>3i</b> was obtained according to method described for the synthesis of <b>3</b>; mp 150–151 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.65 (s, 1H), 5.80 (bs, 1H), 4.52 (s, 2H), 4.45–4.50 (m, 1H), 2.50 (s, 3H), 2.00–2.15 (m, 2H), 1.62–1.78 (m, 4H), 1.40–1.49 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 240.10; calcd for C<sub>11</sub>H<sub>17</sub>N<sub>3</sub>OS <i>m</i>/<i>z</i>, 239.11.</div></div><div id="sec3_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (4-Cyclohexylamino-2-methylsulfanyl-pyridine-5-yl)-methanol (<b>3j</b>)</h4><div class="NLM_p last">Starting from <b>2j</b>, 84% of <b>3j</b> was obtained according to method described for the synthesis of <b>3</b>; mp 175–177 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.59 (s, 1H), 5.80 (bs, 1H), 4.45 (s, 2H), 3.95–4.08 (m, 1H), 2.51 (s, 3H), 1.99–2.08 (m, 2H), 1.61–1.78 (m, 4H), 1.24–1.43 (m, 4H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 254.10; calcd for C<sub>12</sub>H<sub>19</sub>N<sub>3</sub>OS <i>m</i>/<i>z</i>, 253.12.</div></div><div id="sec3_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> General Procedure for the Synthesis of 4-Alkyl/cycloalkylamino-2-methylsulfanyl-pyrimidine-5-carbaldehyde (<b>4</b>)</h4><div class="NLM_p last">The compound <b>3</b> (20.8 mmol) was dissolved in chloroform to which manganese dioxide (MnO<sub>2</sub>) (119 mmol) was added and stirred for overnight, and an additional portion of MnO<sub>2</sub> (31.3 mmol) was added and stirred for 12 h. The solids were removed by filtration through a Celite pad and washed with chloroform. The chloroform was evaporated in vacuum to get the product.</div></div><div id="sec3_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 4-Amino-2-methylsulfanyl-pyrimidine-5-carbaldehyde (<b>4a</b>)</h4><div class="NLM_p last">Starting from <b>3a</b>, 72% of <b>4a</b> was obtained according to the procedure described for the synthesis of <b>4</b>; mp 186–188 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.80 (s, 1H), 8.45 (s, 1H), 8.20 (bs, 1H), 5.74 (bs, 1H), 2.55 (s, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 170.00; calcd for C<sub>6</sub>H<sub>7</sub>N<sub>3</sub>OS <i>m</i>/<i>z</i>, 169.03.</div></div><div id="sec3_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 4-Methylamino-2-methylsulfanyl-pyrimidine-5-carbaldehyde (<b>4b</b>)</h4><div class="NLM_p last">Starting from <b>3b</b>, 75% of <b>4b</b> was obtained according to the procedure described for the synthesis of <b>4</b>; mp 98–99 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.71 (s, 1H), 8.59 (bs, 1H), 8.30 (s, 1H), 3.14 (d, 3H), 2.58 (s, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 184.10; calcd for C<sub>7</sub>H<sub>9</sub>N<sub>3</sub>OS <i>m</i>/<i>z</i>, 183.05.</div></div><div id="sec3_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 4-Ethylamino-2-methylsulfanyl-pyrimidine-5-carbaldehyde (<b>4c</b>)</h4><div class="NLM_p last">Starting from <b>3c</b>, 72% of <b>4c</b> was obtained according to the procedure described for the synthesis of <b>4</b>; mp 60–61 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.72 (s, 1H), 8.64 (bs, 1H), 8.29 (s, 1H), 3.56 (q, 2H), 2.50 (s, 3H), 1.18 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 198.10; calcd for C<sub>8</sub>H<sub>11</sub>N<sub>3</sub>OS <i>m</i>/<i>z</i>, 197.06.</div></div><div id="sec3_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 2-Methylsulfanyl-4-propylmino-pyrimidine-5-carbaldehyde (<b>4d</b>)</h4><div class="NLM_p last">Starting from <b>3d</b>, 70% of <b>4d</b> was obtained according to the procedure described for the synthesis of <b>4</b>; mp 50–51 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.69 (s, 1H), 8.63 (bs, 1H), 8.28 (s, 1H), 3.53–3.57 (m, 2H), 2.52 (s, 3H), 1.61–1.73 (m, 2H), 0.86 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 212.10; calcd for C<sub>9</sub>H<sub>13</sub>N<sub>3</sub>OS <i>m</i>/<i>z</i>, 211.08.</div></div><div id="sec3_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 4-Isopropylamino-2-methylsulfanyl-pyrimidine-5-carbaldehyde (<b>4e</b>)</h4><div class="NLM_p last">Starting from <b>3e</b>, 90% of <b>4e</b> was obtained as low melting solid according to the procedure described for the synthesis of <b>4</b>; mp 54–55 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.69 (s, 1H), 8.48 (bs, 1H), 8.29 (s, 1H), 4.51–4.40 (m, 1H), 2.55 (s, 3H), 1.30 (d, 6H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 212.00; calcd for C<sub>9</sub>H<sub>13</sub>N<sub>3</sub>OS <i>m</i>/<i>z</i>, 211.08.</div></div><div id="sec3_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 4-Butylamino-2-methylsulfanyl-pyrimidine-5-carbaldehyde (<b>4f</b>)</h4><div class="NLM_p last">Starting from <b>3f</b>, 90% of <b>4f</b> was obtained as thick liquid according to the procedure described for the synthesis of <b>4</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.70 (s, 1H), 8.63 (bs, 1H), 8.29 (s, 1H), 3.63–3.56 (m, 2H), 2.53 (s, 3H), 1.70–1.60 (m, 2H), 1.49–1.39 (m, 2H), 0.97 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 226.10; calcd for C<sub>10</sub>H<sub>15</sub>N<sub>3</sub>OS <i>m</i>/<i>z</i>, 225.09.</div></div><div id="sec3_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 2-Methylsulfanyl-4-pentylmino-pyrimidine-5-carbaldehyde (<b>4g</b>)</h4><div class="NLM_p last">Starting from <b>3g</b>, 87% of <b>4g</b> was obtained as thick liquid according to the procedure described for the synthesis of <b>4</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.70 (s, 1H), 8.63 (bs, 1H), 8.29 (s, 1H), 3.61–3.55 (m, 2H), 2.55 (s, 3H), 1.70–1.74 (m, 2H), 1.40–1.34 (m, 4H), 0.95–0.91 (m, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 240.10; calcd for C<sub>11</sub>H<sub>17</sub>N<sub>3</sub>OS <i>m</i>/<i>z</i>, 239.11.</div></div><div id="sec3_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 4-Cyclopropylamino-2-methylsulfanyl-pyrimidine-5-carbaldehyde (<b>4h</b>)</h4><div class="NLM_p last">Starting from <b>3h</b>, 80% of <b>4h</b> was obtained as low melting solid according to the procedure described for the synthesis of <b>4</b>; mp 69–70 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.61 (s, 1H), 8. 49 (bs, 1H), 8.23 (s, 1H), 2.98–2.92 (m, 1H), 2.50 (s, 3H), 0.85–0.78 (m, 2H), 0.60–0.57 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 210.10; calcd for C<sub>9</sub>H<sub>11</sub>N<sub>3</sub>OS <i>m</i>/<i>z</i>, 209.06.</div></div><div id="sec3_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 4-Cyclopentylamino-2-methylsulfanyl-pyrimidine-5-carbaldehyde (<b>4i</b>)</h4><div class="NLM_p last">Starting from <b>3i</b>, 87% of <b>4i</b> was obtained as solid according to the procedure described for the synthesis of <b>4</b>; mp 41–42 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.65 (s, 1H), 8.60 (bs, 1H), 8.25 (s, 1H), 4.49–4.54 (m, 1H), 2.52 (s, 3H), 2.01–2.12 (m, 2H), 1.50–1.82 (m, 6H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 238.10; calcd for C<sub>11</sub>H<sub>15</sub>N<sub>3</sub>OS <i>m</i>/<i>z</i>, 237.09.</div></div><div id="sec3_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 4-Cyclohexylamino-2-methylsulfanyl-pyrimidine-5-carbaldehyde (<b>4j</b>)</h4><div class="NLM_p last">Starting from <b>3j</b>, 90% of <b>4j</b> was obtained as thick liquid according to the method described for the synthesis of <b>4</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.62 (s, 1H), 8.55 (bs, 1H), 8.15 (s, 1H), 4.01–4.09 (m, 1H), 2.51 (s, 3H), 1.97–2.05 (m, 2H), 1.60–1.80 (m, 4H), 1.22–1.44 (m, 4H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 252.10; calcd for C<sub>12</sub>H<sub>17</sub>N<sub>3</sub>OS <i>m</i>/<i>z</i>, 251.11.</div></div><div id="sec3_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> General Procedure for 8-Alkyl/cycloalkyl-2-methylsulfanyl-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine (<b>5</b>)</h4><div class="NLM_p last">A mixture of 4-alkylamino-2-methylsulfanyl-pyrimidine-5-carbaldehyde <b>4</b> (4.2 mmol), 1.2 equiv of active methylene compound, and a catalytic amount of benzylamine was taken in to acetic acid and refluxed for about 6 h. After completion of the reaction (checked with TLC), the reaction mixture was cooled to room temperature and the precipitated product was filtered. In some cases, the reaction mixture was diluted with hexane to get solid out. The solid was washed with saturated NaHCO<sub>3</sub> and water and dried over vacuo. The crude product was recrystallized in 2-propanol to get pure product (<b>5</b>).</div></div><div id="sec3_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 2-Methylsulfanyl-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>5a</b>)</h4><div class="NLM_p last">Starting from <b>4a</b> and cyanoacetic acid, 65% of <b>5a</b> was obtained according to the method described for the synthesis of <b>5</b>; mp 328–330 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.12 (bs, 1H), 8.94 (s, 1H), 8.71 (s, 1H), 2.56 (s, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 219.10; calcd for C<sub>9</sub>H<sub>6</sub>N<sub>4</sub>OS <i>m</i>/<i>z</i>, 218.03.</div></div><div id="sec3_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 8-Methyl-2-methylsulfanyl-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>5b</b>)</h4><div class="NLM_p last">Starting from <b>4b</b> and cyanoacetic acid, 67% of <b>5b</b> was obtained according to the method described for the synthesis of <b>5</b>; mp 292–294 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.95 (s, 1H), 8.79 (s, 1H), 3.61 (s, 3H), 2.51 (s, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 233.10; calcd for C<sub>10</sub>H<sub>8</sub>N<sub>4</sub>OS <i>m</i>/<i>z</i>, 232.04.</div></div><div id="sec3_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 8-Ethyl-2-methylsulfanyl-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>5c</b>)</h4><div class="NLM_p last">Starting from <b>4c</b> and cyanoacetic acid, 70% of <b>5c</b> was obtained according to the method described for the synthesis of <b>5</b>; mp 244–245 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.71 (s, 1H), 8.15 (s, 1H), 4.51 (q, 2H), 2.61 (s, 3H), 1.37 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 247.10; calcd for C<sub>11</sub>H<sub>10</sub>N<sub>4</sub>OS <i>m</i>/<i>z</i>, 246.06.</div></div><div id="sec3_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 2-Methylsulfanyl-7-oxo-8-propyl-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>5d</b>)</h4><div class="NLM_p last">Starting from <b>4d</b> and cyanoacetic acid, 70% of <b>5d</b> was obtained according to the method described for the synthesis of <b>5</b>; mp 230–231 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.70 (s, 1H), 8.14 (s, 1H), 4.44–4.39 (m, 2H), 2.60 (s, 3H), 1.83–1.76 (m, 2H), 1.02 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 261.10; calcd for C<sub>12</sub>H<sub>12</sub>N<sub>4</sub>OS <i>m</i>/<i>z</i>, 260.07.</div></div><div id="sec3_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 8-Isopropyl-2-methylsulfanyl-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>5e</b>)</h4><div class="NLM_p last">Starting from <b>4e</b> and cyanoacetic acid, 70% of <b>5e</b> was obtained according to the method described for the synthesis of <b>5</b>; mp 200–202 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.68 (s, 1H), 8.10 (s, 1H), 5.89–5.80 (m, 1H), 2.67 (s, 3H), 1.65 (d, 6H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 261.10; calcd for C<sub>12</sub>H<sub>12</sub>N<sub>4</sub>OS <i>m</i>/<i>z</i>, 260.07.</div></div><div id="sec3_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 8-Butyl-2-methylsulfanyl-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>5f</b>)</h4><div class="NLM_p last">Starting from <b>4f</b> and cyanoacetic acid, 70% of <b>5f</b> was obtained according to the method described for the synthesis of <b>5</b>; mp 220–222 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.70 (s, 1H), 8.14 (s, 1H), 4.45 (t, 2H), 2.65 (s, 3H), 1.77–1.71 (m, 2H), 1.49–1.41 (m, 2H), 1.00 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 275.10; calcd for C<sub>13</sub>H<sub>14</sub>N<sub>4</sub>OS <i>m</i>/<i>z</i>, 274.09.</div></div><div id="sec3_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 2-Methylsulfanyl-7-oxo-8-pentyl-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>5g</b>)</h4><div class="NLM_p last">Starting from <b>4g</b> and cyanoacetic acid, 70% of <b>5g</b> was obtained according to the method described for the synthesis of <b>5</b>; mp 160–161 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.71 (s, 1H), 8.15 (s, 1H), 4.43 (t, 2H), 2.66 (s, 3H), 1.78–1.73 (m, 2H), 1.42–1.38 (m, 4H), 0.93 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 289.10; calcd for C<sub>14</sub>H<sub>16</sub>N<sub>4</sub>OS <i>m</i>/<i>z</i>, 288.10.</div></div><div id="sec3_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 8-Cyclopropyl-2-methylsulfanyl-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>5h</b>)</h4><div class="NLM_p last">Starting from <b>4h</b> and cyanoacetic acid, 71% of <b>5h</b> was obtained according to the method described for the synthesis of <b>5</b>; mp 158–159 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.70 (s, 1H), 8.14 (s, 1H), 2.99–2.97 (m, 1H), 2.65 (s, 3H), 1.27 (bs, 2H), 1.02 (bs, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 259.10; calcd for C<sub>12</sub>H<sub>10</sub>N<sub>4</sub>OS <i>m</i>/<i>z</i>, 258.06.</div></div><div id="sec3_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 8-Cyclopentyl-2-methylsulfanyl-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>5i</b>)</h4><div class="NLM_p last">Starting from <b>4i</b> and cyanoacetic acid, 71% of <b>5i</b> was obtained according to the method described for the synthesis of <b>5</b>; mp 209–210 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.68 (s, 1H), 8.10 (s, 1H), 5.89–5.98 (m, 1H), 2.64 (s, 3H), 2.23–2.35 (m, 2H), 2.09–2.16 (m, 2H), 1.83–1.96 (m, 2H), 1.63–1.76 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 287.10; calcd for C<sub>14</sub>H<sub>14</sub>N<sub>4</sub>OS <i>m</i>/<i>z</i>, 286.09.</div></div><div id="sec3_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 8-Cyclohexyl-2-methylsulfanyl-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>5j</b>)</h4><div class="NLM_p last">Starting from <b>4j</b> and cyanoacetic acid, 71% of <b>5j</b> was obtained according to the method described for the synthesis of <b>5</b>; mp 239–240 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.65 (s, 1H), 8.08 (s, 1H), 5.42 (bs, 1H), 2.62 (s, 3H), 1.90–1.95 (m, 2H), 1.67–1.76 (m, 6H), 1.34–1.45 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 301.10; calcd for C<sub>15</sub>H<sub>16</sub>N<sub>4</sub>OS <i>m</i>/<i>z</i>, 300.10.</div></div><div id="sec3_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 8-Cyclopentyl-2-methylsulfanyl-6-nitro-8<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidin-7-one (<b>5k</b>)</h4><div class="NLM_p last">Starting from <b>4i</b> and nitro-acetic acid ethyl ester, 70% of <b>5k</b> was obtained according to the method described for the synthesis of <b>5</b>; mp 182–84 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.79 (s, 1H), 8.42 (s, 1H), 6.05–6.00 (m, 1H), 2.67 (m, 3H), 2.34–2.30 (m, 2H), 2.15–2.10 (m, 2H), 1.99–1.91 (m, 2H), 1.78–172 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 307.10; calcd for C<sub>13</sub>H<sub>14</sub>N<sub>4</sub>O<sub>3</sub>S <i>m</i>/<i>z</i>, 306.08.</div></div><div id="sec3_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 8-Cyclopentyl-6-methanesulfonyl-2-methylsulfanyl-8<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidin-7-one (<b>5l</b>)</h4><div class="NLM_p last">Starting from <b>4i</b> and methyl sulfonyl acetic acid, 73% of <b>5l</b> was obtained according to the method described for the synthesis of <b>5</b>; mp 190–191 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.76 (s, 1H), 8.49 (s, 1H), 5.88–6.00 (m, 1H), 3.34 (s, 3H), 2.65 (s, 3H), 2.28–2.41 (m, 2H), 2.09–2.16 (m, 2H), 1.84–1.99 (m, 2H), 1.67–1.73 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 340.20; calcd for C<sub>14</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub>S<sub>2</sub><i>m</i>/<i>z</i>, 339.07.</div></div><div id="sec3_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 6-Benzenesulfonyl-8-cyclopentyl-2-methylsulfanyl-8<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidin-7-one (<b>5m</b>)</h4><div class="NLM_p last">Starting from <b>4i</b> and benzene sulfonyl acetic acid, 70% of <b>5m</b> was obtained according to the method described for the synthesis of <b>5</b>; mp 184–185 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.87 (s, 1H), 8.70 (s, 1H), 7.54–7.80 (m, 5H), 5.69–5.72 (m, 1H), 2.66 (s, 3H), 2.20–2.33 (m, 2H), 1.99–2.11 (m, 2H), 1.78–1.88 (m, 2H), 1.61–1.69 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 402.10; calcd for C<sub>19</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>S<sub>2</sub><i>m</i>/<i>z</i>, 401.09.</div></div><div id="sec3_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 6-(4-Chloro-benzenesulfonyl)-8-cyclopentyl-2-methylsulfanyl-8<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidin-7-one (<b>5n</b>)</h4><div class="NLM_p last">Starting from <b>4i</b> and 4-chlorobenzene sulfonyl acetic acid <b>13</b>, 70% of <b>5n</b> was obtained according to the method described for the synthesis of <b>5</b>; mp 222–223 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.78 (s, 1H), 8.65 (s, 1H), 8.05–8.09 (m, 2H), 7.49–7.54 (m, 2H), 5.75–5.81 (m, 1H), 2.63 (s, 3H), 2.21–2.28 (m, 2H), 1.95–2.07 (m, 2H), 1.77–1.83 (m, 2H), 1.64–1.69 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 436.10; calcd for C<sub>19</sub>H<sub>18</sub>ClN<sub>3</sub>O<sub>3</sub>S<sub>2</sub><i>m</i>/<i>z</i>, 435.05.</div></div><div id="sec3_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 6-(4-Chloro-phenylmethanesulfonyl)-8-cyclopentyl-2-methylsulfanyl-8<i>H</i>-pyrido[2,3-<i>d</i>] pyrimidin-7-one (<b>5o</b>)</h4><div class="NLM_p last">Starting from <b>4i</b> and 4-chloro-phenylmethane sulfonyl acetic acid <b>10a</b>, 67% of <b>5o</b> was obtained according to the method described for the synthesis of <b>5</b>; mp 250–252 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.68 (s, 1H), 8.57 (s, 1H), 7.42 (d, 2H), 7.25 (d, 2H), 5.84–5.93 (m, 1H), 4.65 (s, 2H), 2.59 (s, 3H), 2.21–2.29 (m, 2H), 1.99–2.09 (m, 2H), 1.82–1.89 (m, 2H), 1.64–1.72 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 450.10; calcd for C<sub>20</sub>H<sub>20</sub>ClN<sub>3</sub>O<sub>3</sub>S<sub>2</sub><i>m</i>/<i>z</i>, 449.06.</div></div><div id="sec3_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 8-Cyclopentyl-6-(3-hydroxy-4-methoxy-phenylmethanesulfonyl)-2-methylsulfanyl-8<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidin-7-one (<b>5p</b>)</h4><div class="NLM_p last">Starting from <b>4i</b> and 4-hydroxy-3-methoxy-phenylmethane sulfonyl acetic acid <b>10c</b>, 65% of <b>5p</b> was obtained according to the method described for the synthesis of <b>5</b>; mp 180–181 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.48 (s, 1H), 8.12 (s, 1H), 6.52–6.72 (m, 3H), 5.73–5.90 (m, 1H), 4.55 (s, 2H), 3.69 (s, 3H), 2.49 (s, 3H), 2.12–2.28 (m, 2H), 1.89–2.02 (m, 2H), 1.68–1.81 (m, 2H), 1.48–1.61 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 462.10; calcd for C<sub>21</sub>H<sub>23</sub>N<sub>3</sub>O<sub>5</sub>S<sub>2</sub><i>m</i>/<i>z</i>, 461.11.</div></div><div id="sec3_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 8-Cyclopentyl-6-(4-methoxy-3-nitro-phenylmethanesulfonyl)-2-methylsulfanyl-8<i>H</i>-pyrido [2,3-<i>d</i>]pyrimidin-7-one (<b>5q</b>)</h4><div class="NLM_p last">Starting from <b>4i</b> and 4-methoxy-3-nitro-phenylmethane sulfonyl acetic acid <b>10b</b>, 62% of <b>5q</b> was obtained according to the method described for the synthesis of <b>5</b>; mp 200–201 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.68 (s, 1H), 8.27 (s, 1H), 7.85 (s, 1H), 7.80–7.82 (m, 1H), 7.58–7.63 (m, 1H), 5.90–6.09 (m, 1H), 4.82 (s, 2H), 3.90 (s, 3H), 2.67 (s, 3H), 2.32–2.43 (m, 2H), 2.09–2.20 (m, 2H), 1.88–2.00 (m, 2H), 1.69–1.77 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 491.10; calcd for C<sub>21</sub>H<sub>22</sub>N<sub>4</sub>O<sub>6</sub>S<sub>2</sub><i>m</i>/<i>z</i>, 490.10.</div></div><div id="sec3_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 8-Cyclopentyl-2-methylsulfanyl-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid (4-Chloro-phenyl)-amide (<b>5r</b>)</h4><div class="NLM_p last">Starting from <b>4i</b> and <i>N</i>-<b>(</b>4-chloro-phenyl)-malonamic acid <b>16a</b>, 65% of <b>5r</b> was obtained according to the method described for the synthesis of <b>5</b>; mp 260–262 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 11.71 (bs, 1H), 8.86 (s, 1H), 8.82 (s, 1H), 7.68–7.78 (m, 2H), 7.33–7.39 (m, 2H), 6.04–6.10 (m, 1H), 2.65 (s, 3H), 2.30–2.42 (m, 2H), 2.10–2.20 (m, 2H), 1.89–2.00 (m, 2H), 1.79–1.81 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 415.10; calcd for C<sub>20</sub>H<sub>19</sub>ClN<sub>4</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 414.09.</div></div><div id="sec3_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 8-Cyclopentyl-2-methylsulfanyl-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid (4-Fluoro-phenyl)-amide (<b>5s</b>)</h4><div class="NLM_p last">Starting from <b>4i</b> and <i>N</i>-<b>(</b>4-fluoro-phenyl)-malonamic acid <b>16b</b>, 65% of <b>5s</b> was obtained according to the method described for the synthesis of <b>5</b>; mp 243–242 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 11.65 (bs, 1H), 8.87 (s, 1H), 8.83 (s, 1H), 7.69–7.76 (m, 2H), 6.98–7.10 (m, 2H), 6.01–6.13 (m, 1H), 2.66 (s, 3H), 2.31–2.42 (m, 2H), 2.09–2.20 (m, 2H), 1.89–2.00 (m, 2H), 1.72–1.81 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 399.10; calcd for C<sub>20</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 398.12.</div></div><div id="sec3_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> General Procedure for the Synthesis of Compounds (<b>5b</b>–<b>5j</b>) Form 2-Methylsulfanyl-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>5a</b>), (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>)</h4><div class="NLM_p last">The compound <b>5a</b> (5 mmol) was taken into DMF and stirred at 50 °C for 10 min until obtaining the clear solution, and then NaH (5 mmol) was added and stirred about 5 min. The reaction mixture was brought to room temperature and alkyl iodides (6.5 mmol) were added. After 1 h stirring, the reaction was quenched with water and filtered the obtained product. The crude product was purified with flash column chromatography using 10–30% ethyl acetate in hexanes. All physical and spectral data matched with the compounds, which were prepared according to Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>.</div></div><div id="sec3_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> General Procedure for the Synthesis of 8-Alkyl-2-methylsulfinyl-6-substituted-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidines (<b>6</b>)</h4><div class="NLM_p last">A solution of 8-alkyl-2-methylsulfanyl-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine <b>5</b> (3.5 mmol) and 3-chloro-benzenecarboperoxoic acid (<i>m</i>-CPBA) (4.4 mmol) in CH<sub>2</sub>Cl<sub>2</sub> was stirred at room temperature for about 4 h. After completion of the reaction, the reaction mixture was washed with saturated NaHCO<sub>3</sub>, and the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to produce the corresponding methylsuloxide <b>6</b> and was purified with flash chromatography.</div></div><div id="sec3_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 2-Methylsulfinyl-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>6a</b>)</h4><div class="NLM_p last">Starting from <b>5a</b> and 3-chloro-benzenecarboperoxoic acid, 90% of <b>6a</b> was obtained according to the method described for the synthesis of <b>6</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.10 (bs, 1H), 8.93 (s, 1H), 8.72 (s, 1H), 2.92 (s, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 235.10; calcd for C<sub>9</sub>H<sub>6</sub>N<sub>4</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 234.02.</div></div><div id="sec3_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> 2-Methylsulfinyl-8-methyl-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>6b</b>)</h4><div class="NLM_p last">Starting from <b>5b</b> and 3-chloro-benzenecarboperoxoic acid, 92% of <b>6b</b> was obtained according to the method described for the synthesis of <b>6</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.92 (s, 1H), 8.88 (s, 1H), 3.62 (s, 3H), 2.91 (s, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 249.10; calcd for C<sub>10</sub>H<sub>8</sub>N<sub>4</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 248.04.</div></div><div id="sec3_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 8-Ethyl-2-methylsulfinyl-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>6c</b>)</h4><div class="NLM_p last">Starting from <b>5c</b> and 3-chloro-benzenecarboperoxoic acid, 90% of <b>6c</b> was obtained according to the method described for the synthesis of <b>6</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.73 (s, 1H), 8.17 (s, 1H), 4.50 (q, 2H), 2.92 (s, 3H), 1.37 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 263.10; calcd for C<sub>11</sub>H<sub>10</sub>N<sub>4</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 262.05.</div></div><div id="sec3_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> 2-Methylsulfinyl-7-oxo-8-propyl-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>6d</b>)</h4><div class="NLM_p last">Starting from <b>5d</b> and 3-chloro-benzenecarboperoxoic acid, 92% of <b>6d</b> was obtained according to the method described for the synthesis of <b>6</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.72 (s, 1H), 8.13 (s, 1H), 4.42–4.38 (m, 2H), 2.94 (s, 3H), 1.84–1.76 (m, 2H), 1.02 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 277.10; calcd for C<sub>12</sub>H<sub>12</sub>N<sub>4</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 276.07.</div></div><div id="sec3_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> 8-Isopropyl-2-methylsulfinyl-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>6e</b>)</h4><div class="NLM_p last">Starting from <b>5e</b> and 3-chloro-benzenecarboperoxoic acid, 89% of <b>6e</b> was obtained according to the method described for the synthesis of <b>6</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.67 (s, 1H), 8.12 (s, 1H), 5.87–5.79 (m, 1H), 2.95 (s, 3H), 1.63 (d, 6H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 277.10; calcd for C<sub>12</sub>H<sub>12</sub>N<sub>4</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 276.07.</div></div><div id="sec3_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 8-Butyl-2-methylsulfinyl-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>6f</b>)</h4><div class="NLM_p last">Starting from <b>5f</b> and 3-chloro-benzenecarboperoxoic acid, 90% of <b>6f</b> was obtained according to the method described for the synthesis of <b>6</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.69 (s, 1H), 8.15 (s, 1H), 4.43 (t, 2H), 2.96 (s, 3H), 1.75–1.70 (m, 2H), 1.50–1.43 (m, 2H), 1.02 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 291.10; calcd for C<sub>13</sub>H<sub>14</sub>N<sub>4</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 290.08.</div></div><div id="sec3_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 2-Methylsulfinyl-7-oxo-8-pentyl-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>6g</b>)</h4><div class="NLM_p last">Starting from <b>5g</b> and 3-chloro-benzenecarboperoxoic acid, 93% of <b>6g</b> was obtained according to the method described for the synthesis of <b>6</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.72 (s, 1H), 8.14 (s, 1H), 4.44 (t, 2H), 2.93 (s, 3H), 1.77–1.72 (m, 2H), 1.43–1.37 (m, 4H), 0.92 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 305.10; calcd for C<sub>14</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 304.10.</div></div><div id="sec3_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 8-Cyclopropyl-2-methylsulfinyl-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>6h</b>)</h4><div class="NLM_p last">Starting from <b>5h</b> and 3-chloro-benzenecarboperoxoic acid, 91% of <b>6h</b> was obtained according to the method described for the synthesis of <b>6</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.70 (s, 1H), 8.14 (s, 1H), 2.96–2.93 (m, 1H), 2.94 (s, 3H), 1.25 (bs, 2H), 1.03 (bs, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 275.10; calcd for C<sub>12</sub>H<sub>10</sub>N<sub>4</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 274.05.</div></div><div id="sec3_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> 8-Cyclopentyl-2-methylsulfinyl-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>6i</b>)</h4><div class="NLM_p last">Starting from <b>5i</b> and 3-chloro-benzenecarboperoxoic acid, 94% of <b>6i</b> was obtained according to the method described for the synthesis of <b>6</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.69 (s, 1H), 8.13 (s, 1H), 5.98 (bs, 1H), 2.93 (s, 3H), 2.20–2.33 (m, 2H), 2.07–2.15 (m, 2H), 1.82–1.94 (m, 2H), 1.62–1.74 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 303.10; calcd for C<sub>14</sub>H<sub>14</sub>N<sub>4</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 302.08.</div></div><div id="sec3_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> 8-Cyclohexyl-2-methylsulfinyl-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>6j</b>)</h4><div class="NLM_p last">Starting from <b>5j</b> and 3-chloro-benzenecarboperoxoic acid, 92% of <b>6j</b> was obtained according to the method described for the synthesis of <b>6</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.69 (s, 1H), 8.11 (s, 1H), 5.43 (bs, 1H), 2.95 (s, 3H), 1.92–1.96 (m, 2H), 1.66–1.79 (m, 6H), 1.33–1.45 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 317.10; calcd for C<sub>15</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>S <i>m</i>/<i>z</i>, 316.10.</div></div><div id="sec3_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> 8-Cyclopentyl-2-methylsulfinyl-6-nitro-8<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidin-7-one (<b>6k</b>)</h4><div class="NLM_p last">Starting from <b>5k</b> and 3-chloro-benzenecarboperoxoic acid, 91% of <b>6k</b> was obtained according to the method described for the synthesis of <b>6</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.73 (s, 1H), 8.40 (s, 1H), 6.03 (bs, 1H), 2.94 (m, 3H), 2.35–2.32 (m, 2H), 2.16–2.09 (m, 2H), 1.99–1.91 (m, 2H), 1.76–171 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 323.10; calcd for C<sub>13</sub>H<sub>14</sub>N<sub>4</sub>O<sub>4</sub>S <i>m</i>/<i>z</i>, 322.07.</div></div><div id="sec3_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> 8-Cyclopentyl-2-methylsulfinyl-6-methanesulfonyl-8<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidin-7-one (<b>6l</b>)</h4><div class="NLM_p last">Starting from <b>5l</b> and 3-chloro-benzenecarboperoxoic acid, 92% of <b>6l</b> was obtained according to the method described for the synthesis of <b>6</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.78 (s, 1H), 8.51 (s, 1H), 6.00 (bs, 1H), 3.34 (s, 3H), 2.95 (s, 3H), 2.28–2.40 (m, 2H), 2.10–2.15 (m, 2H), 1.86–1.98 (m, 2H), 1.66–1.71 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 356.10; calcd for C<sub>14</sub>H<sub>17</sub>N<sub>3</sub>O<sub>4</sub>S<sub>2</sub><i>m</i>/<i>z</i>, 355.07.</div></div><div id="sec3_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> 6-Benzenesulfonyl-8-cyclopentyl-2-methylsulfinyl-8<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidin-7-one (<b>6m</b>)</h4><div class="NLM_p last">Starting from <b>5m</b> and 3-chloro-benzenecarboperoxoic acid, 90% of <b>6m</b> was obtained according to the method described for the synthesis of <b>6</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.86 (s, 1H), 8.70 (s, 1H), 7.55–7.80 (m, 5H), 5.71 (bs, 1H), 2.95 (s, 3H), 2.19–2.31 (m, 2H), 1.99–2.10 (m, 2H), 1.80–1.87 (m, 2H), 1.60–1.70 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 418.10; calcd for C<sub>19</sub>H<sub>19</sub>N<sub>3</sub>O<sub>4</sub>S<sub>2</sub><i>m</i>/<i>z</i>, 417.08.</div></div><div id="sec3_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> 6-(4-Chloro-benzenesulfonyl)-8-cyclopentyl-2-methylsulfinyl-8<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidin-7-one (<b>6n</b>)</h4><div class="NLM_p last">Starting from <b>5n</b> and 3-chloro-benzenecarboperoxoic acid, 91% of <b>6n</b> was obtained according to the method described for the synthesis of <b>6</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.81 (s, 1H), 8.68 (s, 1H), 8.02–8.06 (m, 2H), 7.50–7.57 (m, 2H), 5.77 (bs, 1H), 2.94 (s, 3H), 2.20–2.26 (m, 2H), 1.96–2.08 (m, 2H), 1.78–1.82 (m, 2H), 1.64–1.69 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 452.10; calcd for C<sub>19</sub>H<sub>18</sub>ClN<sub>3</sub>O<sub>4</sub>S<sub>2</sub><i>m</i>/<i>z</i>, 451.04.</div></div><div id="sec3_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> 6-(4-Chloro-phenylmethanesulfonyl)-8-cyclopentyl-2-methylsulfinyl-8<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidin-7-one (<b>6o</b>)</h4><div class="NLM_p last">Starting from <b>5o</b> and 3-chloro-benzenecarboperoxoic acid, 92% of <b>6o</b> was obtained according to the method described for the synthesis of <b>6</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.70 (s, 1H), 8.56 (s, 1H), 7.43 (d, 2H), 7.24 (d, 2H), 5.83–5.91 (m, 1H), 4.67 (s, 2H), 2.96 (s, 3H), 2.20–2.28 (m, 2H), 1.97–2.10 (m, 2H), 1.81–1.88 (m, 2H), 1.65–1.73 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 466.10; calcd for C<sub>20</sub>H<sub>20</sub>ClN<sub>3</sub>O<sub>4</sub>S<sub>2</sub><i>m</i>/<i>z</i>, 465.06.</div></div><div id="sec3_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> 8-Cyclopentyl-6-(3-hydroxy-4-methoxy-phenylmethanesulfonyl)-2-methylsulfinyl-8<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidin-7-one (<b>6p</b>)</h4><div class="NLM_p last">Starting from <b>5p</b> and 3-chloro-benzenecarboperoxoic acid, 91% of <b>6p</b> was obtained according to the method described for the synthesis of <b>6</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.50 (s, 1H), 8.14 (s, 1H), 6.51–6.72 (m, 3H), 5.74–5.91 (m, 1H), 4.58 (s, 2H), 3.67 (s, 3H), 2.97 (s, 3H), 2.13–2.27 (m, 2H), 1.88–2.02 (m, 2H), 1.66–1.80 (m, 2H), 1.49–1.60 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 478.10; calcd for C<sub>21</sub>H<sub>23</sub>N<sub>3</sub>O<sub>6</sub>S<sub>2</sub><i>m</i>/<i>z</i>, 477.10.</div></div><div id="sec3_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> 8-Cyclopentyl-2-methylsulfinyl-6-(4-methoxy-3-nitro-phenylmethanesulfonyl)-2-methyl-sulfanyl-8<i>H</i>-pyrido [2,3-<i>d</i>]pyrimidin-7-one (<b>6q</b>)</h4><div class="NLM_p last">Starting from <b>5q</b> and 3-chloro-benzene-carboperoxoic acid, 93% of <b>6q</b> was obtained according to the method described for the synthesis of <b>6</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.67 (s, 1H), 8.30 (s, 1H), 7.83 (s, 1H), 7.81–7.83 (m, 1H), 7.59–7.63 (m, 1H), 5.93–6.09 (m, 1H), 4.85 (s, 2H), 3.90 (s, 3H), 2.96 (s, 3H), 2.30–2.42 (m, 2H), 2.08–2.18 (m, 2H), 1.89–2.01 (m, 2H), 1.67–1.78 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 507.10; calcd for C<sub>21</sub>H<sub>22</sub>N<sub>4</sub>O<sub>7</sub>S<sub>2</sub><i>m</i>/<i>z</i>, 506.09.</div></div><div id="sec3_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> 8-Cyclopentyl-2-methylsulfinyl-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid (4-Chloro-phenyl)-amide (<b>6r</b>)</h4><div class="NLM_p last">Starting from <b>5r</b> and 3-chloro-benzenecarboperoxoic acid, 88% of <b>6r</b> was obtained according to the method described for the synthesis of <b>6</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 11.68 (bs, 1H), 8.85 (s, 1H), 8.80 (s, 1H), 7.69–7.77 (m, 2H), 7.35–7.38 (m, 2H), 6.06 (bs, 1H), 2.95 (s, 3H), 2.33–2.43 (m, 2H), 2.13–2.21 (m, 2H), 1.92–2.00 (m, 2H), 1.77–1.80 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 431.10; calcd for C<sub>20</sub>H<sub>19</sub>ClN<sub>4</sub>O<sub>3</sub>S <i>m</i>/<i>z</i>, 430.09.</div></div><div id="sec3_1_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> 8-Cyclopentyl-2-methylsulfinyl-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid (4-Fluoro-phenyl)-amide (<b>6s</b>)</h4><div class="NLM_p last">Starting from <b>5s</b> and <i>m</i>-chloroperbenzoic acid, 87% of <b>6s</b> was obtained according to the method described for the synthesis of <b>6</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 11.60 (bs, 1H), 8.86 (s, 1H), 8.81 (s, 1H), 7.71–7.77 (m, 2H), 6.96–7.09 (m, 2H), 6.03–6.13 (m, 1H), 2.96 (s, 3H), 2.33–2.42 (m, 2H), 2.13–2.21 (m, 2H), 1.92–2.00 (m, 2H), 1.71–1.80 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 415.10; calcd for C<sub>20</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>3</sub>S <i>m</i>/<i>z</i>, 414.12.</div></div><div id="sec3_1_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> General Procedure for 8-Alkyl/cycloalkyl-2-(aryl/heteroarylamino)-6-substituted-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine (<b>7</b>)</h4><div class="NLM_p last">The mixture of 8-alkyl-2-methylsulfinyl-6-substituted-7-oxo-7,8-dihydropyrido[2,3-<i>d</i>]pyrimidine <b>6</b> (1.65 mmol) and aryl/heteroaryl amines (2 mmol) in toluene was stirred at 100 °C for overnight. The reaction mixture was cooled, and solid was collected by filtration. The crude product was washed with toluene and purified by flash chromatography to get pure product.</div></div><div id="sec3_1_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> 2-Benzylamino-8-cyclopentyl-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7a</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and benzylamine, 51% of <b>7a</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 211–212 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.45 (s, 1H), 8.35 (s, 1H), 7.36–7.42 (m, 5H), 5.80–5.86 (m, 1H), 2.48 (s, 2H), 2.10 (bs, 2H), 1.91 (m, 2H), 1.66 (m, 2H), 1.54 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 346.20; calcd for C<sub>20</sub>H<sub>19</sub>N<sub>5</sub>O <i>m</i>/<i>z</i>, 345.16.</div></div><div id="sec3_1_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> 2-(4-Chloro-phenylamino)-8-cyclopentyl-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7b</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 4-chlorophenylamine, 50% of <b>7b</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 272–273 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.63 (s, 1H), 8.02 (s, 1H), 7.58–7.55 (m, 2H), 7.40–7.37 (m, 2H), 5.89–5.83 (m, 1H), 2.30–2.27 (m, 2H), 2.05 (bs, 2H), 1.90–1.87 (m, 2H), 1.71–1.67 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 366.20; calcd for C<sub>19</sub>H<sub>16</sub>ClN<sub>5</sub>O <i>m</i>/<i>z</i>, 365.10.</div></div><div id="sec3_1_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> 2-(4-Cyano-phenylamino)-8-cyclopentyl-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7c</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 4-aminobenzonitrile, 55% of <b>7c</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 285–287 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.61 (s, 1H), 8.03 (s, 1H), 7.62–7.59 (m, 2H), 7.45–7.43 (m, 2H), 5.92–5.89 (m, 1H), 2.31–2.28 (m, 2H), 2.15 (bs, 2H), 1.89–1.86 (m, 2H), 1.75–1.72 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 357.10; calcd for C<sub>20</sub>H<sub>16</sub>N<sub>6</sub>O <i>m</i>/<i>z</i>, 356.14.</div></div><div id="sec3_1_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> 8-Cyclopentyl-2-(2-hydroxy-phenylamino)-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7d</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 2-aminophenol, 42% of <b>7d</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 303–305 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 9.69 (bs, 1H), 8.76 (s, 1H), 8.52 (s, 1H), 7.42–7.45 (m, 1H), 7.03–7.08 (m, 1H), 6.89–6.90 (m, 1H), 6.79–6.84 (m, 1H), 5.58–5.59 (m, 1H), 3.37 (bs, 1H), 2.14–2.21 (m, 2H), 1.59–1.65 (m, 4H), 1.39–1.43 (M, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 348.20; calcd for C<sub>19</sub>H<sub>17</sub>N<sub>5</sub>O<sub>2</sub><i>m</i>/<i>z</i>, 347.14.</div></div><div id="sec3_1_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> 8-Cyclopentyl-2-(2-methoxy-phenylamino)-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7e</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 2-methoxyphenylamine, 54% of <b>7e</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 159–160 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.60 (s, 1H), 8.31–8.33 (m, 1H), 7.99 (s, 1H), 7.10–7.16 (m, 1H), 6.96–7.06 (m, 2H), 5.89–5.98 (m, 1H), 3.90 (s, 3H), 2.28–2.36 (m, 2H), 2.04–2.10 (m, 2H), 1.85–1.96 (m, 2H), 1.64–1.75 (M, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 362.20; calcd for C<sub>20</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub><i>m</i>/<i>z</i>, 361.15.</div></div><div id="sec3_1_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> 8-Cyclopentyl-2-(3-methoxy-phenylamino)-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7f</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 3-methoxyphenylamine, 50% of <b>7f</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 179–180 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 8.61 (s, 1H), 8.00 (s, 1H), 7.56 (bs, 1H), 7.35–7.36 (m, 1H), 7.17–7.19 (m, 1H), 7.05–7.07 (m, 1H), 6.73–6.76 (m, 1H), 5.88–5.94 (m, 1H), 3.85 (s, 3H), 2.24–2.33 (m, 2H), 2.05 (bs, 2H), 1.83–1.90 (m, 2H), 1.62–1.67 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 362.20; calcd for C<sub>20</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub><i>m</i>/<i>z</i>, 361.15.</div></div><div id="sec3_1_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> 8-Cyclopentyl-2-(4-methoxy-phenylamino)-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7g</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 4-methoxyphenylamine, 54% of <b>7g</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 238–239 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.57 (s, 1H), 7.97 (s, 1H), 7.42–7.47 (m, 2H), 6.92–6.97 (m, 2H), 5.83 (bs 1H), 3.84 (s, 3H), 2.21–2.30 (m, 2H), 1.85–2.05 (m, 4H), 1.61–1.74 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 362.30; calcd for C<sub>20</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub><i>m</i>/<i>z</i>, 361.15.</div></div><div id="sec3_1_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> 8-Cyclopentyl-2-(2,4-dimethoxy-phenylamino)-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7h</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 2,4-dimethoxyphenylamine, 52% of <b>7h</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 201–202 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.57 (s, 1H), 7.96 (s, 1H), 7.19–7.23 (m, 1H), 6.51–6.56 (m, 2H), 5.85–5.91 (m, 1H), 3.91 (s, 3H), 3.85 (s, 3H), 2.30 (bs, 2H), 2.03 (bs, 2H), 1.86–1.90 (m, 2H), 1.66–1.69 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 392.20; calcd for C<sub>21</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub><i>m</i>/<i>z</i>, 391.16.</div></div><div id="sec3_1_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> 8-Cyclopentyl-2-(3,4-dimethoxy-phenylamino)-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7i</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 3,4-dimethoxyphenylamine, 50% of <b>7i</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 215–216 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.58 (s, 1H), 7.98 (s, 1H), 7.16–7.26 (m, 1H), 6.90–6.98 (m, 1H), 6.84–6.87 (m, 1H), 5.84–5.95 (m, 1H), 3.91 (s, 6H), 2.20–2.29 (m, 2H), 1.84–2.13 (m, 4H), 1.61 (bs, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 392.20; calcd for C<sub>21</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub><i>m</i>/<i>z</i>, 391.16.</div></div><div id="sec3_1_85" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> 8-Cyclopentyl-2-(3,5-dimethoxy-phenylamino)-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7j</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 3,5-dimethoxyphenylamine, 52% of <b>7j</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 150–151 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.60 (s, 1H), 7.99 (s, 1H), 7.26 (s, 1H), 6.91–6.88 (m, 1H), 6.31–6.30 (m, 1H), 5.88–5.94 (m, 1H), 3.82 (s, 6H), 2.23–2.36 (m, 2H), 2.05–2.18 (m, 2H), 1.83–1.93 (m, 2H), 1.62–1.64 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 392.20; calcd for C<sub>21</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub><i>m</i>/<i>z</i>, 391.16.</div></div><div id="sec3_1_86" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> 8-Cyclopentyl-2-(3,4,5-trimethoxy-phenylamino)-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7k</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 3,4,5-trimethoxyphenylamine, 52% of <b>7k</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 169–170 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.59 (s, 1H), 8.01 (s, 1H), 6.91 (s, 2H), 5.93–5.99 (m, 1H), 3.90 (s, 6H), 3.87 (s, 3H), 2.23–2.32 (m, 2H), 2.03–2.14 (m, 2H), 1.85–1.92 (m, 2H), 1.52–1.58 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 422.30; calcd for C<sub>22</sub>H<sub>23</sub>N<sub>5</sub>O<sub>4</sub><i>m</i>/<i>z</i>, 421.18.</div></div><div id="sec3_1_87" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> 8-Cyclopentyl-2-(5-fluoro-2-methoxy-phenylamino)-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7l</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 5-fluoro-2-methoxy-phenylamine, 50% of <b>7l</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 241–243 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.65 (s, 1H), 8.02 (s, 1H), 7.16–7.19 (m, 1H), 6.76–6.89 (m, 2H), 5.85–8.97 (m, 1H), 3.94 (s, 3H), 2.33–2.36 (m, 2H), 2.05–2.13 (m, 2H), 1.90–1.98 (m, 2H), 1.71–1.75 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 380.20; calcd for C<sub>20</sub>H<sub>18</sub>FN<sub>5</sub>O<sub>2</sub><i>m</i>/<i>z</i>, 379.14.</div></div><div id="sec3_1_88" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> 8-Cyclopentyl-7-oxo-2-(pyridin-2-ylamino)-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7m</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 2-aminopyridine, 48% of <b>7m</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 284–286 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.74 (s, 1H), 8.42–8.43 (m, 1H), 8.29–8.32 (m, 1H), 8.08 (s, 1H), 7.75–7.81 (m, 1H), 7.07–7.12 (m, 1H), 5.87–5.93 (m, 1H), 2.30–2.33 (m, 2H), 2.11–2.14 (m, 2H), 1.92–1.98 (m, 2H), 1.68–1.74 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 333.20; calcd for C<sub>18</sub>H<sub>16</sub>N<sub>6</sub>O <i>m</i>/<i>z</i>, 332.14.</div></div><div id="sec3_1_89" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> 2-(4-Cyano-pyridin-2-ylamino)-8-cyclopentyl-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7n</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 2-amino-4-cyanopyridine, 40% of <b>7n</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 285–287 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 11.29 (s, 1H), 8.96 (s, 1H), 8.65 (s, 1H), 8.59–8.61 (m, 1H), 8.49 (s, 1H), 7.54–7.56 (m, 1H), 5.72–5.80 (m, 1H), 2.18–2.25 (m, 2H), 1.83–1.93 (m, 4H), 1.56–1.68 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 358.20; calcd for C<sub>19</sub>H<sub>15</sub>N<sub>7</sub>O <i>m</i>/<i>z</i>, 357.13.</div></div><div id="sec3_1_90" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> 8-Cyclopentyl-2-(1<i>H</i>-indole-4-ylamino)-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7o</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 4-aminoindole, 40% of <b>7o</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 320–322 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 11.15 (bs, 1H), 10.36 (bs, 1H), 9.80 (s, 1H), 8.53 (s, 1H), 7.05–7.29 (m, 4H), 6.50 (bs, 1H), 5.62 (bs, 1H), 2.06 (bs, 2H), 1.35–1.60 (m, 6H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 371.30; calcd for C<sub>21</sub>H<sub>18</sub>N<sub>6</sub>O <i>m</i>/<i>z</i>, 370.15.</div></div><div id="sec3_1_91" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> 8-Cyclopentyl-2-(1<i>H</i>-indole-5-ylamino)-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7p</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 5-aminoindole, 42% of <b>7p</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 192–193 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 11.09 (bs, 1H), 10.57 (bs, 1H), 8.80 (s, 1H), 8.51 (s, 1H), 7.10–7.37 (m, 4H), 6.36 (s, 1H), 5.73–5.87 (m, 1H), 2.18–2.28 (m, 2H), 1.70–1.89 (m, 4H), 1.45–1.57 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 371.20; calcd for C<sub>21</sub>H<sub>18</sub>N<sub>6</sub>O <i>m</i>/<i>z</i>, 370.15.</div></div><div id="sec3_1_92" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> 8-Cyclopentyl-7-oxo-2-[quinolin-3-ylamino]-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7q</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 3-aminoquinoline, 40% of <b>7q</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 212–213 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 10.92 (bs, 1H), 8.07–9.08 (m, 1H), 8.88 (s, 1H), 8.69–8.70 (m, 1H), 8.62 (s, 1H), 7.99–8.09 (m, 1H), 7.81–7.85 (m, 1H), 7.58–7.68 (m, 2H), 5.85–5.87 (m, 1H), 2.10–2.28 (m, 2H), 1.85 (bs, 4H), 1.56 (bs, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 383.30; calcd for C<sub>22</sub>H<sub>18</sub>N<sub>6</sub>O <i>m</i>/<i>z</i>, 382.15.</div></div><div id="sec3_1_93" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> 8-Cyclopentyl-7-oxo-2-[quinolin-8-ylamino]-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7r</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 8-aminoquinoline, 40% of <b>7r</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 222–224 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 10.84 (bs, 1H), 8.91 (s, 1H), 8.79–8.81 (m, 1H), 8.62 (s, 1H), 8.39–8.41 (m, 1H), 8.18–8.21 (m, 1H), 7.94–8.02 (m, 2H), 7.50–7.54 (m, 1H), 5.87–5.89 (m, 1H), 2.20–2.28 (m, 2H), 1.83–1.87 (m, 4H), 1.57–1.59 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 383.20; calcd for C<sub>22</sub>H<sub>18</sub>N<sub>6</sub>O <i>m</i>/<i>z</i>, 382.15.</div></div><div id="sec3_1_94" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> 8-Cyclopentyl-2-(2-methoxy-quinolin-6-ylamino)-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7s</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 6-amino-2-methoxy-quinoline, 40% of <b>7s</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 223–224 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 10.82 (bs, 1H), 8.64 (s, 1H), 8.10–8.11 (m, 1H), 8.01 (s, 1H), 7.90–7.96 (m, 1H), 7.86 (s, 1H), 7.68–6.72 (m, 1H), 6.95 (d, 1H), 5.86–5.98 (m, 1H), 4.09 (s, 3H), 2.29–2.36 (m, 2H), 2.01 (bs, 2H), 1.88–1.95 (m, 2H), 1.65 (bs, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 413.20; calcd for C<sub>23</sub>H<sub>20</sub>N<sub>6</sub>O<sub>2</sub><i>m</i>/<i>z</i>, 412.16.</div></div><div id="sec3_1_95" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124"> 8-Cyclopentyl-2-(4-morpholin-4-yl-phenylamino)-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7t</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 4-morpholin-4-yl-phenylamine, 53% of <b>7t</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 294–296 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.55 (s, 1H), 7.98 (s, 1H), 7.43–7.48 (m, 2H), 6.93–6.99 (m, 2H), 5.82–5.89 (m, 1H), 3.87–3.92 (m, 4H), 3.15–3.22 (m, 4H), 2.22–2.31 (m, 2H), 1.80–1.91 (m, 4H), 1.59–1.68 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 417.10; calcd for C<sub>23</sub>H<sub>24</sub>N<sub>6</sub>O<sub>2</sub><i>m</i>/<i>z</i>, 416.20.</div></div><div id="sec3_1_96" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> 8-Cyclopentyl-2-(5-morpholin-4-yl-pyridin-2-ylamino)-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>] pyrimidine-6-carbonitrile (<b>7u</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 5-morpholin-4-yl-pyridin-2-ylamine, 40% of <b>7u</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 240–242 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 10.30 (bs, 1H), 8.57 (s, 1H), 8.31 (s, 1H), 7.87–7.87 (m, 1H), 7.84–7.88 (m, 1H), 6.71 (d, 1H), 5.80 (bs, 1H), 3.88–3.84 (m, 4H), 3.55–3.52 (m, 4H), 2.22–2.06 (m, 2H), 1.63–1.29 (m, 6H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 418.20; calcd for C<sub>22</sub>H<sub>23</sub>N<sub>7</sub>O<sub>2</sub><i>m</i>/<i>z</i>, 417.19.</div></div><div id="sec3_1_97" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> 8-Cyclopentyl-2-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7v</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamine <b>22</b>, 50% of <b>7v</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 295–297 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 10.53 (bs, 1H), 8.82 (s, 1H), 8.56 (s, 1H), 8.08 (d, 1H), 7.77 (d, 1H), 7.49–7.45 (m, 1H), 5.79–5.73 (m, 1H), 3.19–3.17 (m, 4H), 2.55–2.52 (m, 4H), 2.32 (s, 3H), 2.19–2.16 (m, 2H), 1.84–1.75 (m, 4H), 1.58–1.55 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 431.20; calcd for C<sub>23</sub>H<sub>26</sub>N<sub>8</sub>O <i>m</i>/<i>z</i>, 430.22.</div></div><div id="sec3_1_98" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> 8-Cyclopentyl-7-oxo-2-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7w</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 1-(5-trifluoromethyl-pyridin-2-yl)-piperazine, 40% of <b>7w</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 259–260 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.53 (s, 1H), 8.44 (s, 1H), 7.94 (s, 1H), 7.68–7.71 (m, 1H), 6.68–6.71 (m, 1H), 5.82–5.88 (m, 1H), 4.09–4.14 (m, 4H), 3.82 (bs, 4H), 2.27–2.38 (m, 2H), 2.02–2.09 (m, 2H), 1.82–1.93 (m, 2H), 1.70–1.76 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 470.10; calcd for C<sub>23</sub>H<sub>22</sub>F<sub>3</sub>N<sub>7</sub>O <i>m</i>/<i>z</i>, 469.18.</div></div><div id="sec3_1_99" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7x</b>)</h4><div class="NLM_p last">Starting from <b>6i</b> and 4-(4-methyl-piperazin-1-yl)-phenyl amine <b>21</b>, 55% of <b>7x</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 290–292 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.55 (s, 1H), 7.79 (s, 1H), 7.40–7.45 (m, 2H), 6.91–6.99 (m, 2H), 5.83–5.84 (m, 1H), 3.23–3.27 (m, 4H), 2.63–2.66 (m, 4H), 2.43 (s, 3H), 2.21–2.30 (m, 2H), 1.85 (bs, 4H), 1.62 (bs, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 300 MHz) δ 25.6, 28.0, 46.1, 49.2, 54.7, 55.0, 102.9, 105.6, 105.7, 115.3, 116.3, 123.0, 129.3, 143.4, 148.9, 157.0, 160.2. HPLC purity 99.63%, retention time 8.41 min. HRMS: <i>m</i>/<i>z</i> calcd [M + H], 430.2355; found, 430.2374. Anal. Calcd for C<sub>24</sub>H<sub>27</sub>N<sub>7</sub>O: C 67.11, H 6.34, N 22.83. Found: C 67.00, H 6.27, N 22.77.</div></div><div id="sec3_1_100" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> 2-[4-(4-Methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7y</b>)</h4><div class="NLM_p last">Starting from <b>6a</b> and 4-(4-methyl-piperazin-1-yl)-phenylamine <b>21</b>, 45% of <b>7y</b> was obtained according to the method described for the synthesis of <b>7</b>; mp >300 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 13.10 (bs, 1H), 9.03 (s, 1H), 8.82 (s, 1H), 7.85–7.82 (m, 2H), 7.55–7.53 (m, 2H), 3.88–3.86 (m, 4H), 2.97–2.95 (m, 4H), 2.47 (s, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 362.20; calcd for C<sub>19</sub>H<sub>19</sub>N<sub>7</sub>O <i>m</i>/<i>z</i>, 361.17.</div></div><div id="sec3_1_101" class="NLM_sec NLM_sec_level_3"><div id="ac_i130" class="anchor-spacer"></div><h4 class="article-section__title" id="_i130"> 8-Methyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>] pyrimidine-6-carbonitrile (<b>7z</b>)</h4><div class="NLM_p last">Starting from <b>6b</b> and 4-(4-methyl-piperazin-1-yl)-phenylamine <b>21</b>, 55% of <b>7z</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 211–212 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 8.57 (s, 1H), 8.04 (s, 1H), 7.89 (bs, 1H), 7.58–7.54 (m, 2H), 7.12–7.09 (m, 2H), 3.30–3.24 (m, 4H), 2.65–2.61 (m, 4H), 2.65 (s, 3H), 2.44 (s, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 376.20; calcd for C<sub>20</sub>H<sub>21</sub>N<sub>7</sub>O <i>m</i>/<i>z</i>, 375.18.</div></div><div id="sec3_1_102" class="NLM_sec NLM_sec_level_3"><div id="ac_i131" class="anchor-spacer"></div><h4 class="article-section__title" id="_i131"> 8-Ethyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>] pyrimidine-6-carbonitrile (<b>7aa</b>)</h4><div class="NLM_p last">Starting from <b>6c</b> and 4-(4-methyl-piperazin-1-yl)-phenylamine <b>21</b>, 60% of <b>7aa</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 262–264 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 8.58 (s, 1H), 8.01 (s, 1H), 7.71 (bs, 1H), 7.53–7.50 (m, 2H), 6.99–6.96 (m, 2H), 4.44 (q, 2H), 3.27–3.24 (m, 4H), 2.67–2.63 (m, 4H), 2.40 (s, 3H), 1.36 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 390.20; calcd for C<sub>21</sub>H<sub>23</sub>N<sub>7</sub>O <i>m</i>/<i>z</i>, 389.20.</div></div><div id="sec3_1_103" class="NLM_sec NLM_sec_level_3"><div id="ac_i132" class="anchor-spacer"></div><h4 class="article-section__title" id="_i132"> 2-[4-(4-Methyl-piperazin-1-yl)-phenylamino]-7-oxo-8-propyl-7,8-dihydro-pyrido[2,3-<i>d</i>] pyrimidine-6-carbonitrile (<b>7ab</b>)</h4><div class="NLM_p last">Starting from <b>6d</b> and 4-(4-methyl-piperzin-1-yl)-phenylamine <b>21</b>, 52% of <b>7ab</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 291–293 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.56 (s, 1H), 8.07 (s, 1H), 7.51–7.57 (m, 2H), 6.93–6.99 (2H), 4.30 (t, 2H), 3.21–3.25 (m, 4H), 2.61–2.63 (m, 4H), 2.38 (s, 3H), 1.73–1.78 (m, 2H), 1.02 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 404.21; calcd for C<sub>22</sub>H<sub>25</sub>N<sub>7</sub>O <i>m</i>/<i>z</i>, 403.21.</div></div><div id="sec3_1_104" class="NLM_sec NLM_sec_level_3"><div id="ac_i133" class="anchor-spacer"></div><h4 class="article-section__title" id="_i133"> 8-Isopropyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7ac</b>)</h4><div class="NLM_p last">Starting from <b>6e</b> and 4-(4-methyl-piperazin-1-yl)-phenylamine <b>21</b>, 65% of <b>7ac</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 296–298 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.56 (s, 1H), 7.96 (s, 1H), 7.47–7.44 (m, 2H,), 6.99–6.96 (m, 2H), 5.78–5.71 (m, 1H), 3.27–3.24 (bs, 4H), 2.66–2.62 (m, 4H), 2.40 (s, 3H), 1.60–1.57 (m, 6H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 404.30; calcd for C<sub>22</sub>H<sub>25</sub>N<sub>7</sub>O <i>m</i>/<i>z</i>, 403.21.</div></div><div id="sec3_1_105" class="NLM_sec NLM_sec_level_3"><div id="ac_i134" class="anchor-spacer"></div><h4 class="article-section__title" id="_i134"> 8-Butyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7ad</b>)</h4><div class="NLM_p last">Starting from <b>6f</b> and 4-(4-methyl-piperazin-1-yl)-phenylamine <b>21</b>, 60% of <b>7ad</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 282–283 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 8.58 (s, 1H), 8.00 (s, 1H), 7.64 (bs, 1H), 7.54–7.52 (m, 2H), 6.98–6.95 (m, 2H), 4.37–4.32 (m, 2H), 3.30–3.26 (m, 4H), 2.73–2.70 (m, 4H), 2.45 (s, 3H), 1.75–1.68 (m, 2H), 1.49–126 (m, 2H), 1.01–0.94 (t, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 418.30; calcd for C<sub>23</sub>H<sub>27</sub>N<sub>7</sub>O <i>m</i>/<i>z</i>, 417.23.</div></div><div id="sec3_1_106" class="NLM_sec NLM_sec_level_3"><div id="ac_i135" class="anchor-spacer"></div><h4 class="article-section__title" id="_i135"> 2-[4-(4-Methyl-piperazin-1-yl)-phenylamino]-7-oxo-8-pentyl-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7ae</b>)</h4><div class="NLM_p last">Starting from <b>6g</b> and 4-(4-methyl-piperazin-1-yl)-phenylamine <b>21</b>, 60% of <b>7ae</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 291–292 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 10.48 (bs, 1H), 8.80 (s, 1H), 8.56 (s, 1H), 7.64–7.62 (m, 2H,), 6.95–6.92 (m, 2H), 4.18 (bs, 2H), 3.34 (bs, 4H), 3.14 (bs, 4H), 2.30 (s, 3H), 1.63 (bs, 2H), 1.33 (bs, 4H), 0.86 (bs, 3H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 432.40; calcd for C<sub>24</sub>H<sub>29</sub>N<sub>7</sub>O <i>m</i>/<i>z</i>, 431.24.</div></div><div id="sec3_1_107" class="NLM_sec NLM_sec_level_3"><div id="ac_i136" class="anchor-spacer"></div><h4 class="article-section__title" id="_i136"> 8-Cyclopropyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7af</b>)</h4><div class="NLM_p last">Starting from <b>6h</b> and 4-(4-methyl-piperazin-1-yl)-phenylamine <b>21</b>, 55% of <b>7af</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 285–287 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 10.44 (bs, 1H), 8.74 (s, 1H), 8.50 (s, 1H), 7.84–7.82 (m, 2H,), 6.98–6.95 (m, 2H), 3.36–3.34 (bs, 4H), 3.15–3.12 (m, 4H), 2.91–2.85 (m, 1H), 2.29 (s, 3H), 1.25 (bs, 2H), 0.86 (bs, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 402.30; calcd for C<sub>22</sub>H<sub>23</sub>N<sub>7</sub>O <i>m</i>/<i>z</i>, 401.20.</div></div><div id="sec3_1_108" class="NLM_sec NLM_sec_level_3"><div id="ac_i137" class="anchor-spacer"></div><h4 class="article-section__title" id="_i137"> 8-Cyclohexyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7ag</b>)</h4><div class="NLM_p last">Starting from <b>6j</b> and 4-(4-methyl-piperazin-1-yl)-phenylamine <b>21</b>, 52% of <b>7ag</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 279–281 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.53 (s, 1H), 7.94 (s, 1H), 7.45–7.66 (m, 2H), 6.95–6.98 (m, 2H), 5.43–5.47 (m, 1H), 3.22–3.26 (m, 4H), 2.62–2.65 (m, 4H), 2.39 (s, 3H), 1.88 (bs, 2H), 1.64 (bs, 4H), 1.33 (bs, 4H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 444.30; calcd for C<sub>25</sub>H<sub>29</sub>N<sub>7</sub>O <i>m</i>/<i>z</i>, 443.24.</div></div><div id="sec3_1_109" class="NLM_sec NLM_sec_level_3"><div id="ac_i138" class="anchor-spacer"></div><h4 class="article-section__title" id="_i138"> 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-6-nitro-8<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidin-7-one (<b>7ah</b>)</h4><div class="NLM_p last">Starting from <b>6k</b> and 4-(4-methyl-piperazin-1-yl)-phenylamine <b>21</b>, 55% of <b>7ah</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 220–222 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 8.67 (s, 1H), 8.46 (s, 1H), 7.72 (bs, 1H), 7.47–7.44 (m, 2H), 6.99–6.96 (m, 2H), 5.90 (bs, 1H), 3.28–3.25 (bs, 4H), 2.68–2.64 (m, 4H), 2.41 (s, 3H), 2.32–2.28 (m, 2H), 2.07 (bs, 2H), 1.88 (bs, 2H), 1.63 (bs, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 450.20; calcd for C<sub>23</sub>H<sub>27</sub>N<sub>7</sub>O<sub>3</sub><i>m</i>/<i>z</i>, 449.22.</div></div><div id="sec3_1_110" class="NLM_sec NLM_sec_level_3"><div id="ac_i139" class="anchor-spacer"></div><h4 class="article-section__title" id="_i139"> 8-Cyclopentyl-6-methylsulfonyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-8<i>H</i>-pyrido[2, 3-<i>d</i>]pyrimidin-7-one (<b>7ai</b>)</h4><div class="NLM_p last">Starting from <b>6l</b> and 4-(4-methyl-piperazin-1-yl)-phenyl amine <b>21</b>, 52% of <b>7ai</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 255–257 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.56 (s, 1H), 8.35 (s, 1H), 7.35 (d, 2H), 6.90 (d, 2H), 5.75 (bs, 1H), 3.25 (s, 3H), 3.14–3.23 (m, 4H), 2.52–2.55 (m, 4H), 2.30 (s, 3H), 2.12–2.27 (m, 2H), 1.75–1.97 (m, 2H), 1.57–1.76 (m, 4H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 483.20; calcd for C<sub>24</sub>H<sub>30</sub>N<sub>6</sub>O<sub>3</sub>S <i>m</i>/<i>z</i>, 482.21.</div></div><div id="sec3_1_111" class="NLM_sec NLM_sec_level_3"><div id="ac_i140" class="anchor-spacer"></div><h4 class="article-section__title" id="_i140"> 6-Benzenesulfonyl-8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-8<i>H</i>-pyrido [2,3-<i>d</i>]pyrimidine-7-one (<b>7aj</b>)</h4><div class="NLM_p last">Starting from <b>6m</b> and 4-(4-methyl-piperazin-1-yl)-phenylamine <b>21</b>, 51% of <b>7aj</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 199–200 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.65 (s, 1H), 8.58 (s, 1H), 8.09–8.13 (m, 2H), 7.55–7.63 (m, 3H), 7.37–7.46 (m, 1H), 7.13–7.24 (m, 1H), 6.80–6.96 (m, 2H), 5.82–5.84 (m, 1H), 3.22–3.32 (m, 4H), 2.63–2.71 (m, 4H), 2.46 (s, 3H), 2.18–2.33 (m, 2H), 1.45–1.76 (m, 6H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 545.30; calcd for C<sub>29</sub>H<sub>32</sub>N<sub>6</sub>O<sub>3</sub>S <i>m</i>/<i>z</i>, 544.23.</div></div><div id="sec3_1_112" class="NLM_sec NLM_sec_level_3"><div id="ac_i141" class="anchor-spacer"></div><h4 class="article-section__title" id="_i141"> 6-(4-Chloro-benzenesulfonyl)-8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-8<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidine-7-one (<b>7ak</b>)</h4><div class="NLM_p last">Starting from <b>6n</b> and 4-(4-methyl-piperazin-1-yl)-phenylamine <b>21</b>, 50% of <b>7ak</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 220–221 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.64 (s, 1H), 8.62 (s, 1H), 8.04–8.06 (m, 2H), 7.49–7.50 (m, 2H), 7.37–7.40 (m, 2H), 6.92–6.95 (m, 2H), 5.65–5.69 (m, 1H), 3.23–3.27 (m, 4H), 2.67–2.70 (m, 4H), 2.42 (s, 3H), 2.09–2.2.20 (m, 2H), 1.71–1.82 (m, 4H), 1.51–1.63 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 579.30; calcd for C<sub>29</sub>H<sub>31</sub>ClN<sub>6</sub>O<sub>3</sub>S <i>m</i>/<i>z</i>, 578.19.</div></div><div id="sec3_1_113" class="NLM_sec NLM_sec_level_3"><div id="ac_i142" class="anchor-spacer"></div><h4 class="article-section__title" id="_i142"> 6-(4-Chloro-phenylmethanesulfonyl)-8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenyl-amino]-8<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidine-7-one (<b>7al</b>)</h4><div class="NLM_p last">Starting from <b>6o</b> and 4-(4-methyl-piperazin-1-yl)-phenylamine <b>21</b>, 60% of <b>7al</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 200–202 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 10.59 (bs, 1H), 8.98 (s, 1H), 8.41 (s, 1H), 8.09–8.11 (m, 1H), 7.77–7.81 (d, 2H), 7.48–7.53 (m, 1H), 7.33–7.42 (m, 2H), 7.20–7.31 (m, 2H), 5.75–7.91 (m, 1H), 4.83 (s, 2H), 3.24–3.29 (m, 4H), 2.68–2.72 (m, 4H), 2.31–2.44 (s, 3H), 2.37 (m, 2H), 2.11–2.20 (m, 2H), 1.55–2.05 (m, 4H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 593.10; calcd for C<sub>30</sub>H<sub>33</sub>ClN<sub>6</sub>O<sub>3</sub>S <i>m</i>/<i>z</i>, 592.20.</div></div><div id="sec3_1_114" class="NLM_sec NLM_sec_level_3"><div id="ac_i143" class="anchor-spacer"></div><h4 class="article-section__title" id="_i143"> 8-Cyclopentyl-6-(3-hydroxy-4-methoxy-phenylmethanesulfonyl)-2-[4-(4-methyl-piperzin-1-yl)-phenylamino]-8<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidin-7-one (<b>7am</b>)</h4><div class="NLM_p last">Starting from <b>6p</b> and 4-(4-methyl-piperazin-1-yl)-phenylamine <b>21</b>, 53% of <b>7am</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 165–166 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6,</sub> 300 MHz) δ 10.35 (bs, 1H), 9.08 (s, 1H), 8.88 (s, 1H), 7.46–7.51 (m, 2H), 6.95–6.92 (m, 2H), 6.83 (d, 1H), 6.67–6.68 (m, 1H), 6.56–6.60 (m, 1H), 5.89 (bs, 1H), 4.61 (s, 2H), 3.71 (s, 3H), 2.48–2.50 (m, 4H), 2.42–2.45 (m, 4H), 2.41 (s, 3H), 2.23–2.25 (m, 2H), 1.83–1.97 (m, 4H), 1.60 (bs, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 605.30; calcd for C<sub>31</sub>H<sub>36</sub>N<sub>6</sub>O<sub>5</sub>S <i>m</i>/<i>z</i>, 604.25.</div></div><div id="sec3_1_115" class="NLM_sec NLM_sec_level_3"><div id="ac_i144" class="anchor-spacer"></div><h4 class="article-section__title" id="_i144"> 8-Cyclopentyl-6-(4-methoxy-3-nitro-phenylmethanesulfonyl)-2-[4-(4-methyl-piperzin-1-yl)-phenylamino]-8<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidin-7-one (<b>7an</b>)</h4><div class="NLM_p last">Starting from <b>6q</b> and 4-(4-methyl-piperazin-1-yl)-phenylamine <b>21</b>, 45% of <b>7an</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 260–262 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.52 (s, 1H), 8.12 (s, 1H), 7.80–7.81 (m, 1H), 7.59–7.62 (m, 1H), 7.38–7.42 (m, 2H), 7.02–7.05 (m, 1H), 6.91–1.94 (m, 2H), 5.89 (bs, 1H), 4.81 (s, 2H), 3.93 (s, 3H), 3.23–2.35 (m, 4H), 2.64–2.66 (m, 4H), 2.41 (s, 3H), 1.93–2.05 (m, 6H), 1.64–1.76 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 634.30; calcd for C<sub>31</sub>H<sub>35</sub>N<sub>7</sub>O<sub>6</sub>S <i>m</i>/<i>z</i>, 633.24.</div></div><div id="sec3_1_116" class="NLM_sec NLM_sec_level_3"><div id="ac_i145" class="anchor-spacer"></div><h4 class="article-section__title" id="_i145"> 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid (4-Chloro-phenyl)-amide (<b>7ao</b>)</h4><div class="NLM_p last">Starting from <b>6r</b> and 4-(4-methyl-piperazin-1-yl)-phenylamine <b>21</b>, 55% of <b>7ao</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 301–302 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 11.79 (s, 1H), 10.23 (bs, 1H), 8.77 (s, 1H), 8.67 (s, 1H), 7.71–7.74 (m, 2H), 7.44–7.61 (m, 2H), 7.31–7.33 (m, 2H), 6.91–6.99 (m, 2H), 5.89–6.03 (m, 1H), 3.47–3.499 (m, 4H), 3.22–3.25 (m, 4H), 2.63 (s, 3H), 2.28–2.38 (m, 2H), 1.89–2.05 (m, 4H), 1.67 (bs 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 558.30; calcd for C<sub>30</sub>H<sub>32</sub>ClN<sub>7</sub>O<sub>2</sub><i>m</i>/<i>z</i>, 557.23.</div></div><div id="sec3_1_117" class="NLM_sec NLM_sec_level_3"><div id="ac_i146" class="anchor-spacer"></div><h4 class="article-section__title" id="_i146"> 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carboxylic Acid (4-Fluoro-phenyl)-amide (<b>7ap</b>)</h4><div class="NLM_p last">Starting from <b>6s</b> and 4-(4-methyl-piperazin-1-yl)-phenylamine <b>21</b>, 55% of <b>7ap</b> was obtained according to the method described for the synthesis of <b>7</b>; mp 289–290 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 11.63 (bs, 1H), 10.25 (bs, 1H), 9.01 (s, 1H), 8.77 (s, 1H), 7.76–7.77 (m, 2H), 7.43–7.52 (m, 2H), 7.19–7.29 (m, 2H), 6.92–6.95 (m, 2H), 5.88–5.97 (m, 1H), 3.08–3.11 (m, 4H), 2.50 (s, 3H), 2.45–2.48 (m, 4H), 2.20–2.30 (m, 2H), 1.81–1.96 (m, 4H), 1.46–1.60 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 542.30; calcd for C<sub>30</sub>H<sub>32</sub>FN<sub>7</sub>O<sub>2</sub><i>m</i>/<i>z</i>, 541.26.</div></div><div id="sec3_1_118" class="NLM_sec NLM_sec_level_3"><div id="ac_i147" class="anchor-spacer"></div><h4 class="article-section__title" id="_i147"> <i>N</i>-(6-Cyano-8-cyclopentyl-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrim-idin-2-yl)-<i>N</i>-[4-(4-methyl-piperazin-1-yl)-phenyl]-acetamide (<b>7aq</b>)</h4><div class="NLM_p last">The compound <b>7x</b> (1 g, 2.3 mmol) was taken into acetic anhydride and stirred at 120 °C temperature for 3 h. The reaction mixture was cooled to room temperature, and the crude product was filtered. The pure product <b>7aq</b> was obtained by flash chromatography with 2% methanol in chloroform. Yield 64%; light orange solid, mp 223–224 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.88 (s, 1H), 8.11 (s, 1H), 7.12–7.09 (m, 2H), 7.01–6.97 (m, 2H), 5.61–5.55 (m, 1H), 3.30–3.26 (m, 4H), 2.62–2.59 (m, 4H), 2.42 (s, 3H), 2.38 (s, 3H), 2.11–2.04 (m, 2H), 1.72–1.68 (m, 4H), 1.54–1.51 (m, 2H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 472.30; calcd for C<sub>26</sub>H<sub>29</sub>N<sub>7</sub>O<sub>2</sub><i>m</i>/<i>z</i>, 471.24.</div></div><div id="sec3_1_119" class="NLM_sec NLM_sec_level_3"><div id="ac_i148" class="anchor-spacer"></div><h4 class="article-section__title" id="_i148"> <i>N</i>-(6-Cyano-8-cyclopentyl-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidin-2-yl)-<i>N</i>-[4-(4-methyl-piperazin-1-yl)-phenyl]-4-trifluoromethyl-benzamide (<b>7ar</b>)</h4><div class="NLM_p last">The compound <b>7x</b> (1 g, 2.3 mmol) was taken into DMF and NaH was added at room temperature. After 10 min, 4-trifluoromethyl benzoyl chloride (0.58 g, 2.8 mmol) was added and stirring continued for about 1 h. The reaction mixture was quenched with water and filter off the crude product, and it was purified with column chromatography by using 1–2% methanol in dichloromethane as eluents. Yield 62%; brown solid, mp 155–156 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.60 (s, 1H), 7.97 (s, 1H), 7.72 (d, 2H), 7.56 (d, 2H), 7.07–7.04 (m, 2H), 6.91–6.88 (m, 2H), 5.01–4.95 (m, 1H), 3.21–3.18 (m, 4H), 2.52–2.48 (m, 4H), 2.29 (s, 3H), 1.87–1.85 (m, 2H), 1.69–1.68 (m, 2H), 1.35–1.33 (m, 4H). MS found (M + H)<sup>+</sup> (<i>m</i>/<i>z</i>), 602.30; calcd for C<sub>32</sub>H<sub>30</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub><i>m</i>/<i>z</i>, 601.24.</div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i149" class="anchor-spacer"></div><h3 class="article-section__title" id="_i149"> Biology: Materials and Methods</h3><div class="NLM_p">Cell lines were purchased from ATCC and were maintained in DMEM or RPM1 (CellGro) supplemented with 10% fetal bovine serum (Cellgeneration, CO) and 1 unit/mL penicillin–streptomycin (Invitrogen) at 37 °C under humidified conditions.</div><div id="sec3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i150" class="anchor-spacer"></div><h4 class="article-section__title" id="_i150"> Cytotoxicity Assays</h4><div class="NLM_p last">Cells were seeded at a cell density of 1.5 × 10<sup>3</sup> cells/0.1 mL/well in a 96-well plate. The compounds were added 24 h postplating at the indicated concentrations. Cell counts were determined from duplicate wells 96 h post-treatment. The total number of viable cells was determined using the Cell Titer Blue assay (Promega, WI) in conjunction with the GloMax plate reader (Promega, WI).</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i151" class="anchor-spacer"></div><h4 class="article-section__title" id="_i151"> Kinase Assays and IC<sub>50</sub> Determination</h4><div class="NLM_p last">First, 10 ng of recombinant CDK4/cyclin D1 (Life Technologies PV4204) was diluted in kinase buffer (20 mM Tris pH 7.5, 10 mM MgCl<sub>2</sub>, 0.01% NP-40, 2 mM DTT) and incubated with the indicated concentration of inhibitor at room temperature for 30 min. Kinase reactions were initiated by the addition of 1 μg (1.5 μM) of recombinant Rb protein, 5 μM ATP, and 10 μCi γ-<sup>32</sup>P-ATP. The reactions were incubated at 30 °C for 20 min, terminated by the addition of 2× Laemmli sample buffer, heated at 95 °C for 3 min, resolved using 12% acrylamide SDS-PAGE, and subjected to autoradiography. The autoradiograms were scanned, and the band corresponding to the phosphorylated protein substrate was quantitated using a densitometer (Bio-Rad). The densitometric values obtained were plotted as a function of log drug concentration using Prism 4 Graphpad software and IC<sub>50</sub> values determined by plotting sigmoidal nonlinear regression curves with a variable slope.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i152" class="anchor-spacer"></div><h4 class="article-section__title" id="_i152"> Flow Cytometry</h4><div class="NLM_p last">MCF-7 (human estrogen positive breast carcinoma) and MDA-MB-231 (human triple negative breast carcinoma) cells were plated onto 100 mm<sup>2</sup> dishes at a cell density of 1.0 × 10<sup>6</sup> cells/dish. All cells were treated with increasing concentrations of the indicated compounds 24 h postplating. Both nonadherent cells (floating) and adherent cells were harvested 24 h post-treatment, washed in phosphate buffered saline (PBS), and fixed in ice cold 70% ethanol for at least 24 h. The fixed cells were then washed with room temperature PBS and stained with propidium iodide (50 mg/mL) in the presence of RNase A (0.5 mg) for 30 min at 37 °C. The stained cells were then analyzed using a FACSCAN (BD Biosciences) and the resulting data analyzed with cell cycle analysis software (Modfit, BD).</div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i153" class="anchor-spacer"></div><h4 class="article-section__title" id="_i153"> Western Blot Analysis</h4><div class="NLM_p last">Cells were treated with increasing concentrations of compound and harvested 24 h post-treatment. All cell pellets were frozen on dry ice before lysis. Cells were lysed in lysis buffer ((50 mM Tris-HCl, 0.1% Triton-X100, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 0.1 mM sodium orthovanadate (pH 7.4), and protease inhibitors), and 100 μg of clarified lysates were resolved by 10%-SDS-polyacrylamide gel electrophoresis. The resolved proteins were transferred onto nitrocellulose filter paper and hybridized with the following antibodies: phosphospecific Rb (Cell Signaling; catalogue no. 9307), Rb (Cell Signaling; catalogue no. 9309), AKT (Cell Signaling, catalogue no. 4691), phosphospecific AKT Ser473 (Cell Signaling; catalogue no. 9271), and PARP (BD Biosciences; catalogue no. 556362). Lysates used for Western blot analysis to detect cleaved PARP were obtained as above except that the cells were lysed in 1% NP40/PBS lysis buffer containing protease inhibitors. Following hybridization with primary antibodies, the blots were washed, treated with secondary antibodies conjugated to infrared dyes (IRDye 800 or IRDye 680) and analyzed on an infrared scanning system (Odyssey, Li-Cor Biosciences, NE) according to the manufacturer’s instructions.</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i154" class="anchor-spacer"></div><h4 class="article-section__title" id="_i154"> Orthotopic Nude Mouse Assay</h4><div class="NLM_p last">MDA-MB-231 triple negative breast cancer cells (1 × 10<sup>6</sup>) were injected bilaterally in the mammary fat pads of 7–8 week old female athymic nude mice (NCR nu/nu, Taconic, NY). Once the tumors grew to a volume of approximately 100 mm<sup>3</sup>, they were placed into two treatment groups (<i>n</i> = 6, with a total tumor number of 11). The mice were treated daily for 15 days (QD × 15), a dose of 100 mg/kg (0.1 mL, intraperitoneally), or placebo (sterile PBS). Body weights and tumor size were determined every other day. Tumor measurements were used using a digital vernier caliper, and the volumes were determined using the following calculation: (short<sup>2</sup>) × long × 0.5. Experiments were performed under an approved IACUC protocol according to federal and institutional guidelines and regulations.</div></div><div id="sec3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i155" class="anchor-spacer"></div><h4 class="article-section__title" id="_i155"> Statistical Analysis</h4><div class="NLM_p last">Statistical analysis was performed using a standard, unpaired, two-tailed Student’s <i>t</i> test. Data are graphed as mean ± SEM.</div></div><div id="sec3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i156" class="anchor-spacer"></div><h4 class="article-section__title" id="_i156"> Model of <b>7x</b> Binding to CDK6</h4><div class="NLM_p last">Small molecule <b>7x</b> binding was predicted by docking and energy minimization using the X-ray crystal structure of CDK6–Vcyclin–PD-0332991 (2EUF) as a reference. Representations of the superimposition of X-ray crystal structure (CDK6/PD-0332991) and predicted lowest energy binding (CDK6/<b>7x</b>) were prepared using PyMOL (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A, ribbon representation of CDK6 (green) bound to PD-0332991 (red) and <b>7x</b> (cyan). Small molecules are shown as sticks. Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B,C, closeup view showing proximal residues of CDK6 to <b>7x</b> (blue) and PD-0332991 (pink), respectively. Hydrogen bonds are shown as a dotted back lines.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i157"><a href="/doi/suppl/10.1021/jm401073p">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61421" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61421" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Effect of <b>7x</b> and PD-0332991 on a panel of human breast carcinoma cell lines, kinase inhibition profile of <b>7x</b> (Reaction Biology Corporation), inhibition of PI3K isoforms by <b>7x</b>, and docking models showing different binding positions of <b>7x</b> to Abl, FGFR, and FMS kinases. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm401073p/suppl_file/jm401073p_si_001.pdf">jm401073p_si_001.pdf (202.6 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm401073p" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55834" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55834" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">M. V. Ramana Reddy</span> - <span class="hlFld-Affiliation affiliation">Department
of Oncological Sciences, Icahn School of
Medicine at Mount Sinai, 1425 Madison Avenue, New York, New York 10029-6514, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f381dd819697978ab39e80809edd969786"><span class="__cf_email__" data-cfemail="2b5905594e4f4f526b46585846054e4f5e">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">E. Premkumar Reddy</span> - <span class="hlFld-Affiliation affiliation">Department
of Oncological Sciences, Icahn School of
Medicine at Mount Sinai, 1425 Madison Avenue, New York, New York 10029-6514, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3055401e4255545449705d43435d1e555445"><span class="__cf_email__" data-cfemail="dbbeabf5a9bebfbfa29bb6a8a8b6f5bebfae">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Balireddy Akula</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Onconova Therapeutics
Inc., 375 Pheasant Run, Newtown, Pennsylvania 18940-3423, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen C. Cosenza</span> - <span class="hlFld-Affiliation affiliation">Department
of Oncological Sciences, Icahn School of
Medicine at Mount Sinai, 1425 Madison Avenue, New York, New York 10029-6514, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Saikrishna Athuluridivakar</span> - <span class="hlFld-Affiliation affiliation">Department
of Oncological Sciences, Icahn School of
Medicine at Mount Sinai, 1425 Madison Avenue, New York, New York 10029-6514, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Muralidhar R. Mallireddigari</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Onconova Therapeutics
Inc., 375 Pheasant Run, Newtown, Pennsylvania 18940-3423, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Venkat R. Pallela</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Onconova Therapeutics
Inc., 375 Pheasant Run, Newtown, Pennsylvania 18940-3423, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vinay K. Billa</span> - <span class="hlFld-Affiliation affiliation">Department
of Oncological Sciences, Icahn School of
Medicine at Mount Sinai, 1425 Madison Avenue, New York, New York 10029-6514, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">D. R. C. Venkata Subbaiah</span> - <span class="hlFld-Affiliation affiliation">Department
of Oncological Sciences, Icahn School of
Medicine at Mount Sinai, 1425 Madison Avenue, New York, New York 10029-6514, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">E. Vijaya Bharathi</span> - <span class="hlFld-Affiliation affiliation">Department
of Oncological Sciences, Icahn School of
Medicine at Mount Sinai, 1425 Madison Avenue, New York, New York 10029-6514, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rodrigo Vasquez-Del Carpio</span> - <span class="hlFld-Affiliation affiliation">Department
of Oncological Sciences, Icahn School of
Medicine at Mount Sinai, 1425 Madison Avenue, New York, New York 10029-6514, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amol Padgaonkar</span> - <span class="hlFld-Affiliation affiliation">Department
of Oncological Sciences, Icahn School of
Medicine at Mount Sinai, 1425 Madison Avenue, New York, New York 10029-6514, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stacey J. Baker</span> - <span class="hlFld-Affiliation affiliation">Department
of Oncological Sciences, Icahn School of
Medicine at Mount Sinai, 1425 Madison Avenue, New York, New York 10029-6514, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>B.A. and S.C.C. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Dr. E. P. Reddy is a stockholder, Board member, grant recipient and paid consultant of Onconova Therapeutics Inc. Dr. M. V. R. Reddy is a stockholder and paid consultant of Onconova Inc. Dr. S. Cosenza is a paid consultant of Onconova Therapeutics Inc.<br /></br></div></li></ul></div><div class="ack" id="ACK-d637e8827-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i159">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31040" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31040" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by grants from the NIH (P01CA-130821) and Onconova Therapeutics Inc. We are thankful to Dr. Ramana Tantravahi for editorial assistance.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i160" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i160"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i161" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i161"> Abbreviations Used</h2><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase</p></td></tr><tr><td class="NLM_term">MPF</td><td class="NLM_def"><p class="first last">M-phase promoting factor</p></td></tr><tr><td class="NLM_term">ARK5</td><td class="NLM_def"><p class="first last">AMPK-related protein kinase 5</p></td></tr><tr><td class="NLM_term">FGFR</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositide 3-kinases</p></td></tr><tr><td class="NLM_term">RB</td><td class="NLM_def"><p class="first last">retinoblastoma protein</p></td></tr><tr><td class="NLM_term">SDS-PAGE</td><td class="NLM_def"><p class="first last">sodium dodecyl sulfate polyacrylamide gel electrophoresis</p></td></tr><tr><td class="NLM_term">PVDF</td><td class="NLM_def"><p class="first last">polyvinylidene difluoride</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">FACS</td><td class="NLM_def"><p class="first last">fluorescence activated cell sorting</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly(ADP-ribose)polymerase</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbecco’s Modified Eagle Medium</p></td></tr><tr><td class="NLM_term">RPMI</td><td class="NLM_def"><p class="first last">Roswell Park Memorial Institute</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate buffered saline</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i162">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54182" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54182" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 58 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Cell cycle, CDKs and cancer: a changing paradigm</span> <span class="citation_source-journal">Nature Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1038%2Fnrc2602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=19238148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=153-166&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+cycle%2C+CDKs+and+cancer%3A+a+changing+paradigm"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle, CDKs and cancer: a changing paradigm</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity.  Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability.  According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumor cells.  However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells.  Emerging evidence suggests that tumor cells may also require specific interphase CDKs for proliferation.  Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlIKlbCPWnLVg90H21EOLACvtfcHk0lhuEsjxO4RX3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D&md5=2a7eb34b2381e288b3f43ec1bffc0aec</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2602%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520cycle%252C%2520CDKs%2520and%2520cancer%253A%2520a%2520changing%2520paradigm%26jtitle%3DNature%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D153%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Graña, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=7624138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADyaK2MXnt1Oqurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1995&pages=211-219&author=X.+Gra%C3%B1aauthor=E.+P.+Reddy&title=Cell+cycle+control+in+mammalian+cells%3A+role+of+cyclins%2C+cyclin+dependent+kinases+%28CDKs%29%2C+growth+suppressor+genes+and+cyclin-dependent+kinase+inhibitors+%28CKIs%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)</span></div><div class="casAuthors">Grana, Xavier; Reddy, E. Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-19</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Scientific & Medical Division</span>)
        </div><div class="casAbstract">A review with >100 refs.  All eukaryotic cells possess similar mechanisms to regulate the progression of the cell cycle.  However, higher eukaryotes have evolved to respond to a large array of pos. and neg. signals with an intracellular or extracellular origin.  These signals are eventually integrated by a conserved protein engine consisting of holoenzymes with kinase activity, which trigger crucial transitions during the cell cycle.  The mechanisms by which the mammalian cell cycle engine integrates intracellular and extracellular signals of different nature are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf64gghjh7-7Vg90H21EOLACvtfcHk0lhuEsjxO4RX3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnt1Oqurc%253D&md5=a7353df5118f195e4c5ec417c25bd4ef</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGra%25C3%25B1a%26aufirst%3DX.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DCell%2520cycle%2520control%2520in%2520mammalian%2520cells%253A%2520role%2520of%2520cyclins%252C%2520cyclin%2520dependent%2520kinases%2520%2528CDKs%2529%252C%2520growth%2520suppressor%2520genes%2520and%2520cyclin-dependent%2520kinase%2520inhibitors%2520%2528CKIs%2529%26jtitle%3DOncogene%26date%3D1995%26volume%3D11%26spage%3D211%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Hunter, T.</span><span> </span><span class="NLM_article-title">Oncoprotein networks</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">333</span><span class="NLM_x">–</span> <span class="NLM_lpage">346</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1997&pages=333-346&author=T.+Hunter&title=Oncoprotein+networks"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DT.%26atitle%3DOncoprotein%2520networks%26jtitle%3DCell%26date%3D1997%26volume%3D88%26spage%3D333%26epage%3D346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Morgan, D. O.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinases: engines, clocks, and microprocessors</span> <span class="citation_source-journal">Ann. Rev. Cell Dev. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">291</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1997&pages=261-291&author=D.+O.+Morgan&title=Cyclin-dependent+kinases%3A+engines%2C+clocks%2C+and+microprocessors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DD.%2BO.%26atitle%3DCyclin-dependent%2520kinases%253A%2520engines%252C%2520clocks%252C%2520and%2520microprocessors%26jtitle%3DAnn.%2520Rev.%2520Cell%2520Dev.%2520Biol.%26date%3D1997%26volume%3D13%26spage%3D261%26epage%3D291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">To cycle or not to cycle: a critical decision in cancer</span> <span class="citation_source-journal">Nature Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1038%2F35106065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=11902577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=222-231&author=M.+Malumbresauthor=M.+Barbacid&title=To+cycle+or+not+to+cycle%3A+a+critical+decision+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Milestones in cell division: to cycle or not to cycle: a critical decision in cancer</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">222-231</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor cells undergo uncontrolled proliferation, yet tumors most often originate from adult tissues, in which most cells are quiescent.  So, the proliferative advantage of tumor cells arises from their ability to bypass quiescence.  This can be due to increased mitogenic signaling and/or alterations that lower the threshold required for cell-cycle commitment.  Understanding the mol. mechanisms that underlie this commitment should provide important insights into how normal cells become tumorigenic and how new anticancer strategies can be devised.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI2EOLFB2ULbVg90H21EOLACvtfcHk0lhuFeW20q7FBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D&md5=2bd8961854332a30c814f8ac2f9bd6f4</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2F35106065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35106065%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DTo%2520cycle%2520or%2520not%2520to%2520cycle%253A%2520a%2520critical%2520decision%2520in%2520cancer%26jtitle%3DNature%2520Rev.%2520Cancer%26date%3D2001%26volume%3D1%26spage%3D222%26epage%3D231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">CDK4 a key player in the cell cycle, development, and cancer</span> <span class="citation_source-journal">Genes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">658</span><span class="NLM_x">–</span> <span class="NLM_lpage">669</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1177%2F1947601913478972" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A280%3ADC%252BC3srpvV2isg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=658-669&author=S.+J.+Bakerauthor=E.+P.+Reddy&title=CDK4+a+key+player+in+the+cell+cycle%2C+development%2C+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">CDK4: A Key Player in the Cell Cycle, Development, and Cancer</span></div><div class="casAuthors">Baker Stacey J; Reddy E Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Genes & cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11-12</span>),
    <span class="NLM_cas:pages">658-69</span>
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    </div><div class="casAbstract">The cell cycle is regulated in part by cyclins and their associated serine/threonine cyclin-dependent kinases, or CDKs.  CDK4, in conjunction with the D-type cyclins, mediates progression through the G1 phase when the cell prepares to initiate DNA synthesis.  Although CDK4-null mutant mice are viable and cell proliferation is not significantly affected in vitro due to compensatory roles played by other CDKs, this gene plays a key role in mammalian development and cancer.  This review discusses the role that CDK4 plays in cell cycle control, normal development, and tumorigenesis as well as how small molecule inhibitors of CDK4 can be used to treat disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS_ZrSWKg0eOwvupmecNw_lfW6udTcc2eY9vFJci9hf57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srpvV2isg%253D%253D&md5=65557d394fc5184521ff0926d5b74c63</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1177%2F1947601913478972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601913478972%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DCDK4%2520a%2520key%2520player%2520in%2520the%2520cell%2520cycle%252C%2520development%252C%2520and%2520cancer%26jtitle%3DGenes%2520Cancer%26date%3D2012%26volume%3D3%26spage%3D658%26epage%3D669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Dyson, N.</span><span> </span><span class="NLM_article-title">The regulation of E2F by pRB-family proteins</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2245</span><span class="NLM_x">–</span> <span class="NLM_lpage">2262</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1101%2Fgad.12.15.2245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=9694791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADyaK1cXltlagu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1998&pages=2245-2262&author=N.+Dyson&title=The+regulation+of+E2F+by+pRB-family+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The regulation of E2F by pRB-family proteins</span></div><div class="casAuthors">Dyson, Nicholas</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2245-2262</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review with over 100 refs.  Topics include: Introduction to the families of E2F and DP proteins (free E2F, complexed E2F), E2F-binding sites mediate both transcriptional activation and repression (E2F as a transcriptional activator, E2F-mediated repression), Activation of E2F-dependent transcription (phosphorylation of pRB-family members, phosphorylation of E2F-1, changes in the subcellular localization of specific E2F complexes, synthesis of new E2Fs), Inactivation of E2F (E2F/DP phosphorylation, degrdn. of free E2F, E2F-repressors), Consequences of elevated E2F activity-ectopic S-phase entry and apoptosis, Is E2F required for S-phase entry, What are the key targets of E2F activity, What is the role of pRB in E2F regulation, Is the ability of pRB to bind E2F important for pRB's role as a tumor suppressor, and How can E2F-1 be both an oncogene and a tumor suppressor gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeXAl9aLvm5bVg90H21EOLACvtfcHk0lizHa6b5jW3Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltlagu74%253D&md5=755af21d258487f59a09899698e860e8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1101%2Fgad.12.15.2245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.12.15.2245%26sid%3Dliteratum%253Aachs%26aulast%3DDyson%26aufirst%3DN.%26atitle%3DThe%2520regulation%2520of%2520E2F%2520by%2520pRB-family%2520proteins%26jtitle%3DGenes%2520Dev.%26date%3D1998%26volume%3D12%26spage%3D2245%26epage%3D2262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Harbour, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, D. C.</span><span> </span><span class="NLM_article-title">The Rb/E2F pathway: expanding roles and emerging paradigms</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2393</span><span class="NLM_x">–</span> <span class="NLM_lpage">2409</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1101%2Fgad.813200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=11018009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntlOqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2000&pages=2393-2409&author=J.+W.+Harbourauthor=D.+C.+Dean&title=The+Rb%2FE2F+pathway%3A+expanding+roles+and+emerging+paradigms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Rb/E2F pathway: expanding roles and emerging paradigms</span></div><div class="casAuthors">Harbour, J. William; Dean, Douglas C.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2393-2409</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_9N9_cVUlgLVg90H21EOLACvtfcHk0lizHa6b5jW3Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntlOqtrc%253D&md5=c7d765e5eda00c9d1b31bc7dcbab255e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1101%2Fgad.813200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.813200%26sid%3Dliteratum%253Aachs%26aulast%3DHarbour%26aufirst%3DJ.%2BW.%26aulast%3DDean%26aufirst%3DD.%2BC.%26atitle%3DThe%2520Rb%252FE2F%2520pathway%253A%2520expanding%2520roles%2520and%2520emerging%2520paradigms%26jtitle%3DGenes%2520Dev.%26date%3D2000%26volume%3D14%26spage%3D2393%26epage%3D2409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Deshpande, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sicinski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinds, P. W.</span><span> </span><span class="NLM_article-title">Cyclins and cdks in development and cancer: a perspective</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2909</span><span class="NLM_x">–</span> <span class="NLM_lpage">2915</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=2909-2915&author=A.+Deshpandeauthor=P.+Sicinskiauthor=P.+W.+Hinds&title=Cyclins+and+cdks+in+development+and+cancer%3A+a+perspective"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDeshpande%26aufirst%3DA.%26aulast%3DSicinski%26aufirst%3DP.%26aulast%3DHinds%26aufirst%3DP.%2BW.%26atitle%3DCyclins%2520and%2520cdks%2520in%2520development%2520and%2520cancer%253A%2520a%2520perspective%26jtitle%3DOncogene%26date%3D2005%26volume%3D24%26spage%3D2909%26epage%3D2915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Graf, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosch, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wuest, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietzsch, J.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase 4/6 (Cdk4/6) inhibitors: perspectives in cancer therapy and imaging</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">527</span><span class="NLM_x">–</span> <span class="NLM_lpage">539</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=527-539&author=F.+Grafauthor=B.+Moschauthor=L.+Koehlerauthor=R.+Bergmannauthor=F.+Wuestauthor=J.+Pietzsch&title=Cyclin-dependent+kinase+4%2F6+%28Cdk4%2F6%29+inhibitors%3A+perspectives+in+cancer+therapy+and+imaging"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGraf%26aufirst%3DF.%26aulast%3DMosch%26aufirst%3DB.%26aulast%3DKoehler%26aufirst%3DL.%26aulast%3DBergmann%26aufirst%3DR.%26aulast%3DWuest%26aufirst%3DF.%26aulast%3DPietzsch%26aufirst%3DJ.%26atitle%3DCyclin-dependent%2520kinase%25204%252F6%2520%2528Cdk4%252F6%2529%2520inhibitors%253A%2520perspectives%2520in%2520cancer%2520therapy%2520and%2520imaging%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D527%26epage%3D539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Wolfel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wölfel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klehmann-Hieb, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Plaen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hankeln, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer zum Büschenfelde, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beach, D.</span><span> </span><span class="NLM_article-title">A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">269</span><span class="NLM_x">, </span> <span class="NLM_fpage">1281</span><span class="NLM_x">–</span> <span class="NLM_lpage">1284</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1995&pages=1281-1284&author=T.+Wolfelauthor=M.+Hauerauthor=J.+Schneiderauthor=M.+Serranoauthor=C.+W%C3%B6lfelauthor=E.+Klehmann-Hiebauthor=E.+De+Plaenauthor=T.+Hankelnauthor=K.+H.+Meyer+zum+B%C3%BCschenfeldeauthor=D.+Beach&title=A+p16INK4a-insensitive+CDK4+mutant+targeted+by+cytolytic+T+lymphocytes+in+a+human+melanoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWolfel%26aufirst%3DT.%26aulast%3DHauer%26aufirst%3DM.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DSerrano%26aufirst%3DM.%26aulast%3DW%25C3%25B6lfel%26aufirst%3DC.%26aulast%3DKlehmann-Hieb%26aufirst%3DE.%26aulast%3DDe%2BPlaen%26aufirst%3DE.%26aulast%3DHankeln%26aufirst%3DT.%26aulast%3DMeyer%2Bzum%2BB%25C3%25BCschenfelde%26aufirst%3DK.%2BH.%26aulast%3DBeach%26aufirst%3DD.%26atitle%3DA%2520p16INK4a-insensitive%2520CDK4%2520mutant%2520targeted%2520by%2520cytolytic%2520T%2520lymphocytes%2520in%2520a%2520human%2520melanoma%26jtitle%3DScience%26date%3D1995%26volume%3D269%26spage%3D1281%26epage%3D1284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Zuo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayward, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dracopoli, N. C.</span><span> </span><span class="NLM_article-title">Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma</span> <span class="citation_source-journal">Nature Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">99</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1038%2Fng0196-97" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=8528263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADyaK28XhsV2gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1996&pages=97-99&author=L.+Zuoauthor=J.+Wegerauthor=Q.+Yangauthor=A.+M.+Goldsteinauthor=M.+A.+Tuckerauthor=G.+J.+Walkerauthor=N.+Haywardauthor=N.+C.+Dracopoli&title=Germline+mutations+in+the+p16INK4a+binding+domain+of+CDK4+in+familial+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma</span></div><div class="casAuthors">Zuo, Lin; Weger, John; Yang, Qingbei; Goldstein, Alisa M.; Tucker, Margaret A.; Walker, Graeme J.; Hayward, Nicholas; Dracopoli, Nicholas C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-9</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">Protein complexes consisting of a cyclin-dependent kinase (CDK4 or CDK6) and cyclin D control passage through the G1 checkpoint of the cell cycle by phosphorylating the retinoblastoma (RB) protein.  The ability of these complexes to phosphorylate RB is inhibited by a family of low-mol.-wt. proteins including p16INK4a, p15INK4B, and p18.  Germline mutations in the p16INK4a gene have been identified in approx. half of families with hereditary melanoma.  In this report, the authors describe an Arg24Cys mutation in CDK4 in 2 unrelated melanoma families which do not carry germline p16INK4a mutations.  This mutation was detected in 11/11 melanoma patients, 2/17 unaffecteds and 0/5 spouses.  The CDK4-Arg24Cys substitution has previously been identified as a somatic mutation in a melanoma that gives rise to a tumor-specific antigen recognized by autologous cytolytic T lymphocytes.  This mutation has a specific effect on the p16INK4a-binding domain of CDK4, but has no effect on its ability to bind cyclin D and form a functional kinase.  Therefore, the germline Arg24Cys mutation in CDK4 generates a dominant oncogene that is resistant to normal physiol. inhibition by p16INK4a.  The only previous examples of a dominant oncogene transmitted in the human germline is the RET gene that gives rise to MEN2A and MEN2B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgtSe1fAjgOLVg90H21EOLACvtfcHk0lhsnJhIYcm4jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhsV2gsw%253D%253D&md5=a70b308ce2c07150c1417dca2b314a88</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fng0196-97&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng0196-97%26sid%3Dliteratum%253Aachs%26aulast%3DZuo%26aufirst%3DL.%26aulast%3DWeger%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DGoldstein%26aufirst%3DA.%2BM.%26aulast%3DTucker%26aufirst%3DM.%2BA.%26aulast%3DWalker%26aufirst%3DG.%2BJ.%26aulast%3DHayward%26aufirst%3DN.%26aulast%3DDracopoli%26aufirst%3DN.%2BC.%26atitle%3DGermline%2520mutations%2520in%2520the%2520p16INK4a%2520binding%2520domain%2520of%2520CDK4%2520in%2520familial%2520melanoma%26jtitle%3DNature%2520Genet.%26date%3D1996%26volume%3D12%26spage%3D97%26epage%3D99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Ortega, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Cyclin D-dependent kinases, INK4 inhibitors and cancer</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1602</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1602&publication_year=2002&pages=73-87&author=S.+Ortegaauthor=M.+Malumbresauthor=M.+Barbacid&title=Cyclin+D-dependent+kinases%2C+INK4+inhibitors+and+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOrtega%26aufirst%3DS.%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCyclin%2520D-dependent%2520kinases%252C%2520INK4%2520inhibitors%2520and%2520cancer%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2002%26volume%3D1602%26spage%3D73%26epage%3D87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Rane, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubus, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mettus, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galbreath, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boden, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia</span> <span class="citation_source-journal">Nature Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">44</span><span class="NLM_x">–</span> <span class="NLM_lpage">52</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1038%2F8751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=10319860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADyaK1MXjtVags7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1999&pages=44-52&author=S.+G.+Raneauthor=P.+D.+Dubusauthor=R.+V.+Mettusauthor=E.+J.+Galbreathauthor=G.+Bodenauthor=E.+P.+Reddyauthor=M.+Barbacid&title=Loss+of+Cdk4+expression+causes+insulin-deficient+diabetes+and+Cdk4+activation+results+in+beta-islet+cell+hyperplasia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia</span></div><div class="casAuthors">Rane, Sushil G.; Dubus, Pierre; Mettus, Richard V.; Galbreath, Elizabeth J.; Boden, Guenther; Reddy, E. Premkumar; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-52</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">To ascertain the role of cyclin-dependent kinase 4 (Cdk4) in vivo, the authors have targeted the mouse Cdk4 locus by homologous recombination to generate two strains of mice, one that lacks Cdk4 expression and one that expresses a Cdk4 mol. with an activating mutation.  Embryonic fibroblasts proliferate normally in the absence of Cdk4 but have a delayed S phase on re-entry into the cell cycle.  Moreover, mice devoid of Cdk4 are viable, but small in size and infertile.  These mice also develop insulin-deficient diabetes due to a redn. in β-islet pancreatic cells.  In contrast, mice expressing a mutant Cdk4 that cannot bind the cell-cycle inhibitor P16INK4a display pancreatic hyperplasia due to abnormal proliferation of β-islet cells.  These results establish Cdk4 as an essential regulator of specific cell types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofmhLD8YQB97Vg90H21EOLACvtfcHk0lh2Bb8bECqRSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjtVags7o%253D&md5=82326fc337b7b1ddabf2cb0fcfd6c288</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2F8751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F8751%26sid%3Dliteratum%253Aachs%26aulast%3DRane%26aufirst%3DS.%2BG.%26aulast%3DDubus%26aufirst%3DP.%2BD.%26aulast%3DMettus%26aufirst%3DR.%2BV.%26aulast%3DGalbreath%26aufirst%3DE.%2BJ.%26aulast%3DBoden%26aufirst%3DG.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DLoss%2520of%2520Cdk4%2520expression%2520causes%2520insulin-deficient%2520diabetes%2520and%2520Cdk4%2520activation%2520results%2520in%2520beta-islet%2520cell%2520hyperplasia%26jtitle%3DNature%2520Genet.%26date%3D1999%26volume%3D22%26spage%3D44%26epage%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Tsutsui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesabi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moons, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandolfi, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansel, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyokawa, H.</span><span> </span><span class="NLM_article-title">Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">7011</span><span class="NLM_x">–</span> <span class="NLM_lpage">7019</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1128%2FMCB.19.10.7011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=10490638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADyaK1MXmtlals7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1999&pages=7011-7019&author=T.+Tsutsuiauthor=B.+Hesabiauthor=D.+S.+Moonsauthor=P.+P.+Pandolfiauthor=K.+S.+Hanselauthor=A.+Koffauthor=H.+Kiyokawa&title=Targeted+disruption+of+CDK4+delays+cell+cycle+entry+with+enhanced+p27%28Kip1%29+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted disruption of CDK4 delays cell cycle entry with enhanced p27Kip1 activity</span></div><div class="casAuthors">Tsutsui, Tateki; Hesabi, Bahar; Moons, David S.; Pandolfi, Pier Paolo; Hansel, Kimberly S.; Koff, Andrew; Kiyokawa, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">7011-7019</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The mechanism by which cyclin-dependent kinase 4 (CDK4) regulates cell cycle progression is not entirely clear.  Cyclin D/CDK4 appears to initiate phosphorylation of retinoblastoma protein (Rb) leading to inactivation of the S-phase-inhibitory action of Rb.  However, cyclin D/CDK4 has been postulated to act in a noncatalytic manner to regulate the cyclin E/CDK2-inhibitory activity of p27Kip1 by sequestration.  In this study we investigated the roles of CDK4 in cell cycle regulation by targeted disruption of the mouse CDK4 gene.  CDK4-/- mice survived embryogenesis and showed growth retardation and reproductive dysfunction assocd. with hypoplastic seminiferous tubules in the testis and perturbed corpus luteum formation in the ovary.  These phenotypes appear to be opposite to those of p27-deficient mice such as gigantism and gonadal hyperplasia.  A majority of CDK4-/- mice developed diabetes mellitus by 6 wk, assocd. with degeneration of pancreatic islets.  Fibroblasts from CDK4-/- mouse embryos proliferated similarly to wild-type embryonic fibroblasts under conditions that promote continuous growth.  However, quiescent CDK4-/- fibroblasts exhibited a substantial (∼6-h) delay in S-phase entry after serum stimulation.  This cell cycle perturbation by CDK4 disruption was assocd. with increased binding of p27 to cyclin E/CDK2 and diminished activation of CDK2 accompanied by impaired Rb phosphorylation.  Importantly, fibroblasts from CDK4-/- p27-/- embryos displayed partially restored kinetics of the G0-S transition, indicating the significance of the sequestration of p27 by CDK4.  These results suggest that at least part of CDK4's participation in the rate-limiting mechanism for the G0-S transition consists of controlling p27 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKIPUccGpY97Vg90H21EOLACvtfcHk0lh2Bb8bECqRSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtlals7c%253D&md5=bba944ba00b313a19943eaa2acad2301</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FMCB.19.10.7011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.19.10.7011%26sid%3Dliteratum%253Aachs%26aulast%3DTsutsui%26aufirst%3DT.%26aulast%3DHesabi%26aufirst%3DB.%26aulast%3DMoons%26aufirst%3DD.%2BS.%26aulast%3DPandolfi%26aufirst%3DP.%2BP.%26aulast%3DHansel%26aufirst%3DK.%2BS.%26aulast%3DKoff%26aufirst%3DA.%26aulast%3DKiyokawa%26aufirst%3DH.%26atitle%3DTargeted%2520disruption%2520of%2520CDK4%2520delays%2520cell%2520cycle%2520entry%2520with%2520enhanced%2520p27%2528Kip1%2529%2520activity%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1999%26volume%3D19%26spage%3D7011%26epage%3D7019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Reddy, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mettus, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rane, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graña, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litvin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">10174</span><span class="NLM_x">–</span> <span class="NLM_lpage">10178</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=10174-10178&author=H.+K.+Reddyauthor=R.+V.+Mettusauthor=S.+G.+Raneauthor=X.+Gra%C3%B1aauthor=J.+Litvinauthor=E.+P.+Reddy&title=Cyclin-dependent+kinase+4+expression+is+essential+for+neu-induced+breast+tumorigenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DH.%2BK.%26aulast%3DMettus%26aufirst%3DR.%2BV.%26aulast%3DRane%26aufirst%3DS.%2BG.%26aulast%3DGra%25C3%25B1a%26aufirst%3DX.%26aulast%3DLitvin%26aufirst%3DJ.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DCyclin-dependent%2520kinase%25204%2520expression%2520is%2520essential%2520for%2520neu-induced%2520breast%2520tumorigenesis%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D10174%26epage%3D10178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Reddy, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graña, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhanasekaran, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litvin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">Requirement of Cdk4 for v-Haras-induced breast tumorigenesis and activation of the v-ras-induced senescence program by the R24C mutation</span> <span class="citation_source-journal">Genes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="NLM_x">–</span> <span class="NLM_lpage">80</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1177%2F1947601909358105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2ntrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=69-80&author=H.+K.+Reddyauthor=X.+Gra%C3%B1aauthor=D.+N.+Dhanasekaranauthor=J.+Litvinauthor=E.+P.+Reddy&title=Requirement+of+Cdk4+for+v-Haras-induced+breast+tumorigenesis+and+activation+of+the+v-ras-induced+senescence+program+by+the+R24C+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of Cdk4 for v-Ha-ras-induced breast tumorigenesis and activation of the v-ras-induced senescence program by the R24C mutation</span></div><div class="casAuthors">Reddy, Haritha K. D. L.; Grana, Xavier; Dhanasekaran, Danny N.; Litvin, Judith; Reddy, E. Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-80</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Activating mutations in CDK4 and inactivation of its key kinase inhibitor, p16INK4A, have been implicated in the genesis and progression of human cancer.  Previous work has demonstrated that CDK4 expression is required for Neu-induced but not Wnt-induced breast tumorigenesis in mice.  However, the role that CDK4 plays in ras-mediated breast tumor development is not well defined.  To gain an understanding of the role of Cdk4 in ras-induced breast tumorigenesis, MMTV-v-Ha-ras transgenic mice were bred with Cdk4(+/neo) and Cdk4(R24C/R24C) mice to generate Cdk4(neo/neo):MMTV-v-Ha-ras, Cdk4(+/+):MMTV-v-Ha-ras, and Cdk4(R24C/R24C):MMTV-v-Ha-ras mice.  The studies presented here demonstrate that Cdk4 expression is essential for Ras-mediated breast tumorigenesis.  Surprisingly, the results also show that coexpression of mutant ras and Cdk4R24C genes in breast epithelial cells leads to an activation of senescent pathways that delay tumorigenesis.  Anal. of the phosphorylated form of H2AX, a marker for DNA damage, indicated its increased presence in the tumors of Cdk4(R24C/R24C):MMTV-v-Ha-ras mice.  These observations indicate that the increased apoptosis and senescence seen in breast tumors of these mice might be due to increased DNA damage response in cells expressing activated forms of ras and Cdk4(R24C).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7V2yZK4gh57Vg90H21EOLACvtfcHk0lgIgnQXAGT93A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2ntrzK&md5=99b0727e7e6e99178521bafe4fd0774e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1177%2F1947601909358105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601909358105%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DH.%2BK.%26aulast%3DGra%25C3%25B1a%26aufirst%3DX.%26aulast%3DDhanasekaran%26aufirst%3DD.%2BN.%26aulast%3DLitvin%26aufirst%3DJ.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DRequirement%2520of%2520Cdk4%2520for%2520v-Haras-induced%2520breast%2520tumorigenesis%2520and%2520activation%2520of%2520the%2520v-ras-induced%2520senescence%2520program%2520by%2520the%2520R24C%2520mutation%26jtitle%3DGenes%2520Cancer%26date%3D2010%26volume%3D1%26spage%3D69%26epage%3D80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Carlson, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubay, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brizuela, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worland, P. J.</span><span> </span><span class="NLM_article-title">Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2973</span><span class="NLM_x">–</span> <span class="NLM_lpage">2978</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1996&pages=2973-2978&author=B.+A.+Carlsonauthor=M.+M.+Dubayauthor=E.+A.+Sausvilleauthor=L.+Brizuelaauthor=P.+J.+Worland&title=Flavopiridol+induces+G1+arrest+with+inhibition+of+cyclin-dependent+kinase+%28CDK%29+2+and+CDK4+in+human+breast+carcinoma+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarlson%26aufirst%3DB.%2BA.%26aulast%3DDubay%26aufirst%3DM.%2BM.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DBrizuela%26aufirst%3DL.%26aulast%3DWorland%26aufirst%3DP.%2BJ.%26atitle%3DFlavopiridol%2520induces%2520G1%2520arrest%2520with%2520inhibition%2520of%2520cyclin-dependent%2520kinase%2520%2528CDK%2529%25202%2520and%2520CDK4%2520in%2520human%2520breast%2520carcinoma%2520cells%26jtitle%3DCancer%2520Res.%26date%3D1996%26volume%3D56%26spage%3D2973%26epage%3D2978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">McClue, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKenzie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melville, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhelev, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheleva, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, D. P.</span><span> </span><span class="NLM_article-title">In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">468</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1002%2Fijc.10738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=12432547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVOksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2002&pages=463-468&author=S.+J.+McClueauthor=D.+Blakeauthor=R.+Clarkeauthor=A.+Cowanauthor=L.+Cummingsauthor=P.+M.+Fischerauthor=M.+MacKenzieauthor=J.+Melvilleauthor=K.+Stewartauthor=S.+Wangauthor=N.+Zhelevauthor=D.+Zhelevaauthor=D.+P.+Lane&title=In+vitro+and+in+vivo+antitumor+properties+of+the+cyclin+dependent+kinase+inhibitor+CYC202+%28R-roscovitine%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)</span></div><div class="casAuthors">McClue, Steven J.; Blake, David; Clarke, Rosemary; Cowan, Angela; Cummings, Lorna; Fischer, Peter M.; MacKenzie, Mairi; Melville, Jean; Stewart, Kevin; Wang, Shudong; Zhelev, Nikolai; Zheleva, Daniella; Lane, David P.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">463-468</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">CDK2 inhibitors have been proposed as effective anti-cancer therapeutics.  We show here that CYC202 (R-roscovitine) is a potent inhibitor of recombinant CDK2/cyclin E kinase activity (IC50 = 0.10 μM) with an av. cytotoxic IC50 of 15.2 μM in a panel of 19 human tumor cell lines, and we also demonstrate selectivity for rapidly proliferating cells over non-proliferating cells.  A study of the cell cycle effects of CYC202 in Lovo colorectal carcinoma cells showed that the major effect was not the predicted arrest in one part of the cycle, but rather an induction of cell death from all compartments of the cell cycle.  The max. tolerated dose given i.v. to mice was in excess of 20 mg/kg.  Doses up to 2,000 mg/kg were tolerated when administered orally in mice.  Following repeated i.p. administration (3 times daily for 5 days) of 100 mg/kg to nude mice bearing the Lovo human colorectal tumor, CYC202 induced a significant antitumor effect with a 45% redn. in tumor growth compared to controls.  A second expt. using the human uterine xenograft MESSA-DX5 treated with orally administered CYC202 (500 mg/kg 3 times daily for 4 days) also exhibited a significant redn. in the rate of growth of the tumor (62%).  These data, showing enzyme and cellular potency together with antitumor activity, confirm the potential of CDK2 inhibitors such as CYC202 as anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrekWf0QH861LVg90H21EOLACvtfcHk0lgIgnQXAGT93A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVOksL4%253D&md5=bf8ed57667ec566b9cc11c27158f6b8b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fijc.10738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10738%26sid%3Dliteratum%253Aachs%26aulast%3DMcClue%26aufirst%3DS.%2BJ.%26aulast%3DBlake%26aufirst%3DD.%26aulast%3DClarke%26aufirst%3DR.%26aulast%3DCowan%26aufirst%3DA.%26aulast%3DCummings%26aufirst%3DL.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DMacKenzie%26aufirst%3DM.%26aulast%3DMelville%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DZhelev%26aufirst%3DN.%26aulast%3DZheleva%26aufirst%3DD.%26aulast%3DLane%26aufirst%3DD.%2BP.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520properties%2520of%2520the%2520cyclin%2520dependent%2520kinase%2520inhibitor%2520CYC202%2520%2528R-roscovitine%2529%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2002%26volume%3D102%26spage%3D463%26epage%3D468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Ullah, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depamphilis, M. L.</span><span> </span><span class="NLM_article-title">Cip/Kip cyclin-dependent protein kinase inhibitors and the road to polyploidy</span> <span class="citation_source-journal">Cell Div.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1186%2F1747-1028-4-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=19490616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A280%3ADC%252BD1MvitlKguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=10&author=Z.+Ullahauthor=C.+Y.+Leeauthor=M.+L.+Depamphilis&title=Cip%2FKip+cyclin-dependent+protein+kinase+inhibitors+and+the+road+to+polyploidy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Cip/Kip cyclin-dependent protein kinase inhibitors and the road to polyploidy</span></div><div class="casAuthors">Ullah Zakir; Lee Chrissie Y; Depamphilis Melvin L</div><div class="citationInfo"><span class="NLM_cas:title">Cell division</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) play a central role in the orderly transition from one phase of the eukaryotic mitotic cell division cycle to the next.  In this context, p27Kip1 (one of the CIP/KIP family of CDK specific inhibitors in mammals) or its functional analogue in other eukarya prevents a premature transition from G1 to S-phase.  Recent studies have revealed that expression of a second member of this family, p57Kip2, is induced as trophoblast stem (TS) cells differentiate into trophoblast giant (TG) cells. p57 then inhibits CDK1 activity, an enzyme essential for initiating mitosis, thereby triggering genome endoreduplication (multiple S-phases without an intervening mitosis).  Expression of p21Cip1, the third member of this family, is also induced in during differentiation of TS cells into TG cells where it appears to play a role in suppressing the DNA damage response pathway.  Given the fact that p21 and p57 are unique to mammals, the question arises as to whether one or both of these proteins are responsible for the induction and maintenance of polyploidy during mammalian development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTIj5fhXJz7BpPlX7E30qdzfW6udTcc2eYgSEofHqYnILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvitlKguw%253D%253D&md5=489ca67ae8539a587a6d9e6b82e0bce7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1186%2F1747-1028-4-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1747-1028-4-10%26sid%3Dliteratum%253Aachs%26aulast%3DUllah%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DC.%2BY.%26aulast%3DDepamphilis%26aufirst%3DM.%2BL.%26atitle%3DCip%252FKip%2520cyclin-dependent%2520protein%2520kinase%2520inhibitors%2520and%2520the%2520road%2520to%2520polyploidy%26jtitle%3DCell%2520Div.%26date%3D2009%26volume%3D4%26spage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Musgrove, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldon, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barraclough, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, R. L.</span><span> </span><span class="NLM_article-title">Cyclin D as a therapeutic target in cancer</span> <span class="citation_source-journal">Nature Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">558</span><span class="NLM_x">–</span> <span class="NLM_lpage">572</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1038%2Fnrc3090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=21734724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Srsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=558-572&author=E.+A.+Musgroveauthor=C.+E.+Caldonauthor=J.+Barracloughauthor=A.+Stoneauthor=R.+L.+Sutherland&title=Cyclin+D+as+a+therapeutic+target+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin D as a therapeutic target in cancer</span></div><div class="casAuthors">Musgrove, Elizabeth A.; Caldon, C. Elizabeth; Barraclough, Jane; Stone, Andrew; Sutherland, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">558-572</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression.  The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target.  Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofR_LZiUkU-LVg90H21EOLACvtfcHk0liFTn4N8SUMGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Srsr0%253D&md5=1bc2dcea427c5650263a5438ecddb5f9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnrc3090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3090%26sid%3Dliteratum%253Aachs%26aulast%3DMusgrove%26aufirst%3DE.%2BA.%26aulast%3DCaldon%26aufirst%3DC.%2BE.%26aulast%3DBarraclough%26aufirst%3DJ.%26aulast%3DStone%26aufirst%3DA.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26atitle%3DCyclin%2520D%2520as%2520a%2520therapeutic%2520target%2520in%2520cancer%26jtitle%3DNature%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D558%26epage%3D572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Lapenna, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, A.</span><span> </span><span class="NLM_article-title">Cell cycle kinases as therapeutic targets for cancer</span> <span class="citation_source-journal">Nature Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">547</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=547-566&author=S.+Lapennaauthor=A.+Giordano&title=Cell+cycle+kinases+as+therapeutic+targets+for+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLapenna%26aufirst%3DS.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DCell%2520cycle%2520kinases%2520as%2520therapeutic%2520targets%2520for%2520cancer%26jtitle%3DNature%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D547%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Shapiro, G. I.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase pathways as targets for cancer treatment</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1770</span><span class="NLM_x">–</span> <span class="NLM_lpage">1783</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1200%2FJCO.2005.03.7689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=16603719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD28XksVKgtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=1770-1783&author=G.+I.+Shapiro&title=Cyclin-dependent+kinase+pathways+as+targets+for+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase pathways as targets for cancer treatment</span></div><div class="casAuthors">Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1770-1783</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Cyclin-dependent kinases (cdks) are crit. regulators of cell cycle progression and RNA transcription.  A variety of genetic and epigenetic events cause universal overactivity of the cell cycle cdks in human cancer, and their inhibition can lead to both cell cycle arrest and apoptosis.  However, built-in redundancy may limit the effects of highly selective cdk inhibition.  Cdk4/6 inhibition has been shown to induce potent G1 arrest in vitro and tumor regression in vivo; cdk2/1 inhibition has the most potent effects during the S and G2 phases and induces E2F transcription factor-dependent cell death.  Modulation of cdk2 and cdk1 activities also affects survival checkpoint responses after exposure to DNA-damaging and microtubule-stabilizing agents.  The transcriptional cdks phosphorylate the carboxy-terminal domain of RNA polymerase II, facilitating efficient transcriptional initiation and elongation.  Inhibition of these cdks primarily affects the accumulation of transcripts with short half-lives, including those encoding antiapoptosis family members, cell cycle regulators, as well as p53 and nuclear factor-kappa B-responsive gene targets.  These effects may account for apoptosis induced by cdk9 inhibitors, esp. in malignant hematopoietic cells, and may also potentiate cytotoxicity mediated by disruption of a variety of pathways in many transformed cell types.  Current work is focusing on overcoming pharmacokinetic barriers that hindered development of flavopiridol, a pan-cdk inhibitor, as well as assessing novel classes of compds. potently targeting groups of cell cycle cdks (cdk4/6 or cdk2/1) with variable effects on the transcriptional cdks 7 and 9.  These efforts will establish whether the strategy of cdk inhibition is able to produce therapeutic benefit in the majority of human tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYfmCpSfvpTbVg90H21EOLACvtfcHk0liFTn4N8SUMGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksVKgtbg%253D&md5=420a31b47f6600625f7d499a4b8a5fc9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.03.7689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.03.7689%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DCyclin-dependent%2520kinase%2520pathways%2520as%2520targets%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D1770%26epage%3D1783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Lane, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pestell, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadler, S.</span><span> </span><span class="NLM_article-title">A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells</span> <span class="citation_source-journal">Canccer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">6170</span><span class="NLM_x">–</span> <span class="NLM_lpage">6177</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=11507069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmt12ktb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=6170-6177&author=M.+E.+Laneauthor=B.+Yuauthor=A.+Riceauthor=K.+E.+Lipsonauthor=C.+Liangauthor=L.+Sunauthor=C.+Tangauthor=G.+McMahonauthor=R.+G.+Pestellauthor=S.+Wadler&title=A+novel+cdk2-selective+inhibitor%2C+SU9516%2C+induces+apoptosis+in+colon+carcinoma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells</span></div><div class="casAuthors">Lane, Maureen E.; Yu, Bo; Rice, Audie; Lipson, Kenneth E.; Liang, Chris; Sun, Li; Tang, Cho; McMahon, Gerald; Pestell, Richard G.; Wadler, Scott</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6170-6177</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recent studies have indicated that the development of cyclin-dependent kinase (cdk)2 inhibitors that deregulate E2F are a plausible pharmacol. strategy for novel antineoplastic agents.  We show here that 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516), a novel 3-substituted indolinone compd., binds to and selectively inhibits the activity of cdk2.  This inhibition results in a time-dependent decrease (4-64%) in the phosphorylation of the retinoblastoma protein pRb, an increase in caspase-3 activation (5-84%), and alterations in cell cycle resulting in either a G0-G1 or a G2-M block.  We also report here cell line differences in the cdk-dependent phosphorylation of pRb.  These findings demonstrate that SU9516 is a selective cdk2 inhibitor and support the theory that compds. that inhibit cdk2 are viable resources in the development of new antineoplastic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq1CWPe7DjeLVg90H21EOLACvtfcHk0lhoDIz3d3OySQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmt12ktb0%253D&md5=ff3d0978c0b5a7d4f0188ef05a13b96a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DM.%2BE.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DRice%26aufirst%3DA.%26aulast%3DLipson%26aufirst%3DK.%2BE.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DPestell%26aufirst%3DR.%2BG.%26aulast%3DWadler%26aufirst%3DS.%26atitle%3DA%2520novel%2520cdk2-selective%2520inhibitor%252C%2520SU9516%252C%2520induces%2520apoptosis%2520in%2520colon%2520carcinoma%2520cells%26jtitle%3DCanccer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D6170%26epage%3D6177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Soni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zumstein-Mecker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fretz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhuri, B.</span><span> </span><span class="NLM_article-title">Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">436</span><span class="NLM_x">–</span> <span class="NLM_lpage">446</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1093%2Fjnci%2F93.6.436" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=11259469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXislCrtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2001&pages=436-446&author=R.+Soniauthor=T.+O%E2%80%99Reillyauthor=P.+Furetauthor=L.+Mullerauthor=C.+Stephanauthor=S.+Zumstein-Meckerauthor=H.+Fretzauthor=D.+Fabbroauthor=B.+Chaudhuri&title=Selective+in+vivo+and+in+vitro+effects+of+a+small+molecule+inhibitor+of+cyclin-dependent+kinase+4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4</span></div><div class="casAuthors">Soni, Rajeev; O'Reilly, Terence; Furet, Pascal; Muller, Lionel; Stephan, Christine; Zumstein-Mecker, Sabine; Fretz, Heinz; Fabbro, Doriano; Chaudhuri, Bhabatosh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">436-446</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Cyclin-dependent kinase 4 (Cdk4) represents a prime target for the treatment of cancer because most human cancers are characterized by overexpression of its activating partner cyclin D1, loss of the natural Cdk4-specific inhibitor p16, or mutation(s) in Cdk4's catalytic subunit.  All of these can cause deregulated cell growth, resulting in tumor formation.  We sought to identify a small mol. that could inhibit the kinase activity of Cdk4 in vitro and to then ascertain the effects of that inhibitor on cell growth and tumor vol. in vivo.  Methods: A triaminopyrimidine deriv., CINK4 (a chem. inhibitor of Cdk4), was identified by screening for compds. that could inhibit Cdk4 enzyme activity in vitro.  Kinase assays were performed on diverse human Cdks and on other kinases that were expressed in and purified from insect cells to det. the specificity of CINK4.  Cell cycle effects of CINK4 on tumor and normal cells were studied by flow cytometry, and changes in phosphorylation of the retinoblastoma protein (pRb), a substrate of Cdk4, were detd. by western blotting.  The effect of the inhibitor on tumor growth in vivo was studied by use of tumors established through xenografts of HCT116 colon carcinoma cells in mice.  Statistical tests were two-sided.  Results: CINK4 specifically inhibited Cdk4/cyclin D1 in vitro.  It caused growth arrest in tumor cells and in normal cells and prevented pRb phosphorylation.  CINK4 treatment resulted in statistically significantly (P = .031) smaller mean tumor vols. in a mouse xenograft model.  Conclusions: Like p16, the natural inhibitor of Cdk4, CINK4 inhibits Cdk4 activity in vitro and slows tumor growth in vivo.  The specificity of CINK4 for Cdk4 raises the possibility that this small mol. or one with a similar structure could have therapeutic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoISmjFVy7B9rVg90H21EOLACvtfcHk0lhoDIz3d3OySQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXislCrtLg%253D&md5=86345a46a2992af68c9dd22fc2e39efe</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F93.6.436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F93.6.436%26sid%3Dliteratum%253Aachs%26aulast%3DSoni%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DT.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DMuller%26aufirst%3DL.%26aulast%3DStephan%26aufirst%3DC.%26aulast%3DZumstein-Mecker%26aufirst%3DS.%26aulast%3DFretz%26aufirst%3DH.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DChaudhuri%26aufirst%3DB.%26atitle%3DSelective%2520in%2520vivo%2520and%2520in%2520vitro%2520effects%2520of%2520a%2520small%2520molecule%2520inhibitor%2520of%2520cyclin-dependent%2520kinase%25204%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2001%26volume%3D93%26spage%3D436%26epage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Honma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayaski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukasawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">wama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeura, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikuta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki-Takahashi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwasawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morishima, H.</span><span> </span><span class="NLM_article-title">Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: New de Novo Design Strategy and Library Design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">4615</span><span class="NLM_x">–</span> <span class="NLM_lpage">4627</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0103256" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXovFagtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=4615-4627&author=T.+Honmaauthor=K.+Hayaskiauthor=T.+Aoyamaauthor=N.+Hashimotoauthor=T.+Machidaauthor=K.+Fukasawaauthor=T.+wamaauthor=C.+Ikeuraauthor=M.+Ikutaauthor=I.+Suzuki-Takahashiauthor=Y.+Iwasawaauthor=T.+Hayamaauthor=S.+Nishimuraauthor=H.+Morishima&title=Structure-Based+Generation+of+a+New+Class+of+Potent+Cdk4+Inhibitors%3A+New+de+Novo+Design+Strategy+and+Library+Design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: New de Novo Design Strategy and Library Design</span></div><div class="casAuthors">Honma, Teruki; Hayashi, Kyoko; Aoyama, Tetsuya; Hashimoto, Noriaki; Machida, Takumitsu; Fukasawa, Kazuhiro; Iwama, Toshiharu; Ikeura, Chinatsu; Ikuta, Mari; Suzuki-Takahashi, Ikuko; Iwasawa, Yoshikazu; Hayama, Takashi; Nishimura, Susumu; Morishima, Hajime</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">4615-4627</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As a first step in structure-based design of highly selective and potent Cdk4 inhibitors, we performed structure-based generation of a novel series of Cdk4 inhibitors.  A Cdk4 homol. model was constructed according to x-ray anal. of an activated form of Cdk2.  Using this model, we applied a new de novo design strategy which combined the de novo design program LEGEND with our inhouse structure selection supporting system SEEDS to generate new scaffold candidates.  In this way, four classes of scaffold candidates including diarylurea were identified.  By constructing diarylurea informer libraries based on the structural requirements of Cdk inhibitors in the ATP binding pocket of the Cdk4 model, we were able to identify a potent Cdk4 inhibitor N-(9-oxo-9H-fluoren-4-yl)-N'-pyridin-2-ylurea (I) with IC50 = 0.10 μM, together with preliminary SAR.  We performed a docking study between I and the Cdk4 model and selected a reasonable binding mode which is consistent with the SAR.  Further modification based on the proposed binding mode provided a more potent compd., N-[(9bR)-5-oxo- 2,3,5,9b-tetrahydro-1H-pyrrolo[2,1-a]isoindol-9-yl]-N'-pyridin-2-ylurea (II) with IC50 = 0.042 μM, x-ray anal. of which was accomplished by the soaking method.  The predicted binding mode of I in Cdk4 was validated by x-ray anal. of the Cdk2-II complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvx3J3Bqyg9LVg90H21EOLACvtfcHk0ljTikv8a54W4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXovFagtrs%253D&md5=0c4458fa88d41c148a672863b3a6daa0</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1021%2Fjm0103256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0103256%26sid%3Dliteratum%253Aachs%26aulast%3DHonma%26aufirst%3DT.%26aulast%3DHayaski%26aufirst%3DK.%26aulast%3DAoyama%26aufirst%3DT.%26aulast%3DHashimoto%26aufirst%3DN.%26aulast%3DMachida%26aufirst%3DT.%26aulast%3DFukasawa%26aufirst%3DK.%26aulast%3Dwama%26aufirst%3DT.%26aulast%3DIkeura%26aufirst%3DC.%26aulast%3DIkuta%26aufirst%3DM.%26aulast%3DSuzuki-Takahashi%26aufirst%3DI.%26aulast%3DIwasawa%26aufirst%3DY.%26aulast%3DHayama%26aufirst%3DT.%26aulast%3DNishimura%26aufirst%3DS.%26aulast%3DMorishima%26aufirst%3DH.%26atitle%3DStructure-Based%2520Generation%2520of%2520a%2520New%2520Class%2520of%2520Potent%2520Cdk4%2520Inhibitors%253A%2520New%2520de%2520Novo%2520Design%2520Strategy%2520and%2520Library%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D4615%26epage%3D4627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Honma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshizumi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawanishi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukasawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeura, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikuta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki-Takahashi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morishima, H.</span><span> </span><span class="NLM_article-title">A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">4628</span><span class="NLM_x">–</span> <span class="NLM_lpage">4640</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm010326y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=4628-4640&author=T.+Honmaauthor=T.+Yoshizumiauthor=N.+Hashimotoauthor=K.+Hayashiauthor=N.+Kawanishiauthor=K.+Fukasawaauthor=T.+Takakiauthor=C.+Ikeuraauthor=M.+Ikutaauthor=I.+Suzuki-Takahashiauthor=T.+Hayamaauthor=S.+Nishimuraauthor=H.+Morishima&title=A+novel+approach+for+the+development+of+selective+Cdk4+inhibitors%3A+library+design+based+on+locations+of+Cdk4+specific+amino+acid+residues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1021%2Fjm010326y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010326y%26sid%3Dliteratum%253Aachs%26aulast%3DHonma%26aufirst%3DT.%26aulast%3DYoshizumi%26aufirst%3DT.%26aulast%3DHashimoto%26aufirst%3DN.%26aulast%3DHayashi%26aufirst%3DK.%26aulast%3DKawanishi%26aufirst%3DN.%26aulast%3DFukasawa%26aufirst%3DK.%26aulast%3DTakaki%26aufirst%3DT.%26aulast%3DIkeura%26aufirst%3DC.%26aulast%3DIkuta%26aufirst%3DM.%26aulast%3DSuzuki-Takahashi%26aufirst%3DI.%26aulast%3DHayama%26aufirst%3DT.%26aulast%3DNishimura%26aufirst%3DS.%26aulast%3DMorishima%26aufirst%3DH.%26atitle%3DA%2520novel%2520approach%2520for%2520the%2520development%2520of%2520selective%2520Cdk4%2520inhibitors%253A%2520library%2520design%2520based%2520on%2520locations%2520of%2520Cdk4%2520specific%2520amino%2520acid%2520residues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D4628%26epage%3D4640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Verdaguer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordà, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canudas, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiménez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sureda, F. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimbau, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pubill, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escubedo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camarasa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallàs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camins, A.</span><span> </span><span class="NLM_article-title">3-Amino thioacridone, a selective cyclin-dependent kinase 4 inhibitor, attenuates kainic acid-induced apoptosis in neurons</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">599</span><span class="NLM_x">–</span> <span class="NLM_lpage">603</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2003&pages=599-603&author=E.+Verdaguerauthor=E.+G.+Jord%C3%A0author=A.+M.+Canudasauthor=A.+Jim%C3%A9nezauthor=F.+X.+Suredaauthor=V.+Rimbauauthor=D.+Pubillauthor=E.+Escubedoauthor=J.+Camarasaauthor=M.+Pall%C3%A0sauthor=A.+Camins&title=3-Amino+thioacridone%2C+a+selective+cyclin-dependent+kinase+4+inhibitor%2C+attenuates+kainic+acid-induced+apoptosis+in+neurons"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerdaguer%26aufirst%3DE.%26aulast%3DJord%25C3%25A0%26aufirst%3DE.%2BG.%26aulast%3DCanudas%26aufirst%3DA.%2BM.%26aulast%3DJim%25C3%25A9nez%26aufirst%3DA.%26aulast%3DSureda%26aufirst%3DF.%2BX.%26aulast%3DRimbau%26aufirst%3DV.%26aulast%3DPubill%26aufirst%3DD.%26aulast%3DEscubedo%26aufirst%3DE.%26aulast%3DCamarasa%26aufirst%3DJ.%26aulast%3DPall%25C3%25A0s%26aufirst%3DM.%26aulast%3DCamins%26aufirst%3DA.%26atitle%3D3-Amino%2520thioacridone%252C%2520a%2520selective%2520cyclin-dependent%2520kinase%25204%2520inhibitor%252C%2520attenuates%2520kainic%2520acid-induced%2520apoptosis%2520in%2520neurons%26jtitle%3DNeuroscience%26date%3D2003%26volume%3D120%26spage%3D599%26epage%3D603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Misra, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawlins, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, S. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bednarz, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellar, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulheron, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batorsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roongta, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranadive, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavletich, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimball, S. D.</span><span> </span><span class="NLM_article-title"><i>N</i>-(Cycloalkylmino) acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. <i>N</i>-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1719</span><span class="NLM_x">–</span> <span class="NLM_lpage">1728</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0305568" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1719-1728&author=R.+N.+Misraauthor=H.+Xiaoauthor=K.+S.+Kimauthor=S.+Luauthor=W.-C.+Hanauthor=S.+A.+Barbosaauthor=J.+T.+Huntauthor=D.+B.+Rawlinsauthor=W.+Shanauthor=S.+Z.+Ahmedauthor=L.+Qianauthor=B.-C.+Chenauthor=R.+Zhaoauthor=M.+S.+Bednarzauthor=K.+A.+Kellarauthor=J.+G.+Mulheronauthor=R.+Batorskyauthor=U.+Roongtaauthor=A.+Kamathauthor=P.+Maratheauthor=S.+A.+Ranadiveauthor=J.+S.+Sackauthor=J.+S.+Tokarskiauthor=N.+P.+Pavletichauthor=F.+Y.+F.+Leeauthor=K.+R.+Websterauthor=S.+D.+Kimball&title=N-%28Cycloalkylmino%29+acyl-2-aminothiazole+Inhibitors+of+Cyclin-Dependent+Kinase+2.+N-%5B5-%5B%5B%5B5-%281%2C1-Dimethylethyl%29-2-oxazolyl%5Dmethyl%5Dthio%5D-2-thiazolyl%5D-4-piperidinecarboxamide+%28BMS-387032%29%2C+a+Highly+Efficacious+and+Selective+Antitumor+Agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm0305568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0305568%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DR.%2BN.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DW.-C.%26aulast%3DBarbosa%26aufirst%3DS.%2BA.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DRawlins%26aufirst%3DD.%2BB.%26aulast%3DShan%26aufirst%3DW.%26aulast%3DAhmed%26aufirst%3DS.%2BZ.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DB.-C.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DBednarz%26aufirst%3DM.%2BS.%26aulast%3DKellar%26aufirst%3DK.%2BA.%26aulast%3DMulheron%26aufirst%3DJ.%2BG.%26aulast%3DBatorsky%26aufirst%3DR.%26aulast%3DRoongta%26aufirst%3DU.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DRanadive%26aufirst%3DS.%2BA.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26aulast%3DLee%26aufirst%3DF.%2BY.%2BF.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26aulast%3DKimball%26aufirst%3DS.%2BD.%26atitle%3DN-%2528Cycloalkylmino%2529%2520acyl-2-aminothiazole%2520Inhibitors%2520of%2520Cyclin-Dependent%2520Kinase%25202.%2520N-%255B5-%255B%255B%255B5-%25281%252C1-Dimethylethyl%2529-2-oxazolyl%255Dmethyl%255Dthio%255D-2-thiazolyl%255D-4-piperidinecarboxamide%2520%2528BMS-387032%2529%252C%2520a%2520Highly%2520Efficacious%2520and%2520Selective%2520Antitumor%2520Agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1719%26epage%3D1728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Zhu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conner, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Considine, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dempsey, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faul, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teicher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, S. A.</span><span> </span><span class="NLM_article-title">Synthesis, structure–activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2027</span><span class="NLM_x">–</span> <span class="NLM_lpage">2030</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0256169" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=2027-2030&author=G.+Zhuauthor=S.+E.+Connerauthor=X.+Zhouauthor=C.+Shihauthor=T.+Liauthor=B.+D.+Andersonauthor=H.+B.+Brooksauthor=R.+M.+Campbellauthor=E.+Considineauthor=J.+A.+Dempseyauthor=M.+M.+Faulauthor=C.+Oggauthor=B.+Patelauthor=R.+M.+Schultzauthor=C.+D.+Spencerauthor=B.+Teicherauthor=S.+A.+Watkins&title=Synthesis%2C+structure%E2%80%93activity+relationship%2C+and+biological+studies+of+indolocarbazoles+as+potent+cyclin+D1-CDK4+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm0256169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0256169%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DG.%26aulast%3DConner%26aufirst%3DS.%2BE.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DAnderson%26aufirst%3DB.%2BD.%26aulast%3DBrooks%26aufirst%3DH.%2BB.%26aulast%3DCampbell%26aufirst%3DR.%2BM.%26aulast%3DConsidine%26aufirst%3DE.%26aulast%3DDempsey%26aufirst%3DJ.%2BA.%26aulast%3DFaul%26aufirst%3DM.%2BM.%26aulast%3DOgg%26aufirst%3DC.%26aulast%3DPatel%26aufirst%3DB.%26aulast%3DSchultz%26aufirst%3DR.%2BM.%26aulast%3DSpencer%26aufirst%3DC.%2BD.%26aulast%3DTeicher%26aufirst%3DB.%26aulast%3DWatkins%26aufirst%3DS.%2BA.%26atitle%3DSynthesis%252C%2520structure%25E2%2580%2593activity%2520relationship%252C%2520and%2520biological%2520studies%2520of%2520indolocarbazoles%2520as%2520potent%2520cyclin%2520D1-CDK4%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D2027%26epage%3D2030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Toogood, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repine, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanderWel, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodfuehrer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barvian, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2388</span><span class="NLM_x">–</span> <span class="NLM_lpage">2406</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049354h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2388-2406&author=P.+L.+Toogoodauthor=P.+J.+Harveyauthor=J.+T.+Repineauthor=D.+J.+Sheehanauthor=S.+N.+VanderWelauthor=H.+Zhouauthor=P.+R.+Kellerauthor=D.+J.+McNamaraauthor=D.+Sherryauthor=T.+Zhuauthor=J.+Brodfuehrerauthor=C.+Choiauthor=M.+R.+Barvianauthor=D.+W.+Fry&title=Discovery+of+a+potent+and+selective+inhibitor+of+cyclin-dependent+kinase+4%2F6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6</span></div><div class="casAuthors">Toogood, Peter L.; Harvey, Patricia J.; Repine, Joseph T.; Sheehan, Derek J.; VanderWel, Scott N.; Zhou, Hairong; Keller, Paul R.; McNamara, Dennis J.; Sherry, Debra; Zhu, Tong; Brodfuehrer, Joanne; Choi, Chung; Barvian, Mark R.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2388-2406</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pharmacol. approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small mol. inhibitors has the potential to provide novel cancer therapies for clin. use.  Achieving high levels of selectivity for Cdk4/6, vs. other ATP-dependent kinases, presents a significant challenge.  The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks.  It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro.  This selectivity profile is recapitulated in cells where the most selective inhibitors create a G1 block at concns. up to 100-fold the IC50 for cell proliferation.  On the basis of its selectivity profile and pharmacokinetic profile, compd. I (PD 0332991) was identified as a drug candidate for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX577J5U0r97Vg90H21EOLACvtfcHk0lgNPg-1D2FKqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D&md5=23cbe58426ff1975695712db7c1b128a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm049354h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049354h%26sid%3Dliteratum%253Aachs%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DSheehan%26aufirst%3DD.%2BJ.%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DSherry%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinase%25204%252F6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2388%26epage%3D2406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Saab, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bills, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miceli, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khoury, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navid, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skapek, S. X.</span><span> </span><span class="NLM_article-title">Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1299</span><span class="NLM_x">–</span> <span class="NLM_lpage">1308</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1158%2F1535-7163.MCT-05-0383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=16731763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD28XltVWms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1299-1308&author=R.+Saabauthor=J.+L.+Billsauthor=A.+P.+Miceliauthor=C.+M.+Andersonauthor=J.+D.+Khouryauthor=D.+W.+Fryauthor=F.+Navidauthor=P.+J.+Houghtonauthor=S.+X.+Skapek&title=Pharmacologic+inhibition+of+cyclin-dependent+kinase+4%2F6+activity+arrests+proliferation+in+myoblasts+and+rhabdomyosarcoma-derived+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells</span></div><div class="casAuthors">Saab, Raya; Bills, Jennifer L.; Miceli, Alexander P.; Anderson, Colleen M.; Khoury, Joseph D.; Fry, David W.; Navid, Fariba; Houghton, Peter J.; Skapek, Stephen X.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1299-1308</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Myoblast cell cycle exit and differentiation are mediated in part by down-regulation of cyclin D1 and assocd. cyclin-dependent kinase (Cdk) activity.  Because rhabdomyosarcoma may represent a malignant tumor composed of myoblast-like cells failing to exit the cell cycle and differentiate, we considered whether excess Cdk activity might contribute to this biol.  Cyclin D-dependent Cdk4 and Cdk6 were expressed in most of a panel of six human rhabdomyosarcoma-derived cell lines.  Cdk4 was expressed in 73% of alveolar and embryonal rhabdomyosarcoma tumors evaluated using a human tissue microarray.  When challenged to differentiate by mitogen deprivation in vitro, mouse C2C12 myoblasts arrested in G1 phase of the cell cycle, whereas four in the panel of rhabdomyosarcoma cell lines failed to do so.  C2C12 myoblasts maintained in mitogen-rich media and exposed to a Cdk4/Cdk6 inhibitor PD 0332991 accumulated in G1 cell cycle phase.  Similar treatment of rhabdomyosarcoma cell lines caused G1 arrest and prevented cell accumulation in vitro, and it delayed growth of rhabdomyosarcoma xenografts in vivo.  Consistent with a role for Cdk4/Cdk6 activity as a regulator of myogenic differentiation, we obsd. that PD 0332991 exposure promoted morphol. changes and enhanced the expression of muscle-specific proteins in cultured myoblasts and in the Rh30 cell line.  Our findings support the concept that pharmacol. inhibition of Cdk4/Cdk6 may represent a useful therapeutic strategy to control cell proliferation and possibly promote myogenic differentiation in rhabdomyosarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA6GrUsfwUtbVg90H21EOLACvtfcHk0lgNPg-1D2FKqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltVWms7s%253D&md5=7c94eb30156f3f61be900b5fd2dc8b4a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0383%26sid%3Dliteratum%253Aachs%26aulast%3DSaab%26aufirst%3DR.%26aulast%3DBills%26aufirst%3DJ.%2BL.%26aulast%3DMiceli%26aufirst%3DA.%2BP.%26aulast%3DAnderson%26aufirst%3DC.%2BM.%26aulast%3DKhoury%26aufirst%3DJ.%2BD.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DNavid%26aufirst%3DF.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26aulast%3DSkapek%26aufirst%3DS.%2BX.%26atitle%3DPharmacologic%2520inhibition%2520of%2520cyclin-dependent%2520kinase%25204%252F6%2520activity%2520arrests%2520proliferation%2520in%2520myoblasts%2520and%2520rhabdomyosarcoma-derived%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1299%26epage%3D1308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Baughn, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Liberto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toogood, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottschalk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niesvizky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ely, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen-Kiang, S.</span><span> </span><span class="NLM_article-title">A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">7661</span><span class="NLM_x">–</span> <span class="NLM_lpage">7667</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=7661-7667&author=L.+B.+Baughnauthor=M.+Di+Libertoauthor=K.+Wuauthor=P.+L.+Toogoodauthor=T.+Louieauthor=R.+Gottschalkauthor=R.+Niesvizkyauthor=H.+Choauthor=S.+Elyauthor=M.+A.+Mooreauthor=S.+Chen-Kiang&title=A+novel+orally+active+small+molecule+potently+induces+G1+arrest+in+primary+myeloma+cells+and+prevents+tumor+growth+by+specific+inhibition+of+cyclin-dependent+kinase+4%2F6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaughn%26aufirst%3DL.%2BB.%26aulast%3DDi%2BLiberto%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DLouie%26aufirst%3DT.%26aulast%3DGottschalk%26aufirst%3DR.%26aulast%3DNiesvizky%26aufirst%3DR.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DEly%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DM.%2BA.%26aulast%3DChen-Kiang%26aufirst%3DS.%26atitle%3DA%2520novel%2520orally%2520active%2520small%2520molecule%2520potently%2520induces%2520G1%2520arrest%2520in%2520primary%2520myeloma%2520cells%2520and%2520prevents%2520tumor%2520growth%2520by%2520specific%2520inhibition%2520of%2520cyclin-dependent%2520kinase%25204%252F6%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D7661%26epage%3D7667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedford, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fattaey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span> </span><span class="NLM_article-title">Cell cycle and biochemical effects of PD 0183812: a potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">16617</span><span class="NLM_x">–</span> <span class="NLM_lpage">16623</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=16617-16623&author=D.+W.+Fryauthor=D.+C.+Bedfordauthor=P.+H.+Harveyauthor=A.+Fritschauthor=P.+R.+Kellerauthor=Z.+Wuauthor=E.+Dobrusinauthor=W.+R.+Leopoldauthor=A.+Fattaeyauthor=M.+D.+Garrett&title=Cell+cycle+and+biochemical+effects+of+PD+0183812%3A+a+potent+inhibitor+of+the+cyclin+D-dependent+kinases+CDK4+and+CDK6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DBedford%26aufirst%3DD.%2BC.%26aulast%3DHarvey%26aufirst%3DP.%2BH.%26aulast%3DFritsch%26aufirst%3DA.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DDobrusin%26aufirst%3DE.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DFattaey%26aufirst%3DA.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26atitle%3DCell%2520cycle%2520and%2520biochemical%2520effects%2520of%2520PD%25200183812%253A%2520a%2520potent%2520inhibitor%2520of%2520the%2520cyclin%2520D-dependent%2520kinases%2520CDK4%2520and%2520CDK6%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D16617%26epage%3D16623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Marzec, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasprzycka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gladden, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wlodarski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomczak, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deprimo, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuster, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasik, M. A.</span><span> </span><span class="NLM_article-title">Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">1744</span><span class="NLM_x">–</span> <span class="NLM_lpage">1750</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=1744-1750&author=M.+Marzecauthor=M.+Kasprzyckaauthor=R.+Laiauthor=A.+B.+Gladdenauthor=P.+Wlodarskiauthor=E.+Tomczakauthor=P.+Nowellauthor=S.+E.+Deprimoauthor=S.+Sadisauthor=S.+Eckauthor=S.+J.+Schusterauthor=J.+A.+Diehlauthor=M.+A.+Wasik&title=Mantle+cell+lymphoma+cells+express+predominantly+cyclin+D1a+isoform+and+are+highly+sensitive+to+selective+inhibition+of+CDK4+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarzec%26aufirst%3DM.%26aulast%3DKasprzycka%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DR.%26aulast%3DGladden%26aufirst%3DA.%2BB.%26aulast%3DWlodarski%26aufirst%3DP.%26aulast%3DTomczak%26aufirst%3DE.%26aulast%3DNowell%26aufirst%3DP.%26aulast%3DDeprimo%26aufirst%3DS.%2BE.%26aulast%3DSadis%26aufirst%3DS.%26aulast%3DEck%26aufirst%3DS.%26aulast%3DSchuster%26aufirst%3DS.%2BJ.%26aulast%3DDiehl%26aufirst%3DJ.%2BA.%26aulast%3DWasik%26aufirst%3DM.%2BA.%26atitle%3DMantle%2520cell%2520lymphoma%2520cells%2520express%2520predominantly%2520cyclin%2520D1a%2520isoform%2520and%2520are%2520highly%2520sensitive%2520to%2520selective%2520inhibition%2520of%2520CDK4%2520kinase%2520activity%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D1744%26epage%3D1750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dering, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalous, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginther, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atefi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fowst, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span> </span><span class="NLM_article-title">PD-0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro</span> <span class="citation_source-journal">Breast Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">R77</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=R77&author=R.+S.+Finnauthor=J.+Deringauthor=D.+Conklinauthor=O.+Kalousauthor=D.+J.+Cohenauthor=A.+J.+Desaiauthor=C.+Gintherauthor=M.+Atefiauthor=I.+Chenauthor=C.+Fowstauthor=G.+Losauthor=D.+J.+Slamon&title=PD-0332991%2C+a+selective+cyclin+D+kinase+4%2F6+inhibitor%2C+preferentially+inhibits+proliferation+of+luminal+estrogen+receptor-positive+human+breast+cancer+cell+lines+in+vitro"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DDering%26aufirst%3DJ.%26aulast%3DConklin%26aufirst%3DD.%26aulast%3DKalous%26aufirst%3DO.%26aulast%3DCohen%26aufirst%3DD.%2BJ.%26aulast%3DDesai%26aufirst%3DA.%2BJ.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DAtefi%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DFowst%26aufirst%3DC.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26atitle%3DPD-0332991%252C%2520a%2520selective%2520cyclin%2520D%2520kinase%25204%252F6%2520inhibitor%252C%2520preferentially%2520inhibits%2520proliferation%2520of%2520luminal%2520estrogen%2520receptor-positive%2520human%2520breast%2520cancer%2520cell%2520lines%2520in%2520vitro%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2009%26volume%3D11%26spage%3DR77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Michaud, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oermann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, W. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prados, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldman, T.</span><span> </span><span class="NLM_article-title">Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">3228</span><span class="NLM_x">–</span> <span class="NLM_lpage">3238</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=3228-3238&author=K.+Michaudauthor=D.+A.+Solomonauthor=E.+Oermannauthor=J.+S.+Kimauthor=W.+Z.+Zhongauthor=M.+D.+Pradosauthor=T.+Ozawaauthor=C.+D.+Jamesauthor=T.+Waldman&title=Pharmacologic+inhibition+of+cyclin-dependent+kinases+4+and+6+arrests+the+growth+of+glioblastoma+multiforme+intracranial+xenografts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMichaud%26aufirst%3DK.%26aulast%3DSolomon%26aufirst%3DD.%2BA.%26aulast%3DOermann%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DJ.%2BS.%26aulast%3DZhong%26aufirst%3DW.%2BZ.%26aulast%3DPrados%26aufirst%3DM.%2BD.%26aulast%3DOzawa%26aufirst%3DT.%26aulast%3DJames%26aufirst%3DC.%2BD.%26aulast%3DWaldman%26aufirst%3DT.%26atitle%3DPharmacologic%2520inhibition%2520of%2520cyclin-dependent%2520kinases%25204%2520and%25206%2520arrests%2520the%2520growth%2520of%2520glioblastoma%2520multiforme%2520intracranial%2520xenografts%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D3228%26epage%3D3238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Wiedemeyer, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, I. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quayle, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chheda, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbluh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, L.</span><span> </span><span class="NLM_article-title">Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci.U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">11501</span><span class="NLM_x">–</span> <span class="NLM_lpage">11506</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=11501-11506&author=W.+R.+Wiedemeyerauthor=I.+F.+Dunnauthor=S.+N.+Quayleauthor=J.+Zhangauthor=M.+G.+Chhedaauthor=G.+P.+Dunnauthor=L.+Zhuangauthor=J.+Rosenbluhauthor=S.+Chenauthor=Y.+Xiaoauthor=G.+I.+Shapiroauthor=W.+C.+Hahnauthor=L.+Chin&title=Pattern+of+retinoblastoma+pathway+inactivation+dictates+response+to+CDK4%2F6+inhibition+in+GBM"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWiedemeyer%26aufirst%3DW.%2BR.%26aulast%3DDunn%26aufirst%3DI.%2BF.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DChheda%26aufirst%3DM.%2BG.%26aulast%3DDunn%26aufirst%3DG.%2BP.%26aulast%3DZhuang%26aufirst%3DL.%26aulast%3DRosenbluh%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DChin%26aufirst%3DL.%26atitle%3DPattern%2520of%2520retinoblastoma%2520pathway%2520inactivation%2520dictates%2520response%2520to%2520CDK4%252F6%2520inhibition%2520in%2520GBM%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D11501%26epage%3D11506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Konecny, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winterhoff, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolarova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manivong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dering, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalukya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalli, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginther, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velculescu, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riehle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cliby, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randolph, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span> </span><span class="NLM_article-title">Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1591</span><span class="NLM_x">–</span> <span class="NLM_lpage">1602</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1158%2F1078-0432.CCR-10-2307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=21278246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFChtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=1591-1602&author=G.+E.+Konecnyauthor=B.+Winterhoffauthor=T.+Kolarovaauthor=J.+Qiauthor=K.+Manivongauthor=J.+Deringauthor=G.+Yangauthor=M.+Chalukyaauthor=H.+J.+Wangauthor=L.+Andersonauthor=K.+R.+Kalliauthor=R.+S.+Finnauthor=C.+Gintherauthor=S.+Jonesauthor=V.+E.+Velculescuauthor=D.+Riehleauthor=W.+A.+Clibyauthor=S.+Randolphauthor=M.+Koehlerauthor=L.+C.+Hartmannauthor=D.+J.+Slamon&title=Expression+of+p16+and+retinoblastoma+determines+response+to+CDK4%2F6+inhibition+in+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer</span></div><div class="casAuthors">Konecny, Gottfried E.; Winterhoff, Boris; Kolarova, Teodora; Qi, Jingwei; Manivong, Kanthinh; Dering, Judy; Yang, Guorong; Chalukya, Meenal; Wang, He-Jing; Anderson, Lee; Kalli, Kimberly R.; Finn, Richard S.; Ginther, Charles; Jones, Sian; Velculescu, Victor E.; Riehle, Darren; Cliby, William A.; Randolph, Sophia; Koehler, Maria; Hartmann, Lynn C.; Slamon, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1591-1602</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PD-0332991 is a selective inhibitor of the CDK4/6 kinases with the ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range.  Here we investigate the role of CDK4/6 inhibition in human ovarian cancer.  We examd. the effects of PD-0332991 on proliferation, cell-cycle, apoptosis, and Rb phosphorylation using a panel of 40 established human ovarian cancer cell lines.  Mol. markers for response prediction, including p16 and Rb, were studied using gene expression profiling, Western blot, and array CGH.  Multiple drug effect anal. was used to study interactions with chemotherapeutic drugs.  Expression of p16 and Rb was studied using immunohistochem. in a large clin. cohort of ovarian cancer patients.  Concn.-dependent antiproliferative effects of PD-0332991 were seen in all ovarian cancer cell lines, but varied significantly between individual lines.  Rb-proficient cell lines with low p16 expression were most responsive to CDK4/6 inhibition.  Copy no. variations of CDKN2A, RB, CCNE1, and CCND1 were assocd. with response to PD-0332991.  CDK4/6 inhibition induced G0/G1 cell cycle arrest, blocked Rb phosphorylation in a concn.-and time-dependent manner, and enhanced the effects of chemotherapy.  Rb-proficiency with low p16 expression was seen in 97/262 (37%) of ovarian cancer patients and was independently assocd. with poor progression-free survival (adjusted relative risk 1.49, 95% CI 1.00-2.24, P = 0.052).  PD-0332991 shows promising biol. activity in ovarian cancer cell lines.  Assessment of Rb and p16 expression may help select patients most likely to benefit from CDK4/6 inhibition in ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyvDPdFFMnq7Vg90H21EOLACvtfcHk0ljPsP6JaIgkgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFChtrc%253D&md5=fc343bf876b690b1904d5955a7b8ba9b</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-2307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-2307%26sid%3Dliteratum%253Aachs%26aulast%3DKonecny%26aufirst%3DG.%2BE.%26aulast%3DWinterhoff%26aufirst%3DB.%26aulast%3DKolarova%26aufirst%3DT.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DManivong%26aufirst%3DK.%26aulast%3DDering%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DChalukya%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DH.%2BJ.%26aulast%3DAnderson%26aufirst%3DL.%26aulast%3DKalli%26aufirst%3DK.%2BR.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26aulast%3DRiehle%26aufirst%3DD.%26aulast%3DCliby%26aufirst%3DW.%2BA.%26aulast%3DRandolph%26aufirst%3DS.%26aulast%3DKoehler%26aufirst%3DM.%26aulast%3DHartmann%26aufirst%3DL.%2BC.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26atitle%3DExpression%2520of%2520p16%2520and%2520retinoblastoma%2520determines%2520response%2520to%2520CDK4%252F6%2520inhibition%2520in%2520ovarian%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D1591%26epage%3D1602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMichele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dial, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courtney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">wilner, K. D</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, G. K.</span><span> </span><span class="NLM_article-title">A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">18S</span><span class="NLM_x">) </span> <span class="NLM_fpage">150S</span><div class="note"><p class="first last">(Suppl Abst-3550)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=150S&issue=18S&author=P.+J.+O%E2%80%99Dwyerauthor=P.+LoRussoauthor=A.+DeMicheleauthor=V.+Guptaauthor=A.+Barbiauthor=H.+Dialauthor=I.+Chenauthor=R.+Courtneyauthor=K.+D+wilnerauthor=G.+K.+Schwartz&title=A+phase+I+dose+escalation+trial+of+a+daily+oral+CDK+4%2F6+inhibitor+PD-0332991"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DDeMichele%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DBarbi%26aufirst%3DA.%26aulast%3DDial%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DCourtney%26aufirst%3DR.%26aulast%3Dwilner%26aufirst%3DK.%2BD%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DA%2520phase%2520I%2520dose%2520escalation%2520trial%2520of%2520a%2520daily%2520oral%2520CDK%25204%252F6%2520inhibitor%2520PD-0332991%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2007%26volume%3D25%26issue%3D18S%26spage%3D150S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Schwartz, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randolph, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaik, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courtney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span> </span><span class="NLM_article-title">Phase I study of PD-0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (schedule 2/1)</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">1862</span><span class="NLM_x">–</span> <span class="NLM_lpage">1868</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1038%2Fbjc.2011.177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=21610706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntV2hsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2011&pages=1862-1868&author=G.+K.+Schwartzauthor=P.+M.+LoRussoauthor=M.+A.+Dicksonauthor=S.+S.+Randolphauthor=M.+N.+Shaikauthor=K.+D.+Wilnerauthor=R.+Courtneyauthor=P.+J.+O%E2%80%99Dwyer&title=Phase+I+study+of+PD-0332991%2C+a+cyclin-dependent+kinase+inhibitor%2C+administered+in+3-week+cycles+%28schedule+2%2F1%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)</span></div><div class="casAuthors">Schwartz, G. K.; LoRusso, P. M.; Dickson, M. A.; Randolph, S. S.; Shaik, M. N.; Wilner, K. D.; Courtney, R.; O'Dwyer, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1862-1868</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: This phase I, open-label, first-in-human study detd. dose-limiting toxicities (DLTs) and max. tolerated dose (MTD) of PD 0332991, an oral cyclin-dependent kinase 4/6 inhibitor with potent anti-proliferative activity in vitro/vivo.  Methods: A total of 33 patients with retinoblastoma protein-pos. advanced solid tumors or non-Hodgkin's lymphoma refractory to std. therapy or for which no therapy was available received PD 0332991 once daily (QD) for 14 days followed by 7 days off treatment (21-day cycles; Schedule 2/1).  Results: Six patients had DLTs (18%; four receiving 200 mg QD; two receiving 225 mg QD); the MTD was 200 mg QD.  Treatment-related, non-haematol. adverse events occurred in 29 patients (88%) during cycle 1 and 27 patients (82%) thereafter.  Adverse events were generally mild-moderate.  Of 31 evaluable patients, one with testicular cancer achieved a partial response; nine had stable disease (≥10 cycles in three cases).  PD 0332991 was slowly absorbed (mean Tmax 4.2 h) and eliminated (mean half-life 26.7 h).  Vol. of distribution was large (mean 3241 l) with dose-proportional exposure.  Using a max. effective concn. model, neutropenia was proportional to exposure.  Conclusion: PD 0332991 was generally well tolerated, with DLTs related mainly to myelosuppression.  The MTD, 200 mg QD, is recommended for phase II study.  British Journal of Cancer (2011) 104, 1862-1868; doi:10.1038/bjc.2011.177 www.bjcancer.com Published online 24 May 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrirHusdI7VjLVg90H21EOLACvtfcHk0ljPsP6JaIgkgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntV2hsLc%253D&md5=5ff27f8f2d06282f567f4e5ed81c554c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2011.177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2011.177%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DDickson%26aufirst%3DM.%2BA.%26aulast%3DRandolph%26aufirst%3DS.%2BS.%26aulast%3DShaik%26aufirst%3DM.%2BN.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DCourtney%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26atitle%3DPhase%2520I%2520study%2520of%2520PD-0332991%252C%2520a%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520administered%2520in%25203-week%2520cycles%2520%2528schedule%25202%252F1%2529%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2011%26volume%3D104%26spage%3D1862%26epage%3D1868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Leonard, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaCasce, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallabhajosula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoder, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">English, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millenson, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ely, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courtney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaik, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randolph, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Abbeele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen-Kiang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D. Yap, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span> </span><span class="NLM_article-title">Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">4597</span><span class="NLM_x">–</span> <span class="NLM_lpage">4607</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=4597-4607&author=J.+P.+Leonardauthor=A.+S.+LaCasceauthor=M.+R.+Smithauthor=A.+Noyauthor=L.+R.+Chirieacauthor=S.+J.+Rodigauthor=J.+Q.+Yuauthor=S.+Vallabhajosulaauthor=H.+Schoderauthor=P.+Englishauthor=D.+S.+Neubergauthor=P.+Martinauthor=M.+M.+Millensonauthor=S.+A.+Elyauthor=R.+Courtneyauthor=N.+Shaikauthor=K.+D.+Wilnerauthor=S.+Randolphauthor=A.+Van+den+Abbeeleauthor=S.+Y.+Chen-Kiangauthor=J.+T.+D.+Yapauthor=G.+I.+Shapiro&title=Selective+CDK4%2F6+inhibition+with+tumor+responses+by+PD0332991+in+patients+with+mantle+cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeonard%26aufirst%3DJ.%2BP.%26aulast%3DLaCasce%26aufirst%3DA.%2BS.%26aulast%3DSmith%26aufirst%3DM.%2BR.%26aulast%3DNoy%26aufirst%3DA.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DYu%26aufirst%3DJ.%2BQ.%26aulast%3DVallabhajosula%26aufirst%3DS.%26aulast%3DSchoder%26aufirst%3DH.%26aulast%3DEnglish%26aufirst%3DP.%26aulast%3DNeuberg%26aufirst%3DD.%2BS.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DMillenson%26aufirst%3DM.%2BM.%26aulast%3DEly%26aufirst%3DS.%2BA.%26aulast%3DCourtney%26aufirst%3DR.%26aulast%3DShaik%26aufirst%3DN.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DRandolph%26aufirst%3DS.%26aulast%3DVan%2Bden%2BAbbeele%26aufirst%3DA.%26aulast%3DChen-Kiang%26aufirst%3DS.%2BY.%26aulast%3DD.%2BYap%26aufirst%3DJ.%2BT.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DSelective%2520CDK4%252F6%2520inhibition%2520with%2520tumor%2520responses%2520by%2520PD0332991%2520in%2520patients%2520with%2520mantle%2520cell%2520lymphoma%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D4597%26epage%3D4607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMichele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abramson, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courtney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randolph, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaik, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, G. K.</span><span> </span><span class="NLM_article-title">Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD0332991, administered using a 21-day schedule in patients with advanced cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">568</span><span class="NLM_x">–</span> <span class="NLM_lpage">576</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1158%2F1078-0432.CCR-11-0509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=22090362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGqs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=568-576&author=K.+T.+Flahertyauthor=P.+M.+Lorussoauthor=A.+DeMicheleauthor=V.+G.+Abramsonauthor=R.+Courtneyauthor=S.+S.+Randolphauthor=M.+N.+Shaikauthor=K.+D.+Wilnerauthor=P.+J.+O%E2%80%99Dwyerauthor=G.+K.+Schwartz&title=Phase+I%2C+dose-escalation+trial+of+the+oral+cyclin-dependent+kinase+4%2F6+inhibitor+PD0332991%2C+administered+using+a+21-day+schedule+in+patients+with+advanced+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer</span></div><div class="casAuthors">Flaherty, Keith T.; LoRusso, Patricia M.; DeMichele, Angela; Abramson, Vandana G.; Courtney, Rachel; Randolph, Sophia S.; Shaik, M. Naveed; Wilner, Keith D.; O'Dwyer, Peter J.; Schwartz, Gary K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">568-576</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: To identify the dose-limiting toxicity (DLT) and max. tolerated dose (MTD) of the first-in-class, oral CDK4/6 inhibitor PD 0332991 administered once daily for 21 of 28 days (3/1 schedule) in patients with retinoblastoma protein (Rb)-pos. advanced solid tumors and to describe pharmacokinetic-pharmacodynamic relationships relative to drug effects.  Exptl. Design: This open-label phase I study (NCT00141297) enrolled patients who received PD 0332991 orally in six dose-escalation cohorts in a std. 3 + 3 design.  RESULTS: Forty-one patients were enrolled.  DLTs were obsd. in five patients (12%) overall; at the 75, 125, and 150 mg once daily dose levels.  The MTD and recommended phase II dose of PD 0332991 was 125 mg once daily.  Neutropenia was the only dose-limiting effect.  After cycle 1, grade 3 neutropenia, anemia, and leukopenia occurred in five (12%), three (7%), and one (2%) patient(s), resp.  The most common non-hematol. adverse events included fatigue, nausea, and diarrhea.  Thirty-seven patients were evaluable for tumor response; 10 (27%) had stable disease for ≥4 cycles of whom six derived prolonged benefit (≥10 cycles).  PD 0332991 was slowly absorbed (median Tmax, 5.5 h), and slowly eliminated (mean half-life was 25.9 h) with a large vol. of distribution (mean, 2,793 L).  The area under the concn.-time curve increased linearly with dose.  Using an Emax model, neutropenia was shown to be proportional to exposure.  CONCLUSIONS: PD 0332991 warrants phase II testing at 125 mg once daily, at which dose neutropenia was the sole significant toxicity.  Clin Cancer Res; 18(2); 568-76.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol_DEqpY-ThbVg90H21EOLACvtfcHk0livUoTb0GmK3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGqs7o%253D&md5=027179d720f67961711b87861cf8cbf2</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0509%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DLorusso%26aufirst%3DP.%2BM.%26aulast%3DDeMichele%26aufirst%3DA.%26aulast%3DAbramson%26aufirst%3DV.%2BG.%26aulast%3DCourtney%26aufirst%3DR.%26aulast%3DRandolph%26aufirst%3DS.%2BS.%26aulast%3DShaik%26aufirst%3DM.%2BN.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DPhase%2520I%252C%2520dose-escalation%2520trial%2520of%2520the%2520oral%2520cyclin-dependent%2520kinase%25204%252F6%2520inhibitor%2520PD0332991%252C%2520administered%2520using%2520a%252021-day%2520schedule%2520in%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D568%26epage%3D576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Niesvizky, R.; Ely, S.; Jayabalan, D. S.; Manco, M.; Singhal, S.; Crann, M.; Courtney, R.; DuFresne, C.; Wilner, K.; Chen, I.; Mark, T.; Leonard, J. P.; Coleman, M.; DiLiberto, M.; Huang, X.; Chen-Kiang, S. A; Phase, I.</span><span> </span><span class="NLM_article-title">Trial of PD-0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma</span>. <span class="NLM_conf-name">51st American Society of Hematology Meeting</span>, <span class="NLM_conf-loc">New Orleans, LA</span>, <span class="NLM_conf-date">December 5–8, 2009</span>,  <span class="NLM_fpage">Abst 1877</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Niesvizky%2C+R.%3B+Ely%2C+S.%3B+Jayabalan%2C+D.+S.%3B+Manco%2C+M.%3B+Singhal%2C+S.%3B+Crann%2C+M.%3B+Courtney%2C+R.%3B+DuFresne%2C+C.%3B+Wilner%2C+K.%3B+Chen%2C+I.%3B+Mark%2C+T.%3B+Leonard%2C+J.+P.%3B+Coleman%2C+M.%3B+DiLiberto%2C+M.%3B+Huang%2C+X.%3B+Chen-Kiang%2C+S.+A%3B+Phase%2C+I.+Trial+of+PD-0332991%2C+a+Novel%2C+Orally-Bioavailable+CDK4%2F6-Specific+Inhibitor+Administered+in+Combination+with+Bortezomib+and+Dexamethasone+to+Patients+with+Relapsed+and+Refractory+Multiple+Myeloma.+51st+American+Society+of+Hematology+Meeting%2C+New+Orleans%2C+LA%2C+December+5%E2%80%938%2C+2009%2C+Abst+1877."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DNiesvizky%26aufirst%3DR.%26atitle%3DTrial%2520of%2520PD-0332991%252C%2520a%2520Novel%252C%2520Orally-Bioavailable%2520CDK4%252F6-Specific%2520Inhibitor%2520Administered%2520in%2520Combination%2520with%2520Bortezomib%2520and%2520Dexamethasone%2520to%2520Patients%2520with%2520Relapsed%2520and%2520Refractory%2520Multiple%2520Myeloma%26spage%3DAbst%25201877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Chen-Kiang, S.; Di Liberto, M.; Louie, T.; Liang, J.; Jayabalan, D. S.; Ely, S.; Moore, M. A.; Niesvizky, R.; Huang, X.</span><span> </span><span class="NLM_article-title">Targeting Cdk4/6 in combination therapy of chemoresistant multiple myeloma</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">Abstract 8503</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=Abstract+8503&author=S.+Chen-Kiang&author=M.+Di+Liberto&author=T.+Louie&author=J.+Liang&author=D.+S.+Jayabalan&author=S.+Ely&author=M.+A.+Moore&author=R.+Niesvizky&author=X.+Huang&title=Targeting+Cdk4%2F6+in+combination+therapy+of+chemoresistant+multiple+myeloma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen-Kiang%26aufirst%3DS.%26atitle%3DTargeting%2520Cdk4%252F6%2520in%2520combination%2520therapy%2520of%2520chemoresistant%2520multiple%2520myeloma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3DAbstract%25208503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Finn, R. S.; Crown, J. P.; Lang, I.; Boer, K.; Bondarenko, I. M.; Kulyk, S. O.; Ettl, J.; Patel, R.; Schmidt, M.; Shparyk, Y.; Thummala, A. R.; Voytko, N. L.; Breazna, A.; Kim, S. T.; Randolph, S.; Salmon, D. J.</span><span> </span><span class="NLM_article-title">Results of randomized phase 2 study of PD 0332991, a cyclic-dependent kinase (CDK) 4/6 inhibitor, in combination with letrazole vs letrazole alone for first-line treatment of ER+/Her2– advanced breast cancer (BC)</span>.  <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span>, <span class="NLM_issue">Suppl 24</span><span class="NLM_x">) </span> <span class="NLM_fpage">Abstract no. S1-6</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=Abstract+no.+S1-6&issue=Suppl+24&author=R.+S.+Finn&author=J.+P.+Crown&author=I.+Lang&author=K.+Boer&author=I.+M.+Bondarenko&author=S.+O.+Kulyk&author=J.+Ettl&author=R.+Patel&author=M.+Schmidt&author=Y.+Shparyk&author=A.+R.+Thummala&author=N.+L.+Voytko&author=A.+Breazna&author=S.+T.+Kim&author=S.+Randolph&author=D.+J.+Salmon&title=Results+of+randomized+phase+2+study+of+PD+0332991%2C+a+cyclic-dependent+kinase+%28CDK%29+4%2F6+inhibitor%2C+in+combination+with+letrazole+vs+letrazole+alone+for+first-line+treatment+of+ER%2B%2FHer2%E2%80%93+advanced+breast+cancer+%28BC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DResults%2520of%2520randomized%2520phase%25202%2520study%2520of%2520PD%25200332991%252C%2520a%2520cyclic-dependent%2520kinase%2520%2528CDK%2529%25204%252F6%2520inhibitor%252C%2520in%2520combination%2520with%2520letrazole%2520vs%2520letrazole%2520alone%2520for%2520first-line%2520treatment%2520of%2520ER%252B%252FHer2%25E2%2580%2593%2520advanced%2520breast%2520cancer%2520%2528BC%2529%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26issue%3DSuppl%252024%26spage%3DAbstract%2520no.%2520S1-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Finn, R. S.; Veronique, D.; Karen, A.; Gelmon, N. H.; Stephen, E. J.; Maria, K.; Maguel, M.; Hope, S. R.; Seock-Aj, I.; Masakazu, T.; Eric, R. G.; Xin, H.; Sophia, R.; Dennis, J. S.</span><span> </span><span class="NLM_article-title">A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrazole for the treatment of postmenopausal women with ER(+), HER2(−) breast cancer who have not received any prior systemic anticancer treatment for advanced disease</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">Abstr TPS652</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=Abstr+TPS652&issue=Suppl&author=R.+S.+Finn&author=D.+Veronique&author=A.+Karen&author=N.+H.+Gelmon&author=E.+J.+Stephen&author=K.+Maria&author=M.+Maguel&author=S.+R.+Hope&author=I.+Seock-Aj&author=T.+Masakazu&author=R.+G.+Eric&author=H.+Xin&author=R.+Sophia&author=J.+S.+Dennis&title=A+randomized%2C+multicenter%2C+double-blind+phase+III+study+of+palbociclib+%28PD-0332991%29%2C+an+oral+CDK+4%2F6+inhibitor%2C+plus+letrozole+versus+placebo+plus+letrazole+for+the+treatment+of+postmenopausal+women+with+ER%28%2B%29%2C+HER2%28%E2%88%92%29+breast+cancer+who+have+not+received+any+prior+systemic+anticancer+treatment+for+advanced+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DA%2520randomized%252C%2520multicenter%252C%2520double-blind%2520phase%2520III%2520study%2520of%2520palbociclib%2520%2528PD-0332991%2529%252C%2520an%2520oral%2520CDK%25204%252F6%2520inhibitor%252C%2520plus%2520letrozole%2520versus%2520placebo%2520plus%2520letrazole%2520for%2520the%2520treatment%2520of%2520postmenopausal%2520women%2520with%2520ER%2528%252B%2529%252C%2520HER2%2528%25E2%2588%2592%2529%2520breast%2520cancer%2520who%2520have%2520not%2520received%2520any%2520prior%2520systemic%2520anticancer%2520treatment%2520for%2520advanced%2520disease%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26issue%3DSuppl%26spage%3DAbstr%2520TPS652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Daren, R. V.; William, B.; Bayard, D. C.; Nikolas, V. B.; Justus, D.</span><span> </span><span class="NLM_article-title">Pyridopyrimidine Kinase Inhibitors</span>. U. S Patent 20050009849 A1, <span class="NLM_month">Jan</span><span class="NLM_day">13</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=R.+V.+Daren&author=B.+William&author=D.+C.+Bayard&author=V.+B.+Nikolas&author=D.+Justus&title=Pyridopyrimidine+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDaren%26aufirst%3DR.%2BV.%26atitle%3DPyridopyrimidine%2520Kinase%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit47b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Buhr, C. A.; Bajjalieh, W.; Joshi, A. B.; Lara, K.; Ma, S.; Marlowe, C. K.; Wang, L.; Yeung, B. N. S.</span><span> </span><span class="NLM_article-title">Pyrido[2,3-<i>d</i>]pyrimidin-7-one compounds as inhibitors of PI3K-ALPHA for the treatment of cancer</span>. Canada Patent 2683784 A1, <span class="NLM_month">Oct</span><span class="NLM_day">23</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=C.+A.+Buhr&author=W.+Bajjalieh&author=A.+B.+Joshi&author=K.+Lara&author=S.+Ma&author=C.+K.+Marlowe&author=L.+Wang&author=B.+N.+S.+Yeung&title=Pyrido%5B2%2C3-d%5Dpyrimidin-7-one+compounds+as+inhibitors+of+PI3K-ALPHA+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBuhr%26aufirst%3DC.%2BA.%26atitle%3DPyrido%255B2%252C3-d%255Dpyrimidin-7-one%2520compounds%2520as%2520inhibitors%2520of%2520PI3K-ALPHA%2520for%2520the%2520treatment%2520of%2520cancer%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Brian, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeff, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellen, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charles, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randall, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">William, A. D.</span><span> </span><span class="NLM_article-title">Structure–activity relationships for 2-anilino-6-phenylpyrido[2,3-<i>d</i>]pyrimidine-7(8<i>H</i>)-ones a inhibitors of the cellular checkpoint kinase wee 1</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1931</span><span class="NLM_x">–</span> <span class="NLM_lpage">1935</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=1931-1935&author=D.+P.+Brianauthor=B.+S.+Jeffauthor=W.+R.+Gordonauthor=M.+D.+Ellenauthor=K.+Alanauthor=W.+M.+Charlesauthor=W.+S.+Randallauthor=A.+D.+William&title=Structure%E2%80%93activity+relationships+for+2-anilino-6-phenylpyrido%5B2%2C3-d%5Dpyrimidine-7%288H%29-ones+a+inhibitors+of+the+cellular+checkpoint+kinase+wee+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrian%26aufirst%3DD.%2BP.%26aulast%3DJeff%26aufirst%3DB.%2BS.%26aulast%3DGordon%26aufirst%3DW.%2BR.%26aulast%3DEllen%26aufirst%3DM.%2BD.%26aulast%3DAlan%26aufirst%3DK.%26aulast%3DCharles%26aufirst%3DW.%2BM.%26aulast%3DRandall%26aufirst%3DW.%2BS.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26atitle%3DStructure%25E2%2580%2593activity%2520relationships%2520for%25202-anilino-6-phenylpyrido%255B2%252C3-d%255Dpyrimidine-7%25288H%2529-ones%2520a%2520inhibitors%2520of%2520the%2520cellular%2520checkpoint%2520kinase%2520wee%25201%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D1931%26epage%3D1935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Reddy, M. V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallireddigari, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosenza, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallela, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iqbal, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robell, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of (<i>E</i>)-Styrylbenzylsulfones as Novel Anticancer Agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">86</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701077b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=86-100&author=M.+V.+R.+Reddyauthor=M.+R.+Mallireddigariauthor=S.+C.+Cosenzaauthor=V.+R.+Pallelaauthor=N.+M.+Iqbalauthor=K.+A.+Robellauthor=A.+D.+Kangauthor=E.+P.+Reddy&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+%28E%29-Styrylbenzylsulfones+as+Novel+Anticancer+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49a&amp;dbid=16384&amp;doi=10.1021%2Fjm701077b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701077b%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26aulast%3DMallireddigari%26aufirst%3DM.%2BR.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DPallela%26aufirst%3DV.%2BR.%26aulast%3DIqbal%26aufirst%3DN.%2BM.%26aulast%3DRobell%26aufirst%3DK.%2BA.%26aulast%3DKang%26aufirst%3DA.%2BD.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520%2528E%2529-Styrylbenzylsulfones%2520as%2520Novel%2520Anticancer%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D86%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit49b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Reddy, M. V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, S.</span><span> </span><span class="NLM_article-title">Synthesis of α,β-Unsaturated Sulfones</span> <span class="citation_source-journal">Acta Chim. Hung.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">269</span><span class="NLM_x">–</span> <span class="NLM_lpage">271</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADyaL2cXkt1ejtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1984&pages=269-271&author=M.+V.+R.+Reddyauthor=S.+Reddy&title=Synthesis+of+%CE%B1%2C%CE%B2-Unsaturated+Sulfones"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49bR"><div class="casContent"><span class="casTitleNuber">49b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of α,β-unsaturated sulfones</span></div><div class="casAuthors">Reddy, M. V. R.; Reddy, S.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Chimica Hungarica</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">269-71</span>CODEN:
                <span class="NLM_cas:coden">ACHUDC</span>;
        ISSN:<span class="NLM_cas:issn">0231-3146</span>.
    </div><div class="casAbstract">Eleven benzyl styryl sulfones, PhCH2SO2CH:CHR (R = substituted Ph), were prepd. in 62.5-89.2% yield by condensation of RCHO with PhCH2SO2CH2CO2H, prepd. by benzylation of HSCH2CO2H followed by oxidn. with H2O2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhTBc39fHWdbVg90H21EOLACvtfcHk0ljPrnxMzK2B8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXkt1ejtL0%253D&md5=ba4c399826e1f66a4e907149ea675062</span></div><a href="/servlet/linkout?suffix=cit49b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26aulast%3DReddy%26aufirst%3DS.%26atitle%3DSynthesis%2520of%2520%25CE%25B1%252C%25CE%25B2-Unsaturated%2520Sulfones%26jtitle%3DActa%2520Chim.%2520Hung.%26date%3D1984%26volume%3D115%26spage%3D269%26epage%3D271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit49c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Reddy, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, M. V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanyam, S.</span><span> </span><span class="NLM_article-title">Preparation of Styryl Benzyl Sulfones and 1,2-Bis-(styrylsulfonylmethyl)-4,5-dimethylbenzenes</span> <span class="citation_source-journal">Org. Prep. Proced. Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">212</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49c&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1080%2F00304948809355812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49c&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADyaL1MXnsV2mtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1988&pages=205-212&author=D.+B.+Reddyauthor=N.+S.+Reddyauthor=M.+V.+R.+Reddyauthor=S.+Balasubramanyam&title=Preparation+of+Styryl+Benzyl+Sulfones+and+1%2C2-Bis-%28styrylsulfonylmethyl%29-4%2C5-dimethylbenzenes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49cR"><div class="casContent"><span class="casTitleNuber">49c</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation of styryl benzyl sulfones and 1,2-bis(styrylsulfonylmethyl)-4,5-dimethylbenzenes</span></div><div class="casAuthors">Reddy, D. Bhaskar; Reddy, N. S.; Reddy, S.; Reddy, M. V. R.; Balasubramanyam, S.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Preparations and Procedures International</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">205-12</span>CODEN:
                <span class="NLM_cas:coden">OPPIAK</span>;
        ISSN:<span class="NLM_cas:issn">0030-4948</span>.
    </div><div class="casAbstract">The Knoevenagel reaction of R1CH2SO2CH2CO2H (R1 = Ph, tolyl, ClC6H4, O2NC6H4) with R2CHO (R2 = Ph, O2NC6H4, anthryl, halophenyl, tolyl, anisyl) in HOAc contg. PhCH2NH2 gave trans-styryl sulfones I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeZN6gdVDNZrVg90H21EOLACvtfcHk0lhqJOft9gT6Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXnsV2mtA%253D%253D&md5=abb98febfd6090c49fd9fdd8e354d4d4</span></div><a href="/servlet/linkout?suffix=cit49c&amp;dbid=16384&amp;doi=10.1080%2F00304948809355812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00304948809355812%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DD.%2BB.%26aulast%3DReddy%26aufirst%3DN.%2BS.%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26aulast%3DBalasubramanyam%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Styryl%2520Benzyl%2520Sulfones%2520and%25201%252C2-Bis-%2528styrylsulfonylmethyl%2529-4%252C5-dimethylbenzenes%26jtitle%3DOrg.%2520Prep.%2520Proced.%2520Int.%26date%3D1988%26volume%3D20%26spage%3D205%26epage%3D212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Reddy, M. V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallireddigari, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallela, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatapuram, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boominathan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of (<i>E</i>)-and (<i>Z</i>)-styryl-2-acetoxyphenyl sulfides and sulfones as cyclooxygenase-2 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1715</span><span class="NLM_x">–</span> <span class="NLM_lpage">1723</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=1715-1723&author=M.+V.+R.+Reddyauthor=M.+R.+Mallireddigariauthor=V.+R.+Pallelaauthor=P.+Venkatapuramauthor=R.+Boominathanauthor=S.+C.+Bellauthor=E.+P.+Reddy&title=Design%2C+synthesis%2C+and+biological+evaluation+of+%28E%29-and+%28Z%29-styryl-2-acetoxyphenyl+sulfides+and+sulfones+as+cyclooxygenase-2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26aulast%3DMallireddigari%26aufirst%3DM.%2BR.%26aulast%3DPallela%26aufirst%3DV.%2BR.%26aulast%3DVenkatapuram%26aufirst%3DP.%26aulast%3DBoominathan%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DS.%2BC.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520%2528E%2529-and%2520%2528Z%2529-styryl-2-acetoxyphenyl%2520sulfides%2520and%2520sulfones%2520as%2520cyclooxygenase-2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26spage%3D1715%26epage%3D1723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Reddy, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gumireddy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallireddigari, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosenza, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatapuram, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, M. V. R.</span><span> </span><span class="NLM_article-title">Novel coumarin-3-(<i>N</i>-aryl)carboxamides arrest breast cancer cell growth by inhibiting ErbB-2 and ERK1</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3141</span><span class="NLM_x">–</span> <span class="NLM_lpage">3147</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=3141-3147&author=N.+S.+Reddyauthor=K.+Gumireddyauthor=M.+R.+Mallireddigariauthor=S.+C.+Cosenzaauthor=P.+Venkatapuramauthor=S.+C.+Bellauthor=E.+P.+Reddyauthor=M.+V.+R.+Reddy&title=Novel+coumarin-3-%28N-aryl%29carboxamides+arrest+breast+cancer+cell+growth+by+inhibiting+ErbB-2+and+ERK1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DN.%2BS.%26aulast%3DGumireddy%26aufirst%3DK.%26aulast%3DMallireddigari%26aufirst%3DM.%2BR.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DVenkatapuram%26aufirst%3DP.%26aulast%3DBell%26aufirst%3DS.%2BC.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26atitle%3DNovel%2520coumarin-3-%2528N-aryl%2529carboxamides%2520arrest%2520breast%2520cancer%2520cell%2520growth%2520by%2520inhibiting%2520ErbB-2%2520and%2520ERK1%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26spage%3D3141%26epage%3D3147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Suzuki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusakai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishimoto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esumi, H.</span><span> </span><span class="NLM_article-title">ARK5 is a tumor invasion-associated factor downstream of Akt signaling</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">3526</span><span class="NLM_x">–</span> <span class="NLM_lpage">3535</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1128%2FMCB.24.8.3526-3535.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=15060171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFKjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=3526-3535&author=A.+Suzukiauthor=J.+Luauthor=G.+Kusakaiauthor=A.+Kishimotoauthor=T.+Oguraauthor=H.+Esumi&title=ARK5+is+a+tumor+invasion-associated+factor+downstream+of+Akt+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">ARK5 is a tumor invasion-associated factor downstream of Akt signaling</span></div><div class="casAuthors">Suzuki, Atsushi; Lu, Jie; Kusakai, Gen-ichi; Kishimoto, Atsuhiro; Ogura, Tsutomu; Esumi, Hiroyasu</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3526-3535</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">AMP-activated protein kinases (AMPKs) are a class of serine/threonine protein kinases that are activated by an increase in intracellular AMP concn.  They are a sensitive indicator of cellular energy status and have been found to promote tumor cell survival during nutrient starvation.  We recently identified a novel AMPK catalytic subunit family member, ARK5, whose activation is directly regulated by Akt, which, in turn, has been reported to be a key player in tumor malignancy.  In this study, we attempted to det. whether ARK5 is involved in tumor malignancy under regulation by Akt.  Matrigel invasion assays demonstrated that both overexpressed and endogenous ARK5 showed strong activity dependent on Akt.  In addn., ARK5 expression induced activation of matrix metalloproteinase 2 (MMP-2) and MMP-9 following new expression of membrane type 1 MMP (MT1-MMP), and the MT1-MMP expression induced by ARK5 was initiated by rapamycin-sensitive signaling.  In nude mice, ARK5 expression was assocd. with a significant increase in tumor growth and significant suppression of necrosis in tumor tissue.  Interestingly, only the ARK5-overexpressing PANC-1 cell line (P/ARK) tumor showed invasion and metastasis in nude mice, although Akt was activated in tumors derived from both P/ARK and its parental cell line.  We report that a novel AMPK catalytic subunit family member, ARK5, plays a key role in tumor malignancy downstream of Akt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp2pQK3k2_uLVg90H21EOLACvtfcHk0lhqJOft9gT6Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFKjtLk%253D&md5=cf805bd959892c2da70eebd31559ce3b</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1128%2FMCB.24.8.3526-3535.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.24.8.3526-3535.2004%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DKusakai%26aufirst%3DG.%26aulast%3DKishimoto%26aufirst%3DA.%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DEsumi%26aufirst%3DH.%26atitle%3DARK5%2520is%2520a%2520tumor%2520invasion-associated%2520factor%2520downstream%2520of%2520Akt%2520signaling%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2004%26volume%3D24%26spage%3D3526%26epage%3D3535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Kusakai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esumi, H.</span><span> </span><span class="NLM_article-title">Strong association of ARK5 with tumor invasion and metastasis</span> <span class="citation_source-journal">J. Exp. Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">268</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=15354411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXms1Kjtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=263-268&author=G.+Kusakaiauthor=A.+Suzukiauthor=T.+Oguraauthor=M.+Kaminishiauthor=H.+Esumi&title=Strong+association+of+ARK5+with+tumor+invasion+and+metastasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Strong association of ARK5 with tumor invasion and metastasis</span></div><div class="casAuthors">Kusakai, G.; Suzuki, A.; Ogura, T.; Kaminishi, M.; Esumi, H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-268</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">0392-9078</span>.
    
            (<span class="NLM_cas:orgname">Regina Elena Institute for Cancer Research</span>)
        </div><div class="casAbstract">The authors recently identified a novel human AMPK family member, ARK5, and discovered that it is a major factor in Akt-dependent cancer cell survival and migration activity through activation of MT1-MMPs in vitro.  The mRNA expression of other AMPK family members and ARK5 was measured using RT-PCR in human colorectal carcinoma cell lines DLD-1, WiDr, HCT-15, SW620, LoVo, SW480, and mRNA expression of AMPK-α1, SNARK, MELK and ARK5, but not AMPK-α2, was detected in every line.  Quant.-PCR (Q-PCR) to est. the amt. of ARK5 mRNA expression in the cell lines showed that there is a variety of ARK5 expressions among the cell lines and high expression was obsd. in a cell line derived from the metastatic lesion, LoVo.  To det. the effect of ARK5 overexpression on metastasis in vivo, the authors established human pancreas cancer cell line PANC-1 stably transfected with ARK5 full-length expression vector (P/ARK) and DLD-1 stably transfected with the same vector (D/ARK).  Migration assay showed a remarkable increase in the activity both in P/ARK and D/ARK, and an in vivo metastasis assay showed a marked increase of P/ARK in liver metastasis.  Based on these observations, it is suggested that ARK5 expression is involved in cancer invasion and metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjb82P4k4HYrVg90H21EOLACvtfcHk0lhqJOft9gT6Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXms1Kjtbk%253D&md5=398d15306b52cfdb1e68016240821743</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKusakai%26aufirst%3DG.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DKaminishi%26aufirst%3DM.%26aulast%3DEsumi%26aufirst%3DH.%26atitle%3DStrong%2520association%2520of%2520ARK5%2520with%2520tumor%2520invasion%2520and%2520metastasis%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D23%26spage%3D263%26epage%3D268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Sutherland, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musgrove, E. A.</span><span> </span><span class="NLM_article-title">CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease</span> <span class="citation_source-journal">Breast Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1186%2Fbcr2454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=20067604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252Fns1Wisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=112&author=R.+L.+Sutherlandauthor=E.+A.+Musgrove&title=CDK+inhibitors+as+potential+breast+cancer+therapeutics%3A+new+evidence+for+enhanced+efficacy+in+ER%2B+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease</span></div><div class="casAuthors">Sutherland Robert L; Musgrove Elizabeth A</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">112</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Loss of cell cycle control is a hallmark of cancer, and aberrations in the cyclin-CDK-RB (cyclin-dependent kinase-retinoblastoma protein) pathway are common in breast cancer.  Consequently, inhibition of this pathway is an attractive therapeutic strategy, but results from clinical trials of CDK inhibitors in breast cancer have been disappointing.  A recent study now shows that in cell culture a selective CDK4/6 inhibitor is preferentially effective in estrogen receptor-positive (ER(+)) disease and apparently acts synergistically with tamoxifen or trastuzumab.  These exciting new preclinical data set the scene for a more targeted approach to further clinical evaluation wherein this class of drugs is targeted to subgroups of ER(+) patients, including those with resistance to endocrine therapy, alone or in combination with current standard therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRE071O4N-bZTEC-75aqa5AfW6udTcc2ea2oZf9xx5Iw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252Fns1Wisg%253D%253D&md5=a5ed3960d3005ba1b45daee096293f9d</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1186%2Fbcr2454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr2454%26sid%3Dliteratum%253Aachs%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26aulast%3DMusgrove%26aufirst%3DE.%2BA.%26atitle%3DCDK%2520inhibitors%2520as%2520potential%2520breast%2520cancer%2520therapeutics%253A%2520new%2520evidence%2520for%2520enhanced%2520efficacy%2520in%2520ER%252B%2520disease%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2009%26volume%3D11%26spage%3D112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Kitagawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki-Takahashi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taya, Y.</span><span> </span><span class="NLM_article-title">The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">7060</span><span class="NLM_x">–</span> <span class="NLM_lpage">7069</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1002%2Fj.1460-2075.1996.tb01097.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=9003781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADyaK2sXosFKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1996&pages=7060-7069&author=M.+Kitagawaauthor=H.+Higashiauthor=H.+K.+Jungauthor=I.+Suzuki-Takahashiauthor=M.+Ikedaauthor=K.+Tamaiauthor=J.+Katoauthor=K.+Segawaauthor=E.+Yoshidaauthor=S.+Nishimuraauthor=Y.+Taya&title=The+consensus+motif+for+phosphorylation+by+cyclin+D1-Cdk4+is+different+from+that+for+phosphorylation+by+cyclin+A%2FE-Cdk2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2</span></div><div class="casAuthors">Kitagawa, Masatoshi; Higashi, Hideaki; Jung, Hai-Kwan; Suzuki-Takahashi, Ikuko; Ikeda, Masako; Tamai, Katsuyuki; Kato, Jun-ya; Segawa, Kaoru; Yoshida, Eisaku; Nishimura, Susumu; Taya, Yoichi</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7060-7069</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Cyclin D-Cdk4/6 and cyclin A/E-Cdk2 are suggested to be involved in phosphorylation of the retinoblastoma protein (pRB) during the G1/S transition of the cell cycle.  However, it is unclear why several Cdks are needed and how they are different from one another.  We found that the consensus amino acid sequence for phosphorylation by cyclin D1-Cdk4 is different from S/T-P-X-K/R, which is the consensus sequence for phosphorylation by cyclin A/E-Cdk2 using various synthetic peptides as substrates.  Cyclin D1-Cdk4 efficiently phosphorylated the G1 peptide, RPPTLS780PIPhipr that contained a part of the sequence of pRB, while cyclins E-Cdk2 and A-Cdk2 did not.  To det. the phosphorylation state of pRB in vitro and in vivo, we raised the specific antibody against phospho-Ser780 in pRB.  We confirmed that cyclin D1-Cdk4, but not cyclin E-Cdk2, phosphorylated Ser780 in recombinant pRB.  The Ser780 in pRB was phosphorylated in the G1 phase in a cell cycle-dependent manner.  Furthermore, we found that pRB phosphorylated at Ser780 cannot bind to E2F-1 in vivo.  Our data show that cyclin D1-Cdk4 and cyclin A/E Cdk2 phosphorylate different sites of pRB in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogbhxXMzHcPrVg90H21EOLACvtfcHk0lgrYqa7Jb6P3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXosFKlsQ%253D%253D&md5=a0bb66af6ded3baa26d56771f0fd5d67</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fj.1460-2075.1996.tb01097.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1460-2075.1996.tb01097.x%26sid%3Dliteratum%253Aachs%26aulast%3DKitagawa%26aufirst%3DM.%26aulast%3DHigashi%26aufirst%3DH.%26aulast%3DJung%26aufirst%3DH.%2BK.%26aulast%3DSuzuki-Takahashi%26aufirst%3DI.%26aulast%3DIkeda%26aufirst%3DM.%26aulast%3DTamai%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DJ.%26aulast%3DSegawa%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DE.%26aulast%3DNishimura%26aufirst%3DS.%26aulast%3DTaya%26aufirst%3DY.%26atitle%3DThe%2520consensus%2520motif%2520for%2520phosphorylation%2520by%2520cyclin%2520D1-Cdk4%2520is%2520different%2520from%2520that%2520for%2520phosphorylation%2520by%2520cyclin%2520A%252FE-Cdk2%26jtitle%3DEMBO%2520J.%26date%3D1996%26volume%3D15%26spage%3D7060%26epage%3D7069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Connell-Crowley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, D. W.</span><span> </span><span class="NLM_article-title">Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation</span> <span class="citation_source-journal">Mol. Biol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1091%2Fmbc.8.2.287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=9190208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADyaK2sXhsV2itr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1997&pages=287-301&author=L.+Connell-Crowleyauthor=J.+W.+Harperauthor=D.+W.+Goodrich&title=Cyclin+D1%2FCdk4+regulates+retinoblastoma+protein-mediated+cell+cycle+arrest+by+site-specific+phosphorylation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation</span></div><div class="casAuthors">Connell-Crowley, Lisa; Harper, J. Wade; Goodrich, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">287-301</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1059-1524</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">The retinoblastoma protein (pRb) inhibits progression through the cell cycle.  Although pRb is phosphorylated when G1 cyclin-dependent kinases (Cdks) are active, the mechanisms underlying pRb regulation are unknown.  In vitro phosphorylation by cyclin D1/Cdk4 leads to inactivation of pRb in a microinjection-based in vivo cell cycle assay.  In contrast, phosphorylation of pRb by Cdk2 or Cdk3 in complexes with A- or E-type cyclins is not sufficient to inactivate pRb function in this assay, despite extensive phosphorylation and conversion to a slowly migrating "hyperphosphorylated form." The differential effects of phosphorylation on pRb function coincide with modification of distinct sets of sites.  Serine 795 is phosphorylated efficiently by Cdk4, even in the absence of an intact LXCXE motif in cyclin D, but not by Cdk2 or Cdk3.  Mutation of serine 795 to alanine prevents pRb inactivation by Cdk4 phosphorylation in the microinjection assay.  This study identifies a residue whose phosphorylation is crit. for inactivation of pRb-mediated growth suppression, and it indicates that hyperphosphorylation and inactivation of pRb are not necessarily synonymous.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYuGVSOFEDFLVg90H21EOLACvtfcHk0lgrYqa7Jb6P3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhsV2itr0%253D&md5=4e25b2edd6f4bcb0aeb6beff4465c5de</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1091%2Fmbc.8.2.287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.8.2.287%26sid%3Dliteratum%253Aachs%26aulast%3DConnell-Crowley%26aufirst%3DL.%26aulast%3DHarper%26aufirst%3DJ.%2BW.%26aulast%3DGoodrich%26aufirst%3DD.%2BW.%26atitle%3DCyclin%2520D1%252FCdk4%2520regulates%2520retinoblastoma%2520protein-mediated%2520cell%2520cycle%2520arrest%2520by%2520site-specific%2520phosphorylation%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D1997%26volume%3D8%26spage%3D287%26epage%3D301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Grafstrom, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoess, R. H.</span><span> </span><span class="NLM_article-title">Defining the substrate specificity of cdk4 kinase-cyclin D1 complex</span> <span class="citation_source-journal">Carcinogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">202</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">198</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=1999&pages=193-198&author=R.+H.+Grafstromauthor=W.+Panauthor=R.+H.+Hoess&title=Defining+the+substrate+specificity+of+cdk4+kinase-cyclin+D1+complex"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrafstrom%26aufirst%3DR.%2BH.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DHoess%26aufirst%3DR.%2BH.%26atitle%3DDefining%2520the%2520substrate%2520specificity%2520of%2520cdk4%2520kinase-cyclin%2520D1%2520complex%26jtitle%3DCarcinogenesis%26date%3D1999%26volume%3D202%26spage%3D193%26epage%3D198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Hua, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiaoping, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jyoti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, M. V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M. G.</span><span> </span><span class="NLM_article-title">Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotheraphy</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">250</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=250-257&author=L.+V.+Huaauthor=Z.+Xiaopingauthor=S.+Jyotiauthor=M.+V.+R.+Reddyauthor=E.+P.+Reddyauthor=M.+G.+James&title=Integrated+pharmacokinetic-driven+approach+to+screen+candidate+anticancer+drugs+for+brain+tumor+chemotheraphy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DL.%2BV.%26aulast%3DXiaoping%26aufirst%3DZ.%26aulast%3DJyoti%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26aulast%3DJames%26aufirst%3DM.%2BG.%26atitle%3DIntegrated%2520pharmacokinetic-driven%2520approach%2520to%2520screen%2520candidate%2520anticancer%2520drugs%2520for%2520brain%2520tumor%2520chemotheraphy%26jtitle%3DAAPS%2520J.%26date%3D2013%26volume%3D15%26spage%3D250%26epage%3D257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26a','cit26b'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47a','cit47b'],'ref48':['cit48'],'ref49':['cit49a','cit49b','cit49c'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 40 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Muhammad Faisal, Jae Ho Kim, Kyung Ho Yoo, Eun Joo Roh, Soon Sun Hong, <span class="NLM_string-name hlFld-ContribAuthor">So Ha Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Development and Therapeutic Potential of NUAKs Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 2-25. <a href="https://doi.org/10.1021/acs.jmedchem.0c00533" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00533</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00533%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Band%252BTherapeutic%252BPotential%252Bof%252BNUAKs%252BInhibitors%26aulast%3DFaisal%26aufirst%3DMuhammad%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D01042020%26date%3D24122020%26volume%3D64%26issue%3D1%26spage%3D2%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Radek Jorda, Denisa Hendrychová, Jiří Voller, Eva Řezníčková, Tomáš Gucký, <span class="NLM_string-name hlFld-ContribAuthor">Vladimír Kryštof</span>. </span><span class="cited-content_cbyCitation_article-title">How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (20)
                                     , 9105-9120. <a href="https://doi.org/10.1021/acs.jmedchem.8b00049" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00049%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHow%252BSelective%252BAre%252BPharmacological%252BInhibitors%252Bof%252BCell-Cycle-Regulating%252BCyclin-Dependent%252BKinases%25253F%26aulast%3DJorda%26aufirst%3DRadek%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D31012018%26date%3D05102018%26date%3D20092018%26volume%3D61%26issue%3D20%26spage%3D9105%26epage%3D9120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yongtao Li, Xiaohe Luo, Qingxiang Guo, Yongwei Nie, Tianqi Wang, Chao Zhang, Zhi Huang, Xin Wang, Yanhua Liu, Yanan Chen, Jianyu Zheng, Shengyong Yang, Yan Fan, <span class="NLM_string-name hlFld-ContribAuthor">Rong Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (7)
                                     , 3166-3192. <a href="https://doi.org/10.1021/acs.jmedchem.8b00209" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00209</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00209%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BN1-%2525284-%252528%2525287-Cyclopentyl-6-%252528dimethylcarbamoyl%252529-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-2-yl%252529amino%252529phenyl%252529-N8-hydroxyoctanediamide%252Bas%252Ba%252BNovel%252BInhibitor%252BTargeting%252BCyclin-dependent%252BKinase%252B4%25252F9%252B%252528CDK4%25252F9%252529%252Band%252BHistone%252BDeacetlyase1%252B%252528HDAC1%252529%252Bagainst%252BMalignant%252BCancer%26aulast%3DLi%26aufirst%3DYongtao%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D07022018%26date%3D23032018%26date%3D08032018%26volume%3D61%26issue%3D7%26spage%3D3166%26epage%3D3192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raghupathi  Neelarapu</span>, <span class="hlFld-ContribAuthor ">Jordany R.  Maignan</span>, <span class="hlFld-ContribAuthor ">Cynthia L.  Lichorowic</span>, <span class="hlFld-ContribAuthor ">Andrii  Monastyrskyi</span>, <span class="hlFld-ContribAuthor ">Tina S.  Mutka</span>, <span class="hlFld-ContribAuthor ">Alexis N.  LaCrue</span>, <span class="hlFld-ContribAuthor ">Lynn D.  Blake</span>, <span class="hlFld-ContribAuthor ">Debora  Casandra</span>, <span class="hlFld-ContribAuthor ">Sherwin  Mashkouri</span>, <span class="hlFld-ContribAuthor ">Jeremy N.  Burrows</span>, <span class="hlFld-ContribAuthor ">Paul A.  Willis</span>, <span class="hlFld-ContribAuthor ">Dennis E.  Kyle</span>, and <span class="hlFld-ContribAuthor ">Roman  Manetsch</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure–Activity and Structure–Property Relationship Studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (4)
                                     , 1450-1473. <a href="https://doi.org/10.1021/acs.jmedchem.7b00738" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00738</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00738%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BOrally%252BBioavailable%252BPiperazine%252BSubstituted%252B4%2525281H%252529-Quinolones%252Bwith%252BPotent%252BAntimalarial%252BActivity%25253A%252BStructure%2525E2%252580%252593Activity%252Band%252BStructure%2525E2%252580%252593Property%252BRelationship%252BStudies%26aulast%3DNeelarapu%26aufirst%3DRaghupathi%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D22052017%26date%3D09022018%26date%3D22022018%26date%3D07122017%26volume%3D61%26issue%3D4%26spage%3D1450%26epage%3D1473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samuel L. C.  Moors</span>, <span class="hlFld-ContribAuthor ">Ben  Brigou</span>, <span class="hlFld-ContribAuthor ">Dietmar  Hertsen</span>, <span class="hlFld-ContribAuthor ">Balazs  Pinter</span>, <span class="hlFld-ContribAuthor ">Paul  Geerlings</span>, <span class="hlFld-ContribAuthor ">Veronique  Van Speybroeck</span>, <span class="hlFld-ContribAuthor ">Saron  Catak</span>, and <span class="hlFld-ContribAuthor ">Frank  De Proft</span>  . </span><span class="cited-content_cbyCitation_article-title">Influence of Solvation and Dynamics on the Mechanism and Kinetics of Nucleophilic Aromatic Substitution Reactions in Liquid Ammonia. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>81 </em>
                                    (4)
                                     , 1635-1644. <a href="https://doi.org/10.1021/acs.joc.5b02794" title="DOI URL">https://doi.org/10.1021/acs.joc.5b02794</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.5b02794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.5b02794%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DInfluence%252Bof%252BSolvation%252Band%252BDynamics%252Bon%252Bthe%252BMechanism%252Band%252BKinetics%252Bof%252BNucleophilic%252BAromatic%252BSubstitution%252BReactions%252Bin%252BLiquid%252BAmmonia%26aulast%3DMoors%26aufirst%3DSamuel%2BL.%2BC.%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D10122015%26date%3D05022016%26date%3D19022016%26date%3D22012016%26volume%3D81%26issue%3D4%26spage%3D1635%26epage%3D1644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arumugam Ramachandran  Muralidharan</span>, <span class="hlFld-ContribAuthor ">Chandrabose  Selvaraj</span>, <span class="hlFld-ContribAuthor ">Sanjeev Kumar  Singh</span>, <span class="hlFld-ContribAuthor ">Joen-Rong  Sheu</span>, <span class="hlFld-ContribAuthor ">Philip A.  Thomas</span>, and <span class="hlFld-ContribAuthor ">Pitchairaj  Geraldine</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure-Based Virtual Screening and Biological Evaluation of a Calpain Inhibitor for Prevention of Selenite-Induced Cataractogenesis in an in Vitro System. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2015,</strong> <em>55 </em>
                                    (8)
                                     , 1686-1697. <a href="https://doi.org/10.1021/acs.jcim.5b00092" title="DOI URL">https://doi.org/10.1021/acs.jcim.5b00092</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.5b00092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.5b00092%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DStructure-Based%252BVirtual%252BScreening%252Band%252BBiological%252BEvaluation%252Bof%252Ba%252BCalpain%252BInhibitor%252Bfor%252BPrevention%252Bof%252BSelenite-Induced%252BCataractogenesis%252Bin%252Ban%252Bin%252BVitro%252BSystem%26aulast%3DMuralidharan%26aufirst%3DArumugam%2BRamachandran%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D17022015%26date%3D13082015%26date%3D24082015%26volume%3D55%26issue%3D8%26spage%3D1686%26epage%3D1697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tingting  Lin</span>, <span class="hlFld-ContribAuthor ">Jiacheng  Li</span>, <span class="hlFld-ContribAuthor ">Liping  Liu</span>, <span class="hlFld-ContribAuthor ">Yuanqing  Li</span>, <span class="hlFld-ContribAuthor ">Hualiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Kaixian  Chen</span>, <span class="hlFld-ContribAuthor ">Pan  Xu</span>, <span class="hlFld-ContribAuthor ">Cheng  Luo</span>, <span class="hlFld-ContribAuthor ">Bing  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>215 </em>, 113281. <a href="https://doi.org/10.1016/j.ejmech.2021.113281" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113281</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113281%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252B4-benzoylamino-1H-pyrazole-3-carboxamide%252Bderivatives%252Bas%252Bpotent%252BCDK2%252Binhibitors%26aulast%3DLin%26aufirst%3DTingting%26date%3D2021%26volume%3D215%26spage%3D113281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Khaled R. A.  Abdellatif</span>, <span class="hlFld-ContribAuthor ">Rania B.  Bakr</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrimidine and fused pyrimidine derivatives as promising protein kinase inhibitors for cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2021,</strong> <em>30 </em>
                                    (1)
                                     , 31-49. <a href="https://doi.org/10.1007/s00044-020-02656-8" title="DOI URL">https://doi.org/10.1007/s00044-020-02656-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-020-02656-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-020-02656-8%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DPyrimidine%252Band%252Bfused%252Bpyrimidine%252Bderivatives%252Bas%252Bpromising%252Bprotein%252Bkinase%252Binhibitors%252Bfor%252Bcancer%252Btreatment%26aulast%3DAbdellatif%26aufirst%3DKhaled%2BR.%2BA.%26date%3D2021%26date%3D2020%26volume%3D30%26issue%3D1%26spage%3D31%26epage%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kai  Yuan</span>, <span class="hlFld-ContribAuthor ">Xiao  Wang</span>, <span class="hlFld-ContribAuthor ">Haojie  Dong</span>, <span class="hlFld-ContribAuthor ">Wenjian  Min</span>, <span class="hlFld-ContribAuthor ">Haiping  Hao</span>, <span class="hlFld-ContribAuthor ">Peng  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     , 30-54. <a href="https://doi.org/10.1016/j.apsb.2020.05.001" title="DOI URL">https://doi.org/10.1016/j.apsb.2020.05.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2020.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2020.05.001%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DSelective%252Binhibition%252Bof%252BCDK4%25252F6%25253A%252BA%252Bsafe%252Band%252Beffective%252Bstrategy%252Bfor%252Bdeveloping%252Banticancer%252Bdrugs%26aulast%3DYuan%26aufirst%3DKai%26date%3D2021%26volume%3D11%26issue%3D1%26spage%3D30%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amany  Belal</span>. </span><span class="cited-content_cbyCitation_article-title">3D-Pharmacophore Modeling, Molecular Docking, and Virtual Screening for Discovery of Novel CDK4/6 Selective Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>47 </em>
                                    (1)
                                     , 317-333. <a href="https://doi.org/10.1134/S1068162021330013" title="DOI URL">https://doi.org/10.1134/S1068162021330013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1068162021330013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1068162021330013%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Bioorganic%2520Chemistry%26atitle%3D3D-Pharmacophore%252BModeling%25252C%252BMolecular%252BDocking%25252C%252Band%252BVirtual%252BScreening%252Bfor%252BDiscovery%252Bof%252BNovel%252BCDK4%25252F6%252BSelective%252BInhibitors%26aulast%3DBelal%26aufirst%3DAmany%26date%3D2021%26date%3D2021%26volume%3D47%26issue%3D1%26spage%3D317%26epage%3D333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E. G.  Paronikyan</span>, <span class="hlFld-ContribAuthor ">Sh. Sh.  Dashyan</span>, <span class="hlFld-ContribAuthor ">H. M.  Stepanyan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Activity of Partially Hydrogenated 1-Aminopyrimido[4,5-c]isoquinoline Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>56 </em>
                                    (11)
                                     , 1963-1968. <a href="https://doi.org/10.1134/S1070428020110111" title="DOI URL">https://doi.org/10.1134/S1070428020110111</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428020110111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428020110111%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Band%252BBiological%252BActivity%252Bof%252BPartially%252BHydrogenated%252B1-Aminopyrimido%25255B4%25252C5-c%25255Disoquinoline%252BDerivatives%26aulast%3DParonikyan%26aufirst%3DE.%2BG.%26date%3D2020%26date%3D2021%26volume%3D56%26issue%3D11%26spage%3D1963%26epage%3D1968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniela  Tomaselli</span>, <span class="hlFld-ContribAuthor ">Alessia  Lucidi</span>, <span class="hlFld-ContribAuthor ">Dante  Rotili</span>, <span class="hlFld-ContribAuthor ">Antonello  Mai</span>. </span><span class="cited-content_cbyCitation_article-title">Epigenetic polypharmacology: A new frontier for epi‐drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2020,</strong> <em>40 </em>
                                    (1)
                                     , 190-244. <a href="https://doi.org/10.1002/med.21600" title="DOI URL">https://doi.org/10.1002/med.21600</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21600%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DEpigenetic%252Bpolypharmacology%25253A%252BA%252Bnew%252Bfrontier%252Bfor%252Bepi%2525E2%252580%252590drug%252Bdiscovery%26aulast%3DTomaselli%26aufirst%3DDaniela%26date%3D2020%26date%3D2019%26volume%3D40%26issue%3D1%26spage%3D190%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pingping  Chen</span>, <span class="hlFld-ContribAuthor ">Yinqiu  Xu</span>, <span class="hlFld-ContribAuthor ">Xuanyi  Li</span>, <span class="hlFld-ContribAuthor ">Hequan  Yao</span>, <span class="hlFld-ContribAuthor ">Kejiang  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Development and strategies of CDK4/6 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (2)
                                     , 127-145. <a href="https://doi.org/10.4155/fmc-2019-0062" title="DOI URL">https://doi.org/10.4155/fmc-2019-0062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0062%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Band%252Bstrategies%252Bof%252BCDK4%25252F6%252Binhibitors%26aulast%3DChen%26aufirst%3DPingping%26date%3D2020%26volume%3D12%26issue%3D2%26spage%3D127%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guillem  Jubete</span>, <span class="hlFld-ContribAuthor ">Raimon  Puig de la Bellacasa</span>, <span class="hlFld-ContribAuthor ">Roger  Estrada-Tejedor</span>, <span class="hlFld-ContribAuthor ">Jordi  Teixidó</span>, <span class="hlFld-ContribAuthor ">José I.  Borrell</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrido[2,3-d]pyrimidin-7(8H)-ones: Synthesis and Biomedical Applications. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (22)
                                     , 4161. <a href="https://doi.org/10.3390/molecules24224161" title="DOI URL">https://doi.org/10.3390/molecules24224161</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24224161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24224161%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DPyrido%25255B2%25252C3-d%25255Dpyrimidin-7%2525288H%252529-ones%25253A%252BSynthesis%252Band%252BBiomedical%252BApplications%26aulast%3DJubete%26aufirst%3DGuillem%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D22%26spage%3D4161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abida  Ashraf</span>, <span class="hlFld-ContribAuthor ">Muhammad  Khalid</span>, <span class="hlFld-ContribAuthor ">Muhammad Nawaz  Tahir</span>, <span class="hlFld-ContribAuthor ">Muhammad  Yaqub</span>, <span class="hlFld-ContribAuthor ">Muhammad Moazzam  Naseer</span>, <span class="hlFld-ContribAuthor ">Ghulam Mustafa  Kamal</span>, <span class="hlFld-ContribAuthor ">Bullo  Saifullah</span>, <span class="hlFld-ContribAuthor ">Ataualpa Albert Carmo  Braga</span>, <span class="hlFld-ContribAuthor ">Zahid  Shafiq</span>, <span class="hlFld-ContribAuthor ">Waqar  Rauf</span>. </span><span class="cited-content_cbyCitation_article-title">A facile and concise route to (hydroxybenzoyl)pyrido[2,3-
              d
              ]pyrimidine heterocycle derivatives: synthesis, and structural, spectral and computational exploration. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2019,</strong> <em>9 </em>
                                    (59)
                                     , 34567-34580. <a href="https://doi.org/10.1039/C9RA05415D" title="DOI URL">https://doi.org/10.1039/C9RA05415D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9RA05415D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9RA05415D%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DA%252Bfacile%252Band%252Bconcise%252Broute%252Bto%252B%252528hydroxybenzoyl%252529pyrido%25255B2%25252C3-%252Bd%252B%25255Dpyrimidine%252Bheterocycle%252Bderivatives%25253A%252Bsynthesis%25252C%252Band%252Bstructural%25252C%252Bspectral%252Band%252Bcomputational%252Bexploration%26aulast%3DAshraf%26aufirst%3DAbida%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D59%26spage%3D34567%26epage%3D34580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chen  Shi</span>, <span class="hlFld-ContribAuthor ">Qian  Wang</span>, <span class="hlFld-ContribAuthor ">Xuemei  Liao</span>, <span class="hlFld-ContribAuthor ">Hui  Ge</span>, <span class="hlFld-ContribAuthor ">Guoyong  Huo</span>, <span class="hlFld-ContribAuthor ">Leduo  Zhang</span>, <span class="hlFld-ContribAuthor ">Na  Chen</span>, <span class="hlFld-ContribAuthor ">Xiong  Zhai</span>, <span class="hlFld-ContribAuthor ">Yuan  Hong</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Yanan  Han</span>, <span class="hlFld-ContribAuthor ">Wenbo  Xiao</span>, <span class="hlFld-ContribAuthor ">Zhe  Wang</span>, <span class="hlFld-ContribAuthor ">Weijun  Shi</span>, <span class="hlFld-ContribAuthor ">Yu  Mao</span>, <span class="hlFld-ContribAuthor ">Jianxin  Yu</span>, <span class="hlFld-ContribAuthor ">Guangxin  Xia</span>, <span class="hlFld-ContribAuthor ">Yanjun  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>178 </em>, 352-364. <a href="https://doi.org/10.1016/j.ejmech.2019.06.005" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.005%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B6-%2525282-%252528dimethylamino%252529ethyl%252529-N-%2525285-fluoro-4-%2525284-fluoro-1-isopropyl-2-methyl-1H-benzo%25255Bd%25255Dimidazole-6-yl%252529pyrimidin-2-yl%252529-5%25252C6%25252C7%25252C8-tetrahydro-1%25252C6-naphthyridin-2-amine%252Bas%252Ba%252Bhighly%252Bpotent%252Bcyclin-dependent%252Bkinase%252B4%25252F6%252Binhibitor%252Bfor%252Btreatment%252Bof%252Bcancer%26aulast%3DShi%26aufirst%3DChen%26date%3D2019%26volume%3D178%26spage%3D352%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A. V.  Komkov</span>, <span class="hlFld-ContribAuthor ">T. V.  Potapova</span>, <span class="hlFld-ContribAuthor ">M. I.  Zuev</span>, <span class="hlFld-ContribAuthor ">S. V.  Baranin</span>, <span class="hlFld-ContribAuthor ">Yu. N.  Bubnov</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of new trichloromethyl- and alkoxy-substituted pyrido[2,3-d]pyrimidine derivatives. </span><span class="cited-content_cbyCitation_journal-name">Russian Chemical Bulletin</span><span> <strong>2019,</strong> <em>68 </em>
                                    (2)
                                     , 365-373. <a href="https://doi.org/10.1007/s11172-019-2394-6" title="DOI URL">https://doi.org/10.1007/s11172-019-2394-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11172-019-2394-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11172-019-2394-6%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Chemical%2520Bulletin%26atitle%3DSynthesis%252Bof%252Bnew%252Btrichloromethyl-%252Band%252Balkoxy-substituted%252Bpyrido%25255B2%25252C3-d%25255Dpyrimidine%252Bderivatives%26aulast%3DKomkov%26aufirst%3DA.%2BV.%26date%3D2019%26date%3D2019%26volume%3D68%26issue%3D2%26spage%3D365%26epage%3D373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wendy A.  Loughlin</span>, <span class="hlFld-ContribAuthor ">Asmaa  Boufridi</span>. </span><span class="cited-content_cbyCitation_article-title">6-6 Bicyclic Systems: Three Heteroatoms 1:2. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,<a href="https://doi.org/10.1016/B978-0-12-409547-2.14794-8" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.14794-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.14794-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.14794-8%26sid%3Dliteratum%253Aachs%26atitle%3D6-6%252BBicyclic%252BSystems%25253A%252BThree%252BHeteroatoms%252B1%25253A2%26aulast%3DLoughlin%26aufirst%3DWendy%2BA.%26date%3D2019%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna M.  Zinchenko</span>, <span class="hlFld-ContribAuthor ">Lyubov V.  Muzychka</span>, <span class="hlFld-ContribAuthor ">Olexandr V.  Kucher</span>, <span class="hlFld-ContribAuthor ">Iryna V.  Sadkova</span>, <span class="hlFld-ContribAuthor ">Pavel K.  Mykhailiuk</span>, <span class="hlFld-ContribAuthor ">Oleg B.  Smolii</span>. </span><span class="cited-content_cbyCitation_article-title">One-Pot Synthesis of 6-Aminopyrido[2,3-
              d
              ]pyrimidin-7-ones. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>2018 </em>
                                    (46)
                                     , 6519-6523. <a href="https://doi.org/10.1002/ejoc.201801204" title="DOI URL">https://doi.org/10.1002/ejoc.201801204</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201801204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201801204%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOne-Pot%252BSynthesis%252Bof%252B6-Aminopyrido%25255B2%25252C3-%252Bd%252B%25255Dpyrimidin-7-ones%26aulast%3DZinchenko%26aufirst%3DAnna%2BM.%26date%3D2018%26date%3D2018%26volume%3D2018%26issue%3D46%26spage%3D6519%26epage%3D6523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">V.  Divya</span>, <span class="hlFld-ContribAuthor ">V.L.  Pushpa</span>, <span class="hlFld-ContribAuthor ">S.  Sarithamol</span>, <span class="hlFld-ContribAuthor ">K.B.  Manoj</span>. </span><span class="cited-content_cbyCitation_article-title">Computational approach for generating robust models for discovering novel molecules as Cyclin Dependent Kinase 4 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2018,</strong> <em>82 </em>, 48-58. <a href="https://doi.org/10.1016/j.jmgm.2018.04.001" title="DOI URL">https://doi.org/10.1016/j.jmgm.2018.04.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2018.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2018.04.001%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DComputational%252Bapproach%252Bfor%252Bgenerating%252Brobust%252Bmodels%252Bfor%252Bdiscovering%252Bnovel%252Bmolecules%252Bas%252BCyclin%252BDependent%252BKinase%252B4%252Binhibitors%26aulast%3DDivya%26aufirst%3DV.%26date%3D2018%26volume%3D82%26spage%3D48%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huan  He</span>, <span class="hlFld-ContribAuthor ">Juan  Xu</span>, <span class="hlFld-ContribAuthor ">Wen  Xie</span>, <span class="hlFld-ContribAuthor ">Qing-Lian  Guo</span>, <span class="hlFld-ContribAuthor ">Feng-Lei  Jiang</span>, <span class="hlFld-ContribAuthor ">Yi  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Reduced state transition barrier of CDK6 from open to closed state induced by Thr177 phosphorylation and its implication in binding modes of inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - General Subjects</span><span> <strong>2018,</strong> <em>1862 </em>
                                    (3)
                                     , 501-512. <a href="https://doi.org/10.1016/j.bbagen.2017.11.001" title="DOI URL">https://doi.org/10.1016/j.bbagen.2017.11.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbagen.2017.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbagen.2017.11.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520General%2520Subjects%26atitle%3DReduced%252Bstate%252Btransition%252Bbarrier%252Bof%252BCDK6%252Bfrom%252Bopen%252Bto%252Bclosed%252Bstate%252Binduced%252Bby%252BThr177%252Bphosphorylation%252Band%252Bits%252Bimplication%252Bin%252Bbinding%252Bmodes%252Bof%252Binhibitors%26aulast%3DHe%26aufirst%3DHuan%26date%3D2018%26volume%3D1862%26issue%3D3%26spage%3D501%26epage%3D512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jia  Liu</span>, <span class="hlFld-ContribAuthor ">Bian  Ming</span>, <span class="hlFld-ContribAuthor ">Guo-Hua  Gong</span>, <span class="hlFld-ContribAuthor ">Di  Wang</span>, <span class="hlFld-ContribAuthor ">Gui-Lan  Bao</span>, <span class="hlFld-ContribAuthor ">Li-Jun  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Current research on anti-breast cancer synthetic compounds. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2018,</strong> <em>8 </em>
                                    (8)
                                     , 4386-4416. <a href="https://doi.org/10.1039/C7RA12912B" title="DOI URL">https://doi.org/10.1039/C7RA12912B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7RA12912B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7RA12912B%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DCurrent%252Bresearch%252Bon%252Banti-breast%252Bcancer%252Bsynthetic%252Bcompounds%26aulast%3DLiu%26aufirst%3DJia%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D8%26spage%3D4386%26epage%3D4416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna N.  Zinchenko</span>, <span class="hlFld-ContribAuthor ">Lyubov V.  Muzychka</span>, <span class="hlFld-ContribAuthor ">Igor I.  Biletskii</span>, <span class="hlFld-ContribAuthor ">Oleg B.  Smolii</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of new 4-amino-substituted 7-iminopyrido[2,3-d]pyrimidines. </span><span class="cited-content_cbyCitation_journal-name">Chemistry of Heterocyclic Compounds</span><span> <strong>2017,</strong> <em>53 </em>
                                    (5)
                                     , 589-596. <a href="https://doi.org/10.1007/s10593-017-2096-7" title="DOI URL">https://doi.org/10.1007/s10593-017-2096-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10593-017-2096-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10593-017-2096-7%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520of%2520Heterocyclic%2520Compounds%26atitle%3DSynthesis%252Bof%252Bnew%252B4-amino-substituted%252B7-iminopyrido%25255B2%25252C3-d%25255Dpyrimidines%26aulast%3DZinchenko%26aufirst%3DAnna%2BN.%26date%3D2017%26date%3D2017%26volume%3D53%26issue%3D5%26spage%3D589%26epage%3D596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kazuhiro  Kobayashi</span>, <span class="hlFld-ContribAuthor ">Ippei  Nozawa</span>, <span class="hlFld-ContribAuthor ">Hiroaki  Utsumi</span>, <span class="hlFld-ContribAuthor ">Takuma  Ueyama</span>, <span class="hlFld-ContribAuthor ">Hidetaka  Hiyoshi</span>, <span class="hlFld-ContribAuthor ">Kazuto  Umezu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 7,8-Dihydropyrido[2,3-d]pyrimidine Derivatives from 4,6-Dichloro-2-(methylsulfanyl)pyrimidine. </span><span class="cited-content_cbyCitation_journal-name">HETEROCYCLES</span><span> <strong>2017,</strong> <em>94 </em>
                                    (8)
                                     , 1427. <a href="https://doi.org/10.3987/COM-17-13720" title="DOI URL">https://doi.org/10.3987/COM-17-13720</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3987/COM-17-13720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3987%2FCOM-17-13720%26sid%3Dliteratum%253Aachs%26jtitle%3DHETEROCYCLES%26atitle%3DSynthesis%252Bof%252B7%25252C8-Dihydropyrido%25255B2%25252C3-d%25255Dpyrimidine%252BDerivatives%252Bfrom%252B4%25252C6-Dichloro-2-%252528methylsulfanyl%252529pyrimidine%26aulast%3DKobayashi%26aufirst%3DKazuhiro%26date%3D2017%26volume%3D94%26issue%3D8%26spage%3D1427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tinghan  Li</span>, <span class="hlFld-ContribAuthor ">Tianwei  Weng</span>, <span class="hlFld-ContribAuthor ">Minzan  Zuo</span>, <span class="hlFld-ContribAuthor ">Zhihui  Wei</span>, <span class="hlFld-ContribAuthor ">Ming  Chen</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2016,</strong> <em>8 </em>
                                    (17)
                                     , 2047-2076. <a href="https://doi.org/10.4155/fmc-2016-0129" title="DOI URL">https://doi.org/10.4155/fmc-2016-0129</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2016-0129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2016-0129%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bof%252Bcyclin-dependent%252Bkinase%252Binhibitors%252Bas%252Bpotential%252Banticancer%252Bagents%26aulast%3DLi%26aufirst%3DTinghan%26date%3D2016%26volume%3D8%26issue%3D17%26spage%3D2047%26epage%3D2076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carmen  Di Giovanni</span>, <span class="hlFld-ContribAuthor ">Ettore  Novellino</span>, <span class="hlFld-ContribAuthor ">Adriana  Chilin</span>, <span class="hlFld-ContribAuthor ">Antonio  Lavecchia</span>, <span class="hlFld-ContribAuthor ">Giovanni  Marzaro</span>. </span><span class="cited-content_cbyCitation_article-title">Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2016,</strong> <em>25 </em>
                                    (10)
                                     , 1215-1230. <a href="https://doi.org/10.1080/13543784.2016.1234603" title="DOI URL">https://doi.org/10.1080/13543784.2016.1234603</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2016.1234603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2016.1234603%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DInvestigational%252Bdrugs%252Btargeting%252Bcyclin-dependent%252Bkinases%252Bfor%252Bthe%252Btreatment%252Bof%252Bcancer%25253A%252Ban%252Bupdate%252Bon%252Brecent%252Bfindings%252B%2525282013-2016%252529%26aulast%3DDi%2BGiovanni%26aufirst%3DCarmen%26date%3D2016%26date%3D2016%26volume%3D25%26issue%3D10%26spage%3D1215%26epage%3D1230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Albino  Troilo</span>, <span class="hlFld-ContribAuthor ">Erica K.  Benson</span>, <span class="hlFld-ContribAuthor ">Davide  Esposito</span>, <span class="hlFld-ContribAuthor ">Rachel-Ann A.  Garibsingh</span>, <span class="hlFld-ContribAuthor ">E. Premkumar  Reddy</span>, <span class="hlFld-ContribAuthor ">Sathish Kumar  Mungamuri</span>, <span class="hlFld-ContribAuthor ">Stuart A.  Aaronson</span>. </span><span class="cited-content_cbyCitation_article-title">Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2016,</strong> <em>7 </em>
                                    (20)
                                     , 28765-28782. <a href="https://doi.org/10.18632/oncotarget.9117" title="DOI URL">https://doi.org/10.18632/oncotarget.9117</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.9117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.9117%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DAngiomotin%252Bstabilization%252Bby%252Btankyrase%252Binhibitors%252Bantagonizes%252Bconstitutive%252BTEAD-dependent%252Btranscription%252Band%252Bproliferation%252Bof%252Bhuman%252Btumor%252Bcells%252Bwith%252BHippo%252Bpathway%252Bcore%252Bcomponent%252Bmutations%26aulast%3DTroilo%26aufirst%3DAlbino%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D20%26spage%3D28765%26epage%3D28782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Khamid U.  Khodjaniyazov</span>, <span class="hlFld-ContribAuthor ">Jamshid M.  Ashurov</span>. </span><span class="cited-content_cbyCitation_article-title">Crystal structure of (
              E
              )-9-(4-nitrobenzylidene)-8,9-dihydropyrido[2,3-
              d
              ]pyrrolo[1,2-
              a
              ]pyrimidin-5(7
              H
              )-one. </span><span class="cited-content_cbyCitation_journal-name">Acta Crystallographica Section E Crystallographic Communications</span><span> <strong>2016,</strong> <em>72 </em>
                                    (4)
                                     , 452-455. <a href="https://doi.org/10.1107/S2056989016003583" title="DOI URL">https://doi.org/10.1107/S2056989016003583</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1107/S2056989016003583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1107%2FS2056989016003583%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Crystallographica%2520Section%2520E%2520Crystallographic%2520Communications%26atitle%3DCrystal%252Bstructure%252Bof%252B%252528%252BE%252B%252529-9-%2525284-nitrobenzylidene%252529-8%25252C9-dihydropyrido%25255B2%25252C3-%252Bd%252B%25255Dpyrrolo%25255B1%25252C2-%252Ba%252B%25255Dpyrimidin-5%2525287%252BH%252B%252529-one%26aulast%3DKhodjaniyazov%26aufirst%3DKhamid%2BU.%26date%3D2016%26date%3D2016%26volume%3D72%26issue%3D4%26spage%3D452%26epage%3D455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deepak  Perumal</span>, <span class="hlFld-ContribAuthor ">Pei-Yu  Kuo</span>, <span class="hlFld-ContribAuthor ">Violetta V.  Leshchenko</span>, <span class="hlFld-ContribAuthor ">Zewei  Jiang</span>, <span class="hlFld-ContribAuthor ">Sai Krishna Athaluri  Divakar</span>, <span class="hlFld-ContribAuthor ">Hearn Jay  Cho</span>, <span class="hlFld-ContribAuthor ">Ajai  Chari</span>, <span class="hlFld-ContribAuthor ">Joshua  Brody</span>, <span class="hlFld-ContribAuthor ">M.V. Ramana  Reddy</span>, <span class="hlFld-ContribAuthor ">Weijia  Zhang</span>, <span class="hlFld-ContribAuthor ">E. Premkumar  Reddy</span>, <span class="hlFld-ContribAuthor ">Sundar  Jagannath</span>, <span class="hlFld-ContribAuthor ">Samir  Parekh</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2016,</strong> <em>76 </em>
                                    (5)
                                     , 1225-1236. <a href="https://doi.org/10.1158/0008-5472.CAN-15-2934" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-15-2934</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-15-2934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-15-2934%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DDual%252BTargeting%252Bof%252BCDK4%252Band%252BARK5%252BUsing%252Ba%252BNovel%252BKinase%252BInhibitor%252BON123300%252BExerts%252BPotent%252BAnticancer%252BActivity%252Bagainst%252BMultiple%252BMyeloma%26aulast%3DPerumal%26aufirst%3DDeepak%26date%3D2016%26date%3D2016%26volume%3D76%26issue%3D5%26spage%3D1225%26epage%3D1236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M.V. Ramana  Reddy</span>, <span class="hlFld-ContribAuthor ">Balireddy  Akula</span>, <span class="hlFld-ContribAuthor ">Shashidhar  Jatiani</span>, <span class="hlFld-ContribAuthor ">Rodrigo  Vasquez-Del Carpio</span>, <span class="hlFld-ContribAuthor ">Vinay K.  Billa</span>, <span class="hlFld-ContribAuthor ">Muralidhar R.  Mallireddigari</span>, <span class="hlFld-ContribAuthor ">Stephen C.  Cosenza</span>, <span class="hlFld-ContribAuthor ">D.R.C.  Venkata Subbaiah</span>, <span class="hlFld-ContribAuthor ">E. Vijaya  Bharathi</span>, <span class="hlFld-ContribAuthor ">Venkat R.  Pallela</span>, <span class="hlFld-ContribAuthor ">Poornima  Ramkumar</span>, <span class="hlFld-ContribAuthor ">Rinku  Jain</span>, <span class="hlFld-ContribAuthor ">Aneel K.  Aggarwal</span>, <span class="hlFld-ContribAuthor ">E. Premkumar  Reddy</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (4)
                                     , 521-544. <a href="https://doi.org/10.1016/j.bmc.2015.11.045" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.11.045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.11.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.11.045%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-%2525281H-indol-5-ylamino%252529-6-%2525282%25252C4-difluorophenylsulfonyl%252529-8-methylpyrido%25255B2%25252C3-d%25255Dpyrimidin-7%2525288H%252529-one%252B%2525287ao%252529%252Bas%252Ba%252Bpotent%252Bselective%252Binhibitor%252Bof%252BPolo%252Blike%252Bkinase%252B2%252B%252528PLK2%252529%26aulast%3DReddy%26aufirst%3DM.V.%2BRamana%26date%3D2016%26volume%3D24%26issue%3D4%26spage%3D521%26epage%3D544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S K A  Divakar</span>, <span class="hlFld-ContribAuthor ">M V  Ramana Reddy</span>, <span class="hlFld-ContribAuthor ">S C  Cosenza</span>, <span class="hlFld-ContribAuthor ">S J  Baker</span>, <span class="hlFld-ContribAuthor ">D  Perumal</span>, <span class="hlFld-ContribAuthor ">A C  Antonelli</span>, <span class="hlFld-ContribAuthor ">J  Brody</span>, <span class="hlFld-ContribAuthor ">B  Akula</span>, <span class="hlFld-ContribAuthor ">S  Parekh</span>, <span class="hlFld-ContribAuthor ">E  Premkumar Reddy</span>. </span><span class="cited-content_cbyCitation_article-title">Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas. </span><span class="cited-content_cbyCitation_journal-name">Leukemia</span><span> <strong>2016,</strong> <em>30 </em>
                                    (1)
                                     , 86-93. <a href="https://doi.org/10.1038/leu.2015.185" title="DOI URL">https://doi.org/10.1038/leu.2015.185</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/leu.2015.185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fleu.2015.185%26sid%3Dliteratum%253Aachs%26jtitle%3DLeukemia%26atitle%3DDual%252Binhibition%252Bof%252BCDK4%25252FRb%252Band%252BPI3K%25252FAKT%25252FmTOR%252Bpathways%252Bby%252BON123300%252Binduces%252Bsynthetic%252Blethality%252Bin%252Bmantle%252Bcell%252Blymphomas%26aulast%3DDivakar%26aufirst%3DS%2BK%2BA%26date%3D2016%26date%3D2015%26volume%3D30%26issue%3D1%26spage%3D86%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ling  Wang</span>, <span class="hlFld-ContribAuthor ">Yecheng  Li</span>, <span class="hlFld-ContribAuthor ">Mengyan  Xu</span>, <span class="hlFld-ContribAuthor ">Xiaoqian  Pang</span>, <span class="hlFld-ContribAuthor ">Zhihong  Liu</span>, <span class="hlFld-ContribAuthor ">Wen  Tan</span>, <span class="hlFld-ContribAuthor ">Jun  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical fragment-based CDK4/6 inhibitors prediction and web server. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2016,</strong> <em>6 </em>
                                    (21)
                                     , 16972-16981. <a href="https://doi.org/10.1039/C5RA23289A" title="DOI URL">https://doi.org/10.1039/C5RA23289A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5RA23289A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5RA23289A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DChemical%252Bfragment-based%252BCDK4%25252F6%252Binhibitors%252Bprediction%252Band%252Bweb%252Bserver%26aulast%3DWang%26aufirst%3DLing%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D21%26spage%3D16972%26epage%3D16981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Solomon  Tadesse</span>, <span class="hlFld-ContribAuthor ">Mingfeng  Yu</span>, <span class="hlFld-ContribAuthor ">Malika  Kumarasiri</span>, <span class="hlFld-ContribAuthor ">Bich Thuy  Le</span>, <span class="hlFld-ContribAuthor ">Shudong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting CDK6 in cancer: State of the art and new insights. </span><span class="cited-content_cbyCitation_journal-name">Cell Cycle</span><span> <strong>2015,</strong> <em>14 </em>
                                    (20)
                                     , 3220-3230. <a href="https://doi.org/10.1080/15384101.2015.1084445" title="DOI URL">https://doi.org/10.1080/15384101.2015.1084445</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/15384101.2015.1084445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F15384101.2015.1084445%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Cycle%26atitle%3DTargeting%252BCDK6%252Bin%252Bcancer%25253A%252BState%252Bof%252Bthe%252Bart%252Band%252Bnew%252Binsights%26aulast%3DTadesse%26aufirst%3DSolomon%26date%3D2015%26date%3D2015%26volume%3D14%26issue%3D20%26spage%3D3220%26epage%3D3230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Concepción  Sánchez-Martínez</span>, <span class="hlFld-ContribAuthor ">Lawrence M.  Gelbert</span>, <span class="hlFld-ContribAuthor ">María José  Lallena</span>, <span class="hlFld-ContribAuthor ">Alfonso  de Dios</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (17)
                                     , 3420-3435. <a href="https://doi.org/10.1016/j.bmcl.2015.05.100" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.05.100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.05.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.05.100%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DCyclin%252Bdependent%252Bkinase%252B%252528CDK%252529%252Binhibitors%252Bas%252Banticancer%252Bdrugs%26aulast%3DS%25C3%25A1nchez-Mart%25C3%25ADnez%26aufirst%3DConcepci%25C3%25B3n%26date%3D2015%26volume%3D25%26issue%3D17%26spage%3D3420%26epage%3D3435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria E.  Chizhova</span>, <span class="hlFld-ContribAuthor ">Olga Yu.  Bakulina</span>, <span class="hlFld-ContribAuthor ">Alexander Yu.  Ivanov</span>, <span class="hlFld-ContribAuthor ">Pavel S.  Lobanov</span>, <span class="hlFld-ContribAuthor ">Dmitrii V.  Dar'in</span>. </span><span class="cited-content_cbyCitation_article-title">Facile synthesis of pyrido[2,3-d]pyrimidines via cyclocondensation of 4,6-dichloro-2-methylsulfanylpyrimidine-5-carbaldehyde with β-substituted β-aminoacrylic esters. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2015,</strong> <em>71 </em>
                                    (36)
                                     , 6196-6203. <a href="https://doi.org/10.1016/j.tet.2015.06.085" title="DOI URL">https://doi.org/10.1016/j.tet.2015.06.085</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2015.06.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2015.06.085%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DFacile%252Bsynthesis%252Bof%252Bpyrido%25255B2%25252C3-d%25255Dpyrimidines%252Bvia%252Bcyclocondensation%252Bof%252B4%25252C6-dichloro-2-methylsulfanylpyrimidine-5-carbaldehyde%252Bwith%252B%2525CE%2525B2-substituted%252B%2525CE%2525B2-aminoacrylic%252Besters%26aulast%3DChizhova%26aufirst%3DMaria%2BE.%26date%3D2015%26volume%3D71%26issue%3D36%26spage%3D6196%26epage%3D6203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marion  Peyressatre</span>, <span class="hlFld-ContribAuthor ">Camille  Prével</span>, <span class="hlFld-ContribAuthor ">Morgan  Pellerano</span>, <span class="hlFld-ContribAuthor ">May  Morris</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2015,</strong> <em>7 </em>
                                    (1)
                                     , 179-237. <a href="https://doi.org/10.3390/cancers7010179" title="DOI URL">https://doi.org/10.3390/cancers7010179</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers7010179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers7010179%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DTargeting%252BCyclin-Dependent%252BKinases%252Bin%252BHuman%252BCancers%25253A%252BFrom%252BSmall%252BMolecules%252Bto%252BPeptide%252BInhibitors%26aulast%3DPeyressatre%26aufirst%3DMarion%26date%3D2015%26date%3D2015%26volume%3D7%26issue%3D1%26spage%3D179%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">T  Narita</span>, <span class="hlFld-ContribAuthor ">A  Inagaki</span>, <span class="hlFld-ContribAuthor ">T  Kobayashi</span>, <span class="hlFld-ContribAuthor ">Y  Kuroda</span>, <span class="hlFld-ContribAuthor ">T  Fukushima</span>, <span class="hlFld-ContribAuthor ">M  Nezu</span>, <span class="hlFld-ContribAuthor ">S  Fuchida</span>, <span class="hlFld-ContribAuthor ">H  Sakai</span>, <span class="hlFld-ContribAuthor ">N  Sekiguchi</span>, <span class="hlFld-ContribAuthor ">I  Sugiura</span>, <span class="hlFld-ContribAuthor ">Y  Maeda</span>, <span class="hlFld-ContribAuthor ">H  Takamatsu</span>, <span class="hlFld-ContribAuthor ">N  Tsukamoto</span>, <span class="hlFld-ContribAuthor ">D  Maruyama</span>, <span class="hlFld-ContribAuthor ">Y  Kubota</span>, <span class="hlFld-ContribAuthor ">M  Kojima</span>, <span class="hlFld-ContribAuthor ">K  Sunami</span>, <span class="hlFld-ContribAuthor ">T  Ono</span>, <span class="hlFld-ContribAuthor ">M  Ri</span>, <span class="hlFld-ContribAuthor ">K  Tobinai</span>, <span class="hlFld-ContribAuthor ">S  Iida</span>. </span><span class="cited-content_cbyCitation_article-title">t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs. </span><span class="cited-content_cbyCitation_journal-name">Blood Cancer Journal</span><span> <strong>2015,</strong> <em>5 </em>
                                    (2)
                                     , e285-e285. <a href="https://doi.org/10.1038/bcj.2015.6" title="DOI URL">https://doi.org/10.1038/bcj.2015.6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/bcj.2015.6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fbcj.2015.6%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%2520Cancer%2520Journal%26atitle%3Dt%25252814%25253B16%252529-positive%252Bmultiple%252Bmyeloma%252Bshows%252Bnegativity%252Bfor%252BCD56%252Bexpression%252Band%252Bunfavorable%252Boutcome%252Beven%252Bin%252Bthe%252Bera%252Bof%252Bnovel%252Bdrugs%26aulast%3DNarita%26aufirst%3DT%26date%3D2015%26date%3D2015%26volume%3D5%26issue%3D2%26spage%3De285%26epage%3De285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jonas  Cicenas</span>, <span class="hlFld-ContribAuthor ">Karthik  Kalyan</span>, <span class="hlFld-ContribAuthor ">Aleksandras  Sorokinas</span>, <span class="hlFld-ContribAuthor ">Asta  Jatulyte</span>, <span class="hlFld-ContribAuthor ">Deividas  Valiunas</span>, <span class="hlFld-ContribAuthor ">Algirdas  Kaupinis</span>, <span class="hlFld-ContribAuthor ">Mindaugas  Valius</span>. </span><span class="cited-content_cbyCitation_article-title">Highlights of the Latest Advances in Research on CDK Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2014,</strong> <em>6 </em>
                                    (4)
                                     , 2224-2242. <a href="https://doi.org/10.3390/cancers6042224" title="DOI URL">https://doi.org/10.3390/cancers6042224</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers6042224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers6042224%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DHighlights%252Bof%252Bthe%252BLatest%252BAdvances%252Bin%252BResearch%252Bon%252BCDK%252BInhibitors%26aulast%3DCicenas%26aufirst%3DJonas%26date%3D2014%26date%3D2014%26volume%3D6%26issue%3D4%26spage%3D2224%26epage%3D2242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei-Feng  Ma</span>, <span class="hlFld-ContribAuthor ">Hai-Kui  Yang</span>, <span class="hlFld-ContribAuthor ">Meng-Jin  Hu</span>, <span class="hlFld-ContribAuthor ">Qian  Li</span>, <span class="hlFld-ContribAuthor ">Tian-Zhu  Ma</span>, <span class="hlFld-ContribAuthor ">Zhong-Zhen  Zhou</span>, <span class="hlFld-ContribAuthor ">Rui-Yuan  Liu</span>, <span class="hlFld-ContribAuthor ">Wen-Wei  You</span>, <span class="hlFld-ContribAuthor ">Pei-Liang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">One-pot synthesis and antiproliferative activity of novel 2,4-diaminopyrimidine derivatives bearing piperidine and piperazine moieties. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>84 </em>, 127-134. <a href="https://doi.org/10.1016/j.ejmech.2014.07.017" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.07.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.07.017%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOne-pot%252Bsynthesis%252Band%252Bantiproliferative%252Bactivity%252Bof%252Bnovel%252B2%25252C4-diaminopyrimidine%252Bderivatives%252Bbearing%252Bpiperidine%252Band%252Bpiperazine%252Bmoieties%26aulast%3DMa%26aufirst%3DWei-Feng%26date%3D2014%26volume%3D84%26spage%3D127%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kazuhiro  Kobayashi</span>, <span class="hlFld-ContribAuthor ">Shohei  Yuba</span>, <span class="hlFld-ContribAuthor ">Aina  Taniguchi</span>, <span class="hlFld-ContribAuthor ">Hiroki  Inouchi</span>, <span class="hlFld-ContribAuthor ">Hidetaka  Hiyoshi</span>, <span class="hlFld-ContribAuthor ">Kazuto  Umezu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 7-Amino-5,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile Derivatives Based on the Reaction of 4-Chloro-5-lithio-6-methoxypyrimidines with 2-(Arylmethylidene)propanedinitriles. </span><span class="cited-content_cbyCitation_journal-name">HETEROCYCLES</span><span> <strong>2014,</strong> <em>89 </em>
                                    (11)
                                     , 2611. <a href="https://doi.org/10.3987/COM-14-13091" title="DOI URL">https://doi.org/10.3987/COM-14-13091</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3987/COM-14-13091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3987%2FCOM-14-13091%26sid%3Dliteratum%253Aachs%26jtitle%3DHETEROCYCLES%26atitle%3DSynthesis%252Bof%252B7-Amino-5%25252C8-dihydropyrido%25255B2%25252C3-d%25255Dpyrimidine-6-carbonitrile%252BDerivatives%252BBased%252Bon%252Bthe%252BReaction%252Bof%252B4-Chloro-5-lithio-6-methoxypyrimidines%252Bwith%252B2-%252528Arylmethylidene%252529propanedinitriles%26aulast%3DKobayashi%26aufirst%3DKazuhiro%26date%3D2014%26volume%3D89%26issue%3D11%26spage%3D2611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0025.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. CDK Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Pyrido[2,3-<i>d</i>]pyrimidines (<b>7</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions (i) X-NH<sub>2</sub>, Et<sub>3</sub>N, THF, rt, 1–3 h, 80–95%; (ii) LiAlH<sub>4</sub>, THF, −10 °C to rt, 1 h, 80–86%; (iii) MnO<sub>2</sub>, CHCl<sub>3</sub>, rt, 24 h, 70–90%; (iv) CNCH<sub>2</sub>CO<sub>2</sub>H or NO<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>Et or <b>10</b> or <b>13</b> or <b>16</b>, BnNH<sub>2</sub>, AcOH, 100 °C, 6 h, 62–73%; (v) <i>m</i>-CPBA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 3 h, 87–94%; (vi) Z-H, toluene, 100 °C, 3–8 h, 40–65%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 8-Alkyl/cycloalkyl-2-methylsulfanyl-7-oxo-7,8-dihydro[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>5b</b>–<b>5j</b>) from 2-Methylsulfanyl-7-oxo-7,8-dihydro[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>5a</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) X-I, NaH, DMF, 50 °C, 1 h, 64–75%.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Acylation and Benzoylation of NH Group of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7- oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7x</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) AC<sub>2</sub>O, 120 °C, 3 h, 64%; (ii) 4-CF<sub>3</sub>PhCOCl, NaH, DMF, rt, 3 h, 62%.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0013.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Arylmethanesulfonyl Acetic Acids<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) HSCH<sub>2</sub>CO<sub>2</sub>H, NaOH, MeOH, HCl, rt, 3 h, 90–95%; (ii) TBAF solution in THF, rt, 2 h, 50%; (iii) 30% H<sub>2</sub>O<sub>2</sub>, AcOH, rt, 24 h, 85–90%.</p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0014.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of 4-Chlorophenylsulfonyl Acetic Acids<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) ClCH<sub>2</sub>CO<sub>2</sub>H, NaOH, MeOH, HCl, rt, 3 h, 98%; (ii) 30% H<sub>2</sub>O<sub>2</sub>, AcOH, rt, 24 h, 80%.</p></p></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0015.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <i>N</i>-Arylmalonamic Acids<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) ClCOCH<sub>2</sub>CO<sub>2</sub>Me, Et<sub>3</sub>N, DCM, rt, 3 h, 90%; (ii) 10% NaOH, HCl, rt, 1 h, 78–80%.</p></p></figure><figure data-id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0016.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of <i>N</i>-Methylpiperazine Arylamines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) <i>N</i>-methylpiperazine, acetonitrile, 100 °C, 5 h, 70%; (ii) <i>N</i>-methylpiperazine, tetra-<i>n</i>-butyl ammonium iodide, DMSO, 80 °C, overnight, 65%; (iii) 10% Pd/C, NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O, rt, 4 h, 75%.</p></p></figure><figure data-id="fig1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0003.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Kinome inhibition map of compound <b>7x</b>: The kinases targeted by <b>7x</b> are indicated. Red circles represent kinases targeted below 20 nM. Yellow, amber, green, and blue circles represent kinases inhibited between 20–50, 50–100, 100–150, and 150–250 nM, respectively. The human kinome map is adapted with permission from Reaction Biology Corp. (<a href="http://reactionbiology.com" class="extLink">http://reactionbiology.com</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0004.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Model of <b>7x</b> binding to CDK6. Small molecule <b>7x</b> binding was predicted by docking and energy minimization using the X-ray crystal structure of CDK6–Vcyclin–PD-0332991 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2EUF">2EUF</a>) as a reference. Representations of the superimposition of X-ray crystal structure (CDK6/PD-0332991) and predicted lowest energy binding (CDK6/<b>7x</b>) were prepared using PyMOL. (A) Ribbon representation of CDK6 (green) bound to PD-0332991 (red) and <b>7x</b> (cyan). Small molecules are shown as sticks. (B,C) Close up view showing proximal residues of CDK6 to <b>7x</b> (blue) and PD-0332991 (pink), respectively. Hydrogen bonds are shown as a dotted back lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0005.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Inhibition of CDK4/cyclin D1 activity by <b>7x</b>: 10 ng of recombinant CDK4/cyclin D1 complex was incubated with the indicated concentrations of <b>7x</b>, flavopiridol (FP), or PD-0332991 for 30 min at room temperature. Kinase reactions were initiated by the addition of the substrate mixture (5 μM ATP, 10 μci γ<sup><sup>32</sup>P</sup>-ATP, 10 mM MgCl<sub>2</sub>, and 1 μg recombinant RB substrate) and incubated at 30 °C for 20 min. The reactions were terminated by the addition of 2× Laemmli sample buffer and heated at 95 °C for 3 min. Proteins were resolved by 12% SDS-PAGE and the resulting gel subjected to autoradiography. (B) <b>7x</b> inhibits RB phosphorylation at serine 780: An estrogen-dependent breast cancer cell line, MCF-7, and the triple negative (C) human breast carcinoma cell line, MDA-MB-231, were treated with increasing concentrations of <b>7x</b> or PD-0332991 (control) for 24 h. Western blot analysis was performed using antibodies directed against phosphorylated (Ser<sup>780</sup>) and nonphosphorylated forms of the retinoblastoma protein. Both <b>7x</b> and PD-0332991 inhibit RB phosphorylation at Ser<sup>780</sup>, a known substrate of CDK4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0006.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of <b>7x</b> on cell cycle progression: MCF-7 (A) and MDA-MB-231 (B) human breast carcinoma cell lines were treated with increasing concentrations of <b>7x</b> or PD-0332991 (control) for 24 h. The cells were then harvested, fixed, and stained with propidium iodide prior to flow cytometric analysis. The percentage of cells at each phase of the cell cycle was calculated and represented as % cells in each phase in the bar graph.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0007.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <b>7x</b> treatment induces apoptosis of breast carcinoma cell lines: MCF-7 (A) and MDA-MB-231 (B) human breast carcinoma cell lines were treated with increasing concentrations of <b>7x</b> or PD-0332991 (control) for 24 h. Total cell lysates were subjected to Western blot analysis using a PARP-specific antibody. The cleaved protein, which is expressed in <b>7x</b> treated cells, is indicative of apoptosis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0008.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <b>7x</b> treatment inhibits AKT phosphorylation: MDA-MB-231 human breast carcinoma cells were treated with increasing concentrations of <b>7x</b> or PD-0332991 or LY294002 (2-morpholino-8-phenyl-4<i>H</i>-chromen-4-one) (PI3Kinase inhibitor) for 24 h. Total cell lysates were subjected to Western blot analysis using antibodies directed against phosphorylated (Ser<sup>473</sup>) and nonphosphorylated forms of AKT. GAPDH was used as a loading control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/medium/jm-2013-01073p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0009.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo efficacy of <b>7x</b> against subcutaneous breast tumor xenografts: MDA-MB-231 cells were orthotopically implanted into the mammary fat pad of 6–8 week old female nude mice (<i>n</i> = 11 per group). Treatment was started when the average tumor volume reached 100 mm<sup>3</sup>. <b>7x</b> (lactate salt dissolved in PBS) or vehicle was administered intraperitoneally every other day (Q2D). Tumor volumes (A) and body weights (B) were recorded every 2 days. All values represent mean ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-3/jm401073p/20150114/images/large/jm-2013-01073p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401073p&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i162">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37454" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37454" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 58 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Cell cycle, CDKs and cancer: a changing paradigm</span> <span class="citation_source-journal">Nature Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1038%2Fnrc2602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=19238148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=153-166&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+cycle%2C+CDKs+and+cancer%3A+a+changing+paradigm"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle, CDKs and cancer: a changing paradigm</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity.  Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability.  According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumor cells.  However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells.  Emerging evidence suggests that tumor cells may also require specific interphase CDKs for proliferation.  Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlIKlbCPWnLVg90H21EOLACvtfcHk0ljPJE79M6nHTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D&md5=2a7eb34b2381e288b3f43ec1bffc0aec</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2602%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520cycle%252C%2520CDKs%2520and%2520cancer%253A%2520a%2520changing%2520paradigm%26jtitle%3DNature%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D153%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Graña, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=7624138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADyaK2MXnt1Oqurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1995&pages=211-219&author=X.+Gra%C3%B1aauthor=E.+P.+Reddy&title=Cell+cycle+control+in+mammalian+cells%3A+role+of+cyclins%2C+cyclin+dependent+kinases+%28CDKs%29%2C+growth+suppressor+genes+and+cyclin-dependent+kinase+inhibitors+%28CKIs%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)</span></div><div class="casAuthors">Grana, Xavier; Reddy, E. Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-19</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Scientific & Medical Division</span>)
        </div><div class="casAbstract">A review with >100 refs.  All eukaryotic cells possess similar mechanisms to regulate the progression of the cell cycle.  However, higher eukaryotes have evolved to respond to a large array of pos. and neg. signals with an intracellular or extracellular origin.  These signals are eventually integrated by a conserved protein engine consisting of holoenzymes with kinase activity, which trigger crucial transitions during the cell cycle.  The mechanisms by which the mammalian cell cycle engine integrates intracellular and extracellular signals of different nature are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf64gghjh7-7Vg90H21EOLACvtfcHk0ljPJE79M6nHTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnt1Oqurc%253D&md5=a7353df5118f195e4c5ec417c25bd4ef</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGra%25C3%25B1a%26aufirst%3DX.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DCell%2520cycle%2520control%2520in%2520mammalian%2520cells%253A%2520role%2520of%2520cyclins%252C%2520cyclin%2520dependent%2520kinases%2520%2528CDKs%2529%252C%2520growth%2520suppressor%2520genes%2520and%2520cyclin-dependent%2520kinase%2520inhibitors%2520%2528CKIs%2529%26jtitle%3DOncogene%26date%3D1995%26volume%3D11%26spage%3D211%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Hunter, T.</span><span> </span><span class="NLM_article-title">Oncoprotein networks</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">333</span><span class="NLM_x">–</span> <span class="NLM_lpage">346</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1997&pages=333-346&author=T.+Hunter&title=Oncoprotein+networks"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DT.%26atitle%3DOncoprotein%2520networks%26jtitle%3DCell%26date%3D1997%26volume%3D88%26spage%3D333%26epage%3D346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Morgan, D. O.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinases: engines, clocks, and microprocessors</span> <span class="citation_source-journal">Ann. Rev. Cell Dev. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">291</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1997&pages=261-291&author=D.+O.+Morgan&title=Cyclin-dependent+kinases%3A+engines%2C+clocks%2C+and+microprocessors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DD.%2BO.%26atitle%3DCyclin-dependent%2520kinases%253A%2520engines%252C%2520clocks%252C%2520and%2520microprocessors%26jtitle%3DAnn.%2520Rev.%2520Cell%2520Dev.%2520Biol.%26date%3D1997%26volume%3D13%26spage%3D261%26epage%3D291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">To cycle or not to cycle: a critical decision in cancer</span> <span class="citation_source-journal">Nature Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1038%2F35106065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=11902577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=222-231&author=M.+Malumbresauthor=M.+Barbacid&title=To+cycle+or+not+to+cycle%3A+a+critical+decision+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Milestones in cell division: to cycle or not to cycle: a critical decision in cancer</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">222-231</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor cells undergo uncontrolled proliferation, yet tumors most often originate from adult tissues, in which most cells are quiescent.  So, the proliferative advantage of tumor cells arises from their ability to bypass quiescence.  This can be due to increased mitogenic signaling and/or alterations that lower the threshold required for cell-cycle commitment.  Understanding the mol. mechanisms that underlie this commitment should provide important insights into how normal cells become tumorigenic and how new anticancer strategies can be devised.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI2EOLFB2ULbVg90H21EOLACvtfcHk0limVhYCAdT1Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D&md5=2bd8961854332a30c814f8ac2f9bd6f4</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2F35106065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35106065%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DTo%2520cycle%2520or%2520not%2520to%2520cycle%253A%2520a%2520critical%2520decision%2520in%2520cancer%26jtitle%3DNature%2520Rev.%2520Cancer%26date%3D2001%26volume%3D1%26spage%3D222%26epage%3D231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">CDK4 a key player in the cell cycle, development, and cancer</span> <span class="citation_source-journal">Genes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">658</span><span class="NLM_x">–</span> <span class="NLM_lpage">669</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1177%2F1947601913478972" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A280%3ADC%252BC3srpvV2isg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=658-669&author=S.+J.+Bakerauthor=E.+P.+Reddy&title=CDK4+a+key+player+in+the+cell+cycle%2C+development%2C+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">CDK4: A Key Player in the Cell Cycle, Development, and Cancer</span></div><div class="casAuthors">Baker Stacey J; Reddy E Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Genes & cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11-12</span>),
    <span class="NLM_cas:pages">658-69</span>
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    </div><div class="casAbstract">The cell cycle is regulated in part by cyclins and their associated serine/threonine cyclin-dependent kinases, or CDKs.  CDK4, in conjunction with the D-type cyclins, mediates progression through the G1 phase when the cell prepares to initiate DNA synthesis.  Although CDK4-null mutant mice are viable and cell proliferation is not significantly affected in vitro due to compensatory roles played by other CDKs, this gene plays a key role in mammalian development and cancer.  This review discusses the role that CDK4 plays in cell cycle control, normal development, and tumorigenesis as well as how small molecule inhibitors of CDK4 can be used to treat disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS_ZrSWKg0eOwvupmecNw_lfW6udTcc2ebF-wqYtMcdcbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srpvV2isg%253D%253D&md5=65557d394fc5184521ff0926d5b74c63</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1177%2F1947601913478972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601913478972%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DCDK4%2520a%2520key%2520player%2520in%2520the%2520cell%2520cycle%252C%2520development%252C%2520and%2520cancer%26jtitle%3DGenes%2520Cancer%26date%3D2012%26volume%3D3%26spage%3D658%26epage%3D669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Dyson, N.</span><span> </span><span class="NLM_article-title">The regulation of E2F by pRB-family proteins</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2245</span><span class="NLM_x">–</span> <span class="NLM_lpage">2262</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1101%2Fgad.12.15.2245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=9694791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADyaK1cXltlagu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1998&pages=2245-2262&author=N.+Dyson&title=The+regulation+of+E2F+by+pRB-family+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The regulation of E2F by pRB-family proteins</span></div><div class="casAuthors">Dyson, Nicholas</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2245-2262</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review with over 100 refs.  Topics include: Introduction to the families of E2F and DP proteins (free E2F, complexed E2F), E2F-binding sites mediate both transcriptional activation and repression (E2F as a transcriptional activator, E2F-mediated repression), Activation of E2F-dependent transcription (phosphorylation of pRB-family members, phosphorylation of E2F-1, changes in the subcellular localization of specific E2F complexes, synthesis of new E2Fs), Inactivation of E2F (E2F/DP phosphorylation, degrdn. of free E2F, E2F-repressors), Consequences of elevated E2F activity-ectopic S-phase entry and apoptosis, Is E2F required for S-phase entry, What are the key targets of E2F activity, What is the role of pRB in E2F regulation, Is the ability of pRB to bind E2F important for pRB's role as a tumor suppressor, and How can E2F-1 be both an oncogene and a tumor suppressor gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeXAl9aLvm5bVg90H21EOLACvtfcHk0limVhYCAdT1Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltlagu74%253D&md5=755af21d258487f59a09899698e860e8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1101%2Fgad.12.15.2245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.12.15.2245%26sid%3Dliteratum%253Aachs%26aulast%3DDyson%26aufirst%3DN.%26atitle%3DThe%2520regulation%2520of%2520E2F%2520by%2520pRB-family%2520proteins%26jtitle%3DGenes%2520Dev.%26date%3D1998%26volume%3D12%26spage%3D2245%26epage%3D2262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Harbour, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, D. C.</span><span> </span><span class="NLM_article-title">The Rb/E2F pathway: expanding roles and emerging paradigms</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2393</span><span class="NLM_x">–</span> <span class="NLM_lpage">2409</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1101%2Fgad.813200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=11018009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntlOqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2000&pages=2393-2409&author=J.+W.+Harbourauthor=D.+C.+Dean&title=The+Rb%2FE2F+pathway%3A+expanding+roles+and+emerging+paradigms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Rb/E2F pathway: expanding roles and emerging paradigms</span></div><div class="casAuthors">Harbour, J. William; Dean, Douglas C.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2393-2409</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_9N9_cVUlgLVg90H21EOLACvtfcHk0lhYzaFHuCXoMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntlOqtrc%253D&md5=c7d765e5eda00c9d1b31bc7dcbab255e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1101%2Fgad.813200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.813200%26sid%3Dliteratum%253Aachs%26aulast%3DHarbour%26aufirst%3DJ.%2BW.%26aulast%3DDean%26aufirst%3DD.%2BC.%26atitle%3DThe%2520Rb%252FE2F%2520pathway%253A%2520expanding%2520roles%2520and%2520emerging%2520paradigms%26jtitle%3DGenes%2520Dev.%26date%3D2000%26volume%3D14%26spage%3D2393%26epage%3D2409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Deshpande, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sicinski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinds, P. W.</span><span> </span><span class="NLM_article-title">Cyclins and cdks in development and cancer: a perspective</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2909</span><span class="NLM_x">–</span> <span class="NLM_lpage">2915</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=2909-2915&author=A.+Deshpandeauthor=P.+Sicinskiauthor=P.+W.+Hinds&title=Cyclins+and+cdks+in+development+and+cancer%3A+a+perspective"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDeshpande%26aufirst%3DA.%26aulast%3DSicinski%26aufirst%3DP.%26aulast%3DHinds%26aufirst%3DP.%2BW.%26atitle%3DCyclins%2520and%2520cdks%2520in%2520development%2520and%2520cancer%253A%2520a%2520perspective%26jtitle%3DOncogene%26date%3D2005%26volume%3D24%26spage%3D2909%26epage%3D2915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Graf, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosch, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wuest, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietzsch, J.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase 4/6 (Cdk4/6) inhibitors: perspectives in cancer therapy and imaging</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">527</span><span class="NLM_x">–</span> <span class="NLM_lpage">539</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=527-539&author=F.+Grafauthor=B.+Moschauthor=L.+Koehlerauthor=R.+Bergmannauthor=F.+Wuestauthor=J.+Pietzsch&title=Cyclin-dependent+kinase+4%2F6+%28Cdk4%2F6%29+inhibitors%3A+perspectives+in+cancer+therapy+and+imaging"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGraf%26aufirst%3DF.%26aulast%3DMosch%26aufirst%3DB.%26aulast%3DKoehler%26aufirst%3DL.%26aulast%3DBergmann%26aufirst%3DR.%26aulast%3DWuest%26aufirst%3DF.%26aulast%3DPietzsch%26aufirst%3DJ.%26atitle%3DCyclin-dependent%2520kinase%25204%252F6%2520%2528Cdk4%252F6%2529%2520inhibitors%253A%2520perspectives%2520in%2520cancer%2520therapy%2520and%2520imaging%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D527%26epage%3D539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Wolfel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wölfel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klehmann-Hieb, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Plaen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hankeln, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer zum Büschenfelde, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beach, D.</span><span> </span><span class="NLM_article-title">A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">269</span><span class="NLM_x">, </span> <span class="NLM_fpage">1281</span><span class="NLM_x">–</span> <span class="NLM_lpage">1284</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1995&pages=1281-1284&author=T.+Wolfelauthor=M.+Hauerauthor=J.+Schneiderauthor=M.+Serranoauthor=C.+W%C3%B6lfelauthor=E.+Klehmann-Hiebauthor=E.+De+Plaenauthor=T.+Hankelnauthor=K.+H.+Meyer+zum+B%C3%BCschenfeldeauthor=D.+Beach&title=A+p16INK4a-insensitive+CDK4+mutant+targeted+by+cytolytic+T+lymphocytes+in+a+human+melanoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWolfel%26aufirst%3DT.%26aulast%3DHauer%26aufirst%3DM.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DSerrano%26aufirst%3DM.%26aulast%3DW%25C3%25B6lfel%26aufirst%3DC.%26aulast%3DKlehmann-Hieb%26aufirst%3DE.%26aulast%3DDe%2BPlaen%26aufirst%3DE.%26aulast%3DHankeln%26aufirst%3DT.%26aulast%3DMeyer%2Bzum%2BB%25C3%25BCschenfelde%26aufirst%3DK.%2BH.%26aulast%3DBeach%26aufirst%3DD.%26atitle%3DA%2520p16INK4a-insensitive%2520CDK4%2520mutant%2520targeted%2520by%2520cytolytic%2520T%2520lymphocytes%2520in%2520a%2520human%2520melanoma%26jtitle%3DScience%26date%3D1995%26volume%3D269%26spage%3D1281%26epage%3D1284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Zuo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayward, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dracopoli, N. C.</span><span> </span><span class="NLM_article-title">Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma</span> <span class="citation_source-journal">Nature Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">99</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1038%2Fng0196-97" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=8528263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADyaK28XhsV2gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1996&pages=97-99&author=L.+Zuoauthor=J.+Wegerauthor=Q.+Yangauthor=A.+M.+Goldsteinauthor=M.+A.+Tuckerauthor=G.+J.+Walkerauthor=N.+Haywardauthor=N.+C.+Dracopoli&title=Germline+mutations+in+the+p16INK4a+binding+domain+of+CDK4+in+familial+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma</span></div><div class="casAuthors">Zuo, Lin; Weger, John; Yang, Qingbei; Goldstein, Alisa M.; Tucker, Margaret A.; Walker, Graeme J.; Hayward, Nicholas; Dracopoli, Nicholas C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-9</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">Protein complexes consisting of a cyclin-dependent kinase (CDK4 or CDK6) and cyclin D control passage through the G1 checkpoint of the cell cycle by phosphorylating the retinoblastoma (RB) protein.  The ability of these complexes to phosphorylate RB is inhibited by a family of low-mol.-wt. proteins including p16INK4a, p15INK4B, and p18.  Germline mutations in the p16INK4a gene have been identified in approx. half of families with hereditary melanoma.  In this report, the authors describe an Arg24Cys mutation in CDK4 in 2 unrelated melanoma families which do not carry germline p16INK4a mutations.  This mutation was detected in 11/11 melanoma patients, 2/17 unaffecteds and 0/5 spouses.  The CDK4-Arg24Cys substitution has previously been identified as a somatic mutation in a melanoma that gives rise to a tumor-specific antigen recognized by autologous cytolytic T lymphocytes.  This mutation has a specific effect on the p16INK4a-binding domain of CDK4, but has no effect on its ability to bind cyclin D and form a functional kinase.  Therefore, the germline Arg24Cys mutation in CDK4 generates a dominant oncogene that is resistant to normal physiol. inhibition by p16INK4a.  The only previous examples of a dominant oncogene transmitted in the human germline is the RET gene that gives rise to MEN2A and MEN2B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgtSe1fAjgOLVg90H21EOLACvtfcHk0lhYzaFHuCXoMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhsV2gsw%253D%253D&md5=a70b308ce2c07150c1417dca2b314a88</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fng0196-97&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng0196-97%26sid%3Dliteratum%253Aachs%26aulast%3DZuo%26aufirst%3DL.%26aulast%3DWeger%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DGoldstein%26aufirst%3DA.%2BM.%26aulast%3DTucker%26aufirst%3DM.%2BA.%26aulast%3DWalker%26aufirst%3DG.%2BJ.%26aulast%3DHayward%26aufirst%3DN.%26aulast%3DDracopoli%26aufirst%3DN.%2BC.%26atitle%3DGermline%2520mutations%2520in%2520the%2520p16INK4a%2520binding%2520domain%2520of%2520CDK4%2520in%2520familial%2520melanoma%26jtitle%3DNature%2520Genet.%26date%3D1996%26volume%3D12%26spage%3D97%26epage%3D99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Ortega, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Cyclin D-dependent kinases, INK4 inhibitors and cancer</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1602</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1602&publication_year=2002&pages=73-87&author=S.+Ortegaauthor=M.+Malumbresauthor=M.+Barbacid&title=Cyclin+D-dependent+kinases%2C+INK4+inhibitors+and+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOrtega%26aufirst%3DS.%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCyclin%2520D-dependent%2520kinases%252C%2520INK4%2520inhibitors%2520and%2520cancer%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2002%26volume%3D1602%26spage%3D73%26epage%3D87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Rane, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubus, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mettus, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galbreath, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boden, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia</span> <span class="citation_source-journal">Nature Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">44</span><span class="NLM_x">–</span> <span class="NLM_lpage">52</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1038%2F8751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=10319860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADyaK1MXjtVags7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1999&pages=44-52&author=S.+G.+Raneauthor=P.+D.+Dubusauthor=R.+V.+Mettusauthor=E.+J.+Galbreathauthor=G.+Bodenauthor=E.+P.+Reddyauthor=M.+Barbacid&title=Loss+of+Cdk4+expression+causes+insulin-deficient+diabetes+and+Cdk4+activation+results+in+beta-islet+cell+hyperplasia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia</span></div><div class="casAuthors">Rane, Sushil G.; Dubus, Pierre; Mettus, Richard V.; Galbreath, Elizabeth J.; Boden, Guenther; Reddy, E. Premkumar; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-52</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">To ascertain the role of cyclin-dependent kinase 4 (Cdk4) in vivo, the authors have targeted the mouse Cdk4 locus by homologous recombination to generate two strains of mice, one that lacks Cdk4 expression and one that expresses a Cdk4 mol. with an activating mutation.  Embryonic fibroblasts proliferate normally in the absence of Cdk4 but have a delayed S phase on re-entry into the cell cycle.  Moreover, mice devoid of Cdk4 are viable, but small in size and infertile.  These mice also develop insulin-deficient diabetes due to a redn. in β-islet pancreatic cells.  In contrast, mice expressing a mutant Cdk4 that cannot bind the cell-cycle inhibitor P16INK4a display pancreatic hyperplasia due to abnormal proliferation of β-islet cells.  These results establish Cdk4 as an essential regulator of specific cell types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofmhLD8YQB97Vg90H21EOLACvtfcHk0liHLdeJCQgIpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjtVags7o%253D&md5=82326fc337b7b1ddabf2cb0fcfd6c288</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2F8751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F8751%26sid%3Dliteratum%253Aachs%26aulast%3DRane%26aufirst%3DS.%2BG.%26aulast%3DDubus%26aufirst%3DP.%2BD.%26aulast%3DMettus%26aufirst%3DR.%2BV.%26aulast%3DGalbreath%26aufirst%3DE.%2BJ.%26aulast%3DBoden%26aufirst%3DG.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DLoss%2520of%2520Cdk4%2520expression%2520causes%2520insulin-deficient%2520diabetes%2520and%2520Cdk4%2520activation%2520results%2520in%2520beta-islet%2520cell%2520hyperplasia%26jtitle%3DNature%2520Genet.%26date%3D1999%26volume%3D22%26spage%3D44%26epage%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Tsutsui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesabi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moons, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandolfi, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansel, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyokawa, H.</span><span> </span><span class="NLM_article-title">Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">7011</span><span class="NLM_x">–</span> <span class="NLM_lpage">7019</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1128%2FMCB.19.10.7011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=10490638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADyaK1MXmtlals7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1999&pages=7011-7019&author=T.+Tsutsuiauthor=B.+Hesabiauthor=D.+S.+Moonsauthor=P.+P.+Pandolfiauthor=K.+S.+Hanselauthor=A.+Koffauthor=H.+Kiyokawa&title=Targeted+disruption+of+CDK4+delays+cell+cycle+entry+with+enhanced+p27%28Kip1%29+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted disruption of CDK4 delays cell cycle entry with enhanced p27Kip1 activity</span></div><div class="casAuthors">Tsutsui, Tateki; Hesabi, Bahar; Moons, David S.; Pandolfi, Pier Paolo; Hansel, Kimberly S.; Koff, Andrew; Kiyokawa, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">7011-7019</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The mechanism by which cyclin-dependent kinase 4 (CDK4) regulates cell cycle progression is not entirely clear.  Cyclin D/CDK4 appears to initiate phosphorylation of retinoblastoma protein (Rb) leading to inactivation of the S-phase-inhibitory action of Rb.  However, cyclin D/CDK4 has been postulated to act in a noncatalytic manner to regulate the cyclin E/CDK2-inhibitory activity of p27Kip1 by sequestration.  In this study we investigated the roles of CDK4 in cell cycle regulation by targeted disruption of the mouse CDK4 gene.  CDK4-/- mice survived embryogenesis and showed growth retardation and reproductive dysfunction assocd. with hypoplastic seminiferous tubules in the testis and perturbed corpus luteum formation in the ovary.  These phenotypes appear to be opposite to those of p27-deficient mice such as gigantism and gonadal hyperplasia.  A majority of CDK4-/- mice developed diabetes mellitus by 6 wk, assocd. with degeneration of pancreatic islets.  Fibroblasts from CDK4-/- mouse embryos proliferated similarly to wild-type embryonic fibroblasts under conditions that promote continuous growth.  However, quiescent CDK4-/- fibroblasts exhibited a substantial (∼6-h) delay in S-phase entry after serum stimulation.  This cell cycle perturbation by CDK4 disruption was assocd. with increased binding of p27 to cyclin E/CDK2 and diminished activation of CDK2 accompanied by impaired Rb phosphorylation.  Importantly, fibroblasts from CDK4-/- p27-/- embryos displayed partially restored kinetics of the G0-S transition, indicating the significance of the sequestration of p27 by CDK4.  These results suggest that at least part of CDK4's participation in the rate-limiting mechanism for the G0-S transition consists of controlling p27 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKIPUccGpY97Vg90H21EOLACvtfcHk0liHLdeJCQgIpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtlals7c%253D&md5=bba944ba00b313a19943eaa2acad2301</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FMCB.19.10.7011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.19.10.7011%26sid%3Dliteratum%253Aachs%26aulast%3DTsutsui%26aufirst%3DT.%26aulast%3DHesabi%26aufirst%3DB.%26aulast%3DMoons%26aufirst%3DD.%2BS.%26aulast%3DPandolfi%26aufirst%3DP.%2BP.%26aulast%3DHansel%26aufirst%3DK.%2BS.%26aulast%3DKoff%26aufirst%3DA.%26aulast%3DKiyokawa%26aufirst%3DH.%26atitle%3DTargeted%2520disruption%2520of%2520CDK4%2520delays%2520cell%2520cycle%2520entry%2520with%2520enhanced%2520p27%2528Kip1%2529%2520activity%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1999%26volume%3D19%26spage%3D7011%26epage%3D7019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Reddy, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mettus, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rane, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graña, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litvin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">10174</span><span class="NLM_x">–</span> <span class="NLM_lpage">10178</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=10174-10178&author=H.+K.+Reddyauthor=R.+V.+Mettusauthor=S.+G.+Raneauthor=X.+Gra%C3%B1aauthor=J.+Litvinauthor=E.+P.+Reddy&title=Cyclin-dependent+kinase+4+expression+is+essential+for+neu-induced+breast+tumorigenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DH.%2BK.%26aulast%3DMettus%26aufirst%3DR.%2BV.%26aulast%3DRane%26aufirst%3DS.%2BG.%26aulast%3DGra%25C3%25B1a%26aufirst%3DX.%26aulast%3DLitvin%26aufirst%3DJ.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DCyclin-dependent%2520kinase%25204%2520expression%2520is%2520essential%2520for%2520neu-induced%2520breast%2520tumorigenesis%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D10174%26epage%3D10178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Reddy, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graña, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhanasekaran, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litvin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">Requirement of Cdk4 for v-Haras-induced breast tumorigenesis and activation of the v-ras-induced senescence program by the R24C mutation</span> <span class="citation_source-journal">Genes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="NLM_x">–</span> <span class="NLM_lpage">80</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1177%2F1947601909358105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2ntrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=69-80&author=H.+K.+Reddyauthor=X.+Gra%C3%B1aauthor=D.+N.+Dhanasekaranauthor=J.+Litvinauthor=E.+P.+Reddy&title=Requirement+of+Cdk4+for+v-Haras-induced+breast+tumorigenesis+and+activation+of+the+v-ras-induced+senescence+program+by+the+R24C+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of Cdk4 for v-Ha-ras-induced breast tumorigenesis and activation of the v-ras-induced senescence program by the R24C mutation</span></div><div class="casAuthors">Reddy, Haritha K. D. L.; Grana, Xavier; Dhanasekaran, Danny N.; Litvin, Judith; Reddy, E. Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-80</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Activating mutations in CDK4 and inactivation of its key kinase inhibitor, p16INK4A, have been implicated in the genesis and progression of human cancer.  Previous work has demonstrated that CDK4 expression is required for Neu-induced but not Wnt-induced breast tumorigenesis in mice.  However, the role that CDK4 plays in ras-mediated breast tumor development is not well defined.  To gain an understanding of the role of Cdk4 in ras-induced breast tumorigenesis, MMTV-v-Ha-ras transgenic mice were bred with Cdk4(+/neo) and Cdk4(R24C/R24C) mice to generate Cdk4(neo/neo):MMTV-v-Ha-ras, Cdk4(+/+):MMTV-v-Ha-ras, and Cdk4(R24C/R24C):MMTV-v-Ha-ras mice.  The studies presented here demonstrate that Cdk4 expression is essential for Ras-mediated breast tumorigenesis.  Surprisingly, the results also show that coexpression of mutant ras and Cdk4R24C genes in breast epithelial cells leads to an activation of senescent pathways that delay tumorigenesis.  Anal. of the phosphorylated form of H2AX, a marker for DNA damage, indicated its increased presence in the tumors of Cdk4(R24C/R24C):MMTV-v-Ha-ras mice.  These observations indicate that the increased apoptosis and senescence seen in breast tumors of these mice might be due to increased DNA damage response in cells expressing activated forms of ras and Cdk4(R24C).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7V2yZK4gh57Vg90H21EOLACvtfcHk0lhca8RJhItU7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2ntrzK&md5=99b0727e7e6e99178521bafe4fd0774e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1177%2F1947601909358105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601909358105%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DH.%2BK.%26aulast%3DGra%25C3%25B1a%26aufirst%3DX.%26aulast%3DDhanasekaran%26aufirst%3DD.%2BN.%26aulast%3DLitvin%26aufirst%3DJ.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DRequirement%2520of%2520Cdk4%2520for%2520v-Haras-induced%2520breast%2520tumorigenesis%2520and%2520activation%2520of%2520the%2520v-ras-induced%2520senescence%2520program%2520by%2520the%2520R24C%2520mutation%26jtitle%3DGenes%2520Cancer%26date%3D2010%26volume%3D1%26spage%3D69%26epage%3D80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Carlson, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubay, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brizuela, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worland, P. J.</span><span> </span><span class="NLM_article-title">Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2973</span><span class="NLM_x">–</span> <span class="NLM_lpage">2978</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1996&pages=2973-2978&author=B.+A.+Carlsonauthor=M.+M.+Dubayauthor=E.+A.+Sausvilleauthor=L.+Brizuelaauthor=P.+J.+Worland&title=Flavopiridol+induces+G1+arrest+with+inhibition+of+cyclin-dependent+kinase+%28CDK%29+2+and+CDK4+in+human+breast+carcinoma+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarlson%26aufirst%3DB.%2BA.%26aulast%3DDubay%26aufirst%3DM.%2BM.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DBrizuela%26aufirst%3DL.%26aulast%3DWorland%26aufirst%3DP.%2BJ.%26atitle%3DFlavopiridol%2520induces%2520G1%2520arrest%2520with%2520inhibition%2520of%2520cyclin-dependent%2520kinase%2520%2528CDK%2529%25202%2520and%2520CDK4%2520in%2520human%2520breast%2520carcinoma%2520cells%26jtitle%3DCancer%2520Res.%26date%3D1996%26volume%3D56%26spage%3D2973%26epage%3D2978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">McClue, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKenzie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melville, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhelev, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheleva, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, D. P.</span><span> </span><span class="NLM_article-title">In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">468</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1002%2Fijc.10738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=12432547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVOksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2002&pages=463-468&author=S.+J.+McClueauthor=D.+Blakeauthor=R.+Clarkeauthor=A.+Cowanauthor=L.+Cummingsauthor=P.+M.+Fischerauthor=M.+MacKenzieauthor=J.+Melvilleauthor=K.+Stewartauthor=S.+Wangauthor=N.+Zhelevauthor=D.+Zhelevaauthor=D.+P.+Lane&title=In+vitro+and+in+vivo+antitumor+properties+of+the+cyclin+dependent+kinase+inhibitor+CYC202+%28R-roscovitine%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)</span></div><div class="casAuthors">McClue, Steven J.; Blake, David; Clarke, Rosemary; Cowan, Angela; Cummings, Lorna; Fischer, Peter M.; MacKenzie, Mairi; Melville, Jean; Stewart, Kevin; Wang, Shudong; Zhelev, Nikolai; Zheleva, Daniella; Lane, David P.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">463-468</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">CDK2 inhibitors have been proposed as effective anti-cancer therapeutics.  We show here that CYC202 (R-roscovitine) is a potent inhibitor of recombinant CDK2/cyclin E kinase activity (IC50 = 0.10 μM) with an av. cytotoxic IC50 of 15.2 μM in a panel of 19 human tumor cell lines, and we also demonstrate selectivity for rapidly proliferating cells over non-proliferating cells.  A study of the cell cycle effects of CYC202 in Lovo colorectal carcinoma cells showed that the major effect was not the predicted arrest in one part of the cycle, but rather an induction of cell death from all compartments of the cell cycle.  The max. tolerated dose given i.v. to mice was in excess of 20 mg/kg.  Doses up to 2,000 mg/kg were tolerated when administered orally in mice.  Following repeated i.p. administration (3 times daily for 5 days) of 100 mg/kg to nude mice bearing the Lovo human colorectal tumor, CYC202 induced a significant antitumor effect with a 45% redn. in tumor growth compared to controls.  A second expt. using the human uterine xenograft MESSA-DX5 treated with orally administered CYC202 (500 mg/kg 3 times daily for 4 days) also exhibited a significant redn. in the rate of growth of the tumor (62%).  These data, showing enzyme and cellular potency together with antitumor activity, confirm the potential of CDK2 inhibitors such as CYC202 as anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrekWf0QH861LVg90H21EOLACvtfcHk0lhca8RJhItU7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVOksL4%253D&md5=bf8ed57667ec566b9cc11c27158f6b8b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fijc.10738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10738%26sid%3Dliteratum%253Aachs%26aulast%3DMcClue%26aufirst%3DS.%2BJ.%26aulast%3DBlake%26aufirst%3DD.%26aulast%3DClarke%26aufirst%3DR.%26aulast%3DCowan%26aufirst%3DA.%26aulast%3DCummings%26aufirst%3DL.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DMacKenzie%26aufirst%3DM.%26aulast%3DMelville%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DZhelev%26aufirst%3DN.%26aulast%3DZheleva%26aufirst%3DD.%26aulast%3DLane%26aufirst%3DD.%2BP.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520properties%2520of%2520the%2520cyclin%2520dependent%2520kinase%2520inhibitor%2520CYC202%2520%2528R-roscovitine%2529%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2002%26volume%3D102%26spage%3D463%26epage%3D468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Ullah, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depamphilis, M. L.</span><span> </span><span class="NLM_article-title">Cip/Kip cyclin-dependent protein kinase inhibitors and the road to polyploidy</span> <span class="citation_source-journal">Cell Div.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1186%2F1747-1028-4-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=19490616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A280%3ADC%252BD1MvitlKguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=10&author=Z.+Ullahauthor=C.+Y.+Leeauthor=M.+L.+Depamphilis&title=Cip%2FKip+cyclin-dependent+protein+kinase+inhibitors+and+the+road+to+polyploidy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Cip/Kip cyclin-dependent protein kinase inhibitors and the road to polyploidy</span></div><div class="casAuthors">Ullah Zakir; Lee Chrissie Y; Depamphilis Melvin L</div><div class="citationInfo"><span class="NLM_cas:title">Cell division</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) play a central role in the orderly transition from one phase of the eukaryotic mitotic cell division cycle to the next.  In this context, p27Kip1 (one of the CIP/KIP family of CDK specific inhibitors in mammals) or its functional analogue in other eukarya prevents a premature transition from G1 to S-phase.  Recent studies have revealed that expression of a second member of this family, p57Kip2, is induced as trophoblast stem (TS) cells differentiate into trophoblast giant (TG) cells. p57 then inhibits CDK1 activity, an enzyme essential for initiating mitosis, thereby triggering genome endoreduplication (multiple S-phases without an intervening mitosis).  Expression of p21Cip1, the third member of this family, is also induced in during differentiation of TS cells into TG cells where it appears to play a role in suppressing the DNA damage response pathway.  Given the fact that p21 and p57 are unique to mammals, the question arises as to whether one or both of these proteins are responsible for the induction and maintenance of polyploidy during mammalian development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTIj5fhXJz7BpPlX7E30qdzfW6udTcc2ebbAmeElDKgWrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvitlKguw%253D%253D&md5=489ca67ae8539a587a6d9e6b82e0bce7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1186%2F1747-1028-4-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1747-1028-4-10%26sid%3Dliteratum%253Aachs%26aulast%3DUllah%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DC.%2BY.%26aulast%3DDepamphilis%26aufirst%3DM.%2BL.%26atitle%3DCip%252FKip%2520cyclin-dependent%2520protein%2520kinase%2520inhibitors%2520and%2520the%2520road%2520to%2520polyploidy%26jtitle%3DCell%2520Div.%26date%3D2009%26volume%3D4%26spage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Musgrove, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldon, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barraclough, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, R. L.</span><span> </span><span class="NLM_article-title">Cyclin D as a therapeutic target in cancer</span> <span class="citation_source-journal">Nature Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">558</span><span class="NLM_x">–</span> <span class="NLM_lpage">572</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1038%2Fnrc3090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=21734724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Srsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=558-572&author=E.+A.+Musgroveauthor=C.+E.+Caldonauthor=J.+Barracloughauthor=A.+Stoneauthor=R.+L.+Sutherland&title=Cyclin+D+as+a+therapeutic+target+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin D as a therapeutic target in cancer</span></div><div class="casAuthors">Musgrove, Elizabeth A.; Caldon, C. Elizabeth; Barraclough, Jane; Stone, Andrew; Sutherland, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">558-572</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression.  The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target.  Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofR_LZiUkU-LVg90H21EOLACvtfcHk0lhp0KRa8Ui3xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Srsr0%253D&md5=1bc2dcea427c5650263a5438ecddb5f9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnrc3090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3090%26sid%3Dliteratum%253Aachs%26aulast%3DMusgrove%26aufirst%3DE.%2BA.%26aulast%3DCaldon%26aufirst%3DC.%2BE.%26aulast%3DBarraclough%26aufirst%3DJ.%26aulast%3DStone%26aufirst%3DA.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26atitle%3DCyclin%2520D%2520as%2520a%2520therapeutic%2520target%2520in%2520cancer%26jtitle%3DNature%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D558%26epage%3D572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Lapenna, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, A.</span><span> </span><span class="NLM_article-title">Cell cycle kinases as therapeutic targets for cancer</span> <span class="citation_source-journal">Nature Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">547</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=547-566&author=S.+Lapennaauthor=A.+Giordano&title=Cell+cycle+kinases+as+therapeutic+targets+for+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLapenna%26aufirst%3DS.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DCell%2520cycle%2520kinases%2520as%2520therapeutic%2520targets%2520for%2520cancer%26jtitle%3DNature%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D547%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Shapiro, G. I.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase pathways as targets for cancer treatment</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1770</span><span class="NLM_x">–</span> <span class="NLM_lpage">1783</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1200%2FJCO.2005.03.7689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=16603719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD28XksVKgtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=1770-1783&author=G.+I.+Shapiro&title=Cyclin-dependent+kinase+pathways+as+targets+for+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase pathways as targets for cancer treatment</span></div><div class="casAuthors">Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1770-1783</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Cyclin-dependent kinases (cdks) are crit. regulators of cell cycle progression and RNA transcription.  A variety of genetic and epigenetic events cause universal overactivity of the cell cycle cdks in human cancer, and their inhibition can lead to both cell cycle arrest and apoptosis.  However, built-in redundancy may limit the effects of highly selective cdk inhibition.  Cdk4/6 inhibition has been shown to induce potent G1 arrest in vitro and tumor regression in vivo; cdk2/1 inhibition has the most potent effects during the S and G2 phases and induces E2F transcription factor-dependent cell death.  Modulation of cdk2 and cdk1 activities also affects survival checkpoint responses after exposure to DNA-damaging and microtubule-stabilizing agents.  The transcriptional cdks phosphorylate the carboxy-terminal domain of RNA polymerase II, facilitating efficient transcriptional initiation and elongation.  Inhibition of these cdks primarily affects the accumulation of transcripts with short half-lives, including those encoding antiapoptosis family members, cell cycle regulators, as well as p53 and nuclear factor-kappa B-responsive gene targets.  These effects may account for apoptosis induced by cdk9 inhibitors, esp. in malignant hematopoietic cells, and may also potentiate cytotoxicity mediated by disruption of a variety of pathways in many transformed cell types.  Current work is focusing on overcoming pharmacokinetic barriers that hindered development of flavopiridol, a pan-cdk inhibitor, as well as assessing novel classes of compds. potently targeting groups of cell cycle cdks (cdk4/6 or cdk2/1) with variable effects on the transcriptional cdks 7 and 9.  These efforts will establish whether the strategy of cdk inhibition is able to produce therapeutic benefit in the majority of human tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYfmCpSfvpTbVg90H21EOLACvtfcHk0lhp0KRa8Ui3xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksVKgtbg%253D&md5=420a31b47f6600625f7d499a4b8a5fc9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.03.7689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.03.7689%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DCyclin-dependent%2520kinase%2520pathways%2520as%2520targets%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D1770%26epage%3D1783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Lane, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pestell, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadler, S.</span><span> </span><span class="NLM_article-title">A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells</span> <span class="citation_source-journal">Canccer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">6170</span><span class="NLM_x">–</span> <span class="NLM_lpage">6177</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=11507069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmt12ktb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=6170-6177&author=M.+E.+Laneauthor=B.+Yuauthor=A.+Riceauthor=K.+E.+Lipsonauthor=C.+Liangauthor=L.+Sunauthor=C.+Tangauthor=G.+McMahonauthor=R.+G.+Pestellauthor=S.+Wadler&title=A+novel+cdk2-selective+inhibitor%2C+SU9516%2C+induces+apoptosis+in+colon+carcinoma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells</span></div><div class="casAuthors">Lane, Maureen E.; Yu, Bo; Rice, Audie; Lipson, Kenneth E.; Liang, Chris; Sun, Li; Tang, Cho; McMahon, Gerald; Pestell, Richard G.; Wadler, Scott</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6170-6177</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recent studies have indicated that the development of cyclin-dependent kinase (cdk)2 inhibitors that deregulate E2F are a plausible pharmacol. strategy for novel antineoplastic agents.  We show here that 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516), a novel 3-substituted indolinone compd., binds to and selectively inhibits the activity of cdk2.  This inhibition results in a time-dependent decrease (4-64%) in the phosphorylation of the retinoblastoma protein pRb, an increase in caspase-3 activation (5-84%), and alterations in cell cycle resulting in either a G0-G1 or a G2-M block.  We also report here cell line differences in the cdk-dependent phosphorylation of pRb.  These findings demonstrate that SU9516 is a selective cdk2 inhibitor and support the theory that compds. that inhibit cdk2 are viable resources in the development of new antineoplastic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq1CWPe7DjeLVg90H21EOLACvtfcHk0liiUltOKHkO3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmt12ktb0%253D&md5=ff3d0978c0b5a7d4f0188ef05a13b96a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DM.%2BE.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DRice%26aufirst%3DA.%26aulast%3DLipson%26aufirst%3DK.%2BE.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DPestell%26aufirst%3DR.%2BG.%26aulast%3DWadler%26aufirst%3DS.%26atitle%3DA%2520novel%2520cdk2-selective%2520inhibitor%252C%2520SU9516%252C%2520induces%2520apoptosis%2520in%2520colon%2520carcinoma%2520cells%26jtitle%3DCanccer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D6170%26epage%3D6177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Soni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zumstein-Mecker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fretz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhuri, B.</span><span> </span><span class="NLM_article-title">Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">436</span><span class="NLM_x">–</span> <span class="NLM_lpage">446</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1093%2Fjnci%2F93.6.436" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=11259469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXislCrtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2001&pages=436-446&author=R.+Soniauthor=T.+O%E2%80%99Reillyauthor=P.+Furetauthor=L.+Mullerauthor=C.+Stephanauthor=S.+Zumstein-Meckerauthor=H.+Fretzauthor=D.+Fabbroauthor=B.+Chaudhuri&title=Selective+in+vivo+and+in+vitro+effects+of+a+small+molecule+inhibitor+of+cyclin-dependent+kinase+4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4</span></div><div class="casAuthors">Soni, Rajeev; O'Reilly, Terence; Furet, Pascal; Muller, Lionel; Stephan, Christine; Zumstein-Mecker, Sabine; Fretz, Heinz; Fabbro, Doriano; Chaudhuri, Bhabatosh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">436-446</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Cyclin-dependent kinase 4 (Cdk4) represents a prime target for the treatment of cancer because most human cancers are characterized by overexpression of its activating partner cyclin D1, loss of the natural Cdk4-specific inhibitor p16, or mutation(s) in Cdk4's catalytic subunit.  All of these can cause deregulated cell growth, resulting in tumor formation.  We sought to identify a small mol. that could inhibit the kinase activity of Cdk4 in vitro and to then ascertain the effects of that inhibitor on cell growth and tumor vol. in vivo.  Methods: A triaminopyrimidine deriv., CINK4 (a chem. inhibitor of Cdk4), was identified by screening for compds. that could inhibit Cdk4 enzyme activity in vitro.  Kinase assays were performed on diverse human Cdks and on other kinases that were expressed in and purified from insect cells to det. the specificity of CINK4.  Cell cycle effects of CINK4 on tumor and normal cells were studied by flow cytometry, and changes in phosphorylation of the retinoblastoma protein (pRb), a substrate of Cdk4, were detd. by western blotting.  The effect of the inhibitor on tumor growth in vivo was studied by use of tumors established through xenografts of HCT116 colon carcinoma cells in mice.  Statistical tests were two-sided.  Results: CINK4 specifically inhibited Cdk4/cyclin D1 in vitro.  It caused growth arrest in tumor cells and in normal cells and prevented pRb phosphorylation.  CINK4 treatment resulted in statistically significantly (P = .031) smaller mean tumor vols. in a mouse xenograft model.  Conclusions: Like p16, the natural inhibitor of Cdk4, CINK4 inhibits Cdk4 activity in vitro and slows tumor growth in vivo.  The specificity of CINK4 for Cdk4 raises the possibility that this small mol. or one with a similar structure could have therapeutic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoISmjFVy7B9rVg90H21EOLACvtfcHk0liiUltOKHkO3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXislCrtLg%253D&md5=86345a46a2992af68c9dd22fc2e39efe</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F93.6.436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F93.6.436%26sid%3Dliteratum%253Aachs%26aulast%3DSoni%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DT.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DMuller%26aufirst%3DL.%26aulast%3DStephan%26aufirst%3DC.%26aulast%3DZumstein-Mecker%26aufirst%3DS.%26aulast%3DFretz%26aufirst%3DH.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DChaudhuri%26aufirst%3DB.%26atitle%3DSelective%2520in%2520vivo%2520and%2520in%2520vitro%2520effects%2520of%2520a%2520small%2520molecule%2520inhibitor%2520of%2520cyclin-dependent%2520kinase%25204%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2001%26volume%3D93%26spage%3D436%26epage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Honma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayaski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukasawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">wama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeura, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikuta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki-Takahashi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwasawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morishima, H.</span><span> </span><span class="NLM_article-title">Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: New de Novo Design Strategy and Library Design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">4615</span><span class="NLM_x">–</span> <span class="NLM_lpage">4627</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0103256" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXovFagtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=4615-4627&author=T.+Honmaauthor=K.+Hayaskiauthor=T.+Aoyamaauthor=N.+Hashimotoauthor=T.+Machidaauthor=K.+Fukasawaauthor=T.+wamaauthor=C.+Ikeuraauthor=M.+Ikutaauthor=I.+Suzuki-Takahashiauthor=Y.+Iwasawaauthor=T.+Hayamaauthor=S.+Nishimuraauthor=H.+Morishima&title=Structure-Based+Generation+of+a+New+Class+of+Potent+Cdk4+Inhibitors%3A+New+de+Novo+Design+Strategy+and+Library+Design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: New de Novo Design Strategy and Library Design</span></div><div class="casAuthors">Honma, Teruki; Hayashi, Kyoko; Aoyama, Tetsuya; Hashimoto, Noriaki; Machida, Takumitsu; Fukasawa, Kazuhiro; Iwama, Toshiharu; Ikeura, Chinatsu; Ikuta, Mari; Suzuki-Takahashi, Ikuko; Iwasawa, Yoshikazu; Hayama, Takashi; Nishimura, Susumu; Morishima, Hajime</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">4615-4627</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As a first step in structure-based design of highly selective and potent Cdk4 inhibitors, we performed structure-based generation of a novel series of Cdk4 inhibitors.  A Cdk4 homol. model was constructed according to x-ray anal. of an activated form of Cdk2.  Using this model, we applied a new de novo design strategy which combined the de novo design program LEGEND with our inhouse structure selection supporting system SEEDS to generate new scaffold candidates.  In this way, four classes of scaffold candidates including diarylurea were identified.  By constructing diarylurea informer libraries based on the structural requirements of Cdk inhibitors in the ATP binding pocket of the Cdk4 model, we were able to identify a potent Cdk4 inhibitor N-(9-oxo-9H-fluoren-4-yl)-N'-pyridin-2-ylurea (I) with IC50 = 0.10 μM, together with preliminary SAR.  We performed a docking study between I and the Cdk4 model and selected a reasonable binding mode which is consistent with the SAR.  Further modification based on the proposed binding mode provided a more potent compd., N-[(9bR)-5-oxo- 2,3,5,9b-tetrahydro-1H-pyrrolo[2,1-a]isoindol-9-yl]-N'-pyridin-2-ylurea (II) with IC50 = 0.042 μM, x-ray anal. of which was accomplished by the soaking method.  The predicted binding mode of I in Cdk4 was validated by x-ray anal. of the Cdk2-II complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvx3J3Bqyg9LVg90H21EOLACvtfcHk0lgTVwOoVDa5NA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXovFagtrs%253D&md5=0c4458fa88d41c148a672863b3a6daa0</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1021%2Fjm0103256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0103256%26sid%3Dliteratum%253Aachs%26aulast%3DHonma%26aufirst%3DT.%26aulast%3DHayaski%26aufirst%3DK.%26aulast%3DAoyama%26aufirst%3DT.%26aulast%3DHashimoto%26aufirst%3DN.%26aulast%3DMachida%26aufirst%3DT.%26aulast%3DFukasawa%26aufirst%3DK.%26aulast%3Dwama%26aufirst%3DT.%26aulast%3DIkeura%26aufirst%3DC.%26aulast%3DIkuta%26aufirst%3DM.%26aulast%3DSuzuki-Takahashi%26aufirst%3DI.%26aulast%3DIwasawa%26aufirst%3DY.%26aulast%3DHayama%26aufirst%3DT.%26aulast%3DNishimura%26aufirst%3DS.%26aulast%3DMorishima%26aufirst%3DH.%26atitle%3DStructure-Based%2520Generation%2520of%2520a%2520New%2520Class%2520of%2520Potent%2520Cdk4%2520Inhibitors%253A%2520New%2520de%2520Novo%2520Design%2520Strategy%2520and%2520Library%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D4615%26epage%3D4627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Honma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshizumi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawanishi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukasawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeura, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikuta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki-Takahashi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morishima, H.</span><span> </span><span class="NLM_article-title">A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">4628</span><span class="NLM_x">–</span> <span class="NLM_lpage">4640</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm010326y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=4628-4640&author=T.+Honmaauthor=T.+Yoshizumiauthor=N.+Hashimotoauthor=K.+Hayashiauthor=N.+Kawanishiauthor=K.+Fukasawaauthor=T.+Takakiauthor=C.+Ikeuraauthor=M.+Ikutaauthor=I.+Suzuki-Takahashiauthor=T.+Hayamaauthor=S.+Nishimuraauthor=H.+Morishima&title=A+novel+approach+for+the+development+of+selective+Cdk4+inhibitors%3A+library+design+based+on+locations+of+Cdk4+specific+amino+acid+residues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1021%2Fjm010326y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010326y%26sid%3Dliteratum%253Aachs%26aulast%3DHonma%26aufirst%3DT.%26aulast%3DYoshizumi%26aufirst%3DT.%26aulast%3DHashimoto%26aufirst%3DN.%26aulast%3DHayashi%26aufirst%3DK.%26aulast%3DKawanishi%26aufirst%3DN.%26aulast%3DFukasawa%26aufirst%3DK.%26aulast%3DTakaki%26aufirst%3DT.%26aulast%3DIkeura%26aufirst%3DC.%26aulast%3DIkuta%26aufirst%3DM.%26aulast%3DSuzuki-Takahashi%26aufirst%3DI.%26aulast%3DHayama%26aufirst%3DT.%26aulast%3DNishimura%26aufirst%3DS.%26aulast%3DMorishima%26aufirst%3DH.%26atitle%3DA%2520novel%2520approach%2520for%2520the%2520development%2520of%2520selective%2520Cdk4%2520inhibitors%253A%2520library%2520design%2520based%2520on%2520locations%2520of%2520Cdk4%2520specific%2520amino%2520acid%2520residues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D4628%26epage%3D4640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Verdaguer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordà, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canudas, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiménez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sureda, F. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimbau, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pubill, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escubedo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camarasa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallàs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camins, A.</span><span> </span><span class="NLM_article-title">3-Amino thioacridone, a selective cyclin-dependent kinase 4 inhibitor, attenuates kainic acid-induced apoptosis in neurons</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">599</span><span class="NLM_x">–</span> <span class="NLM_lpage">603</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2003&pages=599-603&author=E.+Verdaguerauthor=E.+G.+Jord%C3%A0author=A.+M.+Canudasauthor=A.+Jim%C3%A9nezauthor=F.+X.+Suredaauthor=V.+Rimbauauthor=D.+Pubillauthor=E.+Escubedoauthor=J.+Camarasaauthor=M.+Pall%C3%A0sauthor=A.+Camins&title=3-Amino+thioacridone%2C+a+selective+cyclin-dependent+kinase+4+inhibitor%2C+attenuates+kainic+acid-induced+apoptosis+in+neurons"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerdaguer%26aufirst%3DE.%26aulast%3DJord%25C3%25A0%26aufirst%3DE.%2BG.%26aulast%3DCanudas%26aufirst%3DA.%2BM.%26aulast%3DJim%25C3%25A9nez%26aufirst%3DA.%26aulast%3DSureda%26aufirst%3DF.%2BX.%26aulast%3DRimbau%26aufirst%3DV.%26aulast%3DPubill%26aufirst%3DD.%26aulast%3DEscubedo%26aufirst%3DE.%26aulast%3DCamarasa%26aufirst%3DJ.%26aulast%3DPall%25C3%25A0s%26aufirst%3DM.%26aulast%3DCamins%26aufirst%3DA.%26atitle%3D3-Amino%2520thioacridone%252C%2520a%2520selective%2520cyclin-dependent%2520kinase%25204%2520inhibitor%252C%2520attenuates%2520kainic%2520acid-induced%2520apoptosis%2520in%2520neurons%26jtitle%3DNeuroscience%26date%3D2003%26volume%3D120%26spage%3D599%26epage%3D603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Misra, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawlins, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, S. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bednarz, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellar, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulheron, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batorsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roongta, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranadive, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavletich, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimball, S. D.</span><span> </span><span class="NLM_article-title"><i>N</i>-(Cycloalkylmino) acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. <i>N</i>-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1719</span><span class="NLM_x">–</span> <span class="NLM_lpage">1728</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0305568" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1719-1728&author=R.+N.+Misraauthor=H.+Xiaoauthor=K.+S.+Kimauthor=S.+Luauthor=W.-C.+Hanauthor=S.+A.+Barbosaauthor=J.+T.+Huntauthor=D.+B.+Rawlinsauthor=W.+Shanauthor=S.+Z.+Ahmedauthor=L.+Qianauthor=B.-C.+Chenauthor=R.+Zhaoauthor=M.+S.+Bednarzauthor=K.+A.+Kellarauthor=J.+G.+Mulheronauthor=R.+Batorskyauthor=U.+Roongtaauthor=A.+Kamathauthor=P.+Maratheauthor=S.+A.+Ranadiveauthor=J.+S.+Sackauthor=J.+S.+Tokarskiauthor=N.+P.+Pavletichauthor=F.+Y.+F.+Leeauthor=K.+R.+Websterauthor=S.+D.+Kimball&title=N-%28Cycloalkylmino%29+acyl-2-aminothiazole+Inhibitors+of+Cyclin-Dependent+Kinase+2.+N-%5B5-%5B%5B%5B5-%281%2C1-Dimethylethyl%29-2-oxazolyl%5Dmethyl%5Dthio%5D-2-thiazolyl%5D-4-piperidinecarboxamide+%28BMS-387032%29%2C+a+Highly+Efficacious+and+Selective+Antitumor+Agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm0305568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0305568%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DR.%2BN.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DW.-C.%26aulast%3DBarbosa%26aufirst%3DS.%2BA.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DRawlins%26aufirst%3DD.%2BB.%26aulast%3DShan%26aufirst%3DW.%26aulast%3DAhmed%26aufirst%3DS.%2BZ.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DB.-C.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DBednarz%26aufirst%3DM.%2BS.%26aulast%3DKellar%26aufirst%3DK.%2BA.%26aulast%3DMulheron%26aufirst%3DJ.%2BG.%26aulast%3DBatorsky%26aufirst%3DR.%26aulast%3DRoongta%26aufirst%3DU.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DRanadive%26aufirst%3DS.%2BA.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26aulast%3DLee%26aufirst%3DF.%2BY.%2BF.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26aulast%3DKimball%26aufirst%3DS.%2BD.%26atitle%3DN-%2528Cycloalkylmino%2529%2520acyl-2-aminothiazole%2520Inhibitors%2520of%2520Cyclin-Dependent%2520Kinase%25202.%2520N-%255B5-%255B%255B%255B5-%25281%252C1-Dimethylethyl%2529-2-oxazolyl%255Dmethyl%255Dthio%255D-2-thiazolyl%255D-4-piperidinecarboxamide%2520%2528BMS-387032%2529%252C%2520a%2520Highly%2520Efficacious%2520and%2520Selective%2520Antitumor%2520Agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1719%26epage%3D1728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Zhu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conner, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Considine, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dempsey, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faul, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teicher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, S. A.</span><span> </span><span class="NLM_article-title">Synthesis, structure–activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2027</span><span class="NLM_x">–</span> <span class="NLM_lpage">2030</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0256169" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=2027-2030&author=G.+Zhuauthor=S.+E.+Connerauthor=X.+Zhouauthor=C.+Shihauthor=T.+Liauthor=B.+D.+Andersonauthor=H.+B.+Brooksauthor=R.+M.+Campbellauthor=E.+Considineauthor=J.+A.+Dempseyauthor=M.+M.+Faulauthor=C.+Oggauthor=B.+Patelauthor=R.+M.+Schultzauthor=C.+D.+Spencerauthor=B.+Teicherauthor=S.+A.+Watkins&title=Synthesis%2C+structure%E2%80%93activity+relationship%2C+and+biological+studies+of+indolocarbazoles+as+potent+cyclin+D1-CDK4+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm0256169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0256169%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DG.%26aulast%3DConner%26aufirst%3DS.%2BE.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DAnderson%26aufirst%3DB.%2BD.%26aulast%3DBrooks%26aufirst%3DH.%2BB.%26aulast%3DCampbell%26aufirst%3DR.%2BM.%26aulast%3DConsidine%26aufirst%3DE.%26aulast%3DDempsey%26aufirst%3DJ.%2BA.%26aulast%3DFaul%26aufirst%3DM.%2BM.%26aulast%3DOgg%26aufirst%3DC.%26aulast%3DPatel%26aufirst%3DB.%26aulast%3DSchultz%26aufirst%3DR.%2BM.%26aulast%3DSpencer%26aufirst%3DC.%2BD.%26aulast%3DTeicher%26aufirst%3DB.%26aulast%3DWatkins%26aufirst%3DS.%2BA.%26atitle%3DSynthesis%252C%2520structure%25E2%2580%2593activity%2520relationship%252C%2520and%2520biological%2520studies%2520of%2520indolocarbazoles%2520as%2520potent%2520cyclin%2520D1-CDK4%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D2027%26epage%3D2030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Toogood, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repine, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanderWel, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodfuehrer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barvian, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2388</span><span class="NLM_x">–</span> <span class="NLM_lpage">2406</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049354h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2388-2406&author=P.+L.+Toogoodauthor=P.+J.+Harveyauthor=J.+T.+Repineauthor=D.+J.+Sheehanauthor=S.+N.+VanderWelauthor=H.+Zhouauthor=P.+R.+Kellerauthor=D.+J.+McNamaraauthor=D.+Sherryauthor=T.+Zhuauthor=J.+Brodfuehrerauthor=C.+Choiauthor=M.+R.+Barvianauthor=D.+W.+Fry&title=Discovery+of+a+potent+and+selective+inhibitor+of+cyclin-dependent+kinase+4%2F6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6</span></div><div class="casAuthors">Toogood, Peter L.; Harvey, Patricia J.; Repine, Joseph T.; Sheehan, Derek J.; VanderWel, Scott N.; Zhou, Hairong; Keller, Paul R.; McNamara, Dennis J.; Sherry, Debra; Zhu, Tong; Brodfuehrer, Joanne; Choi, Chung; Barvian, Mark R.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2388-2406</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pharmacol. approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small mol. inhibitors has the potential to provide novel cancer therapies for clin. use.  Achieving high levels of selectivity for Cdk4/6, vs. other ATP-dependent kinases, presents a significant challenge.  The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks.  It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro.  This selectivity profile is recapitulated in cells where the most selective inhibitors create a G1 block at concns. up to 100-fold the IC50 for cell proliferation.  On the basis of its selectivity profile and pharmacokinetic profile, compd. I (PD 0332991) was identified as a drug candidate for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX577J5U0r97Vg90H21EOLACvtfcHk0li_mHHIn13mFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D&md5=23cbe58426ff1975695712db7c1b128a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm049354h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049354h%26sid%3Dliteratum%253Aachs%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DSheehan%26aufirst%3DD.%2BJ.%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DSherry%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinase%25204%252F6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2388%26epage%3D2406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Saab, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bills, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miceli, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khoury, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navid, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skapek, S. X.</span><span> </span><span class="NLM_article-title">Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1299</span><span class="NLM_x">–</span> <span class="NLM_lpage">1308</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1158%2F1535-7163.MCT-05-0383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=16731763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD28XltVWms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1299-1308&author=R.+Saabauthor=J.+L.+Billsauthor=A.+P.+Miceliauthor=C.+M.+Andersonauthor=J.+D.+Khouryauthor=D.+W.+Fryauthor=F.+Navidauthor=P.+J.+Houghtonauthor=S.+X.+Skapek&title=Pharmacologic+inhibition+of+cyclin-dependent+kinase+4%2F6+activity+arrests+proliferation+in+myoblasts+and+rhabdomyosarcoma-derived+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells</span></div><div class="casAuthors">Saab, Raya; Bills, Jennifer L.; Miceli, Alexander P.; Anderson, Colleen M.; Khoury, Joseph D.; Fry, David W.; Navid, Fariba; Houghton, Peter J.; Skapek, Stephen X.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1299-1308</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Myoblast cell cycle exit and differentiation are mediated in part by down-regulation of cyclin D1 and assocd. cyclin-dependent kinase (Cdk) activity.  Because rhabdomyosarcoma may represent a malignant tumor composed of myoblast-like cells failing to exit the cell cycle and differentiate, we considered whether excess Cdk activity might contribute to this biol.  Cyclin D-dependent Cdk4 and Cdk6 were expressed in most of a panel of six human rhabdomyosarcoma-derived cell lines.  Cdk4 was expressed in 73% of alveolar and embryonal rhabdomyosarcoma tumors evaluated using a human tissue microarray.  When challenged to differentiate by mitogen deprivation in vitro, mouse C2C12 myoblasts arrested in G1 phase of the cell cycle, whereas four in the panel of rhabdomyosarcoma cell lines failed to do so.  C2C12 myoblasts maintained in mitogen-rich media and exposed to a Cdk4/Cdk6 inhibitor PD 0332991 accumulated in G1 cell cycle phase.  Similar treatment of rhabdomyosarcoma cell lines caused G1 arrest and prevented cell accumulation in vitro, and it delayed growth of rhabdomyosarcoma xenografts in vivo.  Consistent with a role for Cdk4/Cdk6 activity as a regulator of myogenic differentiation, we obsd. that PD 0332991 exposure promoted morphol. changes and enhanced the expression of muscle-specific proteins in cultured myoblasts and in the Rh30 cell line.  Our findings support the concept that pharmacol. inhibition of Cdk4/Cdk6 may represent a useful therapeutic strategy to control cell proliferation and possibly promote myogenic differentiation in rhabdomyosarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA6GrUsfwUtbVg90H21EOLACvtfcHk0lickNoJ1Yrzyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltVWms7s%253D&md5=7c94eb30156f3f61be900b5fd2dc8b4a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0383%26sid%3Dliteratum%253Aachs%26aulast%3DSaab%26aufirst%3DR.%26aulast%3DBills%26aufirst%3DJ.%2BL.%26aulast%3DMiceli%26aufirst%3DA.%2BP.%26aulast%3DAnderson%26aufirst%3DC.%2BM.%26aulast%3DKhoury%26aufirst%3DJ.%2BD.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DNavid%26aufirst%3DF.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26aulast%3DSkapek%26aufirst%3DS.%2BX.%26atitle%3DPharmacologic%2520inhibition%2520of%2520cyclin-dependent%2520kinase%25204%252F6%2520activity%2520arrests%2520proliferation%2520in%2520myoblasts%2520and%2520rhabdomyosarcoma-derived%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1299%26epage%3D1308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Baughn, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Liberto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toogood, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottschalk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niesvizky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ely, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen-Kiang, S.</span><span> </span><span class="NLM_article-title">A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">7661</span><span class="NLM_x">–</span> <span class="NLM_lpage">7667</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=7661-7667&author=L.+B.+Baughnauthor=M.+Di+Libertoauthor=K.+Wuauthor=P.+L.+Toogoodauthor=T.+Louieauthor=R.+Gottschalkauthor=R.+Niesvizkyauthor=H.+Choauthor=S.+Elyauthor=M.+A.+Mooreauthor=S.+Chen-Kiang&title=A+novel+orally+active+small+molecule+potently+induces+G1+arrest+in+primary+myeloma+cells+and+prevents+tumor+growth+by+specific+inhibition+of+cyclin-dependent+kinase+4%2F6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaughn%26aufirst%3DL.%2BB.%26aulast%3DDi%2BLiberto%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DLouie%26aufirst%3DT.%26aulast%3DGottschalk%26aufirst%3DR.%26aulast%3DNiesvizky%26aufirst%3DR.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DEly%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DM.%2BA.%26aulast%3DChen-Kiang%26aufirst%3DS.%26atitle%3DA%2520novel%2520orally%2520active%2520small%2520molecule%2520potently%2520induces%2520G1%2520arrest%2520in%2520primary%2520myeloma%2520cells%2520and%2520prevents%2520tumor%2520growth%2520by%2520specific%2520inhibition%2520of%2520cyclin-dependent%2520kinase%25204%252F6%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D7661%26epage%3D7667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedford, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fattaey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span> </span><span class="NLM_article-title">Cell cycle and biochemical effects of PD 0183812: a potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">16617</span><span class="NLM_x">–</span> <span class="NLM_lpage">16623</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=16617-16623&author=D.+W.+Fryauthor=D.+C.+Bedfordauthor=P.+H.+Harveyauthor=A.+Fritschauthor=P.+R.+Kellerauthor=Z.+Wuauthor=E.+Dobrusinauthor=W.+R.+Leopoldauthor=A.+Fattaeyauthor=M.+D.+Garrett&title=Cell+cycle+and+biochemical+effects+of+PD+0183812%3A+a+potent+inhibitor+of+the+cyclin+D-dependent+kinases+CDK4+and+CDK6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DBedford%26aufirst%3DD.%2BC.%26aulast%3DHarvey%26aufirst%3DP.%2BH.%26aulast%3DFritsch%26aufirst%3DA.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DDobrusin%26aufirst%3DE.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DFattaey%26aufirst%3DA.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26atitle%3DCell%2520cycle%2520and%2520biochemical%2520effects%2520of%2520PD%25200183812%253A%2520a%2520potent%2520inhibitor%2520of%2520the%2520cyclin%2520D-dependent%2520kinases%2520CDK4%2520and%2520CDK6%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D16617%26epage%3D16623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Marzec, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasprzycka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gladden, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wlodarski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomczak, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deprimo, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuster, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasik, M. A.</span><span> </span><span class="NLM_article-title">Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">1744</span><span class="NLM_x">–</span> <span class="NLM_lpage">1750</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=1744-1750&author=M.+Marzecauthor=M.+Kasprzyckaauthor=R.+Laiauthor=A.+B.+Gladdenauthor=P.+Wlodarskiauthor=E.+Tomczakauthor=P.+Nowellauthor=S.+E.+Deprimoauthor=S.+Sadisauthor=S.+Eckauthor=S.+J.+Schusterauthor=J.+A.+Diehlauthor=M.+A.+Wasik&title=Mantle+cell+lymphoma+cells+express+predominantly+cyclin+D1a+isoform+and+are+highly+sensitive+to+selective+inhibition+of+CDK4+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarzec%26aufirst%3DM.%26aulast%3DKasprzycka%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DR.%26aulast%3DGladden%26aufirst%3DA.%2BB.%26aulast%3DWlodarski%26aufirst%3DP.%26aulast%3DTomczak%26aufirst%3DE.%26aulast%3DNowell%26aufirst%3DP.%26aulast%3DDeprimo%26aufirst%3DS.%2BE.%26aulast%3DSadis%26aufirst%3DS.%26aulast%3DEck%26aufirst%3DS.%26aulast%3DSchuster%26aufirst%3DS.%2BJ.%26aulast%3DDiehl%26aufirst%3DJ.%2BA.%26aulast%3DWasik%26aufirst%3DM.%2BA.%26atitle%3DMantle%2520cell%2520lymphoma%2520cells%2520express%2520predominantly%2520cyclin%2520D1a%2520isoform%2520and%2520are%2520highly%2520sensitive%2520to%2520selective%2520inhibition%2520of%2520CDK4%2520kinase%2520activity%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D1744%26epage%3D1750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dering, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalous, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginther, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atefi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fowst, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span> </span><span class="NLM_article-title">PD-0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro</span> <span class="citation_source-journal">Breast Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">R77</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=R77&author=R.+S.+Finnauthor=J.+Deringauthor=D.+Conklinauthor=O.+Kalousauthor=D.+J.+Cohenauthor=A.+J.+Desaiauthor=C.+Gintherauthor=M.+Atefiauthor=I.+Chenauthor=C.+Fowstauthor=G.+Losauthor=D.+J.+Slamon&title=PD-0332991%2C+a+selective+cyclin+D+kinase+4%2F6+inhibitor%2C+preferentially+inhibits+proliferation+of+luminal+estrogen+receptor-positive+human+breast+cancer+cell+lines+in+vitro"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DDering%26aufirst%3DJ.%26aulast%3DConklin%26aufirst%3DD.%26aulast%3DKalous%26aufirst%3DO.%26aulast%3DCohen%26aufirst%3DD.%2BJ.%26aulast%3DDesai%26aufirst%3DA.%2BJ.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DAtefi%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DFowst%26aufirst%3DC.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26atitle%3DPD-0332991%252C%2520a%2520selective%2520cyclin%2520D%2520kinase%25204%252F6%2520inhibitor%252C%2520preferentially%2520inhibits%2520proliferation%2520of%2520luminal%2520estrogen%2520receptor-positive%2520human%2520breast%2520cancer%2520cell%2520lines%2520in%2520vitro%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2009%26volume%3D11%26spage%3DR77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Michaud, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oermann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, W. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prados, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldman, T.</span><span> </span><span class="NLM_article-title">Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">3228</span><span class="NLM_x">–</span> <span class="NLM_lpage">3238</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=3228-3238&author=K.+Michaudauthor=D.+A.+Solomonauthor=E.+Oermannauthor=J.+S.+Kimauthor=W.+Z.+Zhongauthor=M.+D.+Pradosauthor=T.+Ozawaauthor=C.+D.+Jamesauthor=T.+Waldman&title=Pharmacologic+inhibition+of+cyclin-dependent+kinases+4+and+6+arrests+the+growth+of+glioblastoma+multiforme+intracranial+xenografts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMichaud%26aufirst%3DK.%26aulast%3DSolomon%26aufirst%3DD.%2BA.%26aulast%3DOermann%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DJ.%2BS.%26aulast%3DZhong%26aufirst%3DW.%2BZ.%26aulast%3DPrados%26aufirst%3DM.%2BD.%26aulast%3DOzawa%26aufirst%3DT.%26aulast%3DJames%26aufirst%3DC.%2BD.%26aulast%3DWaldman%26aufirst%3DT.%26atitle%3DPharmacologic%2520inhibition%2520of%2520cyclin-dependent%2520kinases%25204%2520and%25206%2520arrests%2520the%2520growth%2520of%2520glioblastoma%2520multiforme%2520intracranial%2520xenografts%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D3228%26epage%3D3238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Wiedemeyer, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, I. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quayle, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chheda, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbluh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, L.</span><span> </span><span class="NLM_article-title">Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci.U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">11501</span><span class="NLM_x">–</span> <span class="NLM_lpage">11506</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=11501-11506&author=W.+R.+Wiedemeyerauthor=I.+F.+Dunnauthor=S.+N.+Quayleauthor=J.+Zhangauthor=M.+G.+Chhedaauthor=G.+P.+Dunnauthor=L.+Zhuangauthor=J.+Rosenbluhauthor=S.+Chenauthor=Y.+Xiaoauthor=G.+I.+Shapiroauthor=W.+C.+Hahnauthor=L.+Chin&title=Pattern+of+retinoblastoma+pathway+inactivation+dictates+response+to+CDK4%2F6+inhibition+in+GBM"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWiedemeyer%26aufirst%3DW.%2BR.%26aulast%3DDunn%26aufirst%3DI.%2BF.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DChheda%26aufirst%3DM.%2BG.%26aulast%3DDunn%26aufirst%3DG.%2BP.%26aulast%3DZhuang%26aufirst%3DL.%26aulast%3DRosenbluh%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DChin%26aufirst%3DL.%26atitle%3DPattern%2520of%2520retinoblastoma%2520pathway%2520inactivation%2520dictates%2520response%2520to%2520CDK4%252F6%2520inhibition%2520in%2520GBM%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D11501%26epage%3D11506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Konecny, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winterhoff, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolarova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manivong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dering, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalukya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalli, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginther, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velculescu, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riehle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cliby, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randolph, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span> </span><span class="NLM_article-title">Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1591</span><span class="NLM_x">–</span> <span class="NLM_lpage">1602</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1158%2F1078-0432.CCR-10-2307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=21278246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFChtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=1591-1602&author=G.+E.+Konecnyauthor=B.+Winterhoffauthor=T.+Kolarovaauthor=J.+Qiauthor=K.+Manivongauthor=J.+Deringauthor=G.+Yangauthor=M.+Chalukyaauthor=H.+J.+Wangauthor=L.+Andersonauthor=K.+R.+Kalliauthor=R.+S.+Finnauthor=C.+Gintherauthor=S.+Jonesauthor=V.+E.+Velculescuauthor=D.+Riehleauthor=W.+A.+Clibyauthor=S.+Randolphauthor=M.+Koehlerauthor=L.+C.+Hartmannauthor=D.+J.+Slamon&title=Expression+of+p16+and+retinoblastoma+determines+response+to+CDK4%2F6+inhibition+in+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer</span></div><div class="casAuthors">Konecny, Gottfried E.; Winterhoff, Boris; Kolarova, Teodora; Qi, Jingwei; Manivong, Kanthinh; Dering, Judy; Yang, Guorong; Chalukya, Meenal; Wang, He-Jing; Anderson, Lee; Kalli, Kimberly R.; Finn, Richard S.; Ginther, Charles; Jones, Sian; Velculescu, Victor E.; Riehle, Darren; Cliby, William A.; Randolph, Sophia; Koehler, Maria; Hartmann, Lynn C.; Slamon, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1591-1602</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PD-0332991 is a selective inhibitor of the CDK4/6 kinases with the ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range.  Here we investigate the role of CDK4/6 inhibition in human ovarian cancer.  We examd. the effects of PD-0332991 on proliferation, cell-cycle, apoptosis, and Rb phosphorylation using a panel of 40 established human ovarian cancer cell lines.  Mol. markers for response prediction, including p16 and Rb, were studied using gene expression profiling, Western blot, and array CGH.  Multiple drug effect anal. was used to study interactions with chemotherapeutic drugs.  Expression of p16 and Rb was studied using immunohistochem. in a large clin. cohort of ovarian cancer patients.  Concn.-dependent antiproliferative effects of PD-0332991 were seen in all ovarian cancer cell lines, but varied significantly between individual lines.  Rb-proficient cell lines with low p16 expression were most responsive to CDK4/6 inhibition.  Copy no. variations of CDKN2A, RB, CCNE1, and CCND1 were assocd. with response to PD-0332991.  CDK4/6 inhibition induced G0/G1 cell cycle arrest, blocked Rb phosphorylation in a concn.-and time-dependent manner, and enhanced the effects of chemotherapy.  Rb-proficiency with low p16 expression was seen in 97/262 (37%) of ovarian cancer patients and was independently assocd. with poor progression-free survival (adjusted relative risk 1.49, 95% CI 1.00-2.24, P = 0.052).  PD-0332991 shows promising biol. activity in ovarian cancer cell lines.  Assessment of Rb and p16 expression may help select patients most likely to benefit from CDK4/6 inhibition in ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyvDPdFFMnq7Vg90H21EOLACvtfcHk0ljcXr4wiFv-1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFChtrc%253D&md5=fc343bf876b690b1904d5955a7b8ba9b</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-2307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-2307%26sid%3Dliteratum%253Aachs%26aulast%3DKonecny%26aufirst%3DG.%2BE.%26aulast%3DWinterhoff%26aufirst%3DB.%26aulast%3DKolarova%26aufirst%3DT.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DManivong%26aufirst%3DK.%26aulast%3DDering%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DChalukya%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DH.%2BJ.%26aulast%3DAnderson%26aufirst%3DL.%26aulast%3DKalli%26aufirst%3DK.%2BR.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DVelculescu%26aufirst%3DV.%2BE.%26aulast%3DRiehle%26aufirst%3DD.%26aulast%3DCliby%26aufirst%3DW.%2BA.%26aulast%3DRandolph%26aufirst%3DS.%26aulast%3DKoehler%26aufirst%3DM.%26aulast%3DHartmann%26aufirst%3DL.%2BC.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26atitle%3DExpression%2520of%2520p16%2520and%2520retinoblastoma%2520determines%2520response%2520to%2520CDK4%252F6%2520inhibition%2520in%2520ovarian%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D1591%26epage%3D1602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMichele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dial, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courtney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">wilner, K. D</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, G. K.</span><span> </span><span class="NLM_article-title">A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">18S</span><span class="NLM_x">) </span> <span class="NLM_fpage">150S</span><div class="note"><p class="first last">(Suppl Abst-3550)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=150S&issue=18S&author=P.+J.+O%E2%80%99Dwyerauthor=P.+LoRussoauthor=A.+DeMicheleauthor=V.+Guptaauthor=A.+Barbiauthor=H.+Dialauthor=I.+Chenauthor=R.+Courtneyauthor=K.+D+wilnerauthor=G.+K.+Schwartz&title=A+phase+I+dose+escalation+trial+of+a+daily+oral+CDK+4%2F6+inhibitor+PD-0332991"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DDeMichele%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DBarbi%26aufirst%3DA.%26aulast%3DDial%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DCourtney%26aufirst%3DR.%26aulast%3Dwilner%26aufirst%3DK.%2BD%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DA%2520phase%2520I%2520dose%2520escalation%2520trial%2520of%2520a%2520daily%2520oral%2520CDK%25204%252F6%2520inhibitor%2520PD-0332991%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2007%26volume%3D25%26issue%3D18S%26spage%3D150S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Schwartz, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randolph, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaik, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courtney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span> </span><span class="NLM_article-title">Phase I study of PD-0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (schedule 2/1)</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">1862</span><span class="NLM_x">–</span> <span class="NLM_lpage">1868</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1038%2Fbjc.2011.177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=21610706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntV2hsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2011&pages=1862-1868&author=G.+K.+Schwartzauthor=P.+M.+LoRussoauthor=M.+A.+Dicksonauthor=S.+S.+Randolphauthor=M.+N.+Shaikauthor=K.+D.+Wilnerauthor=R.+Courtneyauthor=P.+J.+O%E2%80%99Dwyer&title=Phase+I+study+of+PD-0332991%2C+a+cyclin-dependent+kinase+inhibitor%2C+administered+in+3-week+cycles+%28schedule+2%2F1%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)</span></div><div class="casAuthors">Schwartz, G. K.; LoRusso, P. M.; Dickson, M. A.; Randolph, S. S.; Shaik, M. N.; Wilner, K. D.; Courtney, R.; O'Dwyer, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1862-1868</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: This phase I, open-label, first-in-human study detd. dose-limiting toxicities (DLTs) and max. tolerated dose (MTD) of PD 0332991, an oral cyclin-dependent kinase 4/6 inhibitor with potent anti-proliferative activity in vitro/vivo.  Methods: A total of 33 patients with retinoblastoma protein-pos. advanced solid tumors or non-Hodgkin's lymphoma refractory to std. therapy or for which no therapy was available received PD 0332991 once daily (QD) for 14 days followed by 7 days off treatment (21-day cycles; Schedule 2/1).  Results: Six patients had DLTs (18%; four receiving 200 mg QD; two receiving 225 mg QD); the MTD was 200 mg QD.  Treatment-related, non-haematol. adverse events occurred in 29 patients (88%) during cycle 1 and 27 patients (82%) thereafter.  Adverse events were generally mild-moderate.  Of 31 evaluable patients, one with testicular cancer achieved a partial response; nine had stable disease (≥10 cycles in three cases).  PD 0332991 was slowly absorbed (mean Tmax 4.2 h) and eliminated (mean half-life 26.7 h).  Vol. of distribution was large (mean 3241 l) with dose-proportional exposure.  Using a max. effective concn. model, neutropenia was proportional to exposure.  Conclusion: PD 0332991 was generally well tolerated, with DLTs related mainly to myelosuppression.  The MTD, 200 mg QD, is recommended for phase II study.  British Journal of Cancer (2011) 104, 1862-1868; doi:10.1038/bjc.2011.177 www.bjcancer.com Published online 24 May 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrirHusdI7VjLVg90H21EOLACvtfcHk0ljm-4yUKRVAkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntV2hsLc%253D&md5=5ff27f8f2d06282f567f4e5ed81c554c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2011.177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2011.177%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DDickson%26aufirst%3DM.%2BA.%26aulast%3DRandolph%26aufirst%3DS.%2BS.%26aulast%3DShaik%26aufirst%3DM.%2BN.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DCourtney%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26atitle%3DPhase%2520I%2520study%2520of%2520PD-0332991%252C%2520a%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520administered%2520in%25203-week%2520cycles%2520%2528schedule%25202%252F1%2529%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2011%26volume%3D104%26spage%3D1862%26epage%3D1868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Leonard, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaCasce, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallabhajosula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoder, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">English, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millenson, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ely, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courtney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaik, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randolph, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Abbeele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen-Kiang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D. Yap, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span> </span><span class="NLM_article-title">Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">4597</span><span class="NLM_x">–</span> <span class="NLM_lpage">4607</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=4597-4607&author=J.+P.+Leonardauthor=A.+S.+LaCasceauthor=M.+R.+Smithauthor=A.+Noyauthor=L.+R.+Chirieacauthor=S.+J.+Rodigauthor=J.+Q.+Yuauthor=S.+Vallabhajosulaauthor=H.+Schoderauthor=P.+Englishauthor=D.+S.+Neubergauthor=P.+Martinauthor=M.+M.+Millensonauthor=S.+A.+Elyauthor=R.+Courtneyauthor=N.+Shaikauthor=K.+D.+Wilnerauthor=S.+Randolphauthor=A.+Van+den+Abbeeleauthor=S.+Y.+Chen-Kiangauthor=J.+T.+D.+Yapauthor=G.+I.+Shapiro&title=Selective+CDK4%2F6+inhibition+with+tumor+responses+by+PD0332991+in+patients+with+mantle+cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeonard%26aufirst%3DJ.%2BP.%26aulast%3DLaCasce%26aufirst%3DA.%2BS.%26aulast%3DSmith%26aufirst%3DM.%2BR.%26aulast%3DNoy%26aufirst%3DA.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DYu%26aufirst%3DJ.%2BQ.%26aulast%3DVallabhajosula%26aufirst%3DS.%26aulast%3DSchoder%26aufirst%3DH.%26aulast%3DEnglish%26aufirst%3DP.%26aulast%3DNeuberg%26aufirst%3DD.%2BS.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DMillenson%26aufirst%3DM.%2BM.%26aulast%3DEly%26aufirst%3DS.%2BA.%26aulast%3DCourtney%26aufirst%3DR.%26aulast%3DShaik%26aufirst%3DN.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DRandolph%26aufirst%3DS.%26aulast%3DVan%2Bden%2BAbbeele%26aufirst%3DA.%26aulast%3DChen-Kiang%26aufirst%3DS.%2BY.%26aulast%3DD.%2BYap%26aufirst%3DJ.%2BT.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DSelective%2520CDK4%252F6%2520inhibition%2520with%2520tumor%2520responses%2520by%2520PD0332991%2520in%2520patients%2520with%2520mantle%2520cell%2520lymphoma%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D4597%26epage%3D4607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMichele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abramson, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Courtney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randolph, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaik, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, G. K.</span><span> </span><span class="NLM_article-title">Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD0332991, administered using a 21-day schedule in patients with advanced cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">568</span><span class="NLM_x">–</span> <span class="NLM_lpage">576</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1158%2F1078-0432.CCR-11-0509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=22090362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGqs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=568-576&author=K.+T.+Flahertyauthor=P.+M.+Lorussoauthor=A.+DeMicheleauthor=V.+G.+Abramsonauthor=R.+Courtneyauthor=S.+S.+Randolphauthor=M.+N.+Shaikauthor=K.+D.+Wilnerauthor=P.+J.+O%E2%80%99Dwyerauthor=G.+K.+Schwartz&title=Phase+I%2C+dose-escalation+trial+of+the+oral+cyclin-dependent+kinase+4%2F6+inhibitor+PD0332991%2C+administered+using+a+21-day+schedule+in+patients+with+advanced+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer</span></div><div class="casAuthors">Flaherty, Keith T.; LoRusso, Patricia M.; DeMichele, Angela; Abramson, Vandana G.; Courtney, Rachel; Randolph, Sophia S.; Shaik, M. Naveed; Wilner, Keith D.; O'Dwyer, Peter J.; Schwartz, Gary K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">568-576</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: To identify the dose-limiting toxicity (DLT) and max. tolerated dose (MTD) of the first-in-class, oral CDK4/6 inhibitor PD 0332991 administered once daily for 21 of 28 days (3/1 schedule) in patients with retinoblastoma protein (Rb)-pos. advanced solid tumors and to describe pharmacokinetic-pharmacodynamic relationships relative to drug effects.  Exptl. Design: This open-label phase I study (NCT00141297) enrolled patients who received PD 0332991 orally in six dose-escalation cohorts in a std. 3 + 3 design.  RESULTS: Forty-one patients were enrolled.  DLTs were obsd. in five patients (12%) overall; at the 75, 125, and 150 mg once daily dose levels.  The MTD and recommended phase II dose of PD 0332991 was 125 mg once daily.  Neutropenia was the only dose-limiting effect.  After cycle 1, grade 3 neutropenia, anemia, and leukopenia occurred in five (12%), three (7%), and one (2%) patient(s), resp.  The most common non-hematol. adverse events included fatigue, nausea, and diarrhea.  Thirty-seven patients were evaluable for tumor response; 10 (27%) had stable disease for ≥4 cycles of whom six derived prolonged benefit (≥10 cycles).  PD 0332991 was slowly absorbed (median Tmax, 5.5 h), and slowly eliminated (mean half-life was 25.9 h) with a large vol. of distribution (mean, 2,793 L).  The area under the concn.-time curve increased linearly with dose.  Using an Emax model, neutropenia was shown to be proportional to exposure.  CONCLUSIONS: PD 0332991 warrants phase II testing at 125 mg once daily, at which dose neutropenia was the sole significant toxicity.  Clin Cancer Res; 18(2); 568-76.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol_DEqpY-ThbVg90H21EOLACvtfcHk0ljm-4yUKRVAkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGqs7o%253D&md5=027179d720f67961711b87861cf8cbf2</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0509%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DLorusso%26aufirst%3DP.%2BM.%26aulast%3DDeMichele%26aufirst%3DA.%26aulast%3DAbramson%26aufirst%3DV.%2BG.%26aulast%3DCourtney%26aufirst%3DR.%26aulast%3DRandolph%26aufirst%3DS.%2BS.%26aulast%3DShaik%26aufirst%3DM.%2BN.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DPhase%2520I%252C%2520dose-escalation%2520trial%2520of%2520the%2520oral%2520cyclin-dependent%2520kinase%25204%252F6%2520inhibitor%2520PD0332991%252C%2520administered%2520using%2520a%252021-day%2520schedule%2520in%2520patients%2520with%2520advanced%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D568%26epage%3D576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Niesvizky, R.; Ely, S.; Jayabalan, D. S.; Manco, M.; Singhal, S.; Crann, M.; Courtney, R.; DuFresne, C.; Wilner, K.; Chen, I.; Mark, T.; Leonard, J. P.; Coleman, M.; DiLiberto, M.; Huang, X.; Chen-Kiang, S. A; Phase, I.</span><span> </span><span class="NLM_article-title">Trial of PD-0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma</span>. <span class="NLM_conf-name">51st American Society of Hematology Meeting</span>, <span class="NLM_conf-loc">New Orleans, LA</span>, <span class="NLM_conf-date">December 5–8, 2009</span>,  <span class="NLM_fpage">Abst 1877</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Niesvizky%2C+R.%3B+Ely%2C+S.%3B+Jayabalan%2C+D.+S.%3B+Manco%2C+M.%3B+Singhal%2C+S.%3B+Crann%2C+M.%3B+Courtney%2C+R.%3B+DuFresne%2C+C.%3B+Wilner%2C+K.%3B+Chen%2C+I.%3B+Mark%2C+T.%3B+Leonard%2C+J.+P.%3B+Coleman%2C+M.%3B+DiLiberto%2C+M.%3B+Huang%2C+X.%3B+Chen-Kiang%2C+S.+A%3B+Phase%2C+I.+Trial+of+PD-0332991%2C+a+Novel%2C+Orally-Bioavailable+CDK4%2F6-Specific+Inhibitor+Administered+in+Combination+with+Bortezomib+and+Dexamethasone+to+Patients+with+Relapsed+and+Refractory+Multiple+Myeloma.+51st+American+Society+of+Hematology+Meeting%2C+New+Orleans%2C+LA%2C+December+5%E2%80%938%2C+2009%2C+Abst+1877."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DNiesvizky%26aufirst%3DR.%26atitle%3DTrial%2520of%2520PD-0332991%252C%2520a%2520Novel%252C%2520Orally-Bioavailable%2520CDK4%252F6-Specific%2520Inhibitor%2520Administered%2520in%2520Combination%2520with%2520Bortezomib%2520and%2520Dexamethasone%2520to%2520Patients%2520with%2520Relapsed%2520and%2520Refractory%2520Multiple%2520Myeloma%26spage%3DAbst%25201877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Chen-Kiang, S.; Di Liberto, M.; Louie, T.; Liang, J.; Jayabalan, D. S.; Ely, S.; Moore, M. A.; Niesvizky, R.; Huang, X.</span><span> </span><span class="NLM_article-title">Targeting Cdk4/6 in combination therapy of chemoresistant multiple myeloma</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">Abstract 8503</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=Abstract+8503&author=S.+Chen-Kiang&author=M.+Di+Liberto&author=T.+Louie&author=J.+Liang&author=D.+S.+Jayabalan&author=S.+Ely&author=M.+A.+Moore&author=R.+Niesvizky&author=X.+Huang&title=Targeting+Cdk4%2F6+in+combination+therapy+of+chemoresistant+multiple+myeloma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen-Kiang%26aufirst%3DS.%26atitle%3DTargeting%2520Cdk4%252F6%2520in%2520combination%2520therapy%2520of%2520chemoresistant%2520multiple%2520myeloma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3DAbstract%25208503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Finn, R. S.; Crown, J. P.; Lang, I.; Boer, K.; Bondarenko, I. M.; Kulyk, S. O.; Ettl, J.; Patel, R.; Schmidt, M.; Shparyk, Y.; Thummala, A. R.; Voytko, N. L.; Breazna, A.; Kim, S. T.; Randolph, S.; Salmon, D. J.</span><span> </span><span class="NLM_article-title">Results of randomized phase 2 study of PD 0332991, a cyclic-dependent kinase (CDK) 4/6 inhibitor, in combination with letrazole vs letrazole alone for first-line treatment of ER+/Her2– advanced breast cancer (BC)</span>.  <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span>, <span class="NLM_issue">Suppl 24</span><span class="NLM_x">) </span> <span class="NLM_fpage">Abstract no. S1-6</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=Abstract+no.+S1-6&issue=Suppl+24&author=R.+S.+Finn&author=J.+P.+Crown&author=I.+Lang&author=K.+Boer&author=I.+M.+Bondarenko&author=S.+O.+Kulyk&author=J.+Ettl&author=R.+Patel&author=M.+Schmidt&author=Y.+Shparyk&author=A.+R.+Thummala&author=N.+L.+Voytko&author=A.+Breazna&author=S.+T.+Kim&author=S.+Randolph&author=D.+J.+Salmon&title=Results+of+randomized+phase+2+study+of+PD+0332991%2C+a+cyclic-dependent+kinase+%28CDK%29+4%2F6+inhibitor%2C+in+combination+with+letrazole+vs+letrazole+alone+for+first-line+treatment+of+ER%2B%2FHer2%E2%80%93+advanced+breast+cancer+%28BC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DResults%2520of%2520randomized%2520phase%25202%2520study%2520of%2520PD%25200332991%252C%2520a%2520cyclic-dependent%2520kinase%2520%2528CDK%2529%25204%252F6%2520inhibitor%252C%2520in%2520combination%2520with%2520letrazole%2520vs%2520letrazole%2520alone%2520for%2520first-line%2520treatment%2520of%2520ER%252B%252FHer2%25E2%2580%2593%2520advanced%2520breast%2520cancer%2520%2528BC%2529%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26issue%3DSuppl%252024%26spage%3DAbstract%2520no.%2520S1-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Finn, R. S.; Veronique, D.; Karen, A.; Gelmon, N. H.; Stephen, E. J.; Maria, K.; Maguel, M.; Hope, S. R.; Seock-Aj, I.; Masakazu, T.; Eric, R. G.; Xin, H.; Sophia, R.; Dennis, J. S.</span><span> </span><span class="NLM_article-title">A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrazole for the treatment of postmenopausal women with ER(+), HER2(−) breast cancer who have not received any prior systemic anticancer treatment for advanced disease</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">Abstr TPS652</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=Abstr+TPS652&issue=Suppl&author=R.+S.+Finn&author=D.+Veronique&author=A.+Karen&author=N.+H.+Gelmon&author=E.+J.+Stephen&author=K.+Maria&author=M.+Maguel&author=S.+R.+Hope&author=I.+Seock-Aj&author=T.+Masakazu&author=R.+G.+Eric&author=H.+Xin&author=R.+Sophia&author=J.+S.+Dennis&title=A+randomized%2C+multicenter%2C+double-blind+phase+III+study+of+palbociclib+%28PD-0332991%29%2C+an+oral+CDK+4%2F6+inhibitor%2C+plus+letrozole+versus+placebo+plus+letrazole+for+the+treatment+of+postmenopausal+women+with+ER%28%2B%29%2C+HER2%28%E2%88%92%29+breast+cancer+who+have+not+received+any+prior+systemic+anticancer+treatment+for+advanced+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DA%2520randomized%252C%2520multicenter%252C%2520double-blind%2520phase%2520III%2520study%2520of%2520palbociclib%2520%2528PD-0332991%2529%252C%2520an%2520oral%2520CDK%25204%252F6%2520inhibitor%252C%2520plus%2520letrozole%2520versus%2520placebo%2520plus%2520letrazole%2520for%2520the%2520treatment%2520of%2520postmenopausal%2520women%2520with%2520ER%2528%252B%2529%252C%2520HER2%2528%25E2%2588%2592%2529%2520breast%2520cancer%2520who%2520have%2520not%2520received%2520any%2520prior%2520systemic%2520anticancer%2520treatment%2520for%2520advanced%2520disease%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26issue%3DSuppl%26spage%3DAbstr%2520TPS652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Daren, R. V.; William, B.; Bayard, D. C.; Nikolas, V. B.; Justus, D.</span><span> </span><span class="NLM_article-title">Pyridopyrimidine Kinase Inhibitors</span>. U. S Patent 20050009849 A1, <span class="NLM_month">Jan</span><span class="NLM_day">13</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=R.+V.+Daren&author=B.+William&author=D.+C.+Bayard&author=V.+B.+Nikolas&author=D.+Justus&title=Pyridopyrimidine+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDaren%26aufirst%3DR.%2BV.%26atitle%3DPyridopyrimidine%2520Kinase%2520Inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit47b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Buhr, C. A.; Bajjalieh, W.; Joshi, A. B.; Lara, K.; Ma, S.; Marlowe, C. K.; Wang, L.; Yeung, B. N. S.</span><span> </span><span class="NLM_article-title">Pyrido[2,3-<i>d</i>]pyrimidin-7-one compounds as inhibitors of PI3K-ALPHA for the treatment of cancer</span>. Canada Patent 2683784 A1, <span class="NLM_month">Oct</span><span class="NLM_day">23</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=C.+A.+Buhr&author=W.+Bajjalieh&author=A.+B.+Joshi&author=K.+Lara&author=S.+Ma&author=C.+K.+Marlowe&author=L.+Wang&author=B.+N.+S.+Yeung&title=Pyrido%5B2%2C3-d%5Dpyrimidin-7-one+compounds+as+inhibitors+of+PI3K-ALPHA+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBuhr%26aufirst%3DC.%2BA.%26atitle%3DPyrido%255B2%252C3-d%255Dpyrimidin-7-one%2520compounds%2520as%2520inhibitors%2520of%2520PI3K-ALPHA%2520for%2520the%2520treatment%2520of%2520cancer%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Brian, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeff, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellen, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charles, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randall, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">William, A. D.</span><span> </span><span class="NLM_article-title">Structure–activity relationships for 2-anilino-6-phenylpyrido[2,3-<i>d</i>]pyrimidine-7(8<i>H</i>)-ones a inhibitors of the cellular checkpoint kinase wee 1</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1931</span><span class="NLM_x">–</span> <span class="NLM_lpage">1935</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=1931-1935&author=D.+P.+Brianauthor=B.+S.+Jeffauthor=W.+R.+Gordonauthor=M.+D.+Ellenauthor=K.+Alanauthor=W.+M.+Charlesauthor=W.+S.+Randallauthor=A.+D.+William&title=Structure%E2%80%93activity+relationships+for+2-anilino-6-phenylpyrido%5B2%2C3-d%5Dpyrimidine-7%288H%29-ones+a+inhibitors+of+the+cellular+checkpoint+kinase+wee+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrian%26aufirst%3DD.%2BP.%26aulast%3DJeff%26aufirst%3DB.%2BS.%26aulast%3DGordon%26aufirst%3DW.%2BR.%26aulast%3DEllen%26aufirst%3DM.%2BD.%26aulast%3DAlan%26aufirst%3DK.%26aulast%3DCharles%26aufirst%3DW.%2BM.%26aulast%3DRandall%26aufirst%3DW.%2BS.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26atitle%3DStructure%25E2%2580%2593activity%2520relationships%2520for%25202-anilino-6-phenylpyrido%255B2%252C3-d%255Dpyrimidine-7%25288H%2529-ones%2520a%2520inhibitors%2520of%2520the%2520cellular%2520checkpoint%2520kinase%2520wee%25201%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D1931%26epage%3D1935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Reddy, M. V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallireddigari, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosenza, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallela, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iqbal, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robell, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of (<i>E</i>)-Styrylbenzylsulfones as Novel Anticancer Agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">86</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701077b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=86-100&author=M.+V.+R.+Reddyauthor=M.+R.+Mallireddigariauthor=S.+C.+Cosenzaauthor=V.+R.+Pallelaauthor=N.+M.+Iqbalauthor=K.+A.+Robellauthor=A.+D.+Kangauthor=E.+P.+Reddy&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+%28E%29-Styrylbenzylsulfones+as+Novel+Anticancer+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49a&amp;dbid=16384&amp;doi=10.1021%2Fjm701077b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701077b%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26aulast%3DMallireddigari%26aufirst%3DM.%2BR.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DPallela%26aufirst%3DV.%2BR.%26aulast%3DIqbal%26aufirst%3DN.%2BM.%26aulast%3DRobell%26aufirst%3DK.%2BA.%26aulast%3DKang%26aufirst%3DA.%2BD.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520%2528E%2529-Styrylbenzylsulfones%2520as%2520Novel%2520Anticancer%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D86%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit49b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Reddy, M. V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, S.</span><span> </span><span class="NLM_article-title">Synthesis of α,β-Unsaturated Sulfones</span> <span class="citation_source-journal">Acta Chim. Hung.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">269</span><span class="NLM_x">–</span> <span class="NLM_lpage">271</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADyaL2cXkt1ejtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1984&pages=269-271&author=M.+V.+R.+Reddyauthor=S.+Reddy&title=Synthesis+of+%CE%B1%2C%CE%B2-Unsaturated+Sulfones"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49bR"><div class="casContent"><span class="casTitleNuber">49b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of α,β-unsaturated sulfones</span></div><div class="casAuthors">Reddy, M. V. R.; Reddy, S.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Chimica Hungarica</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">269-71</span>CODEN:
                <span class="NLM_cas:coden">ACHUDC</span>;
        ISSN:<span class="NLM_cas:issn">0231-3146</span>.
    </div><div class="casAbstract">Eleven benzyl styryl sulfones, PhCH2SO2CH:CHR (R = substituted Ph), were prepd. in 62.5-89.2% yield by condensation of RCHO with PhCH2SO2CH2CO2H, prepd. by benzylation of HSCH2CO2H followed by oxidn. with H2O2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhTBc39fHWdbVg90H21EOLACvtfcHk0li-Gj2eAqif4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXkt1ejtL0%253D&md5=ba4c399826e1f66a4e907149ea675062</span></div><a href="/servlet/linkout?suffix=cit49b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26aulast%3DReddy%26aufirst%3DS.%26atitle%3DSynthesis%2520of%2520%25CE%25B1%252C%25CE%25B2-Unsaturated%2520Sulfones%26jtitle%3DActa%2520Chim.%2520Hung.%26date%3D1984%26volume%3D115%26spage%3D269%26epage%3D271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit49c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Reddy, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, M. V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanyam, S.</span><span> </span><span class="NLM_article-title">Preparation of Styryl Benzyl Sulfones and 1,2-Bis-(styrylsulfonylmethyl)-4,5-dimethylbenzenes</span> <span class="citation_source-journal">Org. Prep. Proced. Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">212</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49c&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1080%2F00304948809355812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49c&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADyaL1MXnsV2mtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1988&pages=205-212&author=D.+B.+Reddyauthor=N.+S.+Reddyauthor=M.+V.+R.+Reddyauthor=S.+Balasubramanyam&title=Preparation+of+Styryl+Benzyl+Sulfones+and+1%2C2-Bis-%28styrylsulfonylmethyl%29-4%2C5-dimethylbenzenes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49cR"><div class="casContent"><span class="casTitleNuber">49c</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation of styryl benzyl sulfones and 1,2-bis(styrylsulfonylmethyl)-4,5-dimethylbenzenes</span></div><div class="casAuthors">Reddy, D. Bhaskar; Reddy, N. S.; Reddy, S.; Reddy, M. V. R.; Balasubramanyam, S.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Preparations and Procedures International</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">205-12</span>CODEN:
                <span class="NLM_cas:coden">OPPIAK</span>;
        ISSN:<span class="NLM_cas:issn">0030-4948</span>.
    </div><div class="casAbstract">The Knoevenagel reaction of R1CH2SO2CH2CO2H (R1 = Ph, tolyl, ClC6H4, O2NC6H4) with R2CHO (R2 = Ph, O2NC6H4, anthryl, halophenyl, tolyl, anisyl) in HOAc contg. PhCH2NH2 gave trans-styryl sulfones I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeZN6gdVDNZrVg90H21EOLACvtfcHk0li-Gj2eAqif4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXnsV2mtA%253D%253D&md5=abb98febfd6090c49fd9fdd8e354d4d4</span></div><a href="/servlet/linkout?suffix=cit49c&amp;dbid=16384&amp;doi=10.1080%2F00304948809355812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00304948809355812%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DD.%2BB.%26aulast%3DReddy%26aufirst%3DN.%2BS.%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26aulast%3DBalasubramanyam%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Styryl%2520Benzyl%2520Sulfones%2520and%25201%252C2-Bis-%2528styrylsulfonylmethyl%2529-4%252C5-dimethylbenzenes%26jtitle%3DOrg.%2520Prep.%2520Proced.%2520Int.%26date%3D1988%26volume%3D20%26spage%3D205%26epage%3D212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Reddy, M. V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallireddigari, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallela, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatapuram, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boominathan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of (<i>E</i>)-and (<i>Z</i>)-styryl-2-acetoxyphenyl sulfides and sulfones as cyclooxygenase-2 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1715</span><span class="NLM_x">–</span> <span class="NLM_lpage">1723</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=1715-1723&author=M.+V.+R.+Reddyauthor=M.+R.+Mallireddigariauthor=V.+R.+Pallelaauthor=P.+Venkatapuramauthor=R.+Boominathanauthor=S.+C.+Bellauthor=E.+P.+Reddy&title=Design%2C+synthesis%2C+and+biological+evaluation+of+%28E%29-and+%28Z%29-styryl-2-acetoxyphenyl+sulfides+and+sulfones+as+cyclooxygenase-2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26aulast%3DMallireddigari%26aufirst%3DM.%2BR.%26aulast%3DPallela%26aufirst%3DV.%2BR.%26aulast%3DVenkatapuram%26aufirst%3DP.%26aulast%3DBoominathan%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DS.%2BC.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520%2528E%2529-and%2520%2528Z%2529-styryl-2-acetoxyphenyl%2520sulfides%2520and%2520sulfones%2520as%2520cyclooxygenase-2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26spage%3D1715%26epage%3D1723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Reddy, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gumireddy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallireddigari, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosenza, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatapuram, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, M. V. R.</span><span> </span><span class="NLM_article-title">Novel coumarin-3-(<i>N</i>-aryl)carboxamides arrest breast cancer cell growth by inhibiting ErbB-2 and ERK1</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3141</span><span class="NLM_x">–</span> <span class="NLM_lpage">3147</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=3141-3147&author=N.+S.+Reddyauthor=K.+Gumireddyauthor=M.+R.+Mallireddigariauthor=S.+C.+Cosenzaauthor=P.+Venkatapuramauthor=S.+C.+Bellauthor=E.+P.+Reddyauthor=M.+V.+R.+Reddy&title=Novel+coumarin-3-%28N-aryl%29carboxamides+arrest+breast+cancer+cell+growth+by+inhibiting+ErbB-2+and+ERK1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DN.%2BS.%26aulast%3DGumireddy%26aufirst%3DK.%26aulast%3DMallireddigari%26aufirst%3DM.%2BR.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DVenkatapuram%26aufirst%3DP.%26aulast%3DBell%26aufirst%3DS.%2BC.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26atitle%3DNovel%2520coumarin-3-%2528N-aryl%2529carboxamides%2520arrest%2520breast%2520cancer%2520cell%2520growth%2520by%2520inhibiting%2520ErbB-2%2520and%2520ERK1%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26spage%3D3141%26epage%3D3147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Suzuki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusakai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishimoto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esumi, H.</span><span> </span><span class="NLM_article-title">ARK5 is a tumor invasion-associated factor downstream of Akt signaling</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">3526</span><span class="NLM_x">–</span> <span class="NLM_lpage">3535</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1128%2FMCB.24.8.3526-3535.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=15060171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFKjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=3526-3535&author=A.+Suzukiauthor=J.+Luauthor=G.+Kusakaiauthor=A.+Kishimotoauthor=T.+Oguraauthor=H.+Esumi&title=ARK5+is+a+tumor+invasion-associated+factor+downstream+of+Akt+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">ARK5 is a tumor invasion-associated factor downstream of Akt signaling</span></div><div class="casAuthors">Suzuki, Atsushi; Lu, Jie; Kusakai, Gen-ichi; Kishimoto, Atsuhiro; Ogura, Tsutomu; Esumi, Hiroyasu</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3526-3535</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">AMP-activated protein kinases (AMPKs) are a class of serine/threonine protein kinases that are activated by an increase in intracellular AMP concn.  They are a sensitive indicator of cellular energy status and have been found to promote tumor cell survival during nutrient starvation.  We recently identified a novel AMPK catalytic subunit family member, ARK5, whose activation is directly regulated by Akt, which, in turn, has been reported to be a key player in tumor malignancy.  In this study, we attempted to det. whether ARK5 is involved in tumor malignancy under regulation by Akt.  Matrigel invasion assays demonstrated that both overexpressed and endogenous ARK5 showed strong activity dependent on Akt.  In addn., ARK5 expression induced activation of matrix metalloproteinase 2 (MMP-2) and MMP-9 following new expression of membrane type 1 MMP (MT1-MMP), and the MT1-MMP expression induced by ARK5 was initiated by rapamycin-sensitive signaling.  In nude mice, ARK5 expression was assocd. with a significant increase in tumor growth and significant suppression of necrosis in tumor tissue.  Interestingly, only the ARK5-overexpressing PANC-1 cell line (P/ARK) tumor showed invasion and metastasis in nude mice, although Akt was activated in tumors derived from both P/ARK and its parental cell line.  We report that a novel AMPK catalytic subunit family member, ARK5, plays a key role in tumor malignancy downstream of Akt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp2pQK3k2_uLVg90H21EOLACvtfcHk0lhQ7qz2bq-Liw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFKjtLk%253D&md5=cf805bd959892c2da70eebd31559ce3b</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1128%2FMCB.24.8.3526-3535.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.24.8.3526-3535.2004%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DKusakai%26aufirst%3DG.%26aulast%3DKishimoto%26aufirst%3DA.%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DEsumi%26aufirst%3DH.%26atitle%3DARK5%2520is%2520a%2520tumor%2520invasion-associated%2520factor%2520downstream%2520of%2520Akt%2520signaling%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2004%26volume%3D24%26spage%3D3526%26epage%3D3535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Kusakai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esumi, H.</span><span> </span><span class="NLM_article-title">Strong association of ARK5 with tumor invasion and metastasis</span> <span class="citation_source-journal">J. Exp. Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">268</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=15354411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXms1Kjtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=263-268&author=G.+Kusakaiauthor=A.+Suzukiauthor=T.+Oguraauthor=M.+Kaminishiauthor=H.+Esumi&title=Strong+association+of+ARK5+with+tumor+invasion+and+metastasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Strong association of ARK5 with tumor invasion and metastasis</span></div><div class="casAuthors">Kusakai, G.; Suzuki, A.; Ogura, T.; Kaminishi, M.; Esumi, H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-268</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">0392-9078</span>.
    
            (<span class="NLM_cas:orgname">Regina Elena Institute for Cancer Research</span>)
        </div><div class="casAbstract">The authors recently identified a novel human AMPK family member, ARK5, and discovered that it is a major factor in Akt-dependent cancer cell survival and migration activity through activation of MT1-MMPs in vitro.  The mRNA expression of other AMPK family members and ARK5 was measured using RT-PCR in human colorectal carcinoma cell lines DLD-1, WiDr, HCT-15, SW620, LoVo, SW480, and mRNA expression of AMPK-α1, SNARK, MELK and ARK5, but not AMPK-α2, was detected in every line.  Quant.-PCR (Q-PCR) to est. the amt. of ARK5 mRNA expression in the cell lines showed that there is a variety of ARK5 expressions among the cell lines and high expression was obsd. in a cell line derived from the metastatic lesion, LoVo.  To det. the effect of ARK5 overexpression on metastasis in vivo, the authors established human pancreas cancer cell line PANC-1 stably transfected with ARK5 full-length expression vector (P/ARK) and DLD-1 stably transfected with the same vector (D/ARK).  Migration assay showed a remarkable increase in the activity both in P/ARK and D/ARK, and an in vivo metastasis assay showed a marked increase of P/ARK in liver metastasis.  Based on these observations, it is suggested that ARK5 expression is involved in cancer invasion and metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjb82P4k4HYrVg90H21EOLACvtfcHk0lhQ7qz2bq-Liw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXms1Kjtbk%253D&md5=398d15306b52cfdb1e68016240821743</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKusakai%26aufirst%3DG.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DKaminishi%26aufirst%3DM.%26aulast%3DEsumi%26aufirst%3DH.%26atitle%3DStrong%2520association%2520of%2520ARK5%2520with%2520tumor%2520invasion%2520and%2520metastasis%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D23%26spage%3D263%26epage%3D268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Sutherland, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musgrove, E. A.</span><span> </span><span class="NLM_article-title">CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease</span> <span class="citation_source-journal">Breast Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1186%2Fbcr2454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=20067604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252Fns1Wisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=112&author=R.+L.+Sutherlandauthor=E.+A.+Musgrove&title=CDK+inhibitors+as+potential+breast+cancer+therapeutics%3A+new+evidence+for+enhanced+efficacy+in+ER%2B+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease</span></div><div class="casAuthors">Sutherland Robert L; Musgrove Elizabeth A</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">112</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Loss of cell cycle control is a hallmark of cancer, and aberrations in the cyclin-CDK-RB (cyclin-dependent kinase-retinoblastoma protein) pathway are common in breast cancer.  Consequently, inhibition of this pathway is an attractive therapeutic strategy, but results from clinical trials of CDK inhibitors in breast cancer have been disappointing.  A recent study now shows that in cell culture a selective CDK4/6 inhibitor is preferentially effective in estrogen receptor-positive (ER(+)) disease and apparently acts synergistically with tamoxifen or trastuzumab.  These exciting new preclinical data set the scene for a more targeted approach to further clinical evaluation wherein this class of drugs is targeted to subgroups of ER(+) patients, including those with resistance to endocrine therapy, alone or in combination with current standard therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRE071O4N-bZTEC-75aqa5AfW6udTcc2eaf5ogrwn15Zrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252Fns1Wisg%253D%253D&md5=a5ed3960d3005ba1b45daee096293f9d</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1186%2Fbcr2454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr2454%26sid%3Dliteratum%253Aachs%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26aulast%3DMusgrove%26aufirst%3DE.%2BA.%26atitle%3DCDK%2520inhibitors%2520as%2520potential%2520breast%2520cancer%2520therapeutics%253A%2520new%2520evidence%2520for%2520enhanced%2520efficacy%2520in%2520ER%252B%2520disease%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2009%26volume%3D11%26spage%3D112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Kitagawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki-Takahashi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taya, Y.</span><span> </span><span class="NLM_article-title">The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">7060</span><span class="NLM_x">–</span> <span class="NLM_lpage">7069</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1002%2Fj.1460-2075.1996.tb01097.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=9003781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADyaK2sXosFKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1996&pages=7060-7069&author=M.+Kitagawaauthor=H.+Higashiauthor=H.+K.+Jungauthor=I.+Suzuki-Takahashiauthor=M.+Ikedaauthor=K.+Tamaiauthor=J.+Katoauthor=K.+Segawaauthor=E.+Yoshidaauthor=S.+Nishimuraauthor=Y.+Taya&title=The+consensus+motif+for+phosphorylation+by+cyclin+D1-Cdk4+is+different+from+that+for+phosphorylation+by+cyclin+A%2FE-Cdk2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2</span></div><div class="casAuthors">Kitagawa, Masatoshi; Higashi, Hideaki; Jung, Hai-Kwan; Suzuki-Takahashi, Ikuko; Ikeda, Masako; Tamai, Katsuyuki; Kato, Jun-ya; Segawa, Kaoru; Yoshida, Eisaku; Nishimura, Susumu; Taya, Yoichi</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7060-7069</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Cyclin D-Cdk4/6 and cyclin A/E-Cdk2 are suggested to be involved in phosphorylation of the retinoblastoma protein (pRB) during the G1/S transition of the cell cycle.  However, it is unclear why several Cdks are needed and how they are different from one another.  We found that the consensus amino acid sequence for phosphorylation by cyclin D1-Cdk4 is different from S/T-P-X-K/R, which is the consensus sequence for phosphorylation by cyclin A/E-Cdk2 using various synthetic peptides as substrates.  Cyclin D1-Cdk4 efficiently phosphorylated the G1 peptide, RPPTLS780PIPhipr that contained a part of the sequence of pRB, while cyclins E-Cdk2 and A-Cdk2 did not.  To det. the phosphorylation state of pRB in vitro and in vivo, we raised the specific antibody against phospho-Ser780 in pRB.  We confirmed that cyclin D1-Cdk4, but not cyclin E-Cdk2, phosphorylated Ser780 in recombinant pRB.  The Ser780 in pRB was phosphorylated in the G1 phase in a cell cycle-dependent manner.  Furthermore, we found that pRB phosphorylated at Ser780 cannot bind to E2F-1 in vivo.  Our data show that cyclin D1-Cdk4 and cyclin A/E Cdk2 phosphorylate different sites of pRB in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogbhxXMzHcPrVg90H21EOLACvtfcHk0ljVsBWIdztwHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXosFKlsQ%253D%253D&md5=a0bb66af6ded3baa26d56771f0fd5d67</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fj.1460-2075.1996.tb01097.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1460-2075.1996.tb01097.x%26sid%3Dliteratum%253Aachs%26aulast%3DKitagawa%26aufirst%3DM.%26aulast%3DHigashi%26aufirst%3DH.%26aulast%3DJung%26aufirst%3DH.%2BK.%26aulast%3DSuzuki-Takahashi%26aufirst%3DI.%26aulast%3DIkeda%26aufirst%3DM.%26aulast%3DTamai%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DJ.%26aulast%3DSegawa%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DE.%26aulast%3DNishimura%26aufirst%3DS.%26aulast%3DTaya%26aufirst%3DY.%26atitle%3DThe%2520consensus%2520motif%2520for%2520phosphorylation%2520by%2520cyclin%2520D1-Cdk4%2520is%2520different%2520from%2520that%2520for%2520phosphorylation%2520by%2520cyclin%2520A%252FE-Cdk2%26jtitle%3DEMBO%2520J.%26date%3D1996%26volume%3D15%26spage%3D7060%26epage%3D7069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Connell-Crowley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, D. W.</span><span> </span><span class="NLM_article-title">Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation</span> <span class="citation_source-journal">Mol. Biol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Fjm401073p&amp;key=10.1091%2Fmbc.8.2.287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm401073p&amp;key=9190208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm401073p&amp;key=1%3ACAS%3A528%3ADyaK2sXhsV2itr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1997&pages=287-301&author=L.+Connell-Crowleyauthor=J.+W.+Harperauthor=D.+W.+Goodrich&title=Cyclin+D1%2FCdk4+regulates+retinoblastoma+protein-mediated+cell+cycle+arrest+by+site-specific+phosphorylation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation</span></div><div class="casAuthors">Connell-Crowley, Lisa; Harper, J. Wade; Goodrich, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">287-301</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1059-1524</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">The retinoblastoma protein (pRb) inhibits progression through the cell cycle.  Although pRb is phosphorylated when G1 cyclin-dependent kinases (Cdks) are active, the mechanisms underlying pRb regulation are unknown.  In vitro phosphorylation by cyclin D1/Cdk4 leads to inactivation of pRb in a microinjection-based in vivo cell cycle assay.  In contrast, phosphorylation of pRb by Cdk2 or Cdk3 in complexes with A- or E-type cyclins is not sufficient to inactivate pRb function in this assay, despite extensive phosphorylation and conversion to a slowly migrating "hyperphosphorylated form." The differential effects of phosphorylation on pRb function coincide with modification of distinct sets of sites.  Serine 795 is phosphorylated efficiently by Cdk4, even in the absence of an intact LXCXE motif in cyclin D, but not by Cdk2 or Cdk3.  Mutation of serine 795 to alanine prevents pRb inactivation by Cdk4 phosphorylation in the microinjection assay.  This study identifies a residue whose phosphorylation is crit. for inactivation of pRb-mediated growth suppression, and it indicates that hyperphosphorylation and inactivation of pRb are not necessarily synonymous.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYuGVSOFEDFLVg90H21EOLACvtfcHk0ljVsBWIdztwHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhsV2itr0%253D&md5=4e25b2edd6f4bcb0aeb6beff4465c5de</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1091%2Fmbc.8.2.287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.8.2.287%26sid%3Dliteratum%253Aachs%26aulast%3DConnell-Crowley%26aufirst%3DL.%26aulast%3DHarper%26aufirst%3DJ.%2BW.%26aulast%3DGoodrich%26aufirst%3DD.%2BW.%26atitle%3DCyclin%2520D1%252FCdk4%2520regulates%2520retinoblastoma%2520protein-mediated%2520cell%2520cycle%2520arrest%2520by%2520site-specific%2520phosphorylation%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D1997%26volume%3D8%26spage%3D287%26epage%3D301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Grafstrom, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoess, R. H.</span><span> </span><span class="NLM_article-title">Defining the substrate specificity of cdk4 kinase-cyclin D1 complex</span> <span class="citation_source-journal">Carcinogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">202</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">198</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=1999&pages=193-198&author=R.+H.+Grafstromauthor=W.+Panauthor=R.+H.+Hoess&title=Defining+the+substrate+specificity+of+cdk4+kinase-cyclin+D1+complex"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrafstrom%26aufirst%3DR.%2BH.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DHoess%26aufirst%3DR.%2BH.%26atitle%3DDefining%2520the%2520substrate%2520specificity%2520of%2520cdk4%2520kinase-cyclin%2520D1%2520complex%26jtitle%3DCarcinogenesis%26date%3D1999%26volume%3D202%26spage%3D193%26epage%3D198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Hua, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiaoping, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jyoti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, M. V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M. G.</span><span> </span><span class="NLM_article-title">Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotheraphy</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">250</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=250-257&author=L.+V.+Huaauthor=Z.+Xiaopingauthor=S.+Jyotiauthor=M.+V.+R.+Reddyauthor=E.+P.+Reddyauthor=M.+G.+James&title=Integrated+pharmacokinetic-driven+approach+to+screen+candidate+anticancer+drugs+for+brain+tumor+chemotheraphy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DL.%2BV.%26aulast%3DXiaoping%26aufirst%3DZ.%26aulast%3DJyoti%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26aulast%3DJames%26aufirst%3DM.%2BG.%26atitle%3DIntegrated%2520pharmacokinetic-driven%2520approach%2520to%2520screen%2520candidate%2520anticancer%2520drugs%2520for%2520brain%2520tumor%2520chemotheraphy%26jtitle%3DAAPS%2520J.%26date%3D2013%26volume%3D15%26spage%3D250%26epage%3D257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2EUF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2EUF','PDB','2EUF'); return false;">PDB: 2EUF</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i157"><a href="/doi/suppl/10.1021/jm401073p">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_10654"></div></div></div></div></div><hr /></hr><p class="last">Effect of <b>7x</b> and PD-0332991 on a panel of human breast carcinoma cell lines, kinase inhibition profile of <b>7x</b> (Reaction Biology Corporation), inhibition of PI3K isoforms by <b>7x</b>, and docking models showing different binding positions of <b>7x</b> to Abl, FGFR, and FMS kinases. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm401073p/suppl_file/jm401073p_si_001.pdf">jm401073p_si_001.pdf (202.6 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm401073p&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-3%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm401073p%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm401073p" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67996f667fd2247f","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
